

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 November 2002 (14.11.2002)

PCT

(10) International Publication Number
WO 02/090558 A1

- (51) International Patent Classification⁷: C12N 15/86, 15/63, 15/85, A61K 48/00, A61P 31/00
- (21) International Application Number: PCT/FI02/00379
- (22) International Filing Date: 3 May 2002 (03.05.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
20010922 3 May 2001 (03.05.2001) FI
10/138,098 3 May 2002 (03.05.2002) US
- (71) Applicant (for all designated States except US): **FI**
BIOTECH OYJ PLC [FI/FI]; Lenkkeilijänkatu 10,
FIN-33520 Tampere (FI).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **KROHN, Kai**
[FI/FI]; Salmementantie 751, FIN-36450 Salmementaka
(FI). **BLAZEVIC, Vesna** [HR/FI]; Leilikuja 7 C 26,
FIN-33820 Tampere (FI). **TÄHTINEN, Marja** [FI/FI];
Kurunnitienkatu 2, FIN-33730 Tampere (FI). **USTAV,**
Mart [EE/EE]; Jaama Street 58A, 50604 Tartu (EE).
TOOTS, Urve [EE/EE]; Aardla 146-1, 50415 Tartu (EE).
MÄNNIK, Andres [EE/EE]; Narva mnt. 149-25, 51008
Tartu (EE). **RANKI, Annamari** [FI/FI]; Sibeliuksenkatu
11 B 28, FIN-00250 Helsinki (FI). **USTAV, Ene** [EE/EE];
Jaama Street 58A, 50604 Tartu (EE).
- (74) Agent: **KOLSTER OY AB**; Iso Roobertinkatu 23,
P.O.Box 148, FIN-00121 Helsinki (FI).
- (81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (48) Date of publication of this corrected version:
6 February 2003
- (15) Information about Correction:
see PCT Gazette No. 06/2003 of 6 February 2003, Section II
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL EXPRESSION VECTORS AND USES THEREOF

(57) Abstract: The present invention relates to novel vectors, to DNA vaccines and gene therapeutics containing said vectors, to methods for the preparation of the vectors and DNA vaccines and gene therapeutics containing the vectors, and to therapeutic uses of said vectors. More specifically, the present invention relates to novel vectors comprising (a) an expression cassette of a gene of a nuclear-anchoring protein, which contains (i) a DNA binding domain capable of binding to a specific DNA sequence and (ii) a functional domain capable of binding to a nuclear component and (b) a multimerized DNA sequence forming a binding site for the anchoring protein, and optionally (c) one or more expression cassettes of a DNA sequence of interest. In particular the invention relates to vectors that lack a papilloma virus origin of replication. The nuclear-anchoring protein might be the E2 protein of Bovine Papilloma Virus type 1 or Epstein-Barr Virus Nuclear Antigen 1. The invention also relates to vectors that lack an origin of replication functional in a mammalian cell. The invention further relates to methods for expressing a DNA sequence of interest in a subject.

WO 02/090558 A1

NOVEL EXPRESSION VECTORS AND USES THEREOF

1. FIELD OF THE INVENTION

The present invention relates to novel vectors, to DNA vaccines and gene therapeutics containing said vectors, to methods for the preparation of the vectors and DNA vaccines and gene therapeutics containing the vectors, and to therapeutic uses of said vectors. More specifically, the present invention relates to novel vectors comprising (a) an expression cassette of a gene of a nuclear-anchoring protein, which contains (i) a DNA binding domain capable of binding to a specific DNA sequence and (ii) a functional domain capable of binding to a nuclear component and (b) a multimerized DNA forming a binding site for the anchoring protein of a nuclear-anchoring protein, and optionally (c) one or more expression cassettes of a DNA sequence of interest. In particular the invention relates to vectors that lack a papilloma virus origin of replication. The invention also relates to vectors that lack an origin of replication functional in a mammalian cell. The invention further relates to methods for expressing a DNA sequence of interest in a subject.

2. BACKGROUND OF THE INVENTION

Transfer of autologous or heterologous genes into animal or human organisms with suitable vectors is emerging as a technique with immense potential to cure diseases with a genetic background or to prevent or cure infectious diseases. Several types of viral and non-viral vectors have been developed and tested in animals and in human subjects to deliver a gene/genes that are defective by mutations and therefore non-functional. Examples of such vectors include Adenovirus vectors, Herpes virus vectors, Retrovirus vectors, Lentivirus vectors and Adeno-associated vectors.

Vaccination has proven to be a highly effective and economical method to prevent a disease caused by infectious agents. Since the introduction of the Vaccinia virus as an attenuated vaccine against the smallpox virus (Variola), vaccines against a multitude of human pathogens have been developed and taken into routine use. Today small pox has been eradicated by vaccinations and the same

is to be expected shortly for the poliovirus. Several childhood diseases, such as pertussis, diphtheria and tetanus, can be effectively prevented by vaccinations.

In general, the most successful viral vaccines are live avirulent mutants of the disease-causing viruses. The key to the success of this approach is the fact that a living virus targets the same organs, the same type and similar number of cells, and therefore, by multiplying in the recipient, elicits a long-lasting immune response without causing the disease or causing only a mild disease. In effect, a live attenuated vaccine produces a subclinical infection, the nature's own way of immunizing. As a result, a full immune response will be induced, including humoral, cellular and innate responses, providing a long lasting and sometimes a life-long immune protection against the pathogen.

Although live attenuated vaccines are most potent, they can cause harmful side effects. Thus, an attenuated viral vaccine can revert to a virulent strain or in cases where the attenuated virus is apathogenic in adults it can still cause a disease in infants or in disabled persons. This is true in the case of viruses causing chronic infections, such as Human Immunodeficiency Virus type 1 and 2. Vaccines composed of viral and bacterial proteins or immunogenic peptides are less likely to cause unwanted side effects but may not be as potent as the live vaccines. This is especially the case with vaccines against microbes causing chronic infections, such as certain viruses and intracellular bacteria.

The strength and type of immune response is, however, also dependent on how the viral proteins are processed and how they are presented to the immune system by antigen presenting cells (APCs), such as macrophages and dendritic cells. Protein and peptide antigens are taken up by APCs via endocytosis, processed to small immunogenic peptides through an endosomal pathway and presented to T-lymphocytes (T-cells) by MHC (major histocompatibility complex) class II antigens [in man HLAs (human leukocyte antigens) class II]. In contrast, proteins synthesized de novo in APCs or in possible target cells for an immune response, will be processed through a cytoplasmic pathway and presented to T-cells by MHC class I antigens (in man HLAs class I). In general, the presentation of immunogenic peptides through the class II pathway will lead to the activation of the helper/inducer T-cells, which in turn will lead to the activation of B-

cells and to antibody response. In contrast, presentation through class I MHC favors the induction of cytotoxic T-lymphocytes (CTLs), which are capable of recognition and destruction of virally infected cells.

In early 1990's, a method to mimic the antigen processing and presentation that was normally achieved by live attenuated vaccines was introduced [Ulmer, J.B. et al Science 259 (1993) 1745-1749]. It was shown that an injection of eukaryotic expression vectors in the form of circular DNA into the muscle induced take-up of this DNA by the muscle cells (and probably others) and was able to induce the expression of the gene of interest, and to raise an immune response, especially a cellular immune response in the form of CTLs, to the protein encoded by the inserted gene. Since that observation, DNA immunization has become a standard method to induce immune responses to foreign proteins in experimental animals and human studies with several DNA vaccines are under way.

Generally, the DNA vectors used in these vaccine studies contain a cloning site for the gene of interest, a strong viral promoter, such as the immediate early promoter of the CMV virus, in order to drive the expression of the gene of interest, a polyadenylation region, and an antibiotic resistance gene and a bacterial replication origin for the propagation of the DNA vector (plasmid) in bacterial cells.

With the vectors described above it is possible to obtain a detectable level of expression of the gene of interest after administering the vector to experimental animals or to humans, either by a direct injection to muscle or to skin with a particle bombardment technique or by applying the vector in a solution directly to mucous membranes. However, the expression obtained by these vectors is short lived: the vectors tend to disappear from the transfected cells little by little and are not transferred to daughter cells in a dividing cell population. The short-term expression of the gene of interest and limited number of cells targeted are probably the major reasons, why only temporary immune responses are observed in subjects immunized with DNA vectors described above. Thus, for example, Boyer et al. observed only temporary immune responses to HIV-1 Env and Rev proteins in

human subjects, who were immunized several times with a vector similar to the those described above [Boyer, J. D., J Infect Dis 181 (2000) 476 – 483].

There is a growing interest in developing novel products useful in gene therapy and DNA vaccination. For instance papilloma virus vectors carrying the expression cassette for the gene of interest have been suggested to be useful candidates.

To date more than 70 subtypes of human papilloma viruses (HPVs) and many different animal papilloma viruses have been identified [zur Hausen, H. and de Villiers E., Annu Rev Microbiol 48 (1994) 427 – 447; Bernard, H., et al., Curr Top Microbiol Immunol 186 (1994) 33 – 54]. All papilloma viruses share a similar genome organization and the positioning of all of the translational open reading frames (ORFs) is highly conserved.

Papilloma viruses infect squamous epithelial cells of skin or mucosa at different body sites and induce the formation of benign tumors, which in some cases can progress to malignancy. The papilloma virus genomes are replicated and maintained in the infected cells as multicopy nuclear plasmids. The replication, episomal maintenance, expression of the late genes and virus assembly are tightly coupled to the differentiation of the epithelial tissue: the papilloma virus DNA episomal replication takes place during the initial amplificational replication and the second, i.e. latent, and the third, i.e. vegetative, replications in the differentiating epithelium [Howley, P. M.; Papillomavirinae: the viruses and their replication. In Virology, Fields, B. C., Knipe, D. M., Howley, P. M., Eds., Lippincott-Raven Publishers, Philadelphia, USA, 1996, 2. Edition, p. 2045 – 2076].

Two viral factors encoded by the E1 and E2 open reading frames have been shown to be necessary and sufficient for the initiation of the DNA replication from the papilloma virus origin in the cells [Ustav, M. and Stenlund, A., EMBO J 10 (1991) 449 - 57; Ustav, M., et al., EMBO J 10 (1991) 4321 - 4329; Ustav, E., et al., Proc Natl Acad Sci USA 90 (1993) 898 - 902].

Functional origins for the initiation of the DNA replication have been defined for BPV1 [Ustav, M., et al., EMBO J 10 (1991) 4321 – 4329], HPV1a [Gopalakrishnan, V. and Khan, S., supra], HPV11 [Russell, J., Botchan, M., J Virol 69 (1995) 651 – 660], HPV18 [Sverdrup, F. and Khan, S., J Virol 69 (1995)

- 1319 - 1323: Sverdrup, F. and Khan, S., *J Virol* 68 (1994) 505-509] and many others. Characteristically, all these origin fragments have a high A/T content, and they contain several overlapping individual E1 protein recognition sequences, which together constitute the E1 binding site [Ustav, M., et al., *EMBO J* 10 (1991) 4321 - 4329; Holt, S., et al., *J Virol* 68 (1994) 1094 - 1102; Holt, S. and Wilson, V., *J Virol* 69 (1995) 6525 - 3652; Sedman, T., et al. *J Virol* 71 (1997) 2887 - 2996]. In addition, these functional origin fragments contain an E2 binding site, which is essential for the initiation of DNA replication in vivo in most cases (Ustav, E., et al., *supra*). The E2 protein facilitates the first step of the origin recognition by E1. After the initial binding of monomeric E1 to the origin the multimerization of E1 is initiated. This leads to the formation of the complex with the ori melting activity. It has been suggested that E2 has no influence on the following stages of the initiation of the DNA replication [Lusky, M., et al., *Proc Natl Acad Sci USA* 91 (1994) 8895-8899].
- 15 The BPV1 E2 ORF encodes three proteins that originate from selective promoter usage and alternative mRNA splicing [Lambert, P., et al., *Annu. Rev Genet* 22 (1988) 235 - 258]. All these proteins can form homo- and heterodimers with each other and bind specifically to a 12 bp interrupted palindromic sequence 5'-ACCNNNNNNGGT-3' [Androphy, E., et al., *Nature* 325 (1987) 70 - 739].
- 20 There are 17 E2 binding sites in the BPV1 genome and up to four sites in the HPV genomes, which play a crucial role in the initiation of viral DNA replication (Ustav, E., et al., *supra*) and in the regulation of viral gene expression (Howley, P. M., *Papillomavirinae: the viruses and their replication*, in *Virology*, Fields, B. C., Knipe, D. M., Howley, P. M., Eds., Philadelphia: Lippincott-Raven Publishers, 1996. 2. edition, p. 2045 - 2076). Structural and mutational analyses have revealed three distinct functional domains in the full size E2 protein. The N-terminal part (residues 1 to 210) is an activation domain for transcription and replication. It is followed by the unstructured hinge region (residues 211 to 324) and the carboxy-terminal DNA binding-dimerization domain (residues 325 to 410)
- 25 [Dostatni, N., et al., *EMBO J* 7 (1988) 3807 - 3816; Haugen, T., et al. *EMBO J* 7 (1988) 4245 - 4253; McBride, A., et al., *EMBO J* 7 (1988) 533 - 539; McBride, A., et al., *Proc Natl Acad Sci USA* 86 (1989) 510-514]. On the basis of X-ray crys-
- 30

tallographical data, the DNA binding-dimerization domain of E2 has a structure of a dyad-symmetric eight-stranded antiparallel beta barrel, made up of two identical "half-barrel" subunits [Hegde, R., et al., *Nature* 359 (1992) 505 – 512; Hegde, R., *J Nucl Med* 36(6 Suppl) (1995) 25S - 27S]. The functional elements of the trans-
5 activation domain of E2 have a very high structural integrity as confirmed by mutational analysis [Abroi, A., et al., *J Virol* 70 (1996) 6169 – 6179; Brokaw, J., et al., *J Virol* 71 (1996) 23 – 29; Grosse, M., et al., *J Virol* 70 (1996) 7264 – 7269; Ferguson, M. and Botchan, M., *J Virol* 70 (1996) 4193-4199] and by X-ray crystallography [Harris, S., and Botchan, M.R., *Science* 284 (1999) 1673-1677 and Ant-
10 son, A. et al., *Nature* 403 (2000) 805-809]. In addition, X-ray crystallography shows that the N-terminal domain of the E2 protein forms a dimeric structure, where Arg 37 has an important function in dimer formation (Antson, A., et al., *supra*).

As has been described previously, bovine papillomavirus type 1 E2 protein
15 in trans and its multiple binding sites in cis are both necessary and sufficient for the chromatin attachment of the episomal genetic elements. The phenomenon is suggested to provide a mechanism for partitioning viral genome during viral infection in the dividing cells [Ilves, I., et al., *J Virol*. 73 (1999) 4404-4412].

None of the papilloma vectors or other vectors disclosed so far fulfills the
20 criteria and requirements set forth for an optimal vaccine, which are the same for DNA vaccines and for conventional vaccines. (It should be noted that these requirements are preferred but not necessary for use as a vaccine.) First, an optimal vaccine must produce protective immunity with minimal adverse effects. Thus the vaccine should be devoid of components, which are toxic and/or cause symp-
25 toms of the disease to the recipient. Second, an optimal vaccine must induce a pathogen-specific immune response, i.e. it must elicit a strong and measurable immune response to the desired pathogen without causing an immune response to other components of the vaccine. These two requirements imply that a vector to be used as a DNA vaccine should optimally only express the desired gene(s)
30 and optimally should not replicate in the host or contain any sequences homologous with those of the recipient, since nucleotide sequences that are homologous between the vector and the host's genome may effect the integration of the vector

into the host's genome. Third, an optimal vaccine must induce a right type of immune response; i.e. it must raise both humoral and cellular immune responses in order to act on the intracellular and extracellular pathogen. Finally, an optimal vaccine must be stable, i.e. it must retain its potency for a sufficiently long time in the body to raise the immune response in a vaccine formulation for use in various demanding circumstances during storage and preparation. Additionally, vaccines should be of reasonable price. Further, the route and the method of inoculation are important considerations for optimizing a DNA immunization.

When developing a DNA vaccine the stability of the expression of the desired gene is sometimes a major problem. Thus, the maintenance function or the persistence of the vector in the recipient cell has been focused on in the prior art, however, often at the cost of the safety. For example, Ohe, Y., et al. [Hum Gene Ther 6(3) (1995) 325-333] disclose a papilloma virus vector capable of stable, high-level gene expression, which is suggested for use in gene therapy. Transforming early genes E5, E6, and E7 have been deleted from said vector, but it still contains nucleotide sequences encoding other papilloma viral genes, such as the E1 and E2 genes, which are involved in the replication of the virus. Thus, the vector produces several other papilloma proteins, which may elicit undesired immune responses and which induce a risk of the vector's integration in the recipient. Also, the vector is replicable, since it contains the E1 gene. Additionally, it is large in size and therefore subject to bacterial modification during preparation.

International Patent Application PCT/EE96/00004 (WO 97/24451) discloses vectors capable of a long-term maintenance in a host cell and methods using such vectors for obtaining long-term production of a gene product of interest in a mammalian host cell, which expresses E1 and E2. These vectors contain a minimal origin of replication of a papilloma virus (MO), a Minichromosome Maintenance Element (MME) of a papilloma virus and a gene encoding said gene product, the MO and MME consisting of a DNA sequence different from the natural papilloma virus sequence, and in some embodiments the E1 gene. Additionally, vectors containing an MME consisting essentially of ten E2 binding sites are disclosed in some examples. These vectors require the presence of the E1 protein either in the host or in the vector for the expression. This imparts the replica-

tion function to the vectors. These vectors also express the E1 protein in addition to the gene of interest and the E2 protein and contain sequences, such as rabbit β -globin sequences, which are partially homologous to human sequences causing a serious risk of integration to human genome, which reduces the potential of these vectors as DNA vaccines. Additionally, the vectors are unstable due to their size (ca 15 kb): at the preparation stage in a bacterial cell, the bacterial replication machinery tends to modify the vector by random slicing of the vector, which leads to unsatisfactory expression products including products totally lacking the gene of interest.

International Patent Application PCT/EE96/00004 (WO 97/24451) further discloses that E1 and E2 are the only viral proteins necessary for the episomal long-term replication of the vectors. Additionally, the maintenance function of the BPV1 genome is associated with the presence of minimal ori (MO), which is stated to be necessary, although not sufficient, for the long-term persistence or the stable maintenance of the vectors the cells. In addition, the cis-elements, i.e. the Minichromosome Maintenance Elements of the BPV1, are stated to be required for the stable replication of BPV1. In particular, multimeric E2 binding sites (E2BS) are stated to be necessary for the stable maintenance of the vectors.

There is a clear need for improved novel vectors, which would be useful as DNA vaccines.

An object of the invention is therefore to provide novel vectors, which are capable of a long-term maintenance in a large and increasing number of different cells of the host's body and thereby capable of providing a stable expression of the desired antigen(s).

Another object of the invention is to provide novel vectors, which are maintained for a long period of time in the cells that originally received the vector and transferred it to the daughter cells after mitotic cell division.

Yet another object of the invention is to provide novel vectors, which express in addition to the gene or genes of interest preferably only a gene necessary for a long-term maintenance in the recipient cells and thus are devoid of components that are toxic or cause symptoms of the disease to the recipient.

A further object of the invention is to provide novel vectors, which mimic attenuated live viral vaccines, especially in their function of multiplying in the body, without inducing any considerable signs of disease and without expressing undesired proteins, which may induce adverse reactions in a host injected with the
5 DNA vaccine.

Still a further object of the invention is to provide novel vectors, which do not replicate in the recipient.

Still another object of the invention is to provide novel vectors, which induce both humoral and cellular immune responses when used as DNA vaccines.

10 Yet another object of the invention is to provide novel vectors, which are suitable for a large-scale production in bacterial cell.

Yet another object of the invention is to provide novel vectors, which are not host specific and thus enable the production in various bacterial cells.

An additional object of the invention is to provide novel vectors, which are
15 useful as carrier vectors for a gene or genes of interest,

A further object of the invention is to provide novel vectors, which are useful in gene therapy and as gene therapeutic agents and for the production of macromolecular drugs in vivo.

20 3. SUMMARY OF THE INVENTION

The present invention discloses novel vectors, which meet the requirements of a carrier vector of a gene or genes of interest or of an optimal DNA vaccination vector and which are preferably devoid of drawbacks and side effects of prior art vectors.

25 The present invention is based on the surprising finding that a vector (plasmid) carrying (i) an expression cassette of a DNA sequence encoding a nuclear-anchoring protein, and (ii) multiple copies of high affinity binding sites for said nuclear-anchoring protein spreads in proliferating cells. As a result, the number of vector-carrying cells increases even without the replication of the vector.
30 When the vector additionally carries a gene or genes of interest, the number of such cells that express a gene or genes of interest similarly increases without the replication of the vector. Thus, the vector of the invention lacks a papilloma

virus origin of replication. In a preferred embodiment, the vector of the invention lacks an origin of replication that functions in a mammalian cell.

Accordingly, the present invention discloses novel vectors useful as carrier vectors of a gene or genes of interest, in DNA vaccination and gene therapy and as gene therapeutic agents. In a specific embodiment, said vectors are capable of spreading and, if desired, of expressing a gene or genes of interest in an increasing number of cells for an extended time. The vectors of the present invention preferably express only a nuclear-anchoring protein, and, if desired, the gene or genes of interest, and optionally a selectable marker. However, they preferably lack any redundant, oncogenically transforming or potentially toxic sequences, thereby avoiding a severe drawback of the vectors previously disclosed or suggested for use as DNA vaccines, i.e. hypersensitivity reactions against other viral components. In certain embodiments of the invention, this is achieved by low level of the expressed nuclear-anchoring protein in the cells. At the same time, the vectors of the present invention induce both humoral and cellular immune responses, where the gene or genes of interest is included in the vector.

The vectors of the present invention are advantageous for use both in vitro (e.g., in the production level) and in vivo (e.g., vaccination).

The present invention relates to the subject matter of the invention as set forth in the attached claims.

The present invention relates to expression vectors comprising: (a) a DNA sequence encoding a nuclear-anchoring protein operatively linked to a heterologous promoter, said nuclear-anchoring protein comprising (i) a DNA binding domain which binds to a specific DNA sequence, and (ii) a functional domain that binds to a nuclear component, or a functional equivalent thereof; and (b) a multimerized DNA sequence forming a binding site for the nuclear anchoring protein, wherein said vector lacks a papilloma virus origin of replication. In a preferred embodiment a vector of the invention lacks an origin of replication functional in a mammalian cell.

In certain embodiments, the nuclear component is mitotic chromatin, the nuclear matrix, nuclear domain 10 (ND10), or nuclear domain POD.

In certain specific embodiments, the nuclear anchoring-protein is a chromatin-anchoring protein, and said functional domain binds mitotic chromatin.

In certain embodiments, the nuclear-anchoring protein contains a hinge or linker region.

5 In certain embodiments, the nuclear-anchoring protein is a natural protein of eukaryotic, prokaryotic, or viral origin. In certain specific embodiments, the natural protein is of viral origin.

In certain embodiments, the nuclear-anchoring protein is a natural protein of eukaryotic origin.

10 In certain embodiments, the nuclear-anchoring protein is that of a papilloma virus or an Epstein-Barr virus.

In specific embodiments, the nuclear-anchoring protein is the E2 protein of Bovine Papilloma Virus type 1 or Epstein-Barr Virus Nuclear Antigen 1.

15 In a specific embodiment, the nuclear-anchoring protein is the E2 protein of Bovine Papilloma Virus type 1.

In specific embodiments, the nuclear-anchoring protein is a High Mobility Group protein.

In certain embodiments, the nuclear-anchoring protein is a non-natural protein.

20 In certain embodiments, the nuclear-anchoring protein is a recombinant protein, a fusion protein, or a protein obtained by molecular modeling techniques.

In specific embodiments, the recombinant protein, fusion protein, or protein obtained by molecular modeling techniques contains any combination of a DNA binding domain which binds to said specific DNA sequence and a functional domain which binds to a nuclear component, wherein said functional domain which binds to a nuclear component is that of a papilloma virus, an Epstein-Barr Virus, or a High Mobility Group protein.

30 In certain specific embodiments, the recombinant protein, fusion protein, or protein obtained by molecular modeling techniques contains any combination of a DNA binding domain which binds to said specific DNA sequence and a functional domain which binds to a nuclear component, wherein said functional domain which binds to a nuclear component is that of E2 protein of Bovine Papil-

loma Virus type 1, Epstein-Barr Virus Nuclear Antigen 1, or a High Mobility Group protein.

In certain embodiments, the vector further comprises one or more expression cassettes of a DNA sequence of interest.

5 In certain embodiments, the DNA sequence of interest is that of an infectious pathogen. In certain embodiments, the infectious pathogen is a virus. In certain specific embodiments, the virus is selected from the group consisting of Human Immunodeficiency Virus (HIV), Herpes Simplex Virus (HSV), Hepatitis C Virus, Influenzae Virus, and Enterovirus.

10 In certain embodiments, the DNA sequence of interest is that of a bacterium. In certain embodiments, the bacterium is selected from the group consisting of *Chlamydia trachomatis*, *Mycobacterium tuberculosis*, and *Mycoplasma pneumoniae*. In a specific embodiment, the bacterium is *Salmonella*.

In certain embodiments, the DNA sequence of interest is that of a fungal pathogen. In certain embodiments, the fungal pathogen is *Candida albicans*.

In certain embodiments, the DNA sequence of interest is of HIV origin.

In specific embodiments, the DNA sequence of interest encodes a non-structural regulatory protein of HIV. In more specific embodiments, the non-structural regulatory protein of HIV is Nef, Tat and/or Rev. In a specific embodiment, the non-structural regulatory protein of HIV is Nef.

20 In certain embodiments, the DNA sequence of interest encodes a structural protein of HIV. In a specific embodiment, the DNA sequence of interest is the gene encoding HIV gp120/gp160.

In certain embodiments, the vector of the invention comprises a first expression cassette comprising a DNA sequence of interest which encodes Nef, Tat and/or Rev, and a second expression cassette comprising a DNA sequence of interest which encodes Nef, Tat and/or Rev.

30 In certain embodiments, the vector of the invention comprises a first expression cassette comprising a DNA sequence of interest which encodes Nef, Tat and/or Rev, and a second expression cassette comprising a DNA sequence of interest which encodes a structural protein of HIV.

In certain embodiments, the DNA sequence of interest encodes a protein associated with cancer.

In certain embodiments, the DNA sequence of interest encodes a protein associated with immune maturation, regulation of immune responses, or regulation of autoimmune responses. In a specific embodiment, the protein is APE-CED.

In a specific embodiment, the DNA sequence of interest is the Aire gene.

In certain embodiments, the DNA sequence of interest encodes a protein that is defective in any hereditary single gene disease.

10 In certain embodiments, the DNA sequence of interest encodes a macromolecular drug.

In certain embodiments, the DNA sequence of interest encodes a cytokine. In certain specific embodiments, the cytokine is an interleukin selected from the group consisting of IL1, IL2, IL4, IL6 and IL12. In certain other specific em-
15 bodiments, the DNA sequence of interest encodes an interferon.

In certain embodiments, the DNA sequence of interest encodes a biologically active RNA molecule. In certain specific embodiments, the biologically active RNA molecule is selected from the group consisting of inhibitory antisense and ribozyme molecules. In certain specific embodiments, the inhibitory an-
20 tisense or ribozyme molecules antagonize the function of an oncogene.

A vector of the invention is suitable for the use for the production of a therapeutic macromolecular agent in vivo.

In certain embodiments, the invention provides a vector for use as a medicament.

25 In certain embodiments, the invention provides a vector for use as a carrier vector for a gene, genes, or a DNA sequence or DNA sequences of interest, such as a gene, genes, or a DNA sequence or DNA sequences encoding a protein or peptide of an infectious agent, a therapeutic agent, a macromolecular drug, or any combination thereof.

30 In certain specific embodiments, the invention provides a vector for use as a medicament for treating inherited or acquired genetic defects.

In certain embodiments, the invention provides a vector for use as a therapeutic DNA vaccine against an infectious agent.

In certain embodiments, the invention provides a vector for use as a therapeutic agent.

5 The invention further relates to methods for providing a protein to a subject, said method comprising administering to the subject a vector of the invention, wherein said vector (i) further comprises a second DNA sequence encoding the protein to be provided to the subject, which second DNA sequence is operably linked to a second promoter, and (ii) does not encode Bovine Papilloma Virus
10 protein E1, and wherein said subject does not express Bovine Papilloma Virus protein E1.

 The invention further relates to methods for inducing an immune response to a protein in a subject, said method comprising administering to the subject a vector of the invention wherein said vector (i) further comprises a second DNA
15 sequence encoding said protein, which second DNA sequence is operably linked to a second promoter, and (ii) does not encode Bovine Papilloma Virus protein E1, and wherein said subject does not express Bovine Papilloma Virus protein E1.

 The invention further relates to methods for treating an infectious disease
20 in a subject in need of said treatment, said method comprising administering to said subject a therapeutically effective amount of a vector of the invention, wherein the DNA sequence of interest encodes a protein comprising an immunogenic epitope of an infectious agent.

 The invention further relates to methods for treating an inherited or ac-
25 quired genetic defect in a subject in need of said treatment, said method comprising: administering to said subject a therapeutically effective amount of a vector of the invention, wherein said DNA sequence of interest encodes a protein which is affected by said inherited or acquired genetic defect.

 The invention further relates to methods for expressing a DNA sequence
30 in a subject, said method comprising administering a vector of the invention to said subject.

The invention further relates to methods for expressing a DNA sequence in a subject, treating an inherited or acquired genetic defect, treating an infectious disease, inducing an immune-response to a protein, and providing a protein to a subject, wherein the vector of the invention does not encode Bovine Papilloma Virus protein E1, and wherein said subject does not express Bovine Papilloma Virus protein E1.

In certain embodiments, a vector of the invention is used for production of a protein encoded by said DNA sequence of interest in a cell or an organism.

The invention further provides a method for the preparation of a vector of claim 1, 2, or 17 comprising: (a) cultivating a host cell containing said vector and (b) recovering the vector. In a specific embodiment, the method for preparing a vector of the invention further comprises before step (a) a step of transforming said host cell with said vector. In certain specific embodiments, the host cell is a prokaryotic cell. In a specific embodiment, the host cell is an Escherichia coli.

The invention further relates to a host cell that is characterized by containing a vector of the invention. In certain embodiments, the host cell is a bacterial cell. In a certain other embodiments, the host cell is a mammalian cell.

The invention further relates to carrier vectors containing a vector of the invention.

The invention further relates to a pharmaceutical composition comprising a vector of the invention and a suitable pharmaceutical vehicle.

The invention further relates to a DNA vaccine containing a vector of the invention.

The invention further relates to a gene therapeutic agent containing a vector of the invention.

The invention further relates to a method for the preparation of a DNA vaccine, said method comprising combining a vector of the invention with a suitable pharmaceutical vehicle.

The invention further relates to a method for the preparation of an agent for use in gene therapy, said method comprising combining a vector of the invention with a suitable pharmaceutical vehicle.

4. DESCRIPTION OF THE FIGURES

Figure 1 shows the schematic map of plasmid super6.

Figure 2 shows the schematic map of plasmid VI.

Figure 3 shows the schematic map of plasmid II.

5 Figure 4 shows the expression of the Nef and E2 proteins from the vectors super6, super6wt, VI, VIwt, and II in Jurkat cells.

Figure 5 shows the schematic map of plasmid product1.

Figure 6A shows the schematic map of the plasmids NNV-1 and NNV-2 and Figure 6B shows the schematic map of plasmid and NNV-2wt.

10 Figure 7 shows the expression of the Nef protein from the plasmids NNV-1, NNV-2, NNV-1wt, NNV-2wt, super6, and super6wt in Jurkat cells.

Figure 8 shows the expression of the Nef and E2 proteins from the plasmids NNV-2wt, NNV-2wtFS, and product I in Jurkat cells.

15 Figure 9 shows the expression of the Nef and E2 proteins from the plasmids NNV-2wt, NNV-2wtFS, and product I in P815 cells.

Figure 10 shows the expression of the Nef and E2 proteins from the plasmids NNV-2wt, NNV-2wtFS, and product I in CHO cells.

Figure 11 shows the expression of the Nef protein from the plasmids NNV-2wt, NNV-2wtFS, and product I in RD cells.

20 Figure 12 shows the expression of the RNA molecules NNV-2wt in CHO, Jurkat cells, and P815 cells.

Figure 13 shows the stability of NNV-2wt in bacterial cells.

Figure 14 shows the Southern blot analysis of stability of the NNV-2wt as non-replicating episomal element in CHO and Jurkat cell lines.

25 Figure 15 shows that the vectors NNV2wt, NNV2wtFS and product1 are unable to HPV-11 replication factor-dependent replication.

Figure 16 shows the schematic map of the plasmid 2wtd1EGFP.

Figure 17 shows the schematic map of the plasmid gf10bse2

Figure 18 shows the schematic map of the plasmid 2wtd1EGFPFS.

30 Figure 19 shows the schematic map of the plasmid NNVd1EGFP.

Figure 20 shows the growth curves of the Jurkat cells transfected with the plasmids 2wtd1EGFP, 2wtd1EGFPFS, NNVd1EGFP or with carrier DNA only.

Figure 21 shows the growth curves of the Jurkat cells transfected with the plasmids 2wtd1EGFP, 2wtd1EGFPFS, gf10bse2 or with carrier DNA only.

Figure 22 shows the change in the percentage of d1EGFP positive cells in a population of Jurkat cells transfected with the vectors 2wtd1EGFP,
5 2wtd1EGFPFS or NNvd1EGFP.

Figure 23 shows the change in percentage of the d1EGFP positive cells in a population of Jurkat cells transfected with the vectors 2wtd1EGFP, 2wtd1EGFPFS or gf10bse2.

Figure 24 shows the change in the number of d1EGFP expressing cells in
10 a population of Jurkat cells transfected with the vectors 2wtd1EGFP, 2wtd1EGFPFS or NNvd1EGFP.

Figure 25 shows the change in the number of d1EGFP expressing cells in a population of Jurkat cells transfected with the vectors 2wtd1EGFP, 2wtd1EGFPFS or gf10bse2.

15 Figure 26. T-cell responses towards recombinant Nef proteins (5 micrograms/well), measured by T-cell proliferation in five patients immunized with 1 microgram of GTU-Nef.

Figure 27. T-cell responses towards recombinant Nef proteins (5 micrograms/well), measured by T-cell proliferation in five patients immunized with 20
20 micrograms of GTU-Nef.

Figure 28. T-cell responses towards recombinant Nef proteins (5 micrograms/well), measured by T-cell proliferation in patient # 1 immunized with 1 microgram of GTU-Nef. The results are given as stimulation index of the T-cell proliferation assay (Nef SI) and as IFN-Gamma secretion to the supernatant.

25 Figure 29. (A) plasmid pEBO LPP; (B) plasmid s6E2d1EGFP; (C) plasmid FRE2d1EGFP

Figure 30. Plasmid FREBNAd1EGFP

Figure 31. Vectors did not interfere with cell proliferation

Figure 32. Vectors were maintained in the cells with different kinetics

30 Figure 33. Change of the number of d1EGFP expressing cells in time in transfected total population of cells

Figure 34. Change of the number of d1EGFP expressing cells in time in transfected total population of cells. (A) human embryonic cell line 293; (B) mouse cell line 3T6

Figure 35. Nef and E2 antibody response

5 Figure 36. Rev and Tat antibody response

Figure 37. Gag and CTL response

Figure 38. (A) GTU-1; (B) GTU-2Nef; (C) GTU-3Nef; (D) super6wtd1EGFP; (E) FREBNAd1EGFP; (F) E2BSEBNAd1EGFP; (G) NNV-Rev

Figure 39. (A) pNRT; (B) pTRN; (C) pRTN; (D) pTNR; (E) pRNT; (F) p2TRN; (G) p2RNT; (H) p3RNT; (I) pTRN-iE2-GMCSF; (J) pTRN-IMG-GMCSF

10 Figure 40. (A) pMV1NTR; (B) pMV2NTR; (C) pMV1N11TR; (D) pMV2N11TR

Figure 41. (A) pCTL; (B) pdgag; (C) psynp17/24; (D) poptp17/24; (E) p2mCTL; (F) p2optp17/24; (G) p3mCTL; (H) p3optp17/24

15 Figure 42. (A) pTRN-CTL; (B) pRNT-CTL; (C) pTRN-dgag; (D) pTRN-CTL-dgag; (E) pRNT-CTL-dgag; (F) pTRN-dgag-CTL; (G) pRNT-dgag-CTL; (H) pTRN-optp17/24-CTL; (I) pTRN-CTL-optp17/24; (J) pRNT-CTL-optp17/24; (K) p2TRN-optp17/24-CTL; (L) p2RNT-optp17/24-CTL; (M) p2TRN-CTL-optp17/24; (N) p2RNT-CTL-optp17/24; (O) p2TRN-CTL-optp17/24-iE2-mGMCSF; (P) p2RNT-CTL-optp17/24-iE2-mGMCSF; (Q) p3TRN-CTL-optp17/24; (R) p3RNT-CTL-optp17/24; (S) p3TRN-CTL-optp17/24-iE2-mGMCSF; (T) p3RNT-CTL-optp17/24-iE2-mGMCSF; (U) FREBNA-RNT-CTL-optp17/24; (V) super6wt-RNT-CTL-optp17/24; (W) E2BSEBNA-RNT-CTL-optp17/24; (X) pCMV-RNT-CTL-optp17/24

25 Figure 43. Analysis of expression of the multireg antigens.

Figure 44. Analysis of expression of the multireg antigens comprised of immunodominant parts of the proteins.

Figure 45. Analysis of intracellular localization of multireg antigens by immunofluorescence.

30 Figure 46. Analysis of expression of the gag coded structural proteins and the CTL multi-epitope.

47. The p17/24 protein localization in membranes of RD cells.

Figure 48. Analysis expression of the dgag and CTL containing multi-genes in Cos-7 cells.

Figure 49. Western blot analyses of multiHIV antigens expressed in Jurkat cells.

5 Figure 50. Analysis of the expression of the TRN-CTL-optp17/24 and RNT-CTL-optp17/24 antigens as well E2 protein from the GTU-1, GTU-2 and GTU-3 vector.

Figure 51. The maintenance of the multiHIV antigen expression from different vectors.

10 Figure 52. Intracellular localization of the multiHIV antigens in RD cells.

5. DETAILED DESCRIPTION OF THE INVENTION

5.1 VECTORS OF THE INVENTION

The present invention is based on the unexpected finding that expression
15 vectors, which carry (A) an expression cassette of a gene of a nuclear-anchoring protein that binds both to (i) a specific DNA sequence and (ii) to a suitable nuclear component and (B) a multimerized DNA binding sequence for said nuclear-anchoring protein are capable of spreading in a proliferating cell population. Such nuclear-anchoring proteins include, but are not limited to, chromatin-
20 anchoring proteins, such as the Bovine Papilloma Virus type 1 E2 protein (BPV1 E2; SEQ ID NO: 50). The DNA binding sequences can be, but are not limited to, multimerized E2 binding sites. On the basis of prior art, it could not be expected that a segregation/partitioning function of, for instance, the papilloma viruses
25 could be expressed separately and that an addition of such segregation/partitioning function to the vaccine vectors would assure the distribution of the vector in the proliferating cell population. Additionally, on the basis of the prior art, it could not have been expected that functional vectors acting independently of the replication origin can be constructed.

The term "nuclear-anchoring protein" as used in the present invention re-
30 fers to a protein, which binds to a specific DNA sequence and capable of providing a nuclear compartmentalization function to the vector, i.e., to a protein, which is capable of anchoring or attaching the vector to a specific nuclear compartment.

In certain embodiments of the invention, the nuclear-anchoring protein is a natural protein. Examples of such nuclear compartments are the mitotic chromatin or mitotic chromosomes, the nuclear matrix, nuclear domains like ND10 and POD etc. Examples of nuclear-anchoring proteins are the Bovine Papilloma Virus type 1 (BPV1) E2 protein, EBNA1 (Epstein-Barr Virus Nuclear Antigen 1; SEQ ID NO: 52), and High Mobility Group (HMG) proteins etc. The term "functional equivalent of a nuclear-anchoring protein" as used in the present invention refers to a protein or a polypeptide of natural or non-natural origin having the properties of the nuclear-anchoring protein.

In certain other embodiments of the invention, the nuclear-anchoring protein of the invention is a recombinant protein. In certain specific embodiments of the invention, the nuclear-anchoring protein is a fusion protein, a chimeric protein, or a protein obtained by molecular modeling. A fusion protein, or a protein obtained by molecular modeling in connection with the present invention is characterized by its ability to bind to a nuclear component and by its ability to bind sequence-specifically to DNA. In a preferred embodiment of the invention, such a fusion protein is encoded by a vector of the invention which also contains the specific DNA sequence to which the fusion/chimeric protein binds. Nuclear components include, but are not limited to chromatin, the nuclear matrix, the ND10 domain and POD. In order to reduce the risk of interference with the expression of genes endogenous to the host cell, the DNA binding domain and the corresponding DNA sequence is preferably non-endogenous to the host cell/host organism. Such domains include, but are not limited to, the DNA binding domain of the Bovine Papilloma Virus type 1 (BPV1) E2 protein (SEQ ID NO: 50), Epstein-Barr Virus Nuclear Antigen 1 (EBNA1; SEQ ID NO: 52), and High Mobility Group (HMG) proteins (HMG box).

The vector of the invention can further comprise a "DNA sequence of interest", that encodes a protein (including a peptide or polypeptide), e.g., that is an immunogen or a therapeutic. In certain embodiments of the invention, the DNA sequence of interest encodes a biologically active RNA molecule, such as an antisense RNA molecule or a ribozyme.

The expression vectors of the invention carrying an expression cassette for a gene of a nuclear-anchoring protein and multimerized binding sites for said nuclear-anchoring protein spread in a proliferating host cell population. This means that a high copy-number of vectors or plasmids are delivered into the target cells and the use of the segregation/partitioning function of the nuclear-anchoring protein and its multimerized binding sites assures the distribution of the vector to the daughter cells during cell division.

The vector of the invention lacks a papilloma virus origin of replication. Further, in a preferred embodiment, the vector of the invention lacks an origin of replication functional in a mammalian cell. The omission of a papilloma virus origin of replication or a mammalian origin of replication constitutes an improvement over prior art vectors for several reasons. (1) Omission of the origin of replication reduces the size of the vector of the invention compared to prior art vectors. Such a reduction in size increases the stability of the vector and facilitates uptake by the host cell. (2) Omission of the origin of replication reduces the risk for recombination with the host cell's genome, thereby reducing the risk of unwanted side effects. (3) The omission of the origin of replication allows to control the dosage simply by adjusting the amount of vector administered. In contrast, with a functioning origin of replication, replication of the vector has to be taken into consideration when determining the required dosage. (4) If the vector is not administered to a host organism continually, the lack of an origin of replication allows the host organism to clear itself of the vector, thus providing more control over the levels of DNA sequences to be expressed in the host organism. Further, the ability of the organism to clear itself of the vector will be advantageous if the presence of the vector is required only during the course of a therapy but is undesirable in a healthy individual.

The gene of a nuclear-anchoring protein useful in the vectors of the present invention can be any suitable DNA sequence encoding a natural or artificial protein, such as a recombinant protein, a fusion protein or a protein obtained by molecular modeling techniques, having the required properties. Thus the gene of a natural nuclear-anchoring protein, which contains a DNA binding domain capable of binding to a specific DNA sequence and a functional domain capable of

binding to a nuclear component, can be that of a viral protein, such as the E2 protein of Bovine Papilloma Virus or the EBNA1 (Epstein-Barr Virus Nuclear Antigen 1) of the Epstein-Barr Virus, a eukaryotic protein such as one of the High Mobility Group (HMG) proteins or a like protein, or a prokaryotic protein. Alternatively, the gene of a nuclear-anchoring protein, which contains a DNA binding domain capable of binding to a specific DNA sequence and a functional domain capable of binding to a nuclear component, can also be comprised of DNA sequences, which encode a domain from a cellular protein having the ability to attach to a suitable nuclear structure, such as to mitotic chromosomes, the nuclear matrix or nuclear domains like ND10 or POD.

Alternatively, the DNA sequence, which encodes a non-natural or artificial protein, such as a recombinant protein or a fusion protein or a protein obtained by molecular modeling, which contains a DNA binding domain capable of binding to a specific DNA sequence of, e.g., a papilloma virus, such as the DNA binding domain of the E2 protein of the BPV1, but in which the N-terminus of the nuclear-anchoring protein, e.g. that of the E2 protein, has been replaced with domains of any suitable protein of similar capacity, for example, with the N-terminal domain of Epstein-Barr Virus Nuclear Antigen 1 sequence, can be used. Similarly, DNA sequences, which encode a recombinant protein or a fusion protein, which contains a functional domain capable of binding to a nuclear component, e.g., the N-terminal functional domain of a papilloma virus, such as the E2 protein of the BPV1, but in which the C-terminal DNA-binding dimerization domain of the nuclear-anchoring protein, e.g., that of the E2 protein, has been replaced with domains of any protein of a sufficient DNA-binding strength, e.g., the DNA binding domain of the BPV-1 E2 protein and the EBNA-1, can be used.

In a preferred embodiment of the invention, the nuclear-anchoring protein is a chromatin-anchoring protein, which contains a DNA binding domain, which binds to a specific DNA sequence, and a functional domain capable of binding to mitotic chromatin. A preferred example of such a chromatin-anchoring protein and its multimerized binding sites useful in the present invention are the E2 protein of Bovine Papilloma Virus type 1 and E2 protein multimerized binding sites. In the case of E2, the mechanism of the spreading function is due to the dual

function of the E2 protein: the capacity of the E2 protein to attach to mitotic chromosomes through the N-terminal domain of the protein and the sequence-specific binding capacity of the C-terminal domain of the E2 protein, which assures the tethering of vectors, which contain a multimerized E2 binding site, to mitotic
5 chromosomes. A segregation/partitioning function is thus provided to the vectors.

In another preferred embodiment of the invention, the expression cassette of a gene of the chromatin-anchoring protein comprises a gene of any suitable protein of cellular, viral or recombinant origin having analogous properties to E2 of the BPV1, i.e., the ability to attach to the mitotic chromatin through one domain
10 and to cooperatively bind DNA through another domain to multimerized binding sites specific for this DNA binding domain.

In a specific embodiment, sequences obtained from BPV1, are used in the vectors of the present invention, they are extensively shortened in size to include just two elements from BPV1. First, they include the E2 protein coding sequence
15 transcribed from a heterologous eukaryotic promoter and polyadenylated at the heterologous polyadenylation site. Second, they include E2 protein multiple binding sites incorporated into the vector as a cluster, where the sites can be as head-to-tail structures or can be included into the vector by spaced positioning. Both of these elements are necessary and, surprisingly, sufficient for the function of the
20 vectors to spread in proliferating cells. Similarly, when DNA sequences based of other suitable sources are used in the vectors of the present invention, the same principles are applied.

According to the present invention, the expression cassette of a gene of a nuclear-anchoring protein, which contains a DNA binding domain capable of binding
25 to a specific DNA sequence and a functional domain capable of binding to a nuclear component, such as an expression cassette of a gene of a chromatin-anchoring protein, like BPV1 E2, comprises a heterologous eukaryotic promoter, the nuclear-anchoring protein coding sequence, such as a chromatin-anchoring protein coding sequence, for instance the BPV1 E2 protein coding sequence, and
30 a poly A site. Different heterologous, eukaryotic promoters, which control the expression of the nuclear-anchoring protein, can be used. Nucleotide sequences of such heterologous, eukaryotic promoters are well known in the art and are readily

available. Such heterologous eukaryotic promoters are of different strength and tissue-specificity. In a preferred embodiment, the nuclear anchoring protein is expressed at low levels.

The multimerized DNA binding sequences, i.e., DNA sequences containing
5 multimeric binding sites, as defined in the context of the present invention, are the region, to which the DNA binding dimerization domain binds. The multimerized DNA binding sequences of the vectors of the present invention can contain any suitable DNA binding site, provided that it fulfills the above requirements.

In a preferred embodiment, the multimerized DNA binding sequence of a
10 vector of the present invention can contain any one of known 17 different affinity E2 binding sites as a hexamer or a higher oligomer, as a octamer or a higher oligomer, as a decamer or higher oligomer. Oligomers containing different E2 binding sites are also applicable. Specifically preferred E2 binding sites useful in the vectors of the present invention are the BPV1 high affinity sites 9 and 10, affinity
15 site 9 being most preferred. When a higher oligomer is concerned, its size is limited only by the construction circumstances and it may contain from 6 to 30 identical binding sites. Preferred vectors of the invention contain 10 BPV-1 E2 binding sites 9 in tandem. When the multimerized DNA binding sequences are comprised of different E2 binding sites, their size and composition is limited only by the method of construction practice. Thus they may contain two or more different E2 binding
20 sites attached to a series of 6 to 30, most preferably 10, E2 binding sites. The Bovine Papilloma Virus type 1 genome (SEQ ID NO: 49) contains 17 E2 protein binding sites which differ in their affinity to E2. The E2 binding sites are described in Li et al. [Genes Dev 3(4) (1989) 510-526], which is incorporated by
25 reference in its entirety herein.

Alternatively, the multimerized DNA binding sequences may be composed of any suitable multimeric specific sequences capable of inducing the cooperative binding of the protein to the plasmid, such as those of the EBNA1 or a suitable HMG protein. 21x30bp repeats of binding sites for EBNA-1 are localized in the
30 region spanning from nucleotide position 7421 to nucleotide position 8042 of the Epstein-Barr virus genome (SEQ ID NO:51). These EBNA-1 binding sites are described in the following references: Rawlins et al., Cell 42(3) (1985) 859-868;

Reisman et al., Mol Cell Biol 5(8) (1985) 1822-1832; and Lupton and Levine, Mol Cell Biol 5(10) (1985) 2533-2542, all three of which are incorporated by reference in their entireties herein.

The position of the multimerized DNA binding sequences relative to the expression cassette for the DNA binding dimerization domain is not critical and can be any position in the plasmid. Thus the multimerized DNA binding sequences can be positioned either downstream or upstream relative to the expression cassette for the gene of interest, a position close to the promoter of the gene of interest being preferred.

The vectors of the invention also contain, where appropriate, a suitable promoter for the transcription of the gene or genes or the DNA sequences of interest, additional regulatory sequences, polyadenylation sequences and introns. Preferably the vectors may also include a bacterial plasmid origin of replication and one or more genes for selectable markers to facilitate the preparation of the vector in a bacterial host and a suitable promoter for the expression the gene for antibiotic selection.

The selectable marker can be any suitable marker allowable in DNA vaccines, such a kanamycin or neomycin, and others. In addition, other positive and negative selection markers can be included in the vectors of the invention, where applicable.

The vectors of the present invention only comprise the DNA sequences, for instance BPV1 DNA sequences, which are necessary and sufficient for long-term maintenance. All superfluous sequences, which may induce adverse reactions, such as oncogenic sequences, have been deleted. Thus in preferred vectors of the invention the E2 coding sequence is modified by mutational analysis so that this expresses only E2 protein and overlapping E3, E4 and E5 sequences have been inactivated by the introduction of mutations, which inactivate the translation from Open Reading Frames for E3, E4 and E5. The vector of the invention does not contain a papilloma virus origin of replication. Preferably, the vector of the invention further does not contain an origin of replication functional in a mammalian cell or a mammal.

Furthermore, the vectors of the present invention are not host specific, since the expression of the nuclear-anchoring protein, such as the E2 protein, is controlled by non-native or heterologous promoters. Depending on the particular promoter chosen, these promoters may be functional in a broad range of mammalian cells or they can be cell or tissue specific. Examples of promoters for the nuclear-anchoring protein, such as for the E2 protein, useful in the vectors of the present invention are thymidine kinase promoters, Human Cytomegalovirus Immediate Early Promoter, Rous Sarcoma Virus LTR and like. For the expression of the gene of interest, preferred promoters are strong promoters assuring high levels of expression of the gene of interest, an example for such a promoter is the Human Cytomegalovirus Immediate Early Promoter.

5.2 THE VECTORS OF THE INVENTION AS VEHICLES FOR EXPRESSION OF A DNA SEQUENCE OF INTEREST

A gene, genes or a DNA sequence or DNA sequences to be expressed via a vector of the invention can be any DNA sequence of interest, whose expression is desired. Thus the vectors may contain a gene or genes or a DNA sequence or DNA sequences from infectious microbial pathogens, such as viruses, against which live attenuated vaccines or inactivated vaccines cannot be prepared or used. Such DNA sequences of interest include genes or DNA sequences from viruses, such as Human Immunodeficiency Virus (HIV), Herpes Simplex Virus (HSV), Hepatitis C Virus, Influenzae Virus, Enteroviruses etc.; intracellular bacterial, such as Chlamydia trachomatis, Mycobacterium tuberculosis, Mycoplasma pneumonia etc.; extracellular bacteria, such as Salmonella; or fungi, such as Candida albicans.

In a preferred embodiment of the invention, the vectors contain a gene encoding early regulatory proteins of HIV, i.e. the nonstructural regulatory proteins Nef, Tat or Rev, preferably Nef. In another preferred embodiment of the invention the vectors of the invention contain genes encoding structural proteins of the HIV. In another preferred embodiment the vectors of the present invention contain two or more genes encoding any combination of early regulatory proteins and/or structural proteins of HIV. Illustrative examples of such combinations are a com-

combination of a gene encoding the Nef protein and a DNA sequence encoding the Tat protein, possibly together with a DNA sequence encoding outer envelope glycoprotein of HIV, gp120/gp160 or a combination of any immunogenic epitopes of the proteins of pathogens incorporated into artificial recombinant protein.

5 Alternatively, the vectors of the invention may contain genes or DNA sequences for inherited or acquired genetic defects, such as sequences of differentiation antigens for melanoma, like a Tyrosinase A coding sequence or a coding sequence of beta-catenins.

In a preferred embodiment of the invention, the vectors contain a gene encoding proteins relating to cancer or other mutational diseases, preferably diseases related to immune maturation and regulation of immune response towards self and nonself, such as the APECED gene.

In another preferred embodiment of the invention, the vectors contain any DNA sequence coding for a protein that is defective in any hereditary single gene hereditary disease.

15 In another preferred embodiment of the invention, the vectors contain any DNA sequence coding for a macromolecular drug to be delivered and produced in vivo.

The method of the invention for the preparation of the vectors of the invention comprises the following steps: (A) cultivating a host cell containing a vector of the invention, and (B) recovering the vector. In certain specific embodiments, step (A) is preceded by transforming a host cell with a vector of the invention.

The vectors of the invention are preferably amplified in a suitable bacterial host cell, such as *Escherichia coli*. The vectors of the invention are stable and replicate at high copy numbers in bacterial cells. If a vector of the invention is to be amplified in a bacterial host cell, the vector of the invention contains a bacterial origin of replication. Nucleotide sequences of bacterial origins of replication are well known to the skilled artisan and can readily be obtained.

25 Upon transfection into a mammalian host in high copy number, the vector spreads along with cell divisions and the number of cells carrying the vector increases without the replication of the vector, each cell being capable of expressing the protein of interest.

The vectors of the invention result in high expression of the desired protein. For instance, as demonstrated in Examples 4, 7 - 10: a high expression of the Nef protein of the HIV, green fluorescent protein (EGFP) and the AIRE protein could be demonstrated in many different cell lines and the data indicate that not only the number of positive cells, but the quantity of the protein encoded by the gene of interest is increasing in time.

The vectors of the invention also induce both humoral and cellular response as demonstrated in Examples 9 and 10. The results indicate that the vectors of the present invention can effectively be used as DNA vaccines.

10 The vaccines of the present invention contain a vector of the present invention or a mixture of said vectors in a suitable pharmaceutical carrier. The vaccine may for instance contain a mixture of vectors containing genes for the three different regulatory proteins of the HIV and/or structural proteins of the HIV.

The vaccines of the invention are formulated using standard methods of vaccine formulation to produce vaccines to be administered by any conventional route of administration, i.e. intramuscularly, intradermally and like.

The vectors of the invention may contain the ISS stimulatory sequences in order to activate the immune response of the body.

The vaccines of the invention can be used in a conventional preventive manner to protect an individual from infections. Alternatively, the vaccines of the invention can be used as therapeutical vaccines, especially in the case of viral infections, together with a conventional medication.

As mentioned above, the vectors of the present invention carrying the mechanism of spreading in the host cell find numerous applications as vaccines, in gene therapy, in gene transfer and as therapeutic immunogens. The vectors of the invention can be used to deliver a normal gene to a host having a gene defect, thus leading to a cure or therapy of a genetic disease. Furthermore, the vectors can deliver genes of immunogenic proteins of foreign origin, such as those from microbes or autologous tumor antigens, to be used in the development of vaccines against microbes or cancer. Furthermore, the vectors of the invention can deliver suitable genes of marker substances to nucleus, to be used in studies of cellular function or in diagnostics. Finally, the vectors of the invention can be

used to specifically deliver a gene of macromolecular drug to the nucleus, thus enabling the development of novel therapeutic principles to treat and cure diseases, where the expression of the drug in the site of action, the cell nucleus, is of importance. These drugs can be chemical macromolecules, such as any proteins or polypeptides with therapeutic or curative effect, which interfere with any of the nuclear mechanisms, such as the replication or transcription or the transport of substances to and from the nucleus.

Specifically, the vectors of the present invention can be used for the expression of the specific cytokines, like interleukines (IL1, IL2, IL4, IL6, IL12 and others) or interferon, with the aim of modulating the specific immune responses of the organism (immunotherapy) against foreign antigens or boosting of the activity of the immune system against the mutated self-antigens. The vectors of the present invention are also useful in complementing malfunctioning of the brain due to the loss of specific dopamine-ergic neurons leading to the irreversible neurodegeneration, which is cause for Parkinson's disease, by expressing genes involved into synthesis of dopamine, like tyrosine hydroxylase, as well as other genes deficiency of which would have the similar effect. The vectors of the present invention are also useful for the expression of proteins and peptides regulating the brain activity, like dopamine receptors, CCK-A and CCK-B receptors, as well as neurotrophic factors, like GDNF, BDNF and other proteins regulating the brain activity. Further, the vectors of the present invention are useful for a long-term expression of factor IX in hepatocytes and alfa1-antitrypsin in muscle cells with the aim of complementing respective deficiencies of the organism.

5.3 TARGET DISEASES AND DISORDERS

In certain embodiments, a vector of the invention is used as a vaccine. In certain embodiments, a vector of the invention contains a DNA sequence of interest that encodes a protein or a peptide. Upon administering of such a vector to a subject, the protein or peptide encoded by the DNA sequence of interest is expressed and stimulates an immune response specific to the protein or peptide encoded by the DNA sequence of interest.

In specific embodiments, the vector of the invention is used to treat and/or prevent an infectious disease and/or a condition caused by an infectious agent. Such diseases and conditions include, but are not limited to, infectious diseases caused by bacteria, viruses, fungi, protozoa, helminths, and the like. In a more specific embodiment of the invention, the infectious disease is Acquired Immuno-
5 deficiency Syndrome.

Preferably, where it is desired to treat or prevent viral diseases, DNA sequences encoding molecules comprising epitopes of known viruses are used. For example, such DNA sequences encoding antigenic epitopes may be prepared from viruses including, but not limited to, hepatitis type A, hepatitis type B,
10 hepatitis type C, influenza, varicella, adenovirus, herpes simplex type I (HSV-I), herpes simplex type II (HSV-II), rinderpest, rhinovirus, echovirus, rotavirus, respiratory syncytial virus, papilloma virus, papova virus, cytomegalovirus, echinovirus, arbovirus, huntavirus, coxsackie virus, mumps virus, measles virus, rubella virus, polio virus, human immunodeficiency virus type I (HIV-I), and human immunode-
15 ficiency virus type II (HIV-II).

Preferably, where it is desired to treat or prevent bacterial infections, DNA sequences encoding molecules comprising epitopes of known bacteria are used. For example, such DNA sequences encoding antigenic epitopes may be prepared from bacteria including, but not limited to, mycobacteria rickettsia,
20 mycoplasma, neisseria and legionella.

Preferably, where it is desired to treat or prevent protozoal infections, DNA sequences encoding molecules comprising epitopes of known protozoa are used. For example, such DNA sequences encoding antigenic epitopes may be prepared from protozoa including, but not limited to, leishmania, kokzidioa, and try-
25 panosoma.

Preferably, where it is desired to treat or prevent parasitic infections, DNA sequences encoding molecules comprising epitopes of known parasites are used. For example, such DNA sequences encoding antigenic epitopes may be prepared from parasites including, but not limited to, chlamydia and rickettsia.
30

In other specific embodiments, the vector of the invention is used to treat and/or prevent a neoplastic disease in a subject. In these embodiments, the DNA

sequence of interest encodes a protein or peptide that is specific to or associated with the neoplastic disease. By way of non-limiting example, the neoplastic disease can be a fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma; leukemias, e.g., acute lymphocytic leukemia and acute myelocytic leukemia (myeloblastic, promyelocytic, myelomonocytic, monocytic and erythroleukemia); chronic leukemia (chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia); and polycythemia vera, lymphoma (Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenström's macroglobulinemia, and heavy chain disease, etc.

In certain other embodiments of the invention, the DNA sequence of interest encodes a protein that is non-functional or malfunctioning due to an inherited disorder or an acquired mutation in the gene encoding the protein. Such genetic diseases include, but are not limited to, metabolic diseases, e.g., Atherosclerosis (affected gene: APOE); cancer, e.g., Familial Adenomatous Polyposis Coli (affected gene: APC gene); auto-immune diseases, e.g., autoimmune polyendocrinopathy-candidosis-ectodermal dysplasia (affected gene: APECED); disorders of the muscle, e.g., Duchenne muscular dystrophy (affected gene: DMD); diseases of the nervous system, e.g., Alzheimer's Disease (affected genes: PS1 and PS2).

In even other embodiments, the vectors of the invention are used to treat and/or prevent diseases and disorders caused by pathologically high activity of a protein. In these embodiments of the invention, the DNA sequence of interest encodes an antagonist of the overactive protein. Such antagonists include, but
5 are not limited to, antisense RNA molecules, ribozymes, antibodies, and dominant negative proteins. In specific embodiments of the invention, the DNA sequence of interest encodes an inhibitor of an oncogene.

In certain embodiments, the DNA sequence of interest encodes a molecule that antagonizes neoplastic growth. In specific embodiments of the invention, the DNA sequence of interest encodes a tumor suppressor, such as, but not
10 limited to, p53. In other specific embodiments, the DNA sequence of interest encodes an activator of apoptosis, such as but not limited to, a Caspase.

The invention provides methods, whereby a DNA sequence of interest is expressed in a subject. In certain embodiments, a vector containing one or more
15 expression cassettes of a DNA sequence of interest is administered to the subject, wherein the subject does not express the Bovine Papilloma Virus E1 protein.

5.4 THERAPEUTIC METHODS FOR USE WITH THE INVENTION

20 5.4.1 RECOMBINANT DNA

In various embodiments of the invention, the vector of the invention comprises one or more expression cassettes comprising a DNA sequence of interest.

The DNA sequence of interest can encode a protein and/or a biologically active RNA molecule. In either case, the DNA sequence is inserted into the vector of
25 the invention for expression in recombinant cells or in cells of the host in the case of gene therapy.

An expression cassette, as used herein, refers to a DNA sequence of interest operably linked to one or more regulatory regions or enhancer/promoter sequences which enables expression of the protein of the invention in an appropriate host cell. "Operably-linked" refers to an association in which the regulatory
30 regions and the DNA sequence to be expressed are joined and positioned in such a way as to permit transcription, and in the case of a protein, translation.

The regulatory regions necessary for transcription of the DNA sequence of interest can be provided by the vector of the invention. In a compatible host-construct system, cellular transcriptional factors, such as RNA polymerase, will bind to the regulatory regions of the vector to effect transcription of the DNA sequence of interest in the host organism. The precise nature of the regulatory regions needed for gene expression may vary from host cell to host cell. Generally, a promoter is required which is capable of binding RNA polymerase and promoting the transcription of an operably-associated DNA sequence. Such regulatory regions may include those 5'-non-coding sequences involved with initiation of transcription and translation, such as the TATA box, capping sequence, CAAT sequence, and the like. The non-coding region 3' to the coding sequence may contain transcriptional termination regulatory sequences, such as terminators and polyadenylation sites.

Both constitutive and inducible regulatory regions may be used for expression of the DNA sequence of interest. It may be desirable to use inducible promoters when the conditions optimal for growth of the host cells and the conditions for high level expression of the DNA sequence of interest are different. Examples of useful regulatory regions are provided below (section 5.4.4).

In order to attach DNA sequences with regulatory functions, such as promoters, to the DNA sequence of interest or to insert the DNA sequence of interest into the cloning site of a vector, linkers or adapters providing the appropriate compatible restriction sites may be ligated to the ends of the cDNAs by techniques well known in the art [Wu et al., Methods in Enzymol 152 (1987) 343-349]. Cleavage with a restriction enzyme can be followed by modification to create blunt ends by digesting back or filling in single-stranded DNA termini before ligation. Alternatively, a desired restriction enzyme site can be introduced into a fragment of DNA by amplification of the DNA by use of PCR with primers containing the desired restriction enzyme site.

The vector comprising a DNA sequence of interest operably linked to a regulatory region (enhancer/promoter sequences) can be directly introduced into appropriate host cells for expression of the DNA sequence of interest without further cloning.

For expression of the DNA sequence of interest in mammalian host cells, a variety of regulatory regions can be used, for example, the SV40 early and late promoters, the cytomegalovirus (CMV) immediate early promoter, and the Rous sarcoma virus long terminal repeat (RSV-LTR) promoter. Inducible promoters
5 that may be useful in mammalian cells include but are not limited to those associated with the metallothionein II gene, mouse mammary tumor virus glucocorticoid responsive long terminal repeats (MMTV-LTR), β -interferon gene, and hsp70 gene [Williams et al., Cancer Res. 49 (1989) 2735-42; Taylor et al., Mol. Cell Biol., 10 (1990) 165-75]. It may be advantageous to use heat shock promoters or
10 stress promoters to drive expression of the DNA sequence of interest in recombinant host cells.

In addition, the expression vector may contain a selectable or screenable marker gene for initially isolating, identifying or tracking host cells that contain the vector. A number of selection systems may be used for mammalian cells, including
15 but not limited to the Herpes simplex virus thymidine kinase [Wigler et al., Cell 11 (1977) 223], hypoxanthine-guanine phosphoribosyltransferase [Szybalski and Szybalski, Proc. Natl. Acad. Sci. USA 48 (1962) 2026], and adenine phosphoribosyltransferase [Lowy et al., Cell 22 (1980) 817] genes can be employed in tk^- , $hgprt^-$ or $aprt^-$ cells, respectively. Also, antimetabolite resistance can be used as
20 the basis of selection for dihydrofolate reductase (dhfr), which confers resistance to methotrexate [Wigler et al., Natl. Acad. Sci. USA 77 (1980) 3567; O'Hare et al., Proc. Natl. Acad. Sci. USA 78 (1981) 1527]; gpt, which confers resistance to mycophenolic acid [Mulligan & Berg, Proc. Natl. Acad. Sci. USA 78 (1981) 2072]; neomycin phosphotransferase (neo), which confers resistance to the aminoglycoside G-418 [Colberre-Garapin et al., J. Mol. Biol. 150 (1981) 1]; and hygromycin
25 phosphotransferase (hyg), which confers resistance to hygromycin [Santerre et al., 1984, Gene 30 (1984) 147]. Other selectable markers, such as but not limited to histidinol and Zeocin® can also be used.

30 5.4.2 EXPRESSION SYSTEMS AND HOST CELLS

For use with the methods of the invention, the host cell and/or the host organism preferably does not express the Bovine Papilloma Virus E1 protein. Fur-

thermore, preferably the vector of the invention does not encode the Bovine Papilloma Virus E1 protein.

Preferred mammalian host cells include but are not limited to those derived from humans, monkeys and rodents, (see, for example, Kriegler M. in: "Gene
5 Transfer and Expression: A Laboratory Manual", New York, Freeman & Co. 1990), such as monkey kidney cell line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293, 293-EBNA, or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen. Virol., 36 (1977) 59; baby hamster kidney cells (BHK, ATCC CCL 10); chinese hamster ovary-cells-DHFR
10 [CHO, Urlaub and Chasin. Proc. Natl. Acad. Sci. 77 (1980) 4216]; mouse sertoli cells [Mather, Biol. Reprod. 23 (1980) 243-251]; mouse fibroblast cells (NIH-3T3), monkey kidney cells (CV1 ATCC CCL 70); african green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL
15 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); and mouse mammary tumor cells (MMT 060562, ATCC CCL51).

The vectors of the invention may be synthesized and assembled from known DNA sequences by well-known techniques in the art. The regulatory re-
20 gions and enhancer elements can be of a variety of origins, both natural and synthetic. Some host cells may be obtained commercially.

The vectors of the invention containing a DNA sequence of interest can be introduced into the host cell by a variety of techniques known in the art, including but not limited to, for prokaryotic cells, bacterial transformation (Hanahan, 1985,
25 in DNA Cloning, A Practical Approach, 1:109-136), and for eukaryotic cells, calcium phosphate mediated transfection [Wigler et al., Cell 11 (1977) 223-232], liposome-mediated transfection [Schaefer-Ridder et al., Science 215 (1982) 166-168], electroporation [Wolff et al., Proc Natl Acad Sci 84 (1987) 3344], and micro-injection [Cappucci, Cell 22 (1980) 479-4889].

30 In a specific embodiment, cell lines that express the DNA sequence of the invention may be engineered by using a vector that contains a selectable marker. By way of example but not limitation, following the introduction of the vector, en-

gineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the vector confers resistance to the selection and optimally allows only cells that contain the vector with the selectable marker to grow in culture.

5

5.4.3 VACCINE APPROACHES

In certain embodiments, a vector of the invention comprising an expression cassette of a DNA sequence of interest is administered to a subject to induce an immune response. Specifically, the DNA sequence of interest encodes a protein (for example, a peptide or polypeptide), which induces a specific immune response upon its expression. Examples of such proteins are discussed in section 5.3.

For the delivery of a vector of the invention for use as a vaccine, methods may be selected from among those known in the art and/or described in section

15 5.4.6.

5.4.4 GENE THERAPY APPROACHES

In a specific embodiment, a vector of the invention comprising an expression cassette comprising DNA sequences of interest is administered to treat, or prevent various diseases. The DNA sequence of interest may encode a protein and/or a biologically active RNA molecule. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible DNA sequence. In this embodiment of the invention, the DNA sequences produce their encoded protein or RNA molecule that mediates a therapeutic effect.

Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

For general reviews of the method of gene therapy, see, Goldspiel *et al.*, Clinical Pharmacy 12 (1993) 488-505; Wu and Wu, Biotherapy 3 (1991) 87-95; Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32 (1993) 573-596; Mulligan, Science 260 (1993) 926-932; Morgan and Anderson, Ann. Rev. Biochem. 62 (1993) 191-217; May, TIBTECH 1, 1(5) (1993) 155-215. Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel *et*

al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); and Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990).

The following animal regulatory regions, which exhibit tissue specificity and have been utilized in transgenic animals, can be used for expression of the DNA sequence of interest in a particular tissue type: elastase I gene control region which is active in pancreatic acinar cells [Swift et al., Cell 38 (1984) 639-646; Ornitz et al., Cold Spring Harbor Symp. Quant. Biol. 50 (1986) 399-409; MacDonald, Hepatology 7 (1987) 425-515]; insulin gene control region which is active in pancreatic beta cells [Hanahan, Nature 315 (1985) 115-122], immunoglobulin gene control region which is active in lymphoid cells [Grosschedl et al., Cell 38 (1984) 647-658; Adames et al., Nature 318 (1985) 533-538; Alexander et al., Mol. Cell. Biol. 7 (1987) 1436-1444], mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells [Leder et al., Cell 45 (1986) 485-495], albumin gene control region which is active in the liver [Pinkert et al., Genes and Devel. 1 (1987) 268-276], alpha-fetoprotein gene control region which is active in the liver [Krumlauf et al., Mol. Cell. Biol. 5 (1985) 1639-1648; Hammer et al., Science 235 (1987) 53-58; alpha 1-antitrypsin gene control region which is active in the liver [Kelsey et al., Genes and Devel. 1 (1987) 161-171], beta-globin gene control region which is active in myeloid cells [Mogam et al., Nature 315 (1985) 338-340; Kollias et al., Cell 46 (1986) 89-94]; myelin basic protein gene control region which is active in oligodendrocyte cells in the brain [Readhead et al., Cell 48 (1987) 703-712]; myosin light chain-2 gene control region which is active in skeletal muscle [Sani, Nature 314 (1985) 283-286], and gonadotropic releasing hormone gene control region which is active in the hypothalamus [Mason et al., Science 234 (1986) 1372-1378].

Methods of delivery for gene therapy approaches are well known in the art and/or described in section 5.4.6.

5.4.5 INHIBITORY ANTISENSE AND RIBOZYME

In certain embodiments of the invention a vector of the invention contains a DNA sequence of interest that encodes an antisense or ribozyme RNA mole-

cule. Techniques for the production and use of such molecules are well known to those of skill in the art.

Antisense RNA molecules act to directly block the translation of mRNA by hybridizing to targeted mRNA and preventing protein translation. Antisense approaches involve the design of oligonucleotides that are complementary to a target gene mRNA. The antisense oligonucleotides will bind to the complementary target gene mRNA transcripts and prevent translation. Absolute complementarity, although preferred, is not required.

A sequence "complementary" to a portion of an RNA, as referred to herein, means a sequence having sufficient complementarity to be able to hybridize with at least the non-polyA portion of an RNA, forming a stable duplex; in the case of double-stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA it may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

Antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides. In other embodiments of the invention, the antisense nucleic acids are at least 100, at least 250, at least 500, and at least 1000 nucleotides in length.

Regardless of the choice of target sequence, it is preferred that in vitro studies are first performed to quantitate the ability of the antisense oligonucleotide to inhibit gene expression. It is preferred that these studies utilize controls that distinguish between antisense gene inhibition and nonspecific biological effects of oligonucleotides. It is also preferred that these studies compare levels of the target RNA or protein with that of an internal control RNA or protein. Additionally, it is envisioned that results obtained using the antisense DNA sequence

are compared with those obtained using a control DNA sequence. It is preferred that the control DNA sequence is of approximately the same length as the test oligonucleotide and that the DNA sequence of the oligonucleotide differs from the antisense sequence no more than is necessary to prevent specific hybridization to the target sequence.

While antisense DNA sequences complementary to the target gene coding region sequence could be used, those complementary to the transcribed, untranslated region are most preferred.

For expression of the biologically active RNA, e.g., an antisense RNA molecule, from the vector of the invention the DNA sequence encoding the biologically active RNA molecule is operatively linked to a strong pol III or pol II promoter. The use of such a construct to transfect target cells in the patient will result in the transcription of sufficient amounts of single stranded RNAs that will form complementary base pairs with the endogenous target gene transcripts and thereby prevent translation of the target gene mRNA. For example, a vector of the invention can be introduced, e.g., such that it is taken up by a cell and directs the transcription of an antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Expression of the sequence encoding the antisense RNA can be by any promoter known in the art to act in mammalian, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include but are not limited to: the SV40 early promoter region [Bernoist and Chambon, Nature 290 (1981) 304-310], the promoter contained in the 3 long terminal repeat of Rous sarcoma virus [Yamamoto, et al., Cell 22 (1980) 787-797], the herpes thymidine kinase promoter [Wagner, et al., Proc. Natl. Acad. Sci. U.S.A. 78 (1981) 1441-1445], the regulatory sequences of the metallothionein gene [Brinster, et al., 1982, Nature 296 (1982) 39-42], etc.

In certain embodiments of the invention, a vector of the invention contains a DNA sequence, which encodes a ribozyme. Ribozyme molecules designed to catalytically cleave target gene mRNA transcripts can also be used to prevent translation of a target gene mRNA and, therefore, expression of a target gene product [see, e.g., PCT International Publication WO90/11364, published October 4, 1990; Sarver, et al., Science 247 (1990) 1222-1225].

Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. [For a review, see Rossi, Current Biology 4 (1994) 469-471]. The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by an endonucleolytic cleavage event. The composition of ribozyme molecules must include one or more sequences complementary to the target gene mRNA, and must include the well known catalytic sequence responsible for mRNA cleavage. For this sequence, see, e.g., U.S. Patent No. 5,093,246, which is incorporated herein by reference in its entirety.

While ribozymes that cleave mRNA at site-specific recognition sequences can be used to destroy target gene mRNAs, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5'-UG-3'. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Myers, 1995, Molecular Biology and Biotechnology: A Comprehensive Desk Reference, VCH Publishers, New York, (see especially Figure 4, page 833) and in Haseloff & Gerlach, Nature, 334 (1988) 585-591, which is incorporated herein by reference in its entirety.

Preferably the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the target gene mRNA, i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

The ribozymes of the present invention also include RNA endoribonucleases (hereinafter "Cech-type ribozymes") such as the one that occurs naturally in *Tetrahymena thermophila* (known as the IVS, or L-19 IVS RNA) and that has been extensively described by Thomas Cech and collaborators [Zaug, et al., Science, 224 (1984) 574-578; Zaug and Cech, Science, 231 (1986) 470-475; Zaug, et al., Nature, 324 (1986) 429-433; published International patent application No. WO 88/04300 by University Patents Inc.; Been & Cech, Cell, 47 (1986) 207-216].

The Cech-type ribozymes have an eight base pair active site, which hybridizes to a target RNA sequence whereafter cleavage of the target RNA takes place. The

invention encompasses those Cech-type ribozymes, which target eight base-pair active site sequences that are present in the target gene.

Expression of a ribozyme can be under the control of a strong constitutive pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous target gene messages and inhibit translation. Because ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

In instances wherein the antisense and/or ribozyme molecules described herein are utilized to inhibit mutant gene expression, it is possible that the technique may so efficiently reduce or inhibit the translation of mRNA produced by normal target gene alleles that the possibility may arise wherein the concentration of normal target gene product present may be lower than is necessary for a normal phenotype. In such cases, to ensure that substantially normal levels of target gene activity are maintained, therefore, nucleic acid molecules that encode and express target gene polypeptides exhibiting normal target gene activity may be introduced into cells via gene therapy methods such as those described, below, in Section 5.4.4 that do not contain sequences susceptible to whatever antisense, ribozyme, or triple helix treatments are being utilized. Alternatively, in instances whereby the target gene encodes an extracellular protein, it may be preferable to co-administer normal target gene protein in order to maintain the requisite level of target gene activity.

Methods of administering the ribozyme and antisense RNA molecules are well known in the art and/or described in section 5.4.6.

5.4.6 PHARMACEUTICAL FORMULATIONS AND MODES OF ADMINISTRATION

In a preferred aspect, a pharmaceutical of the invention comprises a substantially purified vector of the invention (*e.g.*, substantially free from substances that limit its effect or produce undesired side-effects). The subject to whom the pharmaceutical is administered in the methods of the invention is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, *etc.*, and is preferably a mammal, and most preferably a human.

In certain embodiments, the vector of the invention is directly administered *in vivo*, where the DNA sequence of interest is expressed to produce the encoded product. This can be accomplished by any of numerous methods known in the art. The vectors of the invention can be administered so that the nucleic acid sequences become intracellular. The vectors of the invention can be administered by direct injection of naked DNA; use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont); coating with lipids or cell-surface receptors or transfecting agents; encapsulation in microparticles or microcapsules; administration in linkage to a peptide which is known to enter the nucleus; administration in linkage to a ligand subject to receptor-mediated endocytosis [see, e.g., Wu and Wu, J. Biol. Chem. 262 (1987) 4429-4432] (which can be used to target cell types specifically expressing the receptors); etc. In a specific embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome [see Langer, Science 249 (1990) 1527-1533; Treat *et al.*, 1989, in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353- 365; Lopez-Berestein, *ibid.*, pp. 317-327].

In certain embodiments, the vector of the invention is coated with lipids or cell-surface receptors or transfecting agents, or linked to a homeobox-like peptide which is known to enter the nucleus [see e.g., Joliot *et al.*, Proc. Natl. Acad. Sci. USA 88 (1991) 1864-1868], etc.

In certain other embodiments, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation.

In yet other embodiments, the vector of the invention can be targeted *in vivo* for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06 180; WO 92/22635; W092/20316; W093/14188, and WO 93/20221).

Methods for use with the invention include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. Methods for use with the invention further include administration by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal

and intestinal mucosa, etc.). In a specific embodiment, it may be desirable to administer a vector of the invention by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including a membrane, such as a sialastic membrane, or a fiber. Care must be taken to use materials to which the vector does not absorb. Administration can be systemic or local.

In certain embodiments, a vector of the invention is administered together with other biologically active agents such as chemotherapeutic agents or agents that augment the immune system.

In yet another embodiment, methods for use with the invention include delivery via a controlled release system. In one embodiment, a pump may be used [see Langer, *supra*; Sefton, CRC Crit. Ref. Biomed. Eng. 14 (1989) 201; Buchwald *et al.*, Surgery 88 (1980) 507; Saudek *et al.*, N. Engl. J. Med. 321 (1989) 574]. In another embodiment, polymeric materials can be used [see Medical Applications of Controlled Release, 1974, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida; Controlled Drug Bioavailability, Drug Product Design and Performance, 1984, Smolen and Ball (eds.), Wiley, New York; Ranger and Peppas, Macromol. Sci. Rev. Macromol. Chem. 23 (1983) 61; see also Levy *et al.*, Science 228 (1985) 190; During *et al.*, Ann. Neurol. 25 (1989) 351; Howard *et al.*, J. Neurosurg. 71 (1989) 105].

Other controlled release systems are discussed in the review by Langer, Science 249 (1990) 1527-1533.

Pharmaceutical compositions of the invention comprise a therapeutically effective amount of a vector of the invention, and a suitable pharmaceutical vehicle. In a specific embodiment, the term "suitable pharmaceutical vehicle" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "vehicle" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such suitable pharmaceutical vehicles can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier

when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, *etc.* Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the nucleic acid or protein of the invention, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

In a specific embodiment, the pharmaceutical of the invention is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the pharmaceutical of the invention may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the pharmaceutical of the invention is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the pharmaceutical of the invention is administered by injection, an ampoule of sterile water

for injection or saline can be provided so that the ingredients may be mixed prior to administration.

For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

5 For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol
10 the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The amount of a vector of the invention, which will be effective in the treatment or prevention of the indicated disease, can be determined by standard clinical techniques. In addition, *in vitro* assays may optionally be employed to help
15 identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the stage of indicated disease, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from
20 dose-response curves derived from *in vitro* or animal model test systems.

The present invention may be better understood by reference to the following non-limiting Examples, which are provided as exemplary of the invention. The following examples are presented in order to more fully illustrate the preferred
25 embodiments of the invention. They should in no way be construed, however, as limiting the broad scope of the invention.

6. EXAMPLES

6.1.EXAMPLE 1

30 Cloning and analysis of the expression properties of the vectors super6 and super6wt

The vector plasmids super6 (Figure 1) and super6wt were prepared from previous generation based gene vaccination vectors VI (Figure 2) and VIwt, respectively. Vectors VI and VIwt are principally synthetic bacterial plasmids that contain a transposon Tn903 derived kanamycin resistance marker gene [Oka, A., et al., J Mol Biol 147 (1981) 217-226] and a modified form of pMB1 replicon [Yanisch-Perron, C., et al., Gene 33 (1985) 103-119] needed for the propagation in *Escherichia coli* cells. Vectors VI and VIwt also contain a Cytomegalovirus Immediately Early Promoter combined with a HSV1 TK leader sequence and rabbit β -globin gene sequences, which both are derived from plasmid pCG [Tanaka, M., et al., 60 (1990) Cell 375-386]. The latter elements are needed for expressing from the nef coding sequence derived from a HAN2 isolate of the HIV-1 strain [Sauermann, U., et al., AIDS Research. Hum. Retrov. 6 (1990) 813-823]. The expression vectors for the Nef carry clustered ten high affinity E2 binding sites (derived from plasmid pUC1910BS, unpublished) just upstream of the CMV promoter.

The parent vector VI contains a modified E2 coding sequence: the hinge region of E2 (amino acids 192-311) is replaced with four glycine-alanine repeats from EBNA1 protein of Epstein-Barr Virus [Baer, R. J., et al., Nature 310 (1984) 207-211]. The protein encoded by this sequence was named as E2d192-311+4G.

The parent vector VIwt contains an expression cassette for wild type E2 protein of the bovine papilloma virus type 1 with point mutations introduced for the elimination E3 and E4 open reading frame (ORF) coding capacity by two stop codons into both these ORFs. In the vectors the E2 coding sequences are cloned between a Rous sarcoma virus proviral 5' LTR [Long, E. O., et al., Hum. Immunol. 31 (1991) 229-235] and bovine growth hormone polyadenylation region [Chesnut, J. D., et al., J Immunol Methods 193 (1996) 17-27].

Plasmid vectors super6 and super6wt were constructed by deleting from the respective parent vectors VI and VIwt all beta-globin sequences downstream of the nef gene except the second intron of the rabbit beta-globin gene. The beta-globin sequences (especially the fragment of the exon) show some homology with sequences in the human beta-globin gene, whereas the intron lacks any significant homology to human genomic sequences. The intron was amplified by

PCR from the plasmid pCG [Tanaka, M. et al., Cell 60 (1990) 375-386] using oligonucleotides with some mismatches for modifying the sequences of splicing donor and acceptor sites of the intron to the perfect match to consensus motifs. The Herpes Simplex Virus type 1 thymidine kinase gene polyadenylation region from pHook [Chesnut, J. D., et al., J Immunol Methods 193 (1996) 17-27] was then
5 cloned just next to the 3'-end of the intron, because in parent plasmids the rabbit β -globin polyadenylation signal were used.

The expression properties of the Nef and E2 proteins expressed by the plasmid vectors super6 and super6wt were analyzed and compared with the expression properties of the Nef and E2 proteins expressed by VI and VIwt by Western blotting [Towbin et al., Proc Natl Acad Sci USA 76 (1979) 4350-4354] with
10 monoclonal antibodies against Nef and E2. First, Jurkat cells (a human T-cell lymphoblast cell line) were transfected by electroporation [Ustav et al. EMBO J 2 (1991) 449-457] with 1 μ g of super6, super6WT or equimolar amounts of the plasmids VI, VIwt. As a control an equimolar amount of vector II (Figure 3), which contains an identical Nef cassette but no E2 coding sequence, was used. Carrier
15 DNA was used as a negative control. Briefly, the plasmid and carrier DNA were mixed with the cell suspension in a 0.4 cm electroporation cuvette (BioRad Laboratories, Hercules, USA) followed an electric pulse (200V; 1mF) using Gene Pulser IITM with capacitance extender (BioRad Laboratories, Hercules, USA).
20

Forty-nine hours post-transfection the cells were lysed by treating with a sample buffer containing 50mM Tris-HCl pH 6.8; 2% SDS, 0.1% bromophenol blue, 100mM dithiothreitol, and 10% (v/v) glycerol. The lysates were run on a 10% or 12.5% SDS-polyacrylamide gel and subsequently transferred onto a 0.45
25 μ m PVDF nitrocellulose membrane (Millipore). The membrane was first blocked overnight with a blocking solution containing 5% dry milk (fat-free), 0.1% Tween 20 in 50 mM Tris-HCl pH 7.5; 150mM NaCl and thereafter incubated for 1h with diluted monoclonal anti-Nef antisera (1:100) or anti-E2-antisera (1:1000) in the blocking solution. After each incubation step, unbound proteins were removed by
30 washing strips three times with TBS - 0.1 % Tween-20. The binding of primary immunoglobulins was detected by incubating the strips with horse raddish peroxidase conjugate anti-mouse IgG (Labas, Estonia) followed by visualization using a

chemoluminescence detection system (Amersham Pharmacia Biotech, United Kingdom).

The results are shown in Figure 4. The expression of the Nef protein is shown on panel A and the expression of E2 protein on panel B. The arrows indicate the right molecular sizes of the Nef and E2 proteins. The expression level of the E2d192-311+4GA is very low and for this reason cannot be seen on the blot presented in Figure 4.

The amounts of Nef expressed from the plasmids super6, super6wt, VI and VIwt (lanes 1-4 in Figure 4A) are quite similar (Figure 4, panel A, lanes 1 to 4). Much less protein is produced from plasmid II (lane 5). The expression levels of the Nef protein are higher from vectors containing wtE2 (cf. lane 1 compared with lane 2 and lane 3 compared with lane 4). This is in accordance with the expression levels of E2 and E2d192-311+4GA proteins from these plasmids (Figure 4, panel B).

6.2. EXAMPLE 2

Cloning and analysis of the expression properties of plasmids in series product1 and NNV

To increase the copy number of the vectors super 6 and super6wt in *Escherichia coli* further modifications were made in these vectors. The Tn903 kanamycin resistance gene, pMB1 replicon and ten E2 binding sites were removed by HindIII/NheI digestion followed by replacing with the Hind III/NheI fragment from retroviral vector pBabe Neo [Morgenstern, J.P. and Land, H., Nucleic Acids Research 18 (1990) 3587 - 3596]. This fragment contains a modified pMB1 replicon and the Tn5 kanamycin resistance gene that allow relaxed high copy-number replication of the plasmids in bacteria. The new plasmids were named as the product1 (Figure 5), and product1wt respectively. An unsuccessful attempt to reinsert the ten E2 binding sites back into the blunted NheI site upstream of the CMV promoter of the product1 resulted in vector New Vector NNV, respectively, with only two binding sites integrated in the plasmid.

Additional ten E2 binding sites were inserted from plasmid pUC1910BS into the New Vector in just downstream the E2 expression cassette. These new

vectors were named NNV-1 and NNV-2 (Figure 6A). For replacing the E2d192-311+4GA with wt E2 (with deleted E3 and E4 ORFs), the E2d192-311+4GA coding sequence containing Bsp120I fragment was replaced with wtE2 containing an analogous Bsp120I fragment from the super6wt. Generated plasmids were
5 named NNV-1wt and NNV-2wt (Figure 6B), respectively. The numbers 1 or 2 in vectors of the NNV series mark the orientation of the 10 E2 binding sites region relative to the E2 expression cassette.

The expression properties of the Nef protein from the NNV plasmids, i.e. NNV-1, NNV-2, NNVwt and NNV-2wt, after the transfection of Jurkat cells by
10 electroporation at a concentration of 1 μ g of the plasmid were analyzed and compared with the expression properties of the Nef proteins from super6 and super6wt by Western blotting essentially as described in Example 1. The amounts of super6 and super6wt used for the transfection were 0,95 and 1 μ g, respectively. The results are shown in Figure 7.

15 NNV-1 and NNV-2 vectors have expression potential similar to plasmid super6 as evident from the comparison of lanes 1 and 2 on figure 8 with lane 5. The same applies to vectors NNV-1wt, NNV-2wt and super6wt (compare lanes 3 and 4 with lane 6 on figure 7). In accordance with the previous results the plasmids expressing wt E2 produce more Nef protein than E2d192-311+4GA vectors
20 do (compare lane 1 with lane 3 and lane 2 with lane 4 in figure 7). In view of this and since the Nef expression from NNV-2wt was slightly higher than that from NNV-1wt, vector NNV-2wt was selected for further tests.

6.3 EXAMPLE 3

25 Analysis of the expression properties of NNV-2wt

To analyse the expression properties of NNV-2wt, four different cell lines, i.e. the Jurkat (human T-cell lymphoblasts), P815 (mouse mastocytoma cells), CHO (Chinese Hamster Ovary cells) lines and RD (human embryo rhabdomyo-
30 sarcoma cells), were transfected by electroporation and analyzed for their expression of Nef of and E2. To reveal the transcription activation and maintenance properties mediated by E2 protein and E2 oligomerized binding sites product1wt, which lacks the E2 binding sites (Figure 5), was used as a control. An additional

control plasmid was plasmid NNV-2wtFS, which differs from NNV-2wt by containing a frameshift introduced into E2 coding sequence, whereby it does not express functional E2 protein.

Each cell line was transfected with different amounts of the vector DNA by electroporation essentially as described in Example 1. Time-points were taken approximately two and five days after transfection. The results of analyses are presented in figures 8 to 10.

The Jurkat cells were transfected with 0.5 µg or 2 µg of the NNV-2wt (lanes 1,2, 8, and 9 in Figure 8) and equal amounts of the plasmids NNV-2wtFS (lanes 3, 4, 10, and 11 in Figure 8) and product1wt (lanes 5, 6, 12, and 13 in Figure 8) or carrier only (lanes 7 and 14 in Figure 8). Time-points were taken 44 hours (lanes 1-7) and 114 hours (lanes 8-14) after transfection: The expression of the Nef and E2 proteins was analyzed by Western blotting essentially as described in Example 1.

The P815 cells were transfected with 0.5 µg or 2 µg of the NNV-2wt (lanes 1,2, 8, and 9 in Figure 9) and equal amounts of the plasmids NNV-2wtFS (lanes 3, 4, 10, and 11 in Figure 9) and product1wt (lanes 5, 6, 12, and 13 in Figure 9) or carrier only (lanes 7 and 14 in Figure 9). Time-points were taken 45 hours (lanes 1-7) and 119 hours (lanes 8-14) after transfection: The expression of the Nef proteins was analyzed by Western blotting essentially as described in Example 1. The blot with anti-E2 antibodies 119h post-transfection is not shown, because no special signal could be detected. Generally, the expression level of the Nef protein correlated with the expression level of E2 protein in these cells, which confirms the fact that the function of the E2 protein is to activate the transcription and to help the plasmid to be maintained for a longer time in the proliferating cells.

The CHO cells were transfected with 0.5 µg or 2 µg of the NNV-2wt (lanes 1,2, 8, and 9 in Figure 10) and equal amounts of the plasmids NNV-2wtFS (lanes 3, 4, 10, and 11 in Figure 10) and product1wt (lanes 5, 6, 12, and 13 in Figure 10) or carrier only (lanes 7 and 14 in Figure 10). Time-points were taken 48 hours (lanes 1-7) and 114 hours (lanes 8-14) after transfection. The expression of the Nef and E2 proteins was analyzed by Western blotting essentially as described in Example 1.

The RD cells were transfected with 0.5 μ g or 2 μ g of the NNV-2wt (lanes 1,2, 8, and 9 in Figure 11) and equal amounts of the plasmids NNV-2wtFS (lanes 3, 4, 10, and 11 in Figure 11) and product1wt (lanes 5, 6, 12, and 13 in Figure 11) or carrier only (lanes 7 and 14 in Figure 11). Time-points were taken 39 hours (lanes 1-7) and 110 hours (lanes 8-14) after transfection. The expression of the Nef protein was analyzed by Western blotting essentially as described in Example 1.

In all four cell lines the expression level of the Nef protein, taken at earlier time points (lanes 1-7 in figures 8 - 11) and at later time points (lanes 8-14 in Figures 8-11) hours, from the NNV-2wt was higher than from control vectors. The superiority of the NNV-2wt was more obvious at later time-points as evident from the comparison of lane 8 with lanes 10 and 12 in Figure 8, and also from the comparison of lane 9 with lanes 11 and 13 in figures 8, 9 and 10.

The expression pattern of RNA from these plasmids was also analyzed using the Northern analysis [Alwine, J. C, et al., Proc Natl Acad Sci U S A 74 (1977) 5350-5354] for the NNV-2wt vector. For this purpose, Jurkat and CHO cells were transfected with 2 μ g of the NNV-2wt. For the transfection of P815 cells 10 μ g of NNV-2wt were used. The transfections were made essentially as described in Example 1. Forty-eight hours post-transfection total RNA was extracted using RNAeasy kit (Qiagen) and samples containing 21 μ g (P815), 15 μ g (CHO) or 10 μ g (Jurkat) of the RNA were analysed by electrophoresis under the denaturing conditions (1.3% agarose gel containing 20mM MOPS pH 7.0; 2mM NaOAc; 1mM EDTA pH 8.0; 2.2M formaldehyde). The running buffer contained the same components except formaldehyde. The samples were loaded in a buffer containing formamide and formaldehyde. After the electrophoresis the separated RNAs were blotted onto the HybondN+ membrane (Amersham Pharmacia Biotech, United Kingdom) and hybridization with a radio-labeled nef coding sequence, E2 coding sequence or whole vector probes was carried out. The RNA from cells transfected with the carrier was used as a control. The results of the Northern blot analyses are shown in figure 12.

The results indicate that no other RNA species than complementary mRNAs for E2 and nef are expressed from the vector, since no additional signals

can be detected with the whole vector probe compared with nef and E2 specific hybridizations (compare lanes 1-12 with lanes 13-18 in Figure 12).

6.4 EXAMPLE 4

5 **Analysis of the attachment of the NNV-2wt to mitotic chromosomes**

The attachment of the NNV-2wt to mitotic chromosomes in CHO cells was analyzed by fluorescence in situ hybridisation (FISH) [Tucker J.D., et al., In: J.E.Celis (ed.), Cell Biology: A Laboratory Handbook, vol 2, p. 450-458. Academic Press, Inc. New York, NY. 1994.].

10 Thirty-six hours post-transfection the CHO cells by electroporation with 1 µg of NNV-2wt or with equimolar amounts of the control plasmids NNV-2wtFS and product1wt (performed essentially as described in Example 1) the cultures were treated with colchicin (Gibco) for arresting the cells in metaphase of the mitosis. Briefly, cells were exposed to colchicine added to medium at final concentration of 0.1 µg/ml for 1-4 h to block the cell cycle at mitosis. Blocked cells were
15 harvested by a trypsin treatment and suspended in a 0.075M KCl solution, incubated at room temperature for 15 min, and fixed in ice-cold methanol-glacial acetic acid (3:1, vol/vol). The spread-out chromosomes at metaphase and nuclei at interphase for fluorescence in situ hybridization analyses were prepared by dropping the cell suspension on wet slides. Several slides from one culture were prepared.

Hybridization probes were generated by nick-translation, using biotin-16-dUTP as a label and plasmid Product1wt as template. A typical nick-translation reaction mixture contained a nick-translation buffer, unlabeled dNTPs, biotin-16-dUTP, and E.coli DNA polymerase.
25

Chromosome preparations were denatured at 70°C in 70% formamide (pH 7.0-7.3) for 5 min, then immediately dehydrated in a series of washes (70%, 80%, and 96% ice-cold ethanol washes for 3 min each), and air-dried. The hybridization mixture (18 µl per slide) was composed of 50% formamide in 2xSSC (1xSSC is 0.15 M NaCl plus 0.015 M sodium citrate), 10% dextran sulfate, 150 ng of biotinylated plasmid probe DNA and 10 µg of herring sperm carrier DNA. After 5
30 min of denaturation at 70°C, probe DNA was applied to each slide, sealed under

a coverslip, and hybridized for overnight at 37°C in a moist chamber. The slides were washed with three changes of 2xSSC, and 2xSSC containing 0.1% IGEPAL CA-630 (Sigma Chemical Co.) at 45°C. Prior to the immunofluorescence detection, slides were preincubated for 5 min in PNM a buffer [PN buffer (25.2 g Na₂HPO₄·7 H₂O, 0.83 g NaH₂PO₄·H₂O and 0.6 ml of IGEPAL CA-630 in 1 liter of H₂O) with 5% nonfat dried milk and 0.02% sodium azide).

Subsequently, the probe was detected with fluorescein isothiocyanate (FITC)-conjugated extravidin. The signal was amplified with biotinylated antiavidin antibody and a second round of extravidin-FITC treatment. Between each of the steps, the slides were washed in PN buffer containing 0.05% IGEPAL CA-630 at room temperature for 2x5 min. Chromosomes were counterstained with propidium iodide and mounted in p-phenylenediamine antifade mounting medium.

Slides were analyzed with a Olympus VANOX-S fluorescence microscope equipped with appropriate filter set.

The results are shown in Table 1.

TABLE 1. Chromosomal attachment of the NNV-2wt.

Culture	Meta-phases with episomal signal on chromosomes	Analyzed metaphases	%
0.5µg NNV-2wt	11	158	7
0.5µg NNV-2wtFS	0	100	0
0.48µg product1wt	0	100	0
carrier	0	100	0

The data indicate clearly that the E2 protein and its binding sites are needed for the chromosomal attachment because only the NNV-2wt but not two other vectors have this ability.

6.5 EXAMPLE 5

Stability of NNV-2wt during propagation in bacterial cells

The stability of NNV-2wt during propagation in bacterial cells was tested. The plasmid NNV-2wt was mixed with competent *Escherichia coli* cells of the DH5alpha strain [prepared as described in Inoue, H., et al., *Gene* 96 (1990) 23-28] and incubated on ice for 30 minutes. Subsequently, the cell suspension was subjected to a heat-shock for 3 minutes at 37°C followed by a rapid cooling on ice. One milliliter of LB medium was added to the sample and the mixture was incubated for 45 minutes at 37°C with vigorous shaking. Finally, a portion of the cells was plated onto dishes containing LB medium with 50 µg/ml of kanamycin. On the next day, the cells from a single colony were transferred onto the new dishes containing the same medium. This procedure was repeated until four generations of bacteria had been grown, and the plasmid DNA from the colonies of each generation was analyzed.

One colony from each generation was used for an inoculation of 2 ml LB medium containing 50 µg/ml of kanamycin followed by an overnight incubation at 37°C with vigorous shaking. The cells were harvested and the plasmid DNA was extracted from the cell using classical lysis by boiling. [Sambrook, S., et al., *Molecular Cloning A Laboratory Manual*. Second ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York]. The samples were digested with restriction endonuclease XbaI (Fermentas, Lithuania) and analyzed by agarose gel electrophoresis in comparison with the original DNA used for transformation. The results are shown in Figure 13.

As can be seen in Figure 13, the vector is stable during the passage in *Escherichia coli* cells: no colonies with re-arrangements were observed when compared with the DNA used for transformation (lane 9).

6.6 EXAMPLE 6

Stability of NNV-2wt in eukaryotic cells

The stability of the plasmid NNV-2wt as a non-replicating episomal element was also analyzed in eukaryotic cells. For this purpose the CHO and Jurkat cells were transfected with 2 µg of NNV-2wt. Total DNAs of the cells were extracted at 24, 72 or 96 hours post-transfection. Briefly, the cells were lysed in 20mM Tris-HCl pH 8.0; 10mM EDTA pH 8.0; 100mM NaCl; 0.2% SDS; in presence of 200 µg/ml of proteinase K (Fermentas, Lithuania). Next, the samples were extracted sequentially with phenol and with chloroform and precipitated with ethanol. The nucleic acids were resuspended in 10mM Tris-HCl pH 8.0; 1mM EDTA pH 8.0; 20 µg/ml of RNase A (Fermentas, Lithuania) and incubated for 1 hour at 37°C. Finally the DNA was re-precipitated with ammonium acetate and ethanol, washed with 70% ethanol and resuspended in 10mM Tris-HCl pH 8.0; 1mM EDTA pH 8.0. The samples were digested with different restriction endonucleases: with Eco81I (Fermentas, Lithuania) that has two recognition sites on the plasmid, with HindIII (Fermentas, Lithuania) that does not cut the NNV-2wt DNA and with DpnI (New England Biolabs, USA) that digest only DNA synthesized in Escherichia coli cells. Restricted DNAs were separated on TAE agarose electrophoresis and analyzed by Southern blotting [Southern, E.M. J. Mol. Biol. 98 (1975) 503-517] with a vector specific radiolabeled probe. The results are illustrated on figure 14. As obvious from comparison of the fragment sizes of Eco81I digestion (lanes 1, 2 and 7 in figure 14) with respective marker lanes no arrangements of the vector were detected in the assay. Neither were signals observed at a position different from the marker lanes in cases of the Hind III (lanes 3, 4 and 8 in figure 14) or HindIII/DpnI (lanes 5, 6 and 9 in figure 14) digestion indicating that integration and/or replication events were not observed.

6.7 EXAMPLE 7

Analysis of replication of the NNV-2wt in the presence of human papillomaviral replication factors

It has been demonstrated previously that papillomaviral proteins are able to initiate the replication of heterologous ori-containing plasmids from many other

human and animal papillomaviruses [Chiang, C. M., et al., Proc Natl Acad Sci U S A 89 (1992) 5799-5803]. Although NNV-2wt does not contain an intact viral origin of replication, it was tested how the replication is initiated in the presence of human papillomavirus type 1 E1 and E2 proteins. CHO cells were transfected with one microgram of either plasmids NNV-2wt, NNV-2wtFS or product 1 alone or with 4.5 µg of the HPV-11 E1 expression vector pMT/E1 HPV11 or with same amount of pMT/E1 HPV11 and 4.5 µg HPV-11 E2 protein expression vector pMT/E2 HPV 11 as indicated on the top of the figure 15. Transfections were done essentially as described in Example 1. E1 and E2 expression vectors are described previously (Chiang, C. M. et al., supra). An equimolar amount of HPV-11 replication origin containing plasmid HPV11ORI was transfected with the same expression vectors as a positive control.

Low-molecular weight DNA was extracted by modified Hirt lysis [Ustav, et al., EMBO J 2 (1991) 449-457] at 67 hours post-transfection. Briefly, the cells washed with PBS were lysed on ice at 5 minutes by adding alkaline lysis solutions I (50mM glucose; 25mM Tris-HCl, pH 8.0; 10mM EDTA, pH 8.0) and II (0.2M NaOH; 1% SDS) in a ratio of 1:2 onto the dishes. The lysates were neutralized by 0.5 vol solution III (a mixture of potassium acetate and acetic acid, 3M with respect to potassium and 5M with respect to acetate). After centrifugation the supernatant was precipitated with isopropanol, resuspended and incubated at 55°C in 20mM Tris-HCl pH 8.0; 10mM EDTA pH 8.0; 100mM NaCl; 0.2% SDS; in presence of 200 µg/ml of proteinase K (Fermentas, Lithuania). Next, the samples were extracted sequentially with phenol and with chloroform followed by precipitation with ethanol. The nucleic acids were resuspended in 10mM Tris-HCl pH 8.0; 1mM EDTA pH 8.0; 20 µg/ml RNase A (Fermentas, Lithuania) and incubated for 30 min at 65°C. The samples were digested with linearizing endonuclease (NdeI; Fermentas, Lithuania) in case of the vectors or HindIII (Fermentas, Lithuania) in case of the HPV11ORI) and DpnI (New England Biolabs, USA) (breaks non-replicated DNA), followed by Southern blotting performed essentially as described earlier using a vector specific radiolabeled probe. For positive control of hybridization appropriate markers of the linearized vectors and HPV11ORI were used (la-

(lanes marked as M on figure 15). As seen from the results set forth in figure 15, no replication signal was detected in case of any vector plasmids.

6.8 EXAMPLE 8

5 **Analysis of the E2 and its binding sites dependent segregation function of the vectors in dividing cells**

As has been described previously, bovine papillomavirus type 1 E2 protein in trans and its multiple binding sites in cis are both necessary and sufficient for the chromatin attachment of the episomal genetic elements. The phenomenon is suggested to provide a mechanism for partitioning viral genome during viral infection in the dividing cells [Ilves, I., et al., J Virol. 73 (1999) 4404-4412]. Because both functional elements are also included into our vector system, the aim of this study was analyze the importance of the E2 protein and oligomerized binding sites for maintenance of the transcriptionally active vector element in population of dividing cells.

For this purpose the Nef coding sequence of the vectors NNV-2wt and super6wt was replaced with coding sequence of the destabilized form of green fluorescent protein (d1EGFP) derived from vector pd1EGFP-N1 (Clontech Laboratories). Because the half-life of this protein is as short as 1 hour, it does not accumulate in the cells and the d1EGFP expression detected by flow cytometer correlates with the presence of transcriptionally active vector in these cells.

From NNV-2wt the nef coding sequence was removed and SmaI-NotI fragment from the pd1EGFP-N1 was inserted instead of it. New vector was named as 2wt d1EGFP (Figure 16). Similar replacement was made in case of super6wt for generation gf10bse2 (Figure 17), respectively. The recognition sequence for restrictional endonuclease SpeI was introduced into the EcoRI site in the super6wt just upstream the ten E2BS. The vector gf10bse2 is derived from this plasmid by replacing the Nef coding sequence containing NdeI-Bst1107I fragment with d1EGFP coding sequence containing fragment from 2wt d1EGFP, cut out with same enzymes.

Negative control plasmids lacking either functional E2 coding sequence or its binding sites were also made: The frameshift was introduced into the E2 cod-

ing sequence in context of the 2wtd1EGFP by replacing E2 coding sequence containing Bsp120I-Bsp120I with similar fragment from plasmid NNV-2wtFS. The resulting vector was named as 2wtd1EGFPFS (Figure 18). For the construction the control plasmid NNVd1EGFP (Figure 19) the whole E2 expression cartridge (as well bacterial replicon) from the 2wtd1EGFP was removed by Bst1107 and NheI digestion. The replicon was reconstituted from plasmid product1 as HindIII (filled in)-NheI fragment.

Jurkat cells were transfected by electroporation with 1µg of the vector 2wtd1EGFP or with equimolar amounts of the plasmids 2wtd1EGFPFS, NNVd1EGFP, gf10bse2 or with carrier DNA only as described in Example 1. At different time-points post-transfection the equal aliquots of the cell suspension were collected for analysis and the samples were diluted thereafter with the fresh medium. At every time-point total number of the cells as well the number of the d1EGFP expressing cells were counted by flow cytometer (Becton-Dickinson FACSCalibur System). With these data, the percentages of d1EGFP expressing cells, alterations of total numbers of cells and numbers of d1EGFP expressing cells in samples were calculated using the carrier-only transfected cells as a negative control for background fluorescence. The calculations of cell numbers were done in consideration of the dilutions made. Finally, the error values were calculated based on technical data of the cytometer about fluctuations of speed of the flow.

Two independent experiments were done. First, the maintenance of d1EGFP expressed from the plasmids 2wtd1EGFP, 2wtd1EGFPFS and NNVd1EGFP were analyzed during the eight days post-transfection. In the second experiment the maintenance of d1EGFP expressed from the plasmids 2wtd1EGFP, 2wtd1EGFPFS and gf10bse2 were analyzed during the thirteen days post-transfection.

As is obvious from Figures 20 and 21, there was no difference of the growth speed of the cells transfected with any vector or carrier only. It means that differences in the d1EGFP expression maintenance are not caused by influences of transfected vectors themselves on the dividing of the cells. Also, during the assay the logarithmic growth of the cells were detected, except the period un-

til second time-point in the experiment represented in Figure 20. This lag period of the growth is probably caused by the electroporation shock of the cells, because the first time-point was taken already 19 hours after the transfection.

As illustrated in Figures 22 and 23, the percentages of green fluorescent protein expressing cells decrease in all populations transfected with either plasmid, because the vectors do not replicate in the cells. However, as is seen on the charts, the fraction of positive cells declines more rapidly in cases of control vectors, if compared with the 2wtd1EGFP or gf10bse2. If compared with each other, the gf10bse2 have clear benefit to 2wtd1EGFP (Figure 23.). There is also a notable difference of maintenance between control plasmids 2wtFSd1EGFP and NNvd1EGFP (Figure 22).

These differences between the vectors become much more obvious, if the data are represented as alterations of the numbers of the d1EGFP expressing cells in the populations (Figures 24 and 25). The numbers of the positive cells in cases of the control plasmids are not notable changed during the assay. In contrast, in case of the 2wtd1EGFP the number of d1EGFP expressing cells increases during the first week after the transfection becoming approximately five to ten times higher than in control samples (Figure 24). After this time-point the number start to decrease (Figure 25). The difference of maintenance is strongest in the case of the gf10bse2 vector. The number of positive cells increases continuously during the analyses period. After two weeks it is 6 times higher than in the sample transfected with 2wtd1EGFP and 45 times higher than in the population transfected with frameshift mutant (Figure 25).

The data demonstrate clearly that the vector system of the present invention has active mechanism of segregation based on a nuclear-anchoring protein, i.e. bovine papillomavirus type 1 E2 protein and its binding sites that promotes its maintenance in a population of proliferating cells as a transcriptionally active element.

6.9 EXAMPLE 9:

CLONING OF THE AIRE GENE INTO SUPER6WT AND EXPRESSION IN AN EPITHELIAL CELL LINE

The AIRE gene coding for the AIRE protein (AIRE = autoimmune regulator) is mutated in an autosomally hereditary syndrome APECED (Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy). AIRE is expressed in rare epithelial cells in the medulla of thymus and in the dendritic cells in peripheral blood and in peripheral lymphoid organs. APECED could thus be treated by transferring the non-mutated AIRE gene ex vivo to peripheral blood dendritic cells, followed by the introduction of the corrected dendritic cells back to the patient. To test this possibility human AIRE gene and the homologous murine AIRE gene were transferred to COS-1 cells.

For cloning of the AIRE gene into Super6wt a maxi-preparation of the vector was prepared. First a transfection with Super6wt was done to TOP10 -cells (chemically competent *Escherichia coli* by Invitrogen) according to manufacturer's protocol. Briefly, the cells were incubated on ice for 30 minutes, after which a heat shock was performed in a water bath at +42°C for 30 seconds. The cells were then transferred directly on ice for 2 minutes and grown in 250 µl of SOC-medium (2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl₂, 10 mM MgSO₄, 20 mM glucose) at +37°C with shaking for 1 hour.

Plating was done on LB-plates using kanamycin (50 µg/ml) for selection. For maxiprep, colonies were transferred to 150 ml of LB-solution containing kanamycin (50 µg/ml) and grown overnight at +37°C with shaking. Preparation of maxiprep was done using Qiagen's Plasmid Maxi Kit according to manufacturer's protocol.

A digestion with BamHI and Sall restriction enzymes was used to check the vector. The reaction mixture contained 500 ng of Super6w, 5 U of BamHI, 5 U of Sall, 2 µl of 2XTANGO buffer (both the restriction enzymes and buffer from Fermentas) and sterile water in total volume of 10 µl. The digestion was carried out at +37°C for one hour.

The digested vector was checked with 1% agarose gel containing ethidium bromide 1 µg/ml in 1X TAE-buffer.

For cloning of the PCR amplified AIRE gene and Aire fragments into the Super6wt, 4 µg of Super6wt was digested with 10 U NotI restriction enzyme (MBI Fermentas, in 2 µl enzyme buffer and sterile water added to a final volume of 20

µl. The digestion was carried at +37°C for 1.5 hours, after which 1U of ZIP-enzyme (alkaline phosphatase) was added to the reaction mixture and incubated further for 30 minutes. The ZIP-enzyme treatment was done to facilitate the insertion of the AIRE gene into the vector by preventing the self-ligation of the vector back to a circular mode. After the digestion the vector was purified using GFXTM PCR DNA and Gel Band Purification Kit (Amersham Pharmacia Biotech) and dissolved in to a concentration of 0.2 micrograms/microliter.

Human and mouse AIRE-gene PCR-products were also digested with NotI restriction enzyme. To the digestion, 26 µl of PCR product, 3 µl of an appropriate enzyme buffer and 10U of NotI restriction enzyme (the buffer and enzyme from MBI Fermentas) was used. The digestion was carried out at +37°C for 2 hours, after which digested PCR-products were purified and dissolved in sterile water to a volume of 10 µl.

The PCR amplified and digested human and mouse AIRE genes were ligated to Super6wt by a T4 DNA ligase (MBI Fermentas). The digested insert DNA was taken (a total volume of 10 µl), 1.5 µl of ligase buffer (MBI Fermentas), 5U of T4 DNA ligase and sterile water was added to a final concentration of 15 µl. The ligation was carried out at +17°C overnight.

After the ligation 10 µl of ligation reaction mixture was taken for transfection into TOP10 cells according to manufacturer's protocol. The cells were incubated on ice for 30 minutes, after which a heat shock was performed in a water bath at +42°C for 30 seconds. The cells were then transferred directly on ice for 2 minutes and grown in 250 µl of SOC-medium (2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl₂, 10 mM MgSO₄, 20 mM glucose) at +37°C with shaking for 1 hour.

The transfected bacterial cells were plated onto LB-kanamycin plates and colonies were picked on the following day to 2 ml of LB-medium (1% tryptone, 0.5% yeast extract, 170 mM NaCl) with kanamycin and grown overnight at +37°C.

Miniprep DNA preparations from selected colonies were purified using Qiagen's Plasmid Midi Kit and dissolved to a volume of 50 µl of sterile water. The presence and size of the insert was checked with NotI and BamHI digestion. 10 µl of miniprep DNA was taken for digestion, 5U of NotI and 5U of BamHI enzymes,

2 ml of R+ enzyme buffer and sterile water was added to a final volume of 20 μ l. The digestion was carried out at +37°C for 1 hour.

The orientation of the insert was analysed with BamHI restriction enzyme. Ten μ l of miniprep DNA was taken, 5 U of BamHI, 2 μ l of BamHI buffer (MBI Fermentas) and sterile water was added to a final volume of 20 μ l. The digestion was carried out for 1 hour at +37°C and the products were checked on a 1% agarose gel with EtBr in 1XTAE.

On the basis on these results, a plasmid containing a mouse AIRE-gene and a plasmid containing a human AIRE-gene were picked and maxipreps were prepared. Briefly, 0.5 ml of E. coli cell suspension containing the plasmid of interest or a miniprep culture was added to a 150 ml LB-medium containing kanamycin (50 μ g/ml) and grown overnight at +37°C. Maxiprep DNAs were prepared using Qiagen's Plasmid Maxi Kit.

The plasmid containing the mouse AIRE-gene was designated as pS6wtmAIRE and plasmid containing the human AIRE-gene as pS6wthAIRE.

The generated vectors were sequenced for approximately 500 bp from both ends to verify the orientation and correctness of the insert. The sequencing was performed using the dideoxy method with PE Biosystem's Big Dye Terminator RR-mix, which contains the four different terminating dideoxynucleotide triphosphates labeled with different fluorescent labels.

Plasmids containing the AIRE gene and AIRE gene fragments were inserted into selected cell lines to check the expression of the protein with Western blot after the transfection.

Cos-1 cells were harvested with trypsin-EDTA (Bio Whittaker Europe) solution and suspended 10x10⁶ cells/ml into Dulbecco's MEM (Life Technologies) medium and 250 μ l of cell suspension was taken for transfection. The transfection of Cos-1 cells was performed using electroporation with 2.5x10⁶ cells, 50 μ g of salmon sperm DNA as a carrier and 5 μ g of appropriate vector. The transfections were made with pS6wthAIRE, pS6wtmAIRE, Super6wt, pCAIRE, psiAIRE and pCAIRE S1-4. pCAIRE and psiAIRE are positive human AIRE controls, pCAIRE S1-4 is a positive mouse AIRE control and Super6wt is a negative control.

The electroporation was done using Biorad's Gene Pulser with capacitance 960 μ Fd, 240 V and 1 pulse. After the pulse the cells were kept at room temperature for 10 minutes and 400 μ l of medium was added. The cells were transferred to 5 ml of medium and centrifuged for 5 minutes with 1000 rpm. Cells
5 were plated and grown for 3 days at +37°C, 5% CO₂.

The cells were harvested with trypsin-EDTA and centrifuged. Then Cells were then washed once with 500 ml of 1XPBS (0.14 mM NaCl, 2.7 mM KCl, 7.9 μ M Na₂HPO₄, 1.5 μ M KH₂PO₄). 50 μ l of PBS and 100 μ l of SDS loading buffer (5% mercaptoethanol, 16 μ M Bromphenolblue, 20 μ M Xylene Cyanol, 1.6 mM Ficoll 400) was added and cells were heated at +95°C for 10 minutes.
10

For the western blot analysis SDS-PAGE was prepared with 10% separation and 5% stacking gels in a SDS running buffer (25 mM Tris, 250 mM glycine, 0.1% SDS). Cell samples and biotinylated molecular weight marker were loaded on the gel and electrophoresis was performed with 150 V for 1h 50 minutes. The
15 transfer of proteins to a nitrocellulose membrane was performed at 100 V for 1.5 hours at room temperature with a cooler in transfer buffer.

The membrane was blocked in 5% milk in TBS (0.05 M Tris-Cl, 0.15 M NaCl, pH 7.5) for 30 minutes at room temperature. A primary antibody mixture, anti-AIRE6.1 (human) and anti-AIRE8.1 (mouse) antibodies at a dilution of 1:100
20 in 5% milk in TBS, was added onto membrane and incubated overnight at +4°C. The membrane was washed two times with 0.1% Tween in TBS for 5 minutes and once with TBS for 5 minutes. The secondary antibody, biotinylated anti-mouse IgG at a dilution of 1:500 in 5% milk in TBS was incubated for 1 hour at room temperature. The membrane was washed and horseradish peroxidase avidin D at a dilution of 1:1000 in 5% milk in TBS was added. The membrane was
25 incubated at room temperature for 1 hour and washed. A substrate for the peroxidase was prepared of 5 ml chloronaphthol, 20 ml TBS and 10 μ l hydrogen peroxide and added onto membrane. After the development of the color the membrane was washed with TBS and dried.

30 The antibody detecting with human AIRE (anti-AIRE6.1) detected the AIRE protein expression in the preparates transfected with pS6wthAIRE, pCAIRE and psiAIRE. The antibody detecting murine AIRE detected likewise the murine

AIRE in cells transfected with pS6wtmAIRE and pCAIRE S1-4. The negative control (Super6wt) showed no AIRE/aire proteins.

5 6.10 EXAMPLE 10: DETECTION OF CELLULAR AND HUMORAL
IMMUNE RESPONSE TOWARD HIV.1 NEF IN MICE IMMUNIZED
WITH THE NNV-NEF CONSTRUCT
DNA IMMUNIZATIONS

To further study the induction of humoral immunity by the vectors of the inventions, 5-8 weeks old both male and female BALB/c (H-2d) mice were used.
10 For the DNA immunizations, the mice were anaesthetized with 1,2 mg of pentobarbital (i.p) and DNA was inoculated on shaved abdominal skin using plasmid DNA coated gold particles. The inoculation was made with Helios Gene Gun (Bio-Rad) using the pressure of 300 psi. The gold particles were 1 μ m in diameter, ~1 μ g of DNA/cartridge. The mice were immunized twice (on day 0 and day 7) with a
15 total amount of DNA of 0,4 or 8 μ g/mouse. The control mice were immunized with 8 μ g of the plain vector without the nef-gene, i.e.NNV-deltanef.

A blood sample was taken from the tail of the mice two weeks after the last immunization. The mice were sacrificed four weeks after the last immunization and blood samples (100 μ l) were collected to Eppendorf tubes containing 10 μ l of
20 0,5 M blotting (++) vs. +) and in ELISA (higher OD, more mice in higher-dose above cut-off EDTA. The absolute number of leukocytes/ml of blood was calculated from these samples for each mouse. The sera were collected for antibody assays and stored at -20°C. The spleens were removed aseptically, weighted and then homogenized to single cell suspensions for use in T, B and NK cell as-
25 says and staining.

Detection of the humoral immunogenicity of the vectors of the invention

For the detection of Nef-specific antibodies by Western blotting, serum samples from mice immunized with the vector constructs of the invention were di-
30 luted 1:100 to 5% milk in TBS and applied on nitrocellulose strips made with recombinant HIV-1 Nef protein. For the preparation of the nitrocellulose strips, the purified recombinant protein was boiled in a sample buffer containing 1% SDS

and 1% 2-mercaptoethanol, then run on a 10 or 12.5 % polyacrylamide gel and subsequently transferred onto a 0.45 µm nitrocellulose paper. The strips were first blocked with 2% BSA in 5% defatted milk-TBS and thereafter incubated with diluted sera (1:100) overnight. After incubation, unbound proteins were removed
5 by washing the strips three times with TBS - 0.05% Tween-20 and twice with water. After washings, the strips were probed with a 1:500 dilution of biotinylated anti-mouse IgG (Vector Laboratories, USA) for 2 hour. After further washings, horseradish peroxidase-avidin in a dilution of 1:1000 (Vector Laboratories, USA) was added for 1 h, the strips were washed again and the bound antibodies were
10 detected with a hydrogen peroxidase substrate, 4-chloro-1-naphtol (Sigma, USA).

The sera were also tested in ELISA to determine the exact antibody titers induced by each construct. Nef antibody ELISA was performed as previously described (Tähtinen et al., 2001). Briefly, Nunc Maxi Sorp plates were coated with 50 ng of Nef (isolate HAN), blocked with 2% BSA in phosphate buffered saline
15 (PBS), and the sera in a dilution of 1:100 to 1:25000 were added in duplicate wells for an overnight incubation. After extensive washings, the secondary antibody, peroxidase conjugated anti-mouse IgG or IgM (DAKO), was added, and the plates were incubated for two hours and then washed. Color intensity produced from the substrate (2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid, ABTS,
20 Sigma) in a phosphate-citrate buffer was measured at 405 nm using a Labsystems Multiscan Plus ELISA-plate reader. The optical density cut-off value for positive antibody reactions was determined as follows:

$$\text{cut-off} = \text{OD (xl control mice sera)} + 3 \text{ SD.}$$

Detection of the cellular immunogenicity of the vectors of the invention

25 To analyze the capacity of the vectors of the invention to induce cellular immunity, T-cell and B-cell assays as well as cell surface staining were performed.

T cell proliferation assay. The spleen cells were suspended to a final concentration of $1 \times 10^6/\text{ml}$ RPMI-1640 (GibcoBRL) supplemented with 10% FCS (GibcoBRL), 1% penicillin-streptomycin (GibcoBRL) and 50 µM beta-mercaptoethanol (Sigma). Cells were incubated in microtitre plates at 200 µl/well
30 with media only or with different stimuli. The final concentrations of stimuli were:

Con A 5 µg/ml, HIV-Nef-protein at a concentration of 1 and 10 µg/ml, and a negative control antigen HIV-gag at a concentration of 1 and 10 µg/ml. All reactions were made in quadruplicates. On the sixth day of the incubation 100 µl of supernatant from each well was collected and stored at -80°C for cytokine assays. Six hours before harvesting 1 µCi of 3H-thymidine (Amersham Pharmacia Biotech) was added to each well. The cells were harvested and radioactivity incorporated (cpm) was measured in a scintillation counter. The stimulation indexes (SI) were calculated as follows

$$SI = \text{mean experimental cpm} / \text{mean media cpm}.$$

Lymphocyte activation. T and B cell activation was detected by double surface staining of fresh splenocytes with anti-CD3-FITC plus anti-CD69-PE (early activation marker) and anti-CD19-FITC plus anti-CD69-PE antibodies (all from Pharmingen). Stainings were analyzed with flow cytometer (FACScan, Becton Dickinson).

CTL assays. Mouse splenocytes were co-cultured with fixed antigen presenting cells (P-815 cells infected with MVA-HIV-nef or control MVA-F6) for five days after which they were tested in a standard 4 hour 51chromium release assay [Hiserodt, J., et al., J Immunol 135 (1995) 53-59; Lagranderie, M., et al., J Virol 71 (1997) 2303-2309] against MVA-HIV-nef infected or control target cells. In

CTL assays the specific lysis of 10% or more was considered positive.

Cytokine assay. IFN-gamma and IL-10 were measured from antigen-stimulated cell culture supernatants in order to analyze, whether immunized mice develop a Th1 type or Th2 response. The supernatants were collected from antigen-stimulated cells as described above. Pro-inflammatory cytokines TNF-alfa and IL-10 were measured in the sera of the immunized mice. All cytokines were measured with commercial ELISA kits (Quantikine, R&D Systems).

Spontaneous proliferation. Spontaneous splenocyte proliferation was detected by 3H-thymidine uptake of the cells cultured in the medium only for 6 days.

Anti-double strand (ds) DNA antibodies. dsDNA antibodies were measured in the sera of immunized mice, positive control mice (mrl/lpr, a generous gift from Dr. Gene Shearer, NIH, USA) and normal mice. The antibodies were as-

sayed with ELISA on poly-L-Lysine bounded lambda phage dsDNA. The results are shown in Tables 2 and 3.

Table 2 shows complete immunological results of the mice immunized with HIV-Nef plasmid DNA. Although HIV-1 Nef recombinant protein, which was used for in vitro T cell stimulation, induced some non-HIV-specific proliferation of the cells in each immunized group, there was a significant increase in the mean SI of mice immunized with 0,4 µg of the plasmid (mean SI=72,2) compared to others. Furthermore, negative control protein HIV-gag did not induce any T cell response. Only the T cells of the mice in the group that had nef-specific proliferation also produced nef-specific IFN-gamma. None of the immunized mice had cells producing IL-10, which shows that the T cell response in the immunized mice was of Th1 type and not of Th2 type. In contrast to the T cell response, mice immunized with the higher concentration of nef plasmid DNA (8 µg) had a stronger B cell response compared to mice immunized with 0,4 µg: the humoral response in mice immunized with the higher dose was detectable already three weeks after the last immunization and the response detected was stronger both in Western-). The antibodies detected belonged to IgG-class, no IgM response was detected. None of the mice developed E2 specific antibody.

The mice immunized with 0.4 µg of HIV-nef plasmid DNA had an increased number of leukocytes ($6.38 \times 10^6/\text{ml}$) in the peripheral blood compared to other groups of immunized mice and normal mice ($3.8 \times 10^6/\text{ml}$) (Table 3). The same mice had twice as much activated T cells (21%, CD3+CD69+) compared to other mice (9% and 10%). This finding is in correlation with the positive T cell response to HIV-Nef (Table 2), since the mice with a positive T cell response to Nef also had an increased number of activated T cells in their spleens. The results of Table 3 also show that none of the immunized mice developed anti-dsDNA antibodies as compared to positive control sera (OD=1,208) indicating that there is no adverse effect of the immunization.

Table 2

Mice	HIV-1 nef SI*	HIV-1 gag SI	IFN-g Th1	IL-10 Th2	HIV-1 nef Ab	E2 Ab
NNV-Nef 8						
1	6	1	-	-	++	-
2	8	1	-	-	++	-
3	13	2	-	-	++	-
4	15	1	-	-	++	-
5	7	1	-	-	++	-
Mean	9.8	1.2				
NNV-NEF 0.4						
1	24	1	+	-	+	-
2	112	1	+	-	+	-
3	83	1	+	-	+	-
4	73	1	+	-	+	-
5	69	1	+	-	+	-
Mean	72.2	1				
NNV-ΔNef 8						
1	6	1	-	-	-	-
2	nt	nt	-	-	-	-
3	11	1	-	-	-	-
4	23	2	-	-	-	-
5	12	1	-	-	-	-
Mean	13	1.25				

*SI=stimulation index

nt=not tested

-, negative

+, positive

+++, strong positive

Table 3

Mice	WBC x10 ⁶ /ml	CD3 % spleen	CD3+CD69+ % spleen	CD19 % spleen	CD19+CD69+ % spleen	anti-dsDNA ab OD (1:10 dil)
NM						
1						0.355
2						0.255
3						0.231
Mean						0.280
NNV-Nef 8						
1	5	nt	nt	nt	nt	0.387
2	4.3	50	4	11	3	0.457
3	4.9	57	4	15	4	0.514
4	4.3	55	6	15	4	0.367
5	5.1	54	5	7	0	0.478
mean	4.72	54	4.75 (9%)	12	2.75	0.441
NNV-Nef 0.4						
1	3.9	nt	nt	nt	nt	0.418
2	8	41	9	18	5	0.263
3	7.5	39	8	25	9	0.375
4	5	46	9	16	6	0.285
5	7.5	43	10	13	7	0.396
mean	6.38	42.25	9 (21%)	18	6.75	0.347
NNV-Δ Nef 8						
1	4.5	61	4	9	2	0.413
2	4.6	59	4	15	1	0.353
3	3.8	50	6	17	5	0.382
4	3.1	46	7	25	8	0.448
5	3.5	nt	nt	nt	nt	0.501
mean	3.9	54	5.25 (10%)	16.5	4	0.419

Normal mouse mean WBC=3.8x10⁶/ml.

nt, not tested

a-dsDNA positive control sera OD was 1.208
(1:10 dil)

6.11. EXAMPLE 11: SAFETY AND IMMUNOGENICITY OF A PROTOTYPE HIV VACCINE GTU-NEF IN HIV INFECTED PA- TIENTS

Production of the NNV-2-Nef vaccine (CHECK whether NNV-2 or NNVwt-2 was used)

The investigational vaccine NNV-2-Nef was prepared according to Example 2 with the Manufacturing License No. LLDnro 756/30/2000 (issued by the Finnish National Agency for Medicines on 21.12.2000).

The manufacturing processes performed fulfilled the current Good Manufacturing Practices (cGMP) requirements and provided plasmid DNA preparations suitable for use in clinical phase I and II studies. The manufacturing process consisted of four steps:

- a) Establishment of Master Cell Banks and Working Cell Banks
- b) Fermentation
- c) Purification
- d) Aseptic filling of the vaccine

In detail, NNV-2-Nef was produced in *E. coli* bacteria. The Master Cell Banks (MCBs) and Working Cell Banks (WCBs) containing *E. coli* DH5 alpha T1 phage resistant cell strain were established in accordance with the specific Standard Operating Procedure from pure cultured and released Research Cell Banks.

a) Establishment of Master Cell Banks and Working Cell Banks

The schematic procedure for establishing the cell bank system is illustrated below:

Thaw of one vial of Research Cell Bank [*E. coli* DH5 alpha T1 phage resistant cell strain (Gibco RBL) transformed with the NNV-2-Nef plasmid.

Inoculate of the culture on modified Luria Bertani medium plate (containing 25 µg/ml of kanamycin)

Incubate overnight (14-16h) at 37°C

Select of a single colony from the plate and inoculation into 50 ml of modified Luria Bertani medium (containing 25 µg/ml of kanamycin)

Incubate overnight (14-16h) at 37°C

Measure optical density of the bacterial culture ($OD_{600} = 2.0 - 6.0$)

Add glycerol to bacterial culture

Divide the culture-glycerol mix to aliquots

Label and store the Master Cell Banks

Following the same diagram, the Working Cell Bank was established using one vial of the Master Cell Bank as the starting material. The routine tests performed on the MCB and WCB were: microbiological characterization, absence of contamination, assessment of the plasmid stability by replica plating and the plasmid identity (restriction enzyme digestion and sequencing).

b) Fermentation. In the fermentation the DH5 alpha T1 phage resistant *E. coli* strain (Gibco RBL, UK) transformed with NNV-2-Nef (WCB) was first cultured on plate. From the plate a single colony was inoculated to a 100 ml liquid pre-culture before the actual fermentation in the fermentation reactor. The fermentation was carried out in a 5 l fermentor (B. Braun Medical) on a fed-batch system basis, after which cells were harvested. The culture medium composition for one litre contained 7g of yeast extract, 8g of peptone from soy meal, 10g of NaCl, 800ml of water for injection (WFI), 1N NaOH, pH 7.0, kanamycin 50mg/ml (Sigma), silicon anti-foaming agent (Merck), 1M K_2PO_4 (BioWhittaker).

In the beginning of the fermentation run, a 1 ml sample was taken through the harvesting tube to determine the initial cell density (OD_{600}). The pre-culture was used to inoculate the fermentation medium. During the fermentation, fresh culture medium and 1M potassium phosphate buffer, pH 6.5 - 7.3, were fed to the reactor with the pumps. Addition of the medium allows replenishment of essential nutrients before they run out and phosphate buffer maintains the pH constant. When the fermentation process had continued for approximately 5 hours and at the end of the fermentation run (after approximately 10 hours of fermentation), samples of 1 ml were taken as above and the cell density was measured. After the fermentation, the culture medium was centrifuged (10,000 rpm, 30 minutes, +4°C) and the bacterial pellet (50-60g) was recovered.

c) Purification. The methodology used for the purification of DNA was based on the QIAGEN process scale technology (Qiagen Plasmid Purification Handbook 11/98). The NN2-Nef was purified using the following steps:

Resuspend the bacterial pellet in the resuspension buffer (100-150ml, RT)

Lyse with the lysis buffer (100-150ml, 5 minutes, RT)

- Neutralize with the neutralization buffers (100-150ml, +4°C)
Incubate (30minutes, +4°C)
Centrifugate (10,000 rpm, 30 minutes, +4°C)
Filtrate supernatant (0.22 micrometers)
5 Remove endotoxins with Endotoxin removal buffer (60-90ml)
Equilibrate Ultrapure column with Equilibration buffer (350ml, flow
rate 10ml/min)
Load lysate to the column (flow rate 4-6ml/min)
Wash the column with Wash buffer (3l, overnight, flow rate 4-
10 6ml/min)
Elute the plasmid DNA with Elution buffer (400ml, flow rate
3.1ml/min)
Filtrate the eluate (0.22 micrometer)
Precipitate DNA with isopropanol
15 Centrifuge (20000g, 30 minutes, 4°C)
Purified plasmid DNA

- Buffers used within the purification were as follows. The resuspen-
sion buffer contained 50mM Tris-Cl, pH 8.0, plus RNase A (50mg); the lysis
20 buffer was 200mM NaOH; the neutralization buffer was 3M potassium acetate,
pH 5.5; the endotoxin removal buffer contained 750mM NaCl, 10% Triton X-
100; 50mM MOPS, pH7.0; the equilibration buffer contained 750mM NaCl,
50mM MOPS, pH 7.0; the wash buffer contained 1 M NaCl, 50mM MOPS, pH
7.0, 15% isopropanol; and elution buffer contained 1.6 M NaCl, 50mM MOPS,
25 pH 7.0, 15% isopropanol.

d) Aseptic filling

- The purified DNA representing the final bulk was dissolved in 0.9%
sterile physiological saline to a final concentration of 1 mg/ml and sterile fil-
tered (0.22 micrometer) during the same day. The purified bulk was filled
30 manually (filling volume 0.5 ml) in Schott Type 1 plus glass vials using a steam
sterilized Finnpiette® and sterile endotoxin-free tips. The vials filled with the
NN2-Nef vaccine were closed immediately, labelled and packed in accordance
to the specific Standard Operating Procedure (SOP).

2. Administration of the test vaccine to the patients

- 35 Ten HIV-1 infected patients undergoing Highly Active Anti-
Retroviral therapy (HAART) were immunized with the experimental DNA vac-

cine NN2-Nef, expressing the HIV-1 Nef gene (Clade B). For immunizations, two intramuscular injections in the gluteal muscle were given two weeks apart. The doses were 1 and 20 micrograms/injection. Blood samples were drawn at -4, 0, 1, 2, 4, 8 and 12 weeks. The samples were analyzed for humoral
5 (ELISA, Western blot) and cell mediated immune response (T-cell subsets, T-cell proliferation, ELISPOT, cytokine expression, intracellular cytokines).

A clinical examination was performed to each patient participating the study. The clinical examination included a patient interview (anamnesis) and weight determination. Cardiac and pulmonar functions were checked by
10 auscultation and percussion, the blood pressure and heart rate were recorded. Enlargement of lymph nodes, liver and thyroid gland were determined by palpation.

Laboratory tests to evaluate the safety of the vaccine were performed at each visit. These tests included:

15 Hematology: red blood cell count, haemoglobin, total and differential WBC, platelet count, prothrombin time and activated partial thromboplastin time at baseline; mean erythrocyte corpuscular volume and hemoglobin content has been calculated.

Immunology: nuclear and ds-DNA antibodies.

20 Serum chemistries: total bilirubin, alkaline phosphatase, SGOT/SLT or SGPT/ALT, serum creatinine, protein electrophoresis, total serum cholesterol, triglycerides, glucose (at baseline), sodium, potassium, and calcium.

25 Urine analysis: dipstick protein, glucose, ketones, occult blood, bile pigments, pH, specific gravity and microscopic examination of urinary sediment (RBC, WBC, epithelial cells, bacteria, casts), when dipstick determination showed one or more abnormal values.

Viral load: Increases of more than one log 10 should be followed by a confirmatory viral load estimate after two weeks.

30 None of the patients experienced subjective or objective adverse reactions to the vaccination. No adverse laboratory abnormalities were observed in the panel of clinical chemistry tests (see material and methods for details) performed repeatedly during the vaccination period.

The following immunological studies were performed:

Lymphocyte proliferation assay (LPA)

Peripheral blood mononuclear cells (PBMC) were isolated from heparinized venous blood by Ficoll-Hypaque density-gradient (Pharmacia) centrifugation and resuspended at 1×10^6 cells/ml in RPMI 1640 medium (Gibco) supplemented with 5% pooled, heat-inactivated AB⁺ serum (Sigma), antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin; Gibco) and L-glutamine (complete medium, CM). Quadruplicate cultures were then set up in flat-bottomed micro titer plates (1×10^5 PBMC/well) and the cells were incubated for 6 days in the presence or absence of the following stimuli: rNef (0.2, 1 and 5 µg/ml), GST (0.2, 1 and 5 µg/ml), purified protein derivative of tuberculin (PPD, 12.5 µg/ml; Statens Seruminstitut), *Candida albicans* antigen (20 µg/ml; Greer Laboratories) and Phytohaemagglutinin (PHA; 5 µg/ml; Life Technologies). For the last 6 h of the incubation period ³H-thymidine (1 µCi/well; Amersham) was added to the cultures and the cells were harvested onto glass fiber filters and incorporated radioactivity was measured in a γ-counter. Results are expressed as delta cpm (cpm in the presence of antigen - cpm without antigen) or as stimulation index (cpm in the presence of antigen / cpm without antigen).

The results are shown in Figures 26 and 27. None of the vaccinees showed significant T-cell proliferative response to the test antigen, HIV-1 Nef before the vaccination. In contrast, 2 out of 5 vaccinees in the group that had received 1 microgram dose of the test vaccine (patients 1 and 3) (Figure 26) and 2 out of 5 in the group receiving 20 micrograms of the test vaccine (patients 9 and 10) (Figure 27) showed a strong T-cell proliferative response after the first vaccination. After the second vaccination, one (patient 2) vaccinee responded in the 1-microgram group.

IFN-γ assays

The type of immune response (Th1/Th2) induced by the vaccine was evaluated by measuring interferon-gamma (IFN-γ) released in 6 days old culture supernatant after antigen (rNef, rGST, PPD) or mitogen (PHA) stimulation of PBMC. For determinations, commercial ELISA kits (R&D Quantikine) were used. The assay employs the quantitative sandwich enzyme immunoassay technique where a monoclonal antibody specific for IFN-γ has been coated onto a microplate. Standards and samples are pipetted into the wells and any IFN-γ present is bound by the immobilized antibody. After washing away any unbound substances, an enzyme-linked polyclonal antibody specific

for IFN- γ is added to the wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of the cytokine bound in the initial step. The color development is stopped and the intensity of the color is measured.

5 IFN- γ response data from patient # 1 is shown in Figure 28. As can be seen, the vaccinee responded to the rNef antigen by marked IFN- γ response correlated with the T-cell proliferation, indicating that the response seen in the vaccinee is in fact of the Th1 type.

10 HIV-1 infection is characterized by low or totally lacking cell-mediated immune response towards all HIV proteins. The results show that it is possible to induce a robust CMI in such patients with exceptionally low doses of the DNA vaccine NN2-Nef. The doses used were minimal to what has generally been required with DNA vaccines. Thus, for instance, Merck announced recently good results with their experimental HIV vaccine but the doses required
15 were from 1000 to 5000 micrograms (IAVI report, 2002).

6.12 EXAMPLE 12: CONSTRUCTION OF THE PLASMID EXPRESSING EPSTEIN-BARR VIRUS (EBV) EBNA-1 PROTEIN AND CONTAINING 20 BINDING SITES FOR EBNA-1 (FR ELEMENT)

20 To construct a plasmid expressing Epstein-Barr virus (EBV) EBNA-1 protein and containing 20 binding sites for EBNA-1 (FR element), BPV-1 E2 binding sites were first replaced by EBV EBNA-1 binding sites (oriP without DS element). Plasmid FRE2d1EGFP (Figure 29) was constructed by isolating the *XmiI*(*AccI*)/*Eco32I*(*EcoRV*) DNA fragment (blunt-ended with Klenow enzyme)
25 of pEBO LPP plasmid (Figure 29A) (the fragment contains 20 binding sites for EBNA-1) and inserting it by blunt end ligation into the *SpeI*/*NheI* site of s6E2d1EGFP (Figure 29B) (blunt-ended with Klenow enzyme). The constructed plasmid FRE2d1EGFP (Figure 29) was used as a negative control in further experiments. It contains binding sites for EBNA-1 protein instead of the
30 BPV1 E2 10 binding sites, expressing E2, but not EBNA-1.

Next, the sequence encoding BPV-1 E2 protein in FRE2d1EGFP plasmid was replaced by a sequence encoding EBV EBNA-1 protein as follows. The *XmiI*(*AccI*)/*EcoRI* fragment of pEBO LPP plasmid was isolated and blunt-ended with Klenow enzyme and inserted into the *XbaI*/*XbaI* site of

FRE2d1EGFP plasmid (blunted, with Klenow enzyme). The vector FRE2d1EGFP was previously grown in *Escherichia coli* strain DH5 α lacking Dam⁻ methylation, because one XbaI site is sensitive for methylation. The constructed plasmid FREBNAd1EGFP (Figure 30) expresses EBNA-1 protein
5. and contains 20 binding sites for EBNA-1.

For expression, Jurkat, human embryonic kidney cell line 293 (ATCC CRL 1573) and mouse fibroblast cell line 3T6 cells (ATCC CCL 96) were maintained in Iscove's modified Dulbecco's medium (IMDM) supplemented with 10% fetal calf serum (FCS). Four million cells (Jurkat), 75% confluent
10 dishes (293) or 1/4 of 75% confluent dishes (3T6) were used for each transfection, which were carried out by electroporation as follows. Cells were harvested by centrifugation (1000 rpm, 5 min, at 20 °C, Jouan CR 422), and re-suspended in a complete medium containing 5mM Na-BES buffer (pH 7.5). 250 μ l cell of the cell suspension was mixed with 50 μ g of carrier DNA (salmon
15 sperm DNA) and 1 μ g (in the case of Jurkat and 3T6) or 5 μ g (in the case of 293) of plasmid DNA and electroporated at 200 V and 1000 μ F for Jurkat cells, 170 V and 950 μ F for 293 cells and 230 V and 975 μ F for 3T6 cells. The transfected Jurkat cells were plated on 6-cm dishes with 5 ml of medium; 1/3 of transfected 293 and 3T6 cells were plated on a 6-cm dishes with 5 ml of medium and 2/3 of the cells were plated on a 10-cm dishes with 10 ml of medium.
20

The transfected cells were analysed for the expression of d1EGFP protein (modified enhanced green fluorescent protein). All of the constructed plasmids expressed d1EGFP protein, which was detected by measuring the fluorescence using a flow cytometer. Because of the short half-life of the
25 d1EGFP protein, it does not accumulate, and the expression of this protein reflects the presence of transcriptionally active plasmids in the cells. Becton-Dickinson FACSCalibur system was used. The volume of the Jurkat cell suspension was measured before each time-point (approximately after every 24 hour) and if the volume was less than 5 ml, the missing volume of medium was
30 added. Depending on the cell suspension density the appropriate volume was

taken for measuring (1 or 2 ml) and replaced with the same amount of medium. This was later taken into consideration when the dilution was calculated.

For the first time-point, 293 cells from the 6-cm dish were suspended in 5 ml of medium for measuring. In every following time-point half of the cells were taken from the 10-cm dish, suspended in 5 ml of medium and then measured. An appropriate volume was added to the rest of the cell suspension. For the first time-point, 3T6 cells from the 6-cm dish were suspended in 1 ml of trypsin, which was then inactivated with 100 μ l of FCS. For every following time-point, cells from the 10-cm dish were suspended in 2 ml of trypsin. 1 ml of this suspension was treated as described previously. 9 ml of medium was added to the rest of the suspension. The analyzed cells were taken out of the incubator immediately before the measurement. The appropriate flow speed (500-1000 cells/sec) was determined before each time-point using cells transfected only with carrier DNA as a control. Three different parameters were used to measure size, surface structure and fluorescence of the cells.

The results are presented as graphs in Figure 31. Cells transfected only with carrier DNA were used to measure the auto-fluorescence of the cell-line. 1% of this auto-fluorescence was considered as background fluorescence and was subtracted later from the d1EGFP fluorescence. The received data was analyzed using Microsoft Excel program.

Percentages of the d1EGFP expressing cells were calculated using cells transfected with the carrier only as a negative control for background fluorescence. As shown in Figure 33, the two vectors were maintained in the cells with different kinetics.

The number of the d1EGFP expressing cells was calculated taking the dilutions into consideration using cells transfected with the carrier only as a negative control for background fluorescence. As seen from figure 53, the plasmids expressing EBNA-1 and carrying EBNA-1 specific multimeric binding sites are maintained very efficiently in the transfected cells. At day 1 after transfection approximately 8×10^4 cells expressed EGFP. At day 8, in the case of maintenance vector (FREBNAd1EGFP), the number of the plasmid positive d1EGFP expressing cells had increased ten times to 8×10^5 . With the plasmid

lacking EBNA-1 expression (FRE2d1EGFP) or having no EBNA-1 binding sites, the number of plasmid positive cells was retained or in many cases decreased. This fact reflects the mechanism for segregation/partitioning Epstein-Barr virus. Maintenance and segregation function by EBNA1 and EBNA-1 binding sites provides maintenance function to the plasmid if EBNA-1 is expressed and plasmid carries EBNA-1 binding sites. The same mechanism and the same components actually provide the segregation function to Epstein-Barr Virus in the latent phase of life-cycle.

Similar results were obtained also in human embryonic cell line 293 and mouse cell line 3T6 (Figure 34). As a control for the maintenance for 293 and 3T6 cells, s6HPV11 and 2wtFS, respectively, were used.

6.13 EXAMPLE 13: THE IMMUNOGENICITY OF GTU-MULTIGENE VECTORS

THE IMMUNOGENICITY OF GTU-1- MULTIGENE VECTORS

The immunogenicity of six different multi-gene vaccine constructs prepared in Example 12, i.e. GTU-1-RNT, GTU-1-TRN, GTU-1-RNT-CTL, GTU-1-TRN-CTL, GTU-1-TRN-optgag-CTL, and GTU-1-TRN-CTL-optgag vectors were tested in mice. The vectors were transformed into TOP10 or DH5alpha cells, and the MegaPreps were prepared using commercial Qiagen columns. Endotoxins were removed with Pierce Endotoxin Removal Gel.

The test articles were coated on 1 µm gold particles according to the instructions given by the manufacturer (Bio-Rad) with slight modifications. Balb/c mice were immunized with a Helios Gene Gun using a pressure of 400 psi and 0.5 mg gold/cartridge. Mice were immunized three times at weeks 0, 1, and 3. Mice were sacrificed two weeks after the last immunization.

Mice were divided into six test groups (5 mice/group), which received 3 x 1 µg DNA as follows:

Group 1. GTU-1-RNT

Group 2. GTU-1-TRN

Group 3. GTU-1-RNT-CTL

Group 4. GTU-1-TRN-CTL

Group 5. GTU-1-TRN-optgag-CTL

Group 6. GTU-1-TRN-CTL-optgag

Group 7. Control mice immunized with empty gold particles not loaded with DNA.

The humoral response was followed from tail-blood samples from each mouse. First pre-immunization sample was taken from anesthetized mice before the first immunization was given. Second sample was taken from anesthetized mice before the third immunization. At sacrifice, whole blood sample was used for white blood cell counting, and serum was collected for humoral immunity tests.

The blood samples were tested for antibodies with ELISA using a standard procedure. Nunc Maxi Sorp plates were coated with 100 ng of Nef, Rev, Tat, Gag, CTL or E2 proteins, blocked and sera at a dilution of 1:100 were added in duplicate wells for an overnight incubation. After washing, the plates were incubated for 2 hours with a diluted (1:500) secondary antibody, peroxidase conjugated anti-mouse IgG (DAKO). Color intensity produced from the substrate (2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) in phosphate-citrate buffer was measured at 405 nm using Labsystems ELISA-plate reader.

All vectors induced Nef antibodies in all mice, whereas none of the mice showed E2, CTL or Rev antibodies (Fig. 35, 36, and Table 4). Some of the mice immunized with GTU-1-RNT or GTU-1-RNT-CTL also developed Tat antibodies (Fig. 36 and Table 4). Furthermore, mice immunized with vectors containing the optgag sequence developed also Gag antibodies, but the construct GTU-1-TRN-optgag-CTL was a better antibody inducer than the construct GTU-1-TRN-CTL-optgag (Figure 37 and Table 4). The antibodies induced were mainly of the IgG1 class indicating a Th2 type of response usually seen with gene gun immunization. The antibody assays shown below were done from the sera collected when mice were sacrificed.

The results show that a multigene construct, expressing several HIV genes as a fusion protein, can induce an immune response to most of the gene products. The orientation and order of the genes in the multigene and corresponding proteins in the fusion proteins affects the results, however, dramatically. Thus, a response against Tat was seen only when the Tat gene was placed inside the fusion protein (vectors with RNT motif) and not when Tat was the amino terminal protein (vectors with the TRN motif). Response to the Gag proteins was seen only with the vector, where Gag was placed before the CTL containing a stretch of Th and CTL epitopes.

Table 4.

Immuno III A mice ELISA results (OD mean of five mice)						
Immunogen	Group number	Nef (own prot)	Tat	Rev	Gag	CTL
GTU-1-RNT	1	2.194	1.391	0.31	0.155	0.36
GTU-1-TRN	2	1.849	0.197	0.252	0.302	0.38
GTU-1-RNT-CTL	3	1.922	0.555	0.295	0.154	0.439
GTU-1-TRN-CTL	4	1.677	0.211	0.298	0.14	0.425
GTU-1-TRN-optgag-CTL	5	1.722	0.182	0.24	0.667	0.381
GTU-1-TRN-CTL-optgag	6	0.547	0.225	0.322	0.228	0.43
Controls	7	0.316	0.226	0.282	0.16	0.405
Immunogen	Group	Percent of Nef response	Tat response	Rev response	Gag response	CTL response
GTU-1-RNT	1	100	80	0	0	0
GTU-1-TRN	2	100	0	0	20	0
GTU-1-RNT-CTL	3	100	40	0	0	0
GTU-1-TRN-CTL	4	100	0	0	0	0
GTU-1-TRN-optgag-CTL	5	80	0	0	60	0
GTU-1-TRN-CTL-optgag	6	100	0	0	20	0

6.14. EXAMPLE 14: EXPRESSION OF HYBRID PROTEIN EXPRESSING NEF, REV AND TAT IN DIFFERENT COMBINATIONS (MULTIREG)

For the production of HIV multi-gene vectors, GTU-1 vector with a multi-cloning site (Figure 38A) was used as a backbone. Intact Nef, Rev and Tat coding sequences were amplified by the polymerase chain reaction (PCR) and attached to each other in various orders to multi-regulatory (multireg) antigen coding reading frames (Nef-Tat-Rev, Tat-Rev-Nef, Rev-Tat-Nef, Tat-Nef-Rev and Rev-Nef-Tat; Sequences Id. No. 1 to 5, respectively). These sequences were cloned to the Bsp119I and NotI sites of the GTU-1 vector.

Similarly, Nef protein expressing GTU-2 and GTU-3 vectors (Figure 38B and 38C; see also Figure 6B for NNV-2wt) were also used as backbones for the production of HIV multigene vectors. Additionally, the vector super6wt expressing destabilized enhanced green fluorescent protein or d1EGFP (super6wtd1EGFP; Figure 17 and Figure 38D) and plasmid utilizing the EBNA-1 protein and its binding sites (FREBNAd1EGFP; Figure 38E) were used as a Gene Transfer Unit (GTU) platform. For control "non-GTU"vectors, a regular cytomegalovirus (CMV) vector NNV-Rev expressing Rev and a plasmid EBNA-1 and E2BS containing d1EGFP plasmid (NNV-Rev and E2BSEBNAd1EGFP, respectively; Figures 38G and F) were used as backbones.

For the preparation of different GTU-2 and GTU-3 vectors (pNRT, pTRN, pRTN, pTNR and pRNT; and p2TRN and p2RNT; and p3RNT, Figures 39A-E, 39F-G and 39H, respectively), the Nef gene in vectors GTU-2Nef and GTU-3Nef was substituted by the respective multireg antigen using NdeI and PstI sites. The sequence of the letters N(ef), R(ev) and T(at) in the name shows the position of respective coding sequences of the protein in the multi-gene. Also two vectors, which contain the IRES element placed into the SalI sites following either the multi-antigen or E2 coding sequences, were prepared (pTRN-iE2-GMCSF and pTRN-iMG-GMCSF, respectively; Figures 39I and J). The latter sequence, which controls the translation of the coding sequence of the mouse granulocyte-macrophage colony stimulating factor (GM-CSF), was cloned into the single BspTI site introduced with IRES.

Additionally, a set of the vectors, in which only immunodominant parts of the regulatory proteins were used for building up the polyproteins, were cloned into the Bsp119I and NotI sites of the GTU-1 (pMV1NTR, pMV2NTR, pMV1N11TR and pMV2N11TR; Figures 40A-D). In case of the pMV2 constructs, linkers that could be digested by intracellular proteases separate the regions of the multi-antigene derived from different regulatory proteins.

Further, GTU-1, GTU-2 and GTU-3 vectors, which express the structural proteins encoded by the gag gene or an artificial polyprotein composed by previously described CTL epitopes, were prepared. The coding sequences were cloned as Bsp119I and NotI digested PCR fragments into the GTU-1 vector (pCTL = BNmCTL, pdgag = pBNdgag, psynp17/24 = pBNsynp17+24, poptp17/24 = pBNoptp17/24; Figures 41A-D), and transferred in a NdeI-PacI fragment to the GTU-2 (p2mCTL and p2optp17/24; Figures 41E and F) and GTU-3 (p3mCTL and p3optp17/24; Figures 41G and H).

The coding segment designated as CTL (Sequence Id. No.10) contains fragments from pol and env regions involving many previously identified CTL epitopes. The codon usage is optimized so that only codons used frequently in human cells are involved. This coding sequence also contains a well-characterized mouse CTL epitope used in potency assay and an epitope for recognition by anti-mouse CD43 antibody. Also, a dominant SIV p27 epitope was included for use in potency studies in macaques.

The dgag contains truncated p17 (start at 13 aa) +p24+p2+p7 (p1 and p6 are excluded) (Sequence Id. No. 11) of gag region of the Han2 isolate. The synp17/24 (Sequence Id. No. 12) codes for the p17+p24 polypeptide of the Han2 HIV-1. The codon usage is modified to be optimal in human cells. Also, previously identified AU rich RNA instability elements were removed by this way. The optp17/24 coding (Sequence Id. No. 13) region is very similar to the synp17/24 with the exception that the two synonymous mutations made therein do not change the protein composition but remove a potential splicing donor site.

Further, a set of the multi-HIV vectors, which contain both a multireg antigen and structural antigens as a single polyprotein, were created: pTRN-CTL,

pRNT-CTL, pTRN-dgag, pTRN-CTL-dgag, pRNT-CTL-dgag, pTRN-dgag-CTL, pRNT-dgag-CTL, pTRN-optp17/24-CTL, pTRN-CTL-optp17/24, and pRNT-CTL-optp17/24; p2TRN-optp17/24-CTL, p2RNT-optp17/24-CTL, p2TRN-CTL-optp17/24, p2RNT-CTL-optp17/24, p2TRN-CTL-optp17/24-iE2-mGMCSF, and
 5 p2RNT-CTL-optp17/24-iE2-mGMCSF; and p3TRN-CTL-optp17/24, p3RNT-CTL-optp17/24, p3TRN-CTL-optp17/24-iE2-mGMCSF, and p3RNT-CTL-optp17/24-iE2-mGMCSF, Figures 42A-T.

For cloning, as a first step the STOP codon was removed from the regulatory multi-antigen coding sequences. Then the structural antigen coding sequences were added by cloning into the NotI site at the end of the frame so
 10 that a NotI site was reconstituted. If both CTL and gag were added, the first antigen coding sequence was without the STOP codon. Generally, the clonings were made in context of GTU-1 and for making the respective GTU-2 (p2...) and GTU-3 (p3...) vectors, the Nef gene in the plasmids GTU-2Nef and
 15 GTU-2Nef was replaced using sites for NdeI and PaeI. However, the RNT-optp17/24-CTL antigen was built up directly in GTU-2 vector.

The HIV multi-antigen was cloned to the vectors super6wtd1EGFP and FREBNA-d1EGFP instead of the d1EGFP using sites for Eco105I and NotI (super6wt-RNT-CTL-optp17/24 and FREBNA-RNT-CTL-optp17/24; Figures 43V
 20 and 42 U, respectively). If indicated, the IRES and mouse mGM-CSF were cloned into the GTU-2 and GTU-3 vectors behind the E2 coding sequence into the sites Mph1103I and Eco91I from pTRN-iE2-mGMCSF (cut out using same restrictases).

Finally, "non-GTU" control vector E2BSEBNA-RNT-CTL-optp17/24
 25 (Figure 42W) for the system utilizing EBNA-1 (contains EBNA-1 expression cassette with E2 binding sites) was made in a similar way as the FREBNA-RNT-CTL-optp17/24. The regular CMV vector pCMV-RNT-CTL-optp17/24 expressing the multi HIV antigen (Figure 42D) was made by cloning the multi-HIV coding fragment from respective GTU-1 vector using sites for NdeI and PaeI.

6.15. EXAMPLE 15: EXPRESSION PROPERTIES OF THE MULTIREG ANTIGENS CARRYING ONLY IMMUNODOMINANT REGIONS OF THE REGULATORY PROTEINS.

1. Intracellular localization of the MultiREG antigens

5 The intracellular localization of MultiREG antigens expressed by the vectors of the invention was studied by *in situ* immunofluorescence in RD cells using monoclonal antibodies against Nef, Rev and Tat proteins essentially as described in Example 4. The results are summarized in Table 5 and illustrated in figure 45. All antigens that are comprised of intact Nef, Rev and Tat proteins
10 showed exclusive localization in cytoplasm. The aberrant protein initially designed as N(e_f)T(a_t)R(e_v), which has a frame-shift before the Rev sequence, showed only the nuclear localization. MultiREG antigens carrying truncated sequences of the regulatory proteins were localized in cytoplasm. In this cases distinct structures like "inclusion bodies" were frequently observed. The same
15 was true for antigens, which carried the protease sites expressed from pMV2 vectors. However in these cases the proteins in nucleus were also detected (Figure 45).

Table 5. Intracellular localization in multireg antigens

Construct	anti-Nef	anti-Rev	anti-Tat
empty	negative	negative	negative
GTU-1			
pTRN	strong staining in cytoplasm	good staining in cytoplasm	positive staining in cytoplasm
pNTR	strong staining in nucleus, nucleolus	negative	positive staining in nucleus
pRNT	strong staining in cytoplasm	good staining in cytoplasm	good staining in cytoplasm
pNRT	strong, cytoplasmic	good staining in cytoplasm	good staining in cytoplasm
pRTN	strong, cytoplasmic	good staining in cytoplasm	positive staining in cytoplasm
pTNR	strong, cytoplasmic	good staining in cytoplasm	good staining in cytoplasm
pMV1NTR	strong, cytoplasmic	cytoplasmic+inclusions	cytoplasmic+inclusions
pMV1N11	strong	cytoplasmic+inclusions	cytoplasmic+inclusions
TR	cytoplasmic+inclusions	ons	s
pMV2NTR	inclusions in nuclei and in cytoplasm.	inclusions in nuclei and cytoplasm	inclusions in nuclei and cytoplasm
pMV2N11	only inclusions, in nuclei and in cytoplasm	only inclusions in nuclei and in cytoplasm	only inclusions in nuclei and in cytoplasm.
TR			

The intracellular localization of dgag and p17+p24 proteins was also analyzed in RD cells by immunofluorescence with monoclonal anti p24 antibodies. In accordance with the Western blot results in Jurkat cells, the dgag could not be detected. However, the p17/24 protein showed localization in plasma membranes (Figure 45). The localization of CTL protein was not analyzed, because no suitable antibody was available.

6.2 EXAMPLE 15: ANALYSIS OF VECTORS ENCODING RECOMBINANT GAG ANTIGENS AND CYTOTOXIC T-CELL EPITOPES (CTL) FROM POL

6.2.1. EXPRESSION

Analysis of expression of the vectors expressing CTL cds or proteins from the gag region were performed by western blot. As seen on Figure 46A and 46B, the CTL and dgag expression was clearly demonstrated in Cos-7 cells as predicted size proteins (25kD and 47kD, respectively). The co-transfection of the Nef, Rev and Tat significantly enhanced the expression of the dgag protein. We interpret this as a result of REV protein action on the GAG mRNA expression. We also tried to express the dgag protein from GTU-1 vector in Jurkat cells, but we failed to detect any signal (Figure 46C). The analysis of the codon usage showed that wt GAG sequence had not optimal codon usage for human cells. When the codon usage was optimized (constructs psynp17/24 and poptp17/24), strong p17+p24 (40kD) protein expression was detected in Jurkat cells (Figure 46C and 46D).

6.2.2. INTRACELLULAR LOCALIZATION

For dgag and p17+p24 proteins, the intracellular localization was also analyzed in RD cells by immunofluorescence with anti p24 Mab. Similar to the western blot results in Jurkat cells, the dgag could not be detected. The p17/24 protein showed localization in plasma membranes (Figure 47). The localization of CTL protein was not analyzed caused by lacking of suitable antibody.

6.16 EXAMPLE 16: MULTIREG+STRUCTURAL PROTEINS AS MULTIHIV ANTIGEN EXPRESSION

5 As next step, the expression of the MultiHIV antigens consisting of both, regular multigene together with gag encoded protein and/or CTL multiepitope as single polypeptide was analysed. On Figure 48, the Western blot shows the expression of several multiHIV-antigenes expressing vectors transfected to the Cos-7 cells. It is clearly seen that the expression levels of all
10 regulatory+structural multi-antigenes are significantly lower than of the RNT or TRN proteins. All tested MultiHIV antigens migrate in the gel as distinct bands near the position of predicted size (73kD for multireg+CTL; 95kD for multireg+dgag and 120kD for multireg+CTL+dgag). Similar to the RNT and TRN, the RNT-CTL migrates more slowly than TRN-CTL. Also, in cases of both TRN
15 and RNT constructs, the MultiREG-CTL-dgag combination showed higher expression level than MultiREG-dgag-CTL.

More detailed analysis of the multiHIV antigens was performed in Jurkat cells. For this reason, most of the constructed MultiHIV antigens (multireg+structural), included the MultiREG+CTL+optp17/24 (with predicted size
20 113kD) were analyzed by Western blotting using antibodies against different parts of the antigene. The results are presented on Figure 49 are principally similar to those were reported in previous section in case of Cos-7 cells. As it was seen in the previous experiments, the dgag containing multi-antigenes express very low levels of the hybrid protein in Jurkat cells. The expression
25 from the vector pTRNdag was undetectable on all blots. In lanes loaded material from cells transfected with other dgag containing antigene expression vectors, very faint signals only on the Nef Mab hybridized blot were detected at positions of predicted sizes. In contrast, if the dgag part is replaced with the codon optimized p17/24, the expression level increase was observed. Be-
30 cause the TRN-CTL-optp17/24 and RNT-optp17/24 were initially chosen for further analysis, the expression of the antigenes was analyzed from all GTU vectors containing these expression cassettes. Also, the E2 protein expression

from these plasmids was analyzed. The results are illustrated on Figure 50. There are no big differences between the vectors in expression levels of both multi-antigene and the E2 protein. The E2 expression level is not significantly influenced by presence of IRES element followed mouse GM-CSF gene in the
5 plasmid, translated from the same mRNA as the E2.

6.17. EXAMPLE 17: MAINTENANCE OF EXPRESSION OF ANTIGEN

The maintenance of the plasmid in a population of dividing cells was proved using the green fluorescent protein and Nef protein as markers. The
10 maintenance of the expression of the RNT-CTL-optp17/24 antigen produced from different GTU or non-GTU vectors was also analyzed. Specifically, GTU-1 (p RNT-CTL-optp17/24), GTU-2 (p2 RNT-CTL-optp17/24), GTU-3 (p3 RNT-CTL-optp17/24), super6wt (super6wt-RNT-CTL-optp17/24) vectors each utilize the E2 protein and its binding sites for the plasmid maintenance activity. In this
15 experiment, also EBNA-1 and its binding site utilizing GTU vector FREBNA-RNT-CTL-optp17/24 was included. As negative controls, "non-GTU" plasmid containing a mixed pair of the EBNA-1 expression cassette together with E2 binding sites (E2BSEBNA- RNT-CTL-optp17/24) was used. Also, regular CMV expression vector pCMV- RNT-CTL-optp17/24 was used.

20 Jurkat cells were transfected with equimolar amounts of the plasmids and the antigen expression was studied at 2 and 5 days post-transfection using a monoclonal anti-Nef antibodies. Transfection with carrier DNA only was used as a negative control. The results are presented in Figure 51.

As it seen from figure 51, the expression is detectable only from
25 GTU vectors at the second time-point. The antigen expression from the FREBNA- RNT-CTL-optp17/24 was lower at both time-points, because, unlike E2, the EBNA-1 does not have transcription activation ability.

Also the intracellular localization of the multireg+structural polyproteins was studied by *in situ* immunofluorescence analysis in RD cells essentially as described in Example 4. The results are presented in figure 52.
30

In all cases localization only in cytoplasm was detected using either monoclonal anti-Nef or anti-p24 antibodies. In accordance with Western blot data, the expression level of optp17/24 containing proteins was much stronger than dgag fragment containing antigens.

All references cited herein are incorporated herein by reference in their entirety and for all purposes to the same extent as if each individual publication or patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety for all purposes.

5 Many modifications and variations of this invention can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. The specific embodiments described herein are offered by way of example only, and the invention is to be limited only by the terms of the appended claims along with the full scope of equivalents to which such claims
10 are entitled.

WHAT IS CLAIMED IS:

1. An expression vector comprising:

- 5 (a) a DNA sequence encoding a nuclear-anchoring protein operatively linked to a heterologous promoter, said nuclear-anchoring protein comprising (i) a DNA binding domain which binds to a specific DNA sequence, and (ii) a functional domain that binds to a nuclear component, or a functional equivalent thereof; and
- 10 (b) a multimerized DNA sequence forming a binding site for the nuclear anchoring protein,

wherein said vector lacks a papilloma virus origin of replication.

2. The vector of claim 1, wherein said vector lacks an origin of replication functional in a mammalian cell.

15 3. The vector of claim 1 or 2, wherein said nuclear component is mitotic chromatin, the nuclear matrix, nuclear domain 10 (ND10), or nuclear domain POD.

4. The vector of claim 1 or 2, wherein said nuclear anchoring-protein is a chromatin-anchoring protein, and said functional domain binds mitotic chromatin.

20

5. The vector of claim 1 or 2, wherein said nuclear-anchoring protein contains a hinge or linker region.

6. The vector of claim 1 or 2, wherein said nuclear-anchoring protein is a natural protein of eukaryotic, prokaryotic, or viral origin.

25 7. The vector of claim 6, wherein said natural protein is of viral origin.

8. The vector of claim 6, wherein said nuclear-anchoring protein is a natural protein of eukaryotic origin.

9. The vector of claim 1 or 2, wherein said nuclear-anchoring protein is that of a papilloma virus or an Epstein-Barr virus.

30 10. The vector of claim 9, wherein said nuclear-anchoring protein is the E2 protein of Bovine Papilloma Virus type 1 or Epstein-Barr Virus Nuclear Antigen 1.

11. The vector of claim 10, wherein said nuclear-anchoring protein is the E2 protein of Bovine Papilloma Virus type 1.

12. The vector of claim 1 or 2, wherein said nuclear-anchoring protein is a High Mobility Group protein.

5 13. The vector of claim 1 or 2, wherein said nuclear-anchoring protein is a non-natural protein.

14. The vector of claim 13, wherein said nuclear-anchoring protein is a recombinant protein, a fusion protein, or a protein obtained by molecular modeling techniques.

10 15. The vector of claim 14, wherein said recombinant protein, fusion protein, or protein obtained by molecular modeling techniques contains any combination of a DNA binding domain which binds to said specific DNA sequence and a functional domain which binds to a nuclear component, wherein said functional domain which binds to a nuclear component is that of a papil-
15 loma virus, an Epstein-Barr-Virus, or a High Mobility Group protein.

16. The vector of claim 15, wherein said recombinant protein, fusion protein, or protein obtained by molecular modeling techniques contains any combination of a DNA binding domain which binds to said specific DNA sequence and a functional domain which binds to a nuclear component, wherein
20 said functional domain which binds to a nuclear component is that of E2 protein of Bovine Papilloma Virus type 1, Epstein-Barr Virus Nuclear Antigen 1, or a High Mobility Group protein.

17. The vector of claim 1 or 2, wherein said vector further comprises one or more expression cassettes of a DNA sequence of interest.

25 18. The vector of claim 17, wherein said DNA sequence of interest is that of an infectious pathogen.

19. The vector of claim 18, wherein said infectious pathogen is a virus.

20. The vector of claim 19, wherein said virus is selected from the group consisting of Human Immunodeficiency Virus (HIV), Herpes Simplex Virus (HSV), Hepatitis C Virus, Influenzae Virus, and Enterovirus.
30

21. The vector of claim 18, wherein said DNA sequence of interest is that of a bacterium.

22. The vector of claim 21, wherein said bacterium is selected from the group consisting of *Chlamydia trachomatis*, *Mycobacterium tuberculosis*, and *Mycoplasma pneumonia*.

23. The vector of claim 21, wherein said bacterium is *Salmonella*.

5 24. The vector of claim 17, wherein said DNA sequence of interest is that of a fungal pathogen.

25. The vector of claim 24, wherein said fungal pathogen is *Candida albicans*.

26. The vector of claim 20, wherein said DNA sequence of interest is
10 of HIV origin.

27. The vector of claim 26, wherein said DNA sequence of interest encodes a non-structural regulatory protein of HIV.

28. The vector of claim 27, wherein said non-structural regulatory protein of HIV is Nef, Tat or Rev.

15 29. The vector of claim 28, wherein said nonstructural regulatory protein of HIV is Nef.

30. The vector of claim 17, wherein said DNA sequence of interest encodes a structural protein of HIV.

20 31. The vector of claim 30, wherein said DNA sequence of interest is the gene encoding HIV gp120/gp160.

32. The vector of claim 17, wherein a first said expression cassette comprises a DNA sequence of interest which encodes Nef, Tat or Rev, and wherein a second said expression cassette comprises a DNA sequence of interest which encodes Nef, Tat or Rev.

25 33. The vector of claim 17, wherein a first said expression cassette comprises a DNA sequence of interest which encodes Nef, Tat or Rev, and wherein a second said expression cassette comprises a DNA sequence of interest which encodes a structural protein of HIV.

30 34. The vector of claim 17, wherein the DNA sequence of interest encodes a protein associated with cancer.

35. The vector of claim 17, wherein the DNA sequence of interest encodes a protein associated with immune maturation, regulation of immune responses, or regulation of autoimmune responses.

36. The vector of claim 35, wherein said protein is APECED.

5 37. The vector of claim 17, wherein the DNA sequence of interest is the Aire gene.

38. The vector of claim 17, wherein the DNA sequence of interest encodes a protein that is defective in any hereditary single gene disease.

39. The vector of claim 17, wherein the DNA sequence of interest encodes a macromolecular drug.

40. The vector of claim 39, wherein the DNA sequence of interest encodes a cytokine.

41. The vector of claim 40, wherein said cytokine is an interleukin selected from the group consisting of IL1, IL2, IL4, IL6 and IL12.

15 42. The vector of claim 40, wherein the DNA sequence of interest encodes an interferon.

43. The vector of claim 17, wherein said DNA sequence of interest encodes a biologically active RNA molecule.

44. The vector of claim 43, wherein said biologically active RNA molecule is selected from the group consisting of inhibitory antisense and ribozyme molecules.

45. The vector of claim 44, wherein said inhibitory antisense or ribozyme molecules antagonize the function of an oncogene.

46. The vector of claim 17 for use as a medicament.

25 47. The vector of claim 17 for use as a carrier vector for a gene, genes, or a DNA sequence or DNA sequences of interest, such as a gene, genes, or a DNA sequence or DNA sequences encoding a protein or peptide of an infectious agent, a therapeutic agent, a macromolecular drug, or any combination thereof.

30 48. The vector of claim 17 for use as a medicament for treating inherited or acquired genetic defects.

49. The vector of claim 17 for use as a therapeutic DNA vaccine against an infectious agent.

50. The vector of claim 17 for use as a therapeutic agent.

51. A vector of claim 17 for the use for production of a protein encoded
5 by said DNA sequence of interest in a cell or an organism.

52. A vector of claim 17 for the use for production of a therapeutic macromolecular agent *in vivo*.

53. A method for providing a protein to a subject, said method comprising administering to the subject the vector of claim 1 or 2, wherein said
10 vector (i) further comprises a second DNA sequence encoding the protein to be provided to the subject, which second DNA sequence is operably linked to a second promoter, and (ii) does not encode Bovine Papilloma Virus protein E1, and wherein said subject does not express Bovine Papilloma Virus protein E1.

15 54. A method for inducing an immune response to a protein in a subject, said method comprising administering to the subject the vector of claim 1 or 2, wherein said vector (i) further comprises a second DNA sequence encoding said protein, which second DNA sequence is operably linked to a second promoter, and (ii) does not encode Bovine Papilloma Virus protein E1, and
20 wherein said subject does not express Bovine Papilloma Virus protein E1.

55. A method for treating an infectious disease in a subject in need of said treatment, said method comprising administering to said subject a therapeutically effective amount of the vector of claim 17, wherein said DNA sequence of interest encodes a protein comprising an immunogenic epitope of
25 an infectious agent.

56. A method for treating an inherited or acquired genetic defect in a subject in need of said treatment, said method comprising: administering to said subject a therapeutically effective amount of the vector of claim 17, wherein said DNA sequence of interest encodes a protein which is affected by
30 said inherited or acquired genetic defect.

57. A method for expressing a DNA sequence in a subject, said method comprising administering the vector of claim 17 to said subject.

58. The method of claim 55, 56, or 57, wherein said vector does not encode Bovine Papilloma Virus protein E1, and wherein said subject does not express Bovine Papilloma Virus protein E1.

59. A method for the preparation of a vector of claim 1 or 2 comprising:
5 (a) cultivating a host cell containing said vector; and
(b) recovering the vector.

60. The method of claim 59, further comprising before step (a) a step of transforming said host cell with said vector.

61. The method of claim 59, wherein said host cell is a prokaryotic cell.

10 62. The method of claim 59, wherein said host cell is an Escherichia coli.

63. A host cell, characterized by containing the vector of claim 1 or 2.

64. A host cell, characterized by containing the vector of claim 17.

65. The host cell of claim 63, wherein said host cell is a bacterial cell.

15 66. The host cell of claim 63, wherein said host cell is a mammalian cell.

67. A carrier vector containing the vector of claim 1 or 2.

68. A pharmaceutical composition comprising the vector of claim 17 and a suitable pharmaceutical carrier.

20 69. A DNA vaccine containing the vector of claim 17.

70. A DNA vaccine containing the vector of claim 18.

71. A DNA vaccine containing the vector of claim 19.

72. A DNA vaccine containing the vector of claim 21.

73. A DNA vaccine containing the vector of claim 24.

25 74. A gene therapeutic agent containing the vector of claim 17.

75. A method for the preparation of the DNA vaccine of claim 69, said method comprising combining the vector of claim 17 with a suitable pharmaceutical vehicle.

30 76. A method for the preparation of the DNA vaccine of claim 69, said method comprising combining the vector of claim 18 with a suitable pharmaceutical vehicle.

77. A method for the preparation of the DNA vaccine of claim 69, said method comprising combining the vector of claim 19 with a suitable pharmaceutical vehicle.

5 78. A method for the preparation of the DNA vaccine of claim 69, said method comprising combining the vector of claim 21 with a suitable pharmaceutical vehicle.

79. A method for the preparation of the DNA vaccine of claim 69, said method comprising combining the vector of claim 24 with a suitable pharmaceutical vehicle.

10 80. A method for the preparation of the agent of claim 74, said method comprising combining the vector of claim 17 with a suitable pharmaceutical vehicle.

1/91





FIG. 1

2/91

**FIG. 2**

3/91




FIG. 3

4/91




FIG. 4

5/91




FIG. 5

6/91




FIG. 6A




FIG. 6B

7/91




FIG. 7

8/91




FIG. 8

9/91




FIG. 9

10/91




FIG. 10

11/91




FIG. 11

12/91




FIG. 12

13/91




FIG. 13

14/91




FIG. 14

15/91




FIG. 15

16/91




FIG. 16

17/91




FIG. 17

18/91




FIG. 18

19/91




FIG. 19

20/91




FIG. 20

21/91




FIG. 21

22/91




FIG. 22

23/91




FIG. 23

24/91




FIG. 24

25/91




FIG. 25

26/91




FIG. 26

27/91





FIG. 27

28/91

**FIG. 28**

29/91


Plasmid pEBO LPP

FIG. 29A


Plasmid s6E2d1EGFP

FIG. 29B

30/91


Plasmid FRE2d1EGFP

FIG. 29C

31/91


Plasmid FREBNAd1EGFP

FIG. 30

32/91




FIG. 31

33/91




FIG. 32

34/91




FIG. 33




FIG. 34A




FIG. 34B

36/91




FIG. 35

37/91




FIG. 36

38/91




FIG. 37

39/91




FIG. 38A

40/91




FIG. 38B

41/91




FIG. 38C

42/91




FIG. 38D

43/91




FIG. 38E

44/91




FIG. 38F

45/91




FIG. 38G

46/91




FIG. 39A

47/91




FIG. 39B

48/91




FIG. 39C

49/91




FIG. 39D

50/91




FIG. 39E

51/91




FIG. 39F

52/91




FIG. 39G

53/91




FIG. 39H

54/91




FIG. 39 I

55/91




FIG. 39J

56/91




FIG. 40A

57/91




FIG. 40B

58/91




FIG. 40C

59/91




FIG. 40D

60/91




FIG. 41A

61/91




FIG. 41B

62/91




FIG. 41C

63/91




FIG. 41D

64/91




FIG. 41E

65/91




FIG. 41F

66/91




FIG. 41G

67/91




FIG. 41H

68/91




FIG. 42A

69/91




FIG. 42B

70/91




FIG. 42C

71/91




FIG. 42D

72/91




FIG. 42E

73/91




FIG. 42F

74/91




FIG. 42G

75/91




FIG. 42H

76/91




FIG. 42 I

77/91




FIG. 42J

78/91




FIG. 42K

79/91




FIG. 42L

80/91




FIG. 42M

81/91




FIG. 42N

82/91




FIG. 42 O

83/91




FIG. 42P

84/91




FIG. 42Q

85/91




FIG. 42R

86/91




FIG. 42S

87/91




FIG. 42T

88/91




FIG. 42U

89/91




FIG. 42V

90/91




FIG. 42W

91/91




FIG. 42X

SEQUENCE LISTING

<110> FIT Biotech Oyj Plc

<120> Novel expression vectors and uses thereof

<130> 11041-006-228 (2010149)

<140> To be assigned

<141> 2002-05-03

<150> FI 20010922

<151> 2001-05-03

<160> 52

<170> PatentIn version 3.1

<210> 1

<211> 1260

<212> DNA

<213> Artificial Sequence

<220>

<223> Hybrid protein comprised of Nef-Tat-Rev (NTR)

<400> 1

atggtgggca	agtgggtcaaa	atgtagtgga	tggcctactg	taagggaag	aatgaaacaa	60
gctgagcctg	agccagcagc	agatgggggtg	ggagcagcat	ctcgagacct	ggaaaaacat	120
ggagcaatca	caagtagcaa	tacagcaact	aataacgctg	cttgtgcctg	gctagaagca	180
caagagggaag	aggaagtggg	ttttccagtc	agacctcagg	tacctttaag	accaatgact	240
tacaaggagg	ctttagatct	tagccacttt	ttaaaagaaa	aggggggact	ggaagggtta	300
atttactccc	caaaaagaca	agagatcctt	gatctgtggg	tctaccacac	acaaggctac	360
ttccctgatt	ggcagaacta	cacaccaggg	ccaggggtca	gatatccact	gacctttgga	420
tgggtgcttca	agttagtacc	agttgaacca	gatgaagaag	agaacagcag	cctgttacac	480
cctgcgagcc	tgcattgggac	agaggacacg	gagagagaag	tgttaaagtg	gaagtttgac	540
agccatctag	catttcatca	caaggcccga	gagctgcac	cggagtacta	caaagactgc	600
actagtgccg	gaagaagcgg	agacagcgac	gaagagctcc	tcaagacagt	cagactcatc	660
aagtttctct	accaaagcaa	ccctcctccc	agcaacgagg	ggacccgaca	ggcccgaaga	720
aatcgaagaa	gaaggtggag	agagagacag	aggcagatcc	gttcgattag	tgagcggatt	780
cttagcactt	ttctgggacg	acctgcggag	cctgtgcctc	ttcagctacc	gccgcttgag	840
agacttactc	ttgattgtag	cgaagattgt	ggaaaactctg	ggacgcaggg	ggtgggaagt	900
cctcaagtat	tggtggaatc	tcctgcagta	ttggagccag	gaactaaaga	aaagcttgag	960
ccagtagatc	ctagactaga	gccttggaag	catccaggaa	gtcagcctag	gaccccttgt	1020
accaattgct	attgtaaaaa	gtgttgctt	cattgccaaag	tttgtttcac	aagaaaaggc	1080
ttaggcatct	cctatggcag	gaagaagcgg	agacagcgac	gaagagctcc	tcaagacagt	1140
cagactcatc	aagtttctct	accaaagcaa	ccctcctccc	agcaacgagg	ggacccgaca	1200
ggcccgaaga	aatcgaagaa	gaaggtggag	agagagacag	aggcagatcc	gttcgattag	1260

<210> 2

<211> 1260

<212> DNA

<213> Artificial Sequence

<220>

<223> Hybrid protein comprised of Tat-Rev-Nef (TRN)

<400> 2

atggagccag	tagatcctag	actagagccc	tggaaagcatc	caggaagtca	gcctaggacc	60
ccttgtacca	attgctattg	taaaaagtgt	tgcttccatt	gccaaagttg	tttcacaaga	120
aaaggcttag	gcattctcta	tggcaggaag	aagcggagac	agcgacgaag	agtcctcaa	180
gacagtca	ctcatcaagt	ttctctacca	aagcaacctt	cctcccagca	acgaggggac	240
ccgacaggcc	cgaagaaatc	gaagaagaag	gtggagagag	agacagagc	agatccgttc	300

```

gatactagtg caggaagaag cggagacagc gacgaagagc tcctcaagac agtcagactc 360
atcaagtttc tctaccaaag caacctcct cccagcaacg aggggacccg acaggcccga 420
agaaatcgaa gaagaagggtg gagagagaga cagaggcaga tccgttcgat tagtgagcgg 480
attccttagca cttttctggg acgacctgcg gagcctgtgc ctcttcagct accgccgctt 540
gagagactta ctcttgattg tagcgaagat tgtggaaact ctgggacgca ggggggtggga 600
agtcctcaag tattggtgga atctcctgca gtattggagc caggaactaa agaaaagctt 660
gtgggcaagt ggtcaaaatg tagtggatgg cctactgtaa gggaaagaat gaaacaagct 720
gagcctgagc cagcagcaga tgggggtggga gcagcatctc gagacctgga aaaacatgga 780
gcaatcacaa gtagcaatac agcaactaat aacgctgctt gtgcctggct agaagcacaa 840
gaggaagagg aagtgggttt tccagtcaga cctcaggtag ctttaagacc aatgacttac 900
aagggagctt tagatcttag ccacttttta aaagaaaagg ggggactgga agggttaatt 960
tactcccaa aaagacaaga gatccttgat ctgtgggtct accacacaca aggtacttc 1020
cctgattggc agaactacac accagggcca ggggtcagat atccactgac ctttggatgg 1080
tgcttcaagt tagtaccagt tgaaccagat gaagaagaga acagcagcct gttacaccct 1140
gcgagcctgc atgggacaga ggacacggag agagaagtgt taaagtggaa gtttgacagc 1200
catctagcat ttcatacaaa ggcccagagc ctgcatccgg agtactacaa agactgctga 1260

```

<210> 3
 <211> 1260
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Hybrid protein comprised of Rev-Tat-Nef (RTN)

```

<400> 3
atggcaggaa gaagcggaga cagcgacgaa gagctcctca agacagtcag actcatcaag 60
tttctctacc aaagcaaccc tcctcccagc aacgagggga cccgacaggc ccgaagaaat 120
cgaagaagaa ggtggagaga gagacagagg cagatccgtt cgattagtga gcggattctt 180
agcacttttc tgggacgacc tgcggagcct gtgcctcttc agctaccgcc gcttgagaga 240
cttactcttg attgtagcga agattgtgga aactctggga cgcagggggg ggggaagtcct 300
caagtattgg tggaaatctc tgcagtattg gagccaggaa ctaaagaaac tagtgagcca 360
gtagatccta gactagagcc ctggaagcat ccaggaaagc agcctaggac cccttgtagc 420
aattgctatt gtaaaaagtg ttgccttcac tgccaagtgt gtttcacaa aaaaggctta 480
ggcatctcct atggcaggaa gaagcggaga cagcgacgaa gagctcctca agacagtcag 540
actcatcaag tttctctacc aaagcaaccc tcctcccagc aacgagggga cccgacaggc 600
ccgaagaagt cgaagaagaa ggtggagaga gagacagagg cagatccgtt cgataagctt 660
gtgggcaagt ggtcaaaatg tagtggatgg cctactgtaa gggaaagaat gaaacaagct 720
gagcctgagc cagcagcaga tgggggtggga gcagcatctc gagacctgga aaaacatgga 780
gcaatcacaa gtagcaatac agcaactaat aacgctgctt gtgcctggct agaagcacaa 840
gaggaagagg aagtgggttt tccagtcaga cctcaggtag ctttaagacc aatgacttac 900
aagggagctt tagatcttag ccacttttta aaagaaaagg ggggactgga agggttaatt 960
tactcccaa aaagacaaga gatccttgat ctgtgggtct accacacaca aggtacttc 1020
cctgattggc agaactacac accagggcca ggggtcagat atccactgac ctttggatgg 1080
tgcttcaagt tagtaccagt tgaaccagat gaagaagaga acagcagcct gttacaccct 1140
gcgagcctgc atgggacaga ggacacggag agagaagtgt taaagtggaa gtttgacagc 1200
catctagcat ttcatacaaa ggcccagagc ctgcatccgg agtactacaa agactgctga 1260

```

<210> 4
 <211> 1260
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Hybrid protein comprised of Tat-Nef-Rev (TNR)

```

<400> 4
atggagccag tagatcctag actagagccc tggaaagcatc caggaagtca gcctaggacc 60
ccttgtaacca attgctattg taaaaagtgt tgccttcatt gccaaagtttg tttcacaaaga 120
aaaggcttag gcactcctcta tggcaggaag aagcggagac agcgacgaag agctcctcaa 180
gacagtcaga ctcatcaagt ttctctacca aagcaaccct cctcccagca acgaggggac 240
ccgacaggcc cgaagaatc gaagaagaag gtggagagag agacagaggc agatccgttc 300
gatactagtg tgggcaagtg gtcaaaatgt agtggatggc ctactgtaag ggaagaagt 360

```

```

aaacaagctg agcctgagcc agcagcagat ggggtgggag cagcatctcg agacctggaa 420
aaacatggag caatcacaag tagcaatata gcaactaata acgctgcttg tgccctggcta 480
gaagcacaag aggaagagga agtgggtttt ccagtcagac ctcaggtacc tttaagacca 540
atgacttaca agggagcttt agatcttagc cactttttta aagaaaaggg gggactggaa 600
gggttaattt actccccc aaagacaagag atccttgatc tgtgggtcta ccacacacaa 660
ggctacttcc ctgattggca gaactacaca ccagggccag gggtcagata tccactgacc 720
tttggatggt gcttcaagtt agtaccagtt gaaccagatg aagaagagaa cagcagcctg 780
ttacaccctg cgagcctgca tgggacagag gacacggaga gagaagtgtt aaagtggaa 840
tttgacagcc atctagcatt tcatcacaag gcccagagc tgcatccgga gtactacaaa 900
gactgcaagc ttgcaggaag aagcggagac agcgcagaa agctcctcaa gacagtcaga 960
ctcatcaagt ttctctacca aagcaaccct cctcccagca acgaggggac ccgacaggcc 1020
cgaagaatc gaagaagaag gtggagagag agacagagcc agatccgttc gattagttag 1080
cggattctta gcacttttct gggacgacct gcggagcctg tgcctcttca gctaccgccg 1140
cttgagagac ttactcttga ttgtagcga gattgtggaa actctgggac gcaggggggtg 1200
ggaagtctc aagtattggt ggaatctcct gcagtattgg agccaggaac taaagaatag 1260

```

<210> 5
 <211> 1260
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Hybrid protein comprised of Rev-Nef-Tat (RNT)

```

<400> 5
atggcaggaa gaagcggaga cagcgacgaa gagctcctca agacagtcag actcatcaag 60
tttctctacc aaagcaaccc tctctccagc aacgagggga cccgacaggc ccgaagaaat 120
cgaagaagaa ggtggagaga gagacagagg cagatccgtt cgattagtga gcggattctt 180
agcacttttc tgggacgacc tgcggagcct gtgcctcttc agctaccgcc gcttgagaga 240
cttactcttg attgtagcga agattgtgga aactctggga cgcaggggggt gggaaagtct 300
caagtattgg tggaaatctc tgcagtattg gagccaggaa ctaaagaaac tagtgtgggc 360
aagtgttcaa aatgtagtgg atggcctact gtaagggaaa gaatgaaaca agctgagcct 420
gagccagcag cagatgggggt gggagcagca tctcgagacc tggaaaaaca tggagcaatc 480
acaagtagca atacagcaac taataacgct gcttgtgcct ggctagaagc acaagaggaa 540
gaggaagtgg gttttccagt cagacctcag gtacctttta gaccaatgac ttacaaggga 600
gcttttagatc ttagccactt tttaaaagaa aagggggggac tggaaagggt aatttactcc 660
ccaaaaagac aagagatcct tgatctgtgg gtctaccaca cacaaggcta ctccctgat 720
tggcagaact acacaccagg gccaggggtc agatatccac tgaccttttg atgtgtgctt 780
aagttagtac cagtggaacc agatgaagaa gagaacagca gcctgttaca ccctgcgagc 840
ctgcatggga cagaggacac ggagagagaa gtgttaaaagt ggaagtgtga cagccatcta 900
gcatttcac acaaggcccg agagctgcat ccggagtact acaagactg caagcttgag 960
ccagtagatc ctagactaga gccctggaag catccaggaa gtcagcctag gacccttgt 1020
accaattgct attgtaaaaa gtgttgctt cattgccaag tttgtttcac aagaaaaggc 1080
ttaggcatct cctatggcag gaagaagcgg agacagcgac gaagagctcc tcaagacagt 1140
cagactcatc aagtttctct accaaagcaa ccctcctccc agcaacgagg ggacccgaca 1200
ggcccgaaga aatcgaagaa gaaggtggag agagagacag aggcagatcc gttcgattag 1260

```

<210> 6
 <211> 1164
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Protein comprised of Immunodominant parts of the Nef-Tat-Rev (NTR)

```

<400> 6
atgggatggc ctactgtaag ggaagaatg aaacaagctg agcctgagcc agcagcagat 60
gggggtggag cagcatctcg agacctggaa aaacatggag caatcacaag tagcaatata 120
gcaactaata acgctgcttg tgccctggta gaagcacaag aggaagagga agtgggtttt 180
ccagtcagac ctcaggtacc tttaagacca atgacttaca agggagcttt agatcttagc 240
cactttttta aagaaaaggg gggactggaa gggtaattt actccccc aaagacaagag 300
atccttgatc tgtgggtcta ccacacacaa ggctacttcc ctgattggca gaactacaca 360
ccagggccag gggtcagata tccactgacc tttggatggt gcttcaagtt agtaccagtt 420

```

```

gaaccagatg aagaagagaa cagcagcctg ttacaccctg cgagcctgca tgggacagag 480
gacacggaga gagaagtgtt aaagtggag tttgacagcc atctagcatt tcatacacaag 540
gcccagagagc tgcataccgga gtactacaaa gactgcgctc tggccgcccgt tgagccagta 600
gatcctagac tagagccctg gaagcatcca ggaagtcagc ctaggacccc ttgtaccaat 660
tgctattgta aaaagtgttg ccttcattgc caagtgtgtt tcacaagaaa aggcttaggc 720
atctcctatg gcaggaagaa gcggagacag cgacgaagag ctctcaaga cagtcagact 780
catcaagttt ctctacaaa gcaacccctc tcccagcaac gaggggaccc gacaggcccg 840
aagaaatccg gactggccat cctgctgagc gacgaagagc tcctcaagac agtcagactc 900
atcaagtttc tctacaaaag caaccctcct cccagcaacg aggggacccc acaggcccga 960
agaaatcgaa gagaagggtg gagagagaga cagaggcaga tccgttcgat tagtgagcgg 1020
attcttagca cttttctggg acgacctgag gagcctgtgc ctcttcagct accgccgctt 1080
gagagactta ctcttgattg tagcgaagat tgtggaaact ctgggacgca ggggggtggga 1140
agtctcaag tattggtgga atga 1164

```

<210> 7
 <211> 1173
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Protein comprised of Immunodominant parts of the Nef-Tat-Rev separated by protease sites (NTR)

```

<400> 7
atgggatggc ctactgtaag ggaagaatg aaacaagctg agcctgagcc agcagcagat 60
gggggtggag cagcatctcg agacctggaa aaacatggag caatcacaa tagcaataca 120
gcaactaata acgctgcttg tgcttgcta gaagcacaag aggaagagga agtgggtttt 180
ccagtcagac ctacaggtacc ttttaagacca atgacttaca agggagcttt agatcttagc 240
cactttttta aagaaaaggg gggactggaa gggtttaattt actcccaaaa aagacaagag 300
atccttgatc tgtgggtcta ccacacaca ggctacttcc ctgattggca gaactacaca 360
ccagggccag gggtcagata tccactgacc tttggatggg gcttcaagtt agtaccagtt 420
gaaccagatg aagaagagaa cagcagcctg ttacaccctg cgagcctgca tgggacagag 480
gacacggaga gagaagtgtt aaagtggag tttgacagcc atctagcatt tcatacacaag 540
gcccagagagc tgcataccgga gtactacaaa gactgcgctc tggccttcaa ggggttgag 600
ccagtagatc ctactagaga gccttggaag catccaggaa gtcagcctag gacccctgt 660
accaattgct attgtaaaaa gtgttgctt cattgccaa tttgtttcac aagaaaaggc 720
ttaggcacat cctatggcag gaagaagcgg agacagcgac gaagagctcc tcaagacagt 780
cagactcacc aagtttctct accaaagcaa cctcctccc agcaacgagg ggacccgaca 840
ggcccgaaga aatccgtacg ggagaagcgg ctgctgagcg acgaagagct cctcaagaca 900
gtcagactca tcaagtttct ctacaaaagc aaccctcctc ccagcaacga ggggacccga 960
caggcccga gaaatcgaa agaaagtgag agagagagac agaggcagat ccgttcgatt 1020
agtgagcggg ttcttagcac ttttctggga cgacctgagg agcctgtgac tcttcagcta 1080
ccgccgcttg agagacttac tcttgattgt agcgaagatt gtggaaactc tgggacgcag 1140
ggggtgggaa gtctcaagt attggtgga tga 1173

```

<210> 8
 <211> 1161
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Protein comprised of Immunodominant parts of the regulatory proteins Nef-Tat-Rev started from aal of Nef (N11TR)

```

<400> 8
atgtggccta ctgtaaggga aagaatgaaa caagctgagc ctgagccagc agcagatggg 60
gtgggagcag catctcgaga cctggaaaaa catggagcaa tcacaagtag caatacagca 120
actaataacg ctgcttgctg ctggctagaa gcacaagagg aagaggaagt ggggtttcca 180
gtcagacctc aggtaccttt aagaccaatg acttacaagg gagctttaga tcttagccac 240
tttttaaaag aaaagggggg actggaaggg ttaatttact ccccaaaaag acaagagatc 300
cttgatctgt ggggtctacca cacacaaggc tacttccctg attggcagaa ctacacacca 360
gggccagggg tcagatatcc actgaccttt ggatggtgct tcaagttagt accagttgaa 420
ccagatgaag aagagaacag cagcctgtta caccctgcga gcctgcagtg gacagaggac 480

```

```

acggagagag aagtgttaaa gtggaagttt gacagccatc tagcatttca tcacaaggcc 540
cgagagctgc atccggagta ctacaaagac tgcgctctgg ccgccgttga gccagtagat 600
cctagactag agccctggaa gcatccagga agtcagccta ggacccttg taccaattgc 660
tattgtaaaa agtgttgctt tcattgccaa gtttgtttca caagaaaagg cttaggcatc 720
tcctatggca ggaagaagcg gagacagcga cgaagagctc ctcaagacag tcagactcat 780
caagtttctc taccaaagca accctcctcc cagcaacgag gggacccgac aggcccgaag 840
aaatccggac tggccatcct gctgagcgac gaagagctcc tcaagacagt cagactcatc 900
aagtttctct accaaagcaa ccctcctccc agcaacgagg ggacccgaca ggcccgaaga 960
aatcgaagaa gaaggtggag agagagacag aggcagatcc gttcgattag tgagcggatt 1020
cttagcactt ttctgggacg acctgcggag cctgtgcctc ttcagctacc gccgcttgag 1080
agacttactc ttgattgtag cgaagattgt ggaaactctg ggacgcaggg ggtgggaagt 1140
cctcaagtat tgggtgaatg a 1161

```

<210> 9
 <211> 1170
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Protein comprised of Immunodominant parts of the regulatory proteins
 Nef-Tat-Rev started from aal of Nef separated by protease sites (N11TR)

```

<400> 9
atgtggccta ctgtaaggga aagaatgaaa caagctgagc ctgagccagc agcagatggg 60
gtgggagcag catctcgaga cctggaaaaa catggagcaa tcacaagtag caatacagca 120
actaataacg ctgcttgtgc ctggctagaa gcacaagagg aagaggaagt gggttttcca 180
gtcagacctc aggtaccttt aagaccaatg acttacaagg gagctttaga tcttagccac 240
tttttaaaag aaaagggggg actggaaggg ttaatttact ccccaaaaag acaagagatc 300
cttgatctgt gggcttacca cacacaaggc tacttccctg attggcagaa ctacacacca 360
gggccagggg tcagatatcc actgaccttt ggatgggtgct tcaagttagt accagttgaa 420
ccagatgaag aagagaacag cagcctgtta caccctgcga gcctgcattg gacagaggac 480
acggagagag aagtgttaaa gtggaagttt gacagccatc tagcatttca tcacaaggcc 540
cgagagctgc atccggagta ctacaaagac tgcgctctgg ccttcaagcg ggttgagcca 600
gtagatccta gactagagcc ctggaagcat ccaggaagtc agcctaggac cccttgtacc 660
aattgctatt gtaaaaagtg ttgccttcat tgccaaagttt gtttcacaag aaaaggctta 720
ggcatctcct atggcaggaa gaagcggaga cagcgacgaa gagctcctca agacagtcag 780
actcatcaag ttctcttacc aaagcaaccc tcctcccagc aacgagggga cccgacaggc 840
ccgaagaagt ccgtacggga gaagcggctg ctgagcgagc aagagctcct caagacagtc 900
agactcatca agtttctcta ccaagcaac cctcctccca gcaacgaggg gacccgacag 960
gccgaagaa atcgaagaag aaggtggaga gagagacaga ggcagatccg ttcgattagt 1020
gagcggattc tttagcactt tctgggacga cctgcggagc ctgtgcctct tcagctaccg 1080
ccgcttgaga gacttactct tgattgtagc gaagattgtg gaaactctg gacgcagggg 1140
gtgggaagtc ctcaagtatt ggtggaatga 1170

```

<210> 10
 <211> 663
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Protein comprised of Cytotoxic T-cell epitopes of Pol and Env genes
 (CTL)

```

<400> 10
atgatcaccc tgtggcagcg cccctgggtg gccctgatcg agatctgcac cgagatggag 60
aaggagggca agatcagcaa gatcgcccc gccggcctga agaagaagaa gagcgtgacc 120
gtgctggacg tggcgagcgc ctacttcagc gtgcccctgg ataaggactt ccgcaagtac 180
accgccttca ccatcccccag catctggaag ggcagccccg ccatcttcca gagcagcatg 240
accaagaagc agaaccccga catcgtgatc taccagtaca tggacgacct gtacgtgccc 300
atcgtgctgc ccgagaagga cagctggctg gtgggcaagc tgaactgggc cagccagatc 360
tacgcccggc tcaaggtgaa gcagctgatc ctgaaggagc ccgtgcacgg cgtgtacgag 420
cccacgtggy gcgccgagac cttctacgtg gacggcgccg ccaaccgcgc cggcaacctg 480
tgggtgacgg tgtactacgg cgtgcccgty tgggaaggag ccaccaccac cctggtggag 540

```

```

cgctacctgc gcgaccagca gctgctgggc atctggggct ggcctgcac cccctacgac 600
atcaaccaga tgctgcgcgg ccttggccgc gccttcgtga ccatccgcca gggcagcctg 660
tag 663

```

<210> 11
 <211> 1266
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Truncated Gag protein sequence (dgag)

```

<400> 11
atggttagaca aatgggaaaa aattcgggta aggccagggg gaaagaaaaa atatcaatta 60
aaacatatag tatgggcaag caggagagcta gaacgattcg cagttaatcc tggcctgtta 120
gaaacatcag aaggctgtag acagataatg ggacagctac aaccgtccct tcagacagga 180
tcagaagaac ttagatcatt atataataca gtagcaaccc tctatttgtgt gcatcaaaag 240
atagaggtaa aagacaccaa ggaagcttta gacaaggtag aggaagagca aaacaacagt 300
aagaaaaagg cacagcaaga agcagctgac gcaggaaaca gaaaccaggt cagccaaaat 360
taccctatag tgcaaaacct acagggacaa atgggtacatc aggccatc acctagaact 420
ttaaattgcat gggtaaaagt agtggaagag aaggctttca gcccagaagt aatacccatg 480
ttttcagcat tatcagaagg agccacccca caagatttaa acaccatgct aaacacagt 540
gggggacatc aagcagccat gcaaatgtta aaagaaacca tcaatgagga agctgcagaa 600
tgggatagat tgcacccagt gcatgcaggg cctattgcac caggccagat gagagaacca 660
aggggaagt acatagcagg aactactagt acccttcagg acaaaatagg atggatgaca 720
aataatccac ctatccaggt aggagaaata tataagagat ggataatcct gggattaaat 780
aaaatagtaa gaatgtatag ccctaccagc attctggata taaaacaagg accaaaagaa 840
cccttttagag attatgtaga ccggttctat aaaaccctaa gagccgagca agctacacag 900
gaagtaaaaa attggtatgac agaaaccttg ttggtccaaa atgcgaatcc agattgtaag 960
actattttta aagcatttag accagcagct acactagaag aaatgatgac agcatgtcag 1020
ggagtggggg gaccgggcca taaagcaaga gttttggctg aagcaatgag ccaagtaaca 1080
ggttcagctg ccataatgat gcagagaggg aatttttagga accaaagaaa gactgttaag 1140
tgtttcaatt gtggcaaaag agggcacata gccagaaatt gcaggggccc taggaaaaag 1200
ggctgttgga aatgtggaaa ggaaggacat caaatgaagg attgcacaga aagacaggct 1260
aattag 1266

```

<210> 12
 <211> 1092
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic coding sequence for p17/24 protein of Gag gene (syn 17/24)

```

<400> 12
atgggacgcaa gagcctccgt gctgagcggc ggagagctgg acaagtggga gaagatccgc 60
ctgcgccccg gcggaagaa gaagtaccag ctgaagcaca tcgtgtgggc cagccgcgag 120
ctggagcgct tcgccgtgaa ccccgccctg ctcgagacca gcgaaggctg ccgccagatc 180
atgggacgag tccagcccag cctccagacc ggcagcgagg agctgcgcag cctgtacaac 240
accgtggcca ccctgtactg cgtgcaccag aagatcgagg tgaaggacac caaggaggcc 300
ctggacaagg tcagggagga gcagaacaac agcaagaaga aggccagca ggaaggccgc 360
gacgcccgca accgcaacca ggtgagccag aactacccca tcgtgcagaa cctgcagggc 420
cagatggtgc accaggccat cagccccgc accctgaacg cctgggtgaa ggtgggtggag 480
gagaaggcct tcagccccga ggtgatcccc atgttcagcg ccctgagcga gggcgctacc 540
ccccaggacc tgaacacccat gctgaacacc gtgggcccgc accaggccgc catgcagatg 600
ctgaaggaga ccatcaacga ggaaggccgc gactgggacc gcctgcaccc cgtgcacgcc 660
gggcccacgc cccccggcca gatgcgcgag ccccgcgcca gcgacatcgc cggcaccacc 720
agcacccctc aggagcagat cggctggatg accaacaacc ccccatccc cgtgggagag 780
atctacaagc gctggatcat cctgggcctg aacaagatcg tccgcatgta cagccccacc 840
agcatcctgg acatcaagca gggccccaag gagcccttc gcgactacgt ggaccgcttc 900
tacaagacc tcgcgcgccga gcaggccacc caggaggtga agaactggat gaccgagacc 960
ctgctggtgc agaacgcca ccccgactgc aagaccatcc tcaaggccct gggaccgcgc 1020
gccaccctgg aggatgatg gaccgcctgc caaggcgtgg gcggccccgc ccacaaggcc 1080

```

cgcggtgctgt ga

1092

<210> 13

<211> 1092

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic coding sequence for p17/24 protein of Gag gene optimized for expression in eukaryotic cells (optp17/24)

<400> 13

atgggagcga	gagcctccgt	gctgagcggc	ggagagctgg	acaagtggga	gaagatccgc	60
ctgcgccccg	gcggcaagaa	gaagtaccag	ctgaagcaca	tcgtgtgggc	cagccgcgag	120
ctggagcgct	tcgccgtgaa	ccccggcctg	ctcgagacca	gcgaaggctg	ccgccagatc	180
atgggcccagc	tccagcccag	cctccagacc	ggcagcgagg	agctgcgcag	cctgtacaac	240
accgtggcca	ccctgtactg	cgtgcaccag	aagatcgagg	tgaaggacac	caaggaggcc	300
ctggacaagg	tggaggagga	gcagaacaac	agcaagaaga	aggcccagca	ggaggccgcc	360
gacgcgcgca	accgcaacca	agtcagccag	aactacccca	tcgtgcagaa	cctgcagggc	420
cagatgggtgc	accaggccat	cagccccccg	accctgaacg	cctgggtgaa	ggtggtggag	480
gagaaggcct	tcagccccga	ggtgatcccc	atgttcagcg	ccctgagcga	gggcgctacc	540
ccccaggacc	tgaacacccat	gctgaacacc	gtgggcggcc	accaggccgc	catgcagatg	600
ctgaaggaga	ccatcaacga	ggaggccgcc	gagtgaggcc	gcctgcaccc	cgtgcacgcc	660
gggcccacgc	cccccgggcca	gatgcgcgag	ccccgcggca	gcgacatcgc	cggcaccacc	720
agcaccctcc	aggagcagat	cggctggatg	accaacaacc	cccccatccc	cgtgggcgag	780
atctacaagc	gctggatcat	cctgggcctg	aacaagatcg	tccgcattga	cagccccacc	840
agcatcctgg	acatcaagca	gggcccgaag	gagcccttcc	gcgactacgt	ggaccgcttc	900
tacaagacc	tgcgcgcgca	gcaggccacc	caggaggtga	agaactggat	gaccgagacc	960
ctgctggtgc	agaacgccaa	ccccgactgc	aagaccatcc	tcaaggccct	gggacccgcc	1020
gccaccctgg	aggagatgat	gaccgcctgc	caaggcgtgg	scggcccccg	ccacaaggcc	1080
cgcggtgctgt	ga					1092

<210> 14

<211> 1926

<212> DNA

<213> Artificial Sequence

<220>

<223> Hybrid protein cds comprised of Tat-Rev-Nef and CTL (TRN-CTL)

<400> 14

atggagccag	tagatcctag	actagagccc	tggaaagcatc	caggaagtca	gcctaggacc	60
ccttgtagca	attgctattg	taaaaagtgt	tgccttcatt	gccaaagttg	tttcacaaga	120
aaaggcttag	gcattctccta	tggcaggaag	aagcggagac	agcgacgaag	agctcctcaa	180
gacagtca	ctcatcaagt	ttctctacca	aagcaaccct	cctcccagca	acgaggggac	240
ccgacaggcc	cgaagaaatc	gaagaagaag	gtggagagag	agacagaggc	agatccgttc	300
gatactagt	caggaagaag	cggagacagc	gacgaagagc	tcctcaagac	agtcagactc	360
atcaagtgttc	tcacccaaag	caaccctcct	cccagcaacg	aggggacccg	acaggcccga	420
agaaatcgaa	gaagaaggtg	gagagagaga	cagaggcaga	tcctgttcgat	tagtgagcgg	480
attcttagca	cttttctggg	acgacctgcg	gagcctgtgc	ctcttcagct	accgcgcgtt	540
gagagactta	ctcttgattg	tagcgaagat	tgtggaaact	ctgggacgca	gggggtggga	600
agtcctcaag	tattggtgga	atctcctgca	gtattggagc	caggaactaa	agaaaagctt	660
gtgggcaagt	ggtcaaaatg	tagtggtatg	cctactgtaa	gggaaagaat	gaacaagct	720
gagcctgagc	cagcagcaga	tggggtggga	gcagcatctc	gagacctgga	aaaacatgga	780
gcaatcacaa	gtagcaatac	agcaactaat	aacgctgctt	gtgcttggtc	agaagcacia	840
gaggaagagg	aagtgggttt	tccagtcaga	cctcaggtac	ctttaagacc	aatgacttac	900
aagggagctt	tagatcttag	ccacttttta	aaagaaaagg	ggggactgga	agggttaatt	960
tactccccaa	aaagacaaga	gacccctgat	ctgtgggtct	accacacaca	aggctacttc	1020
cctgattggc	agaactacac	accaggggcca	ggggtcagat	atccactgac	ctttggatgg	1080
tgcttcaagt	tagtaccagt	tgaaccagat	gaagaagaga	acagcagcct	gttacaccct	1140
gcgagcctgc	atgggacaga	ggacacggag	agagaagtgt	taaagtggaa	gtttgacagc	1200
catctagcat	ttcatcacaa	ggcccagagag	ctgcatccgg	agtactacaa	agactgcgcg	1260
gccgctcatca	ccctgtggca	gcgccccctg	gtggccctga	tcgagatctg	caccgagatg	1320

```

gagaaggagg gcaagatcag caagatcggc cccgccggcc tgaagaagaa gaagagcgtg 1380
accgtgctgg acgtgggcca cgcctacttc agcgtgcccc tggataagga cttccgcaag 1440
tacaccgcct tcaccatccc cagcatctgg aagggcagcc ccgccatctt ccagagcagc 1500
atgaccaaga agcagaaccc cgacatcgtg atctaccagt acatggacga cctgtacgtg 1560
cccacgtgtc tggccgagaa ggaagcgtgg ctggtgggca agctgaactg ggccagccag 1620
atctacgccc gcatcaaggt gaagcagctg atcctgaagg agcccgtgca cggcgtgtac 1680
gagcccatcg tgggcgcgca gaccttctac gtggacggcg ccgccaaccg cgccggcaac 1740
ctgtgggtga ccgtgtacta cggcgtgccc gtgtggaagg aggccaccac caccctgggt 1800
gagcgctacc tgcgcgacca gcagctgctg ggcacatctgg gctgcgcctg caccocctac 1860
gacatcaacc agatgctgcg cggccctggc cgcgccttcg tgaccatccg ccagggcagc 1920
ctgtag 1926

```

<210> 15
 <211> 1926
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Hybrid protein cds comprised of Rev-Nef-Tat and CTL (RNT-CTL)

```

<400> 15
atggcaggaa gaagcggaga cagcgacgaa gagctcctca agacagtcag actcatcaag 60
tttctctacc aaagcaaccc tcctcccagc aacgagggga cccgacaggc ccgaagaaat 120
cgaagaagaa ggtggagaga gagacagagg cagatccgtt cgattagtga gcggtattctt 180
agcacttttc tgggacgacc tgcggagcct gtgcctcttc agctaccgcc gcttgagaga 240
cttactcttg attgtagcga agattgtgga aactctggga cgcaggggggt ggggaagtcct 300
caagtattgg tggaaatctc tgcatattg gagccaggaa ctaaagaaac tagtgtgggc 360
aagtgtgcaa aatgtagtgg atggcctact gtaaggga aaatgaaaca agctgagcct 420
gagccagcag cagatgggggt gggagcagca tctcgagacc tggaaaaaca tggagcaatc 480
acaagttagc atacagcaac taataacgct gcttctgcct ggctagaagc acaagaggaa 540
gaggaagtgg gttttccagt cagacctcag gtacctttaa gaccaatgac ttacaaggga 600
gcttttagatc ttagccactt tttaaaagaa aagggggggac tggaaagggtt aatttactcc 660
ccaaaagac aagagatcct tgatctgtgg gtctaccaca cacaaggcta cttccctgat 720
tggcagaact acacaccagg gccaggggtc agatatccac tgaccttttg atggtgcttc 780
aagtttagtac cagtggaacc agatgaagaa gagaacagca gcctgttaca ccctgcgagc 840
ctgcatggga cagaggacac ggagagagaa gtgttaaagt ggaagtttga cagccatcta 900
gcatttcact acaaggcccg agagctgcat ccggagtact acaaagactg caagcctttag 960
ccagtagatc ctagactaga gccctggaag catccaggaa gtcagcctag gacccttgt 1020
accaattgct attgtaaaaa gtgttgctt cattgccaag tttgtttcac aagaaaaggc 1080
ttaggcactc cctatggcag gaagaagcgg agacagcgac gaagagctcc tcaagacagt 1140
cagactcact aagtttctct accaaagcaa cctcctccc agcaacgagg ggacccgaca 1200
ggcccgaaga aatcgaagaa gaaggtggag agagagacag aggcagatcc gttcgatgcg 1260
gccgtcatca ccctgtggca gcgcccctg gtggccctga tcgagatctg caccgagatg 1320
gagaaggagg gcaagatcag caagatcggc cccgccggcc tgaagaagaa gaagagcgtg 1380
accgtgctgg acgtgggcca cgcctacttc agcgtgcccc tggataagga cttccgcaag 1440
tacaccgcct tcaccatccc cagcatctgg aagggcagcc ccgccatctt ccagagcagc 1500
atgaccaaga agcagaaccc cgacatcgtg atctaccagt acatggacga cctgtacgtg 1560
cccatcgtgc tggccgagaa ggacagctgg ctggtgggca agctgaactg ggccagccag 1620
atctacgccc gcatcaaggt gaagcagctg atcctgaagg agcccgtgca cggcgtgtac 1680
gagcccatcg tgggcgcgca gaccttctac gtggacggcg ccgccaaccg cgccggcaac 1740
ctgtgggtga ccgtgtacta cggcgtgccc gtgtggaagg aggccaccac caccctgggt 1800
gagcgctacc tgcgcgacca gcagctgctg ggcacatctgg gctgcgcctg caccocctac 1860
gacatcaacc agatgctgcg cggccctggc cgcgccttcg tgaccatccg ccagggcagc 1920
ctgtag 1926

```

<210> 16
 <211> 2529
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Hybrid protein cds comprised of Tat-Rev-Nef and truncated Gag protein (TRN-dgag)

<400> 16

atggagccag	tagatcctag	actagagccc	tggaagcatc	caggaagtca	gcctaggacc	60
ccttgtagca	attgctattg	taaaaagtgt	tgccttcatt	gccaaagttg	tttcacaaga	120
aaaggcttag	gcatctccta	tggcaggaag	aagcggagac	agcgacgaag	agctcctcaa	180
gacagtcaga	ctcatcaagt	ttctctacca	aagcaaccct	cctcccagca	acgaggggac	240
ccgacagggc	cgaagaaatc	gaagaagaag	gtggagagag	agacagaggg	agatccgttc	300
gatactagtg	caggaagaag	cggagacagc	gacgaagagc	tcctcaagac	agtcagactc	360
atcaagtttc	tctaccaaag	caaccctcct	cccagcaacg	aggggacccg	acaggcccga	420
agaaatcgaa	gaagaagggtg	gagagagaga	cagaggcaga	tccgttcgat	tagtgagcgg	480
attcttagca	cttttctggg	acgacctgcg	gagcctgtgc	ctcttcagct	accgccgctt	540
gagagactta	ctcttgattg	tagcgaagat	tgtggaaact	ctgggacgca	gggggtggga	600
agtctcaag	tattggtgga	atctcctgca	gtattggagc	caggaactaa	agaaaagctt	660
gtgggcaagt	gggtcaaaatg	tagtggatgg	cctactgtaa	gggaaagaat	gaaacaagct	720
gagcctgagc	cagcagcaga	tgggtgggga	gcagcatctc	gagacctgga	aaaacatgga	780
gcaatcacia	gtagcaatac	agcaactaat	aacgctgctt	gtgcctggct	agaagcacaa	840
gaggaagagg	aagtgggttt	tccagtcaga	cctcaggtag	ctttaagacc	aatgacttac	900
aagggagctt	tagatcttag	ccacttttta	aaagaaaagg	ggggactgga	agggttaatt	960
tactcccaaa	aaagacaaga	gatccttgat	ctgtgggtct	accacacaca	aggctacttc	1020
cctgattggc	agaactacac	accagggcca	ggggtcagat	atccactgac	ctttggatgg	1080
tgcttcaagt	tagtaccagt	tgaaccagat	gaagaagaga	acagcagcct	gttacaccct	1140
gcgagcctgc	atgggacaga	ggacacggag	agagaagtgt	taaagtggaa	gtttgacagc	1200
catctagcat	ttcatcacaa	ggcccagagag	ctgcatccgg	agtactacaa	agactgcgag	1260
gccgtgttag	acaaatggga	aaaaattcgg	ttaaggccag	ggggaaagaa	aaaatatcaa	1320
ttaaaacata	tagtatgggc	aagcagggag	ctagaacgat	tcgcagttaa	tcctggcctg	1380
ttagaacatc	cagaaggctg	tagacagata	atgggacagc	tacaaccgtc	ccttcagaca	1440
ggatcagaag	aacttagatc	attatataat	acagtagcaa	ccctctattg	tgtgcatcaa	1500
aagatagagg	taaaagacac	caaggaagct	ttagacaagg	tagaggaaga	gcaaaacaac	1560
agtaagaaaa	aggcacagca	agaagcagct	gacgcaggaa	acagaaacca	ggtcagccaa	1620
aattacccta	tagtgcaaaa	cctacaggga	caaatggtac	atcaggccat	atcacctaga	1680
actttaaatg	catgggtaaa	agtagtggaa	gagaaggctt	tcagcccaga	agtaataccc	1740
atgttttcag	cattatcaga	aggagccacc	ccacaagatt	taaacaccat	gctaaacaca	1800
gtggggggac	atcaagcagc	catgcaaatg	ttaaaagaaa	ccatcaatga	ggaagctgca	1860
gaatgggata	gattgcaccc	agtgcattgca	gggcctattg	caccaggcca	gatgagagaa	1920
ccaaggggaa	gtgacatagc	aggaactact	agtacccttc	aggaacaaat	aggatggatg	1980
acaaataatc	cacctatccc	agtaggagaa	atatataaga	gatggataat	cctgggatta	2040
aataaaaatg	taagaatgta	tagccctacc	agcattctgg	atataaaaac	aggacccaaa	2100
gaacccttta	gagattatgt	agaccggttc	tataaaaacc	taagagccga	gcaagctaca	2160
caggaagtaa	aaaattggat	gacagaaacc	ttgttggtcc	aaaatgcgaa	tcagatttgt	2220
aagactattt	taaaagcatt	aggaccagca	gctacactag	aagaaatgat	gacagcatgt	2280
cagggagtgg	ggggaccggg	ccataaagca	agagttttgg	ctgaagcaat	gagccaagta	2340
acaggttcag	ctgccataat	gatgcagaga	ggcaatttta	ggaaccaaag	aaagactggt	2400
aagtgtttca	attgtggcaa	agaagggcac	atagccagaa	attgcagggc	ccctaggaaa	2460
aagggtctgt	ggaaatgtgg	aaaggaagga	catcaaatga	aggattgcac	agaaagacag	2520
gctaattag						2529

<210> 17

<211> 3195

<212> DNA

<213> Artificial Sequence

<220>

<223> Hybrid protein cds comprised of Tat-Rev-Nef, CTL and truncated Gag protein (TRN-CTL-dgag)

<400> 17

atggagccag	tagatcctag	actagagccc	tggaagcatc	caggaagtca	gcctaggacc	60
ccttgtagca	attgctattg	taaaaagtgt	tgccttcatt	gccaaagttg	tttcacaaga	120
aaaggcttag	gcatctccta	tggcaggaag	aagcggagac	agcgacgaag	agctcctcaa	180
gacagtcaga	ctcatcaagt	ttctctacca	aagcaaccct	cctcccagca	acgaggggac	240
ccgacagggc	cgaagaaatc	gaagaagaag	gtggagagag	agacagaggg	agatccgttc	300
gatactagtg	caggaagaag	cggagacagc	gacgaagagc	tcctcaagac	agtcagactc	360
atcaagtttc	tctaccaaag	caaccctcct	cccagcaacg	aggggacccg	acaggcccga	420
agaaatcgaa	gaagaagggtg	gagagagaga	cagaggcaga	tccgttcgat	tagtgagcgg	480

```

attcttagca cttttctggg acgacctgcg gagcctgtgc ctcttcagct accgccgctt 540
gagagactta ctcttgattg tagcgaagat tgtggaaact ctgggacgca ggggggtggga 600
agtcctcaag tattgggtgga atctcctgca gtattggagc caggaaactaa agaaaaagctt 660
gtgggcaagt ggtcaaaatg tagtggatgg cctactgtaa gggaaagaat gaaacaagct 720
gagcctgagc cagcagcaga tgggggtggga gcagcatctc gagacctgga aaaacatgga 780
gcaatcacaa gtagcaatac agcaactaat aacgctgctt gtgcctggct agaagcacia 840
gaggaagagg aagtgggttt tccagtcaga cctcaggtac ctttaagacc aatgacttac 900
aagggagctt tagatcttag ccacttttta aaagaaaagg ggggactgga agggttaatt 960
tactcccaa aaagacaaga gatccttgat ctgtgggtct accacacaca aggctacttc 1020
cctgattggc agaactacac accagggcca ggggtcagat atccactgac ctttggatgg 1080
tgcttcaagt tagtaccagt tgaaccagat gaagaagaga acagcagcct gttacaccct 1140
gagagcctgc atgggacaga ggacacggag agagaagtgt taaagtggaa gtttgacagc 1200
catctagcat ttcatacaaa ggcccgagag ctgcatccgg agtactacaa agactgcgcg 1260
gccgtcatca cctgtgggca ggcggcctg gtggccctga tcgagatctg caccgagatg 1320
gagaaggagg gcaagatcag caagatcgcc ccgcccggcc tgaagaagaa gaagagcgtg 1380
accgtgctgg acgtgggcca cgcctacttc agcgtgcccc tggataagga cttccgcaag 1440
tacaccgcct tcaccatccc cagcatctgg aagggcagcc ccgccatctt ccagagcagc 1500
atgaccaaga agcagaaccc cgacatcgtg atctaccagt acatggacga cctgtacgtg 1560
cccatcgtgc tgcccagagaa ggacagctgg ctggtgggca agctgaactg ggccagccag 1620
atctacgccc gcatcaaggt gaagcagctg atcctgaagg agcccggtga cggcgtgtac 1680
gagccccatg tgggcgcccga gaccttctac gtggacggcg ccgccaaccg cgcgggaac 1740
ctgtgggtga ccgtgtacta cggcgtgccc gtgtggaaagg aggccaccac caccctggtg 1800
gagcgtacc tgccgcagcca gcagctgctg ggcatctggg gctgcgcctg caccocctac 1860
gacatcaacc agatgctgcy cggccctggc cgcgccttcg tgaccatccg ccagggcagc 1920
ctggcgcccg tgttagacaa atgggaaaaa attcgggttaa ggccaggggg aaagaaaaaa 1980
tatcaattaa aacatatagt atgggcaagc agggagctag aacgattcgc agttaatcct 2040
ggcctgttag aaacatcaga aggctgtaga cagataatgg gacagctaca accgtccctt 2100
cagacaggat cagaagaact tagatcatta tataatacag tagcaaccct ctattgtgtg 2160
catcaaaaga tagaggtaaa agacaccaag gaagctttag acaaggtaga ggaagagcaa 2220
aacaacagta agaaaaaggc acagcaagaa gcagctgacg caggaaacag aaaccaggtc 2280
agccaaaatt accctatagt gcaaaaccta cagggacaaa tggtagatca ggccatatca 2340
cctagaactt taaatgcatg ggtaaaagta gtggaagaga aggctttcag ccagaaagta 2400
ataccatgt tttcagcatt atcagaagga gccacccccc aagatttaa caccatgcta 2460
aacacagtgg ggggacatca agcagccatg caaatgttaa aagaaacat caatgaggaa 2520
gctgcagaat gggatagatt gcaccagtg catgcagggc ctattgcacc aggcagatg 2580
agagaaccaa ggggaagtga catagcagga actactagta cccttcagga acaaatagga 2640
tggatgacaa ataattccac tatcccagta ggagaaatat ataagagatg gataatcctg 2700
ggattaaata aaatagtaag aatgtatagc cctaccagca ttctggatat aaaacaagga 2760
ccaaaagAAC ccttagaga ttatgtagac cggttctata aaacccctaag agccgagcaa 2820
gctacacagg aagtaaaaaa ttggatgaca gaaaccttgt tgggtccaaa tgcaatcca 2880
gattgttaaga ctattttaaa agcattagga ccagcagcta cactagaaga aatgatgaca 2940
gcatgtcagg gagtgggggg acccgcccat aaagcaagag ttttggctga agcaatgagc 3000
caagtaacag gttcagctgc cataatgatg cagagaggca attttaggaa ccaaagaaag 3060
actgttaagt gtttcaattg tggcaaaagaa gggcacatag ccagaaattg cagggcccct 3120
aggaaaaagg gctgttggaa atgtggaaag gaaggacatc aaatgaagga ttgcacagaa 3180
agacaggcta attag                                     3195

```

<210> 18

<211> 3195

<212> DNA

<213> Artificial Sequence

<220>

<223> Hybrid protein cds comprised of Rev-Nef-Tat, CTL and truncated Gag protein (RNT-CTL-dgag)

<400> 18

```

atggcaggaa gaagcggaga cagcgacgaa gagtcctca agacagtcag actcatcaag 60
tttctctacc aaagcaaccc tctcccagc aacgagggga cccgacaggc ccgaagaaat 120
cgaagaagaa ggtggagaga gagacagagg cagatccgtt cgattagtga gcggattctt 180
agcacttttc tgggacgacc tgccgagcct gtgcctcttc agctaccgcc gcttgagaga 240
cttactcttg attgtagcga agattgtgga aactctggga cgcagggggg gggaagtcc 300
caagtattgg tggaaatctc tgcaagtatt gagccaggaa ctaagaaac tagtgtggg 360

```

```

aagtgggtcaa aatgtagtgg atggcctact gtaagggaaa gaatgaaaca agctgagcct 420
gagccagcag cagatgggggt gggagcagca tctcgagacc tggaaaaaca tggagcaatc 480
acaagtagca atacagcaac taataacgct gcttgtgcct ggctagaagc acaagaggaa 540
gaggaagtgg gttttccagt cagacctcag gtacctttaa gaccaatgac ttacaaggga 600
gcttttagatc tttagccactt tttaaaagaa aagggggggac tggaaagggtt aatttactcc 660
ccaaaaagac aagagatcct tgatctgtgg gtctaccaca cacaaggcta cttccctgat 720
tggcagaact acacaccagg gccaggggtc agatatccac tgacctttgg atggtgcttc 780
aagtttagtac cagttgaacc agatgaagaa gagaacagca gcctgttaca cctgcgagc 840
ctgcatggga cagaggacac ggagagagaa gtgttaaagt ggaagtttga cagccatcta 900
gcatttcac acaaggcccg agagctgcat ccggagtact acaaaagactg caagcttgag 960
ccagtagatc ctgactaga gccctggaag catccaggaa gtcagcctag gacctttgt 1020
accaattgct attgtaaaaa gtgttgctt cattgccaag tttgtttcac aagaaaaaggc 1080
ttaggcatct cctatggcag gaagaagcgg agacagcgac gaagagctcc tcaagacagt 1140
cagactcatc aagtttctct accaaagcaa ccctcctccc agcaacgagg ggaccgcaga 1200
ggcccgaaga aatcgaagaa gaaggtggag agagagacag aggcagatcc gttcgatgag 1260
gccgtcatca cctgtggca gcccccctg gtggccctga tgcagatctg caccgagatg 1320
gagaaggagg gcaagatcag caagatcgcc ccgcgcggcc tgaagaagaa gaagagcgtg 1380
accgtgctgg acgtggcgga cgctacttc agcgtgcccc tggataagga cttccgcaag 1440
tacaccgct tcaccatccc cagcatctgg aagggcagcc ccgcatctt ccagagcagc 1500
atgaccaaga agcagaaccc cgacatcgtg atctaccagt acatggagca cctgtacgtg 1560
cccacgtgc tgcgcgagaa ggacagctgg ctggtgggca agctgaactg ggcagccag 1620
atctacgccc gcatcaagg gacagctg atcctgaagg agcccggtga cggcggtac 1680
gagcccatcg tggcgccga gaccttctac gtggacggcg ccgccaaccg cgcgggcaac 1740
ctgtgggtga ccgtgtacta cggcgtgccc gtgtggaagg aggccaccac caccctggtg 1800
gagcgctacc tgcgcgacca gcagctgctg ggcactctgg gctgcgcctg caccctact 1860
gacatcaacc agatgctgcg cggccctggc cgcgccttcg tgaccatccg ccagggcagc 1920
ctggcgccg tgttagacaa atgggaaaaa attcgggttaa ggccaggggg aaagaaaaaa 1980
tatcaattaa aacatatagt atgggcaagc agggagctag aacgattcgc agttaatcct 2040
ggcctgttag aaacatcaga aggctgtaga cagataatgg gacagctaca accgtccctt 2100
cagacaggat cagaagaact tagatcatta tataatacag tagcaacctt ctattgtgtg 2160
catcaaaaga tagaggtaaa agacaccaag gaagctttag acaaggtaga ggaagagcaa 2220
aacaacagta agaaaaaggc acagcaagaa gcagctgacg caggaaacag aaaccaggtc 2280
agccaaaatt accctatagt gcaaaaccta cagggacaaa tggtagatca ggccatatca 2340
cctagaactt taaatgcatg ggtaaaaagta gtggaagaga aggccttcag ccagaaagta 2400
ataccatgt tttcagcatt atcagaagga gccacccac aagattttaa caccatgcta 2460
aacacagtgg ggggacatca agcagccatg caaatgttaa aagaaacat caatgaggaa 2520
gctgcagaat gggatagatt gcacccagtg catgcagggc ctattgcacc aggcagatg 2580
agagaaccaa ggggaagtga catagcagga actactagta ccttccagga acaaatagga 2640
tggatgacaa ataatccacc tatcccagta ggagaaatat ataagagatg gataatcctg 2700
ggattaaata aaatagtaag aatgtatagc cctaccagca ttctggatat aaacaagga 2760
ccaaaagaac cttttagaga ttatgtagac cggttctata aaaccctaag agccgagcaa 2820
gctacacagg aagtaaaaaa ttggatgaca gaaaccttgt tggtoaaaaa tgcaatcca 2880
gattgtaaga ctatttttaa agcattagga ccagcagcta cactagaaga aatgatgaca 2940
gcattgtcagg gagtgggggg acccgccat aaagcaagag ttttggctga agcaatgagc 3000
caagtaacag gttcagctgc cataatgatg cagagaggca attttaggaa ccaaagaaag 3060
actgttaagt gtttcaattg tggcaaaagaa gggcacatag ccagaaatg cagggccct 3120
aggaaaaagg gctgttgga atgtggaag gaaggacatc aaatgaagga ttgcacagaa 3180
agacaggcta attag 3195

```

<210> 19
 <211> 3195
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Hybrid protein cds comprised of Tat-Rev-Nef, truncated Gag protein and CTL (TRN-dgag-CTL)

```

<400> 19
atggagccag tagatcctag actagagccc tggaaagcatc caggaagtca gcctaggacc 60
ccttgtagca attgctattg taaaaagtgt tgccttcatt gccaaagttg tttcacagaa 120
aaaggcttag gcatctccta tggcaggaag aagcggagac agcgacgaag agctcctcaa 180
gacagtcaga ctcatcaagt ttctctacca aagcaacct cctcccagca acgaggggac 240

```

```

ccgacaggcc cgaagaatc gaagaagaag gtggagagag agacagaggc agatccgttc 300
gatactagtg caggaagaag cggagacagc gacgaagagc tcctcaagac agtcagactc 360
atcaagtttc tctaccaaag caaccctcct cccagcaacg aggggaccgc acaggcccgga 420
agaaatcgaa gaagaagggt gagagagaga cagaggcaga tccgttcgat tagtgagcgg 480
attcttagca cttttctggg acgacctgcg gagcctgtgc ctcttcagct accgcccgtt 540
gagagactta ctcttgattg tagcgaagat tgtggaaact ctgggacgca ggggggtggga 600
agtcctcaag tattggtgga atctcctgca gtattggagc caggaactaa agaaaagcct 660
gtgggcaagt ggtcaaaatg tagtggatgg cctactgtaa gggaaagaat gaaacaagct 720
gagcctgagc agcagcaga tgggggtggga gcagcatctc gagacctgga aaaacatgga 780
gcaatcacaa gtacgaatac agcaactaat aacgctgctt gtgcctggct agaagcacia 840
gaggaagagg aagtgggttt tccagtcaga cctcaggtac cttaaagacc aatgacttac 900
aaggagcctt tagatcttag ccacttttta aaagaaaagg ggggactgga agggttaatt 960
tactcccaa aaagacaaga gatccttgat ctgtgggtct accacacaca aggctacttc 1020
cctgattggc agaactacac accagggccca ggggtcagat atccactgac ctttgatgg 1080
tgcttcaagt tagtaccagt tgaaccagat gaagaagaga acagcagcct gttacaccct 1140
gcgagcctgc atgggacaga ggacacggag agagaagtgt taaagtggaa gtttgacagc 1200
catctagcat ttcacacaa ggcccagagag ctgcatccgg agtactacaa agactgccc 1260
gccgtgttag acaaatggga aaaaattcgg ttaaggccag ggggaaagaa aaaatatcaa 1320
ttaaaccata tagtatggg aagcaggag ctagaacgat tgcagttaa tctggcctg 1380
ttagaaacat cagaaggctg tagacagata atgggacagc tacaaccgtc ccttcagaca 1440
ggatcagaag aacttagatc attatataat acagtagcaa ccctctattg tgtgcatcaa 1500
aagatagagg taaaagacac caaggaagct ttagacaagg tagaggaaga gcaaaacaac 1560
agtaagaaaa aggcacagca agaagcagct gacgcaggaa acagaaacca ggtcagccaa 1620
aattacccta tagtgcaaaa cctacaggga caaatggtac atcaggccat atcacctaga 1680
actttaattg catgggtaaa agtagtgga gagaaggctt tcagcccaga agtaataccc 1740
atgttttcag cattatcaga aggagccacc ccacaagatt taaacaccat gctaaacaca 1800
gtggggggac atcaagcagc catgcaaatg ttaaaagaaa ccatcaatga ggaagctgca 1860
gaatgggata gattgcaccc agtgcatgca gggcctattg caccaggcca gatgagagaa 1920
ccaaggggaa gtgacatagc aggaactact agtacccttc aggaacaaat aggatggatg 1980
acaaataatc cacctatccc agtaggagaa atatataaga gatggataat cctgggatta 2040
aataaaatag taagaatgta tagccctacc agcattcttg atataaaaaca aggacccaaa 2100
gaacccttta gagattatgt agaccggttc tataaaaccc taagagccga gcaagctaca 2160
caggaagtaa aaaattggat gacagaaacc ttgttggtcc aaaatgcgaa tccagattgt 2220
aagactatth taaaagcatt aggaccagca gctacactag aagaaatgat gacagcatgt 2280
cagggagtgg ggggaccccg ccataaagca agagtttttg ctgaagcaat gagccaagta 2340
acaggttcga ctgccataat gatgcagaga ggcaatttta ggaaccaaag aaagactgtt 2400
aagtgtttca attgtggcaa agaaggcgac atagccagaa attgcagggc ccctaggaaa 2460
aagggtctgt ggaatgtgg aaaggaaagga catcaaatga aggatgacac agaaagacag 2520
gctaattgagg ccgtcatcac cctgtggcag cgcccccttg tggccctgat cgagatctgc 2580
accgagatgg agaaggagg caagatcagc aagatcgccc ccgcccgcct gaagaagaag 2640
aagagcgtga ccgtgctgga cgtgggcgac gcctacttca gcgtgcccct ggataaggac 2700
ttccgcaagt acaccgctt caccatcccc agcatctgga agggcagccc cgccatcttc 2760
cagagcagca tgaccaagaa gcagaacccc gacatcgtga tctaccagta catggagcag 2820
ctgtacgtgc ccacgtgct gcccagaaag gacagctggc tgggtgggcaa gctgaactgg 2880
gccagccaga tctacgccg catcaagggtg aagcagctga tcctgaagga gcccggtcac 2940
ggcgtgtacg agcccatcgt gggcgccgag accttctacg tggacggcgc cgccaaccgc 3000
gccgcaacc tgtgggtgac cgtgtactac ggcgtgcccc tgtggaagga ggccaccacc 3060
accctggtgg agcgtacct gcgcgaccag cagctgctgg gcatctgggg ctgcgcccgc 3120
acccctacg acatcaacca gatgctgcgc ggccttgccc gcgcttcgt gaccatccgc 3180
cagggcagcc tgtag

```

<210> 20

<211> 3195

<212> DNA

<213> Artificial Sequence

<220>

<223> Hybrid protein cds comprised of Rev-Nef-Tat, truncated Gag protein and CTL (RNT-dgag-CTL)

<400> 20

```

atggcaggaa gaagcggaga cagcgacgaa gagctcctca agacagtcag actcatcaag 60
tttctctacc aaagcaaccc tcctccagc aacgagggga cccgacaggc ccgaagaat 120

```

cgaagaagaa	ggtggagaga	gagacagagg	cagatccggt	cgattagtga	gctgattcct	180
agcacttttc	tgaggacgacc	tgaggagcct	gtgcctcttc	agctaccgcc	gcttgagaga	240
cttactcttg	attgttagcga	agatttgga	aactctggga	cgagggggt	gggaagtcct	300
caagtattgg	tggaatctcc	tgagctattg	gagccaggaa	ctaaagaaac	tagtgtgggc	360
aagtgggtcaa	aatgtagtgg	atggcctact	gtaaggga	gaatgaaaca	agctgagcct	420
gagccagcag	cagatgggggt	gggagcagca	tctcgagacc	tggaataaca	tggagcaatc	480
acaagtagca	atacagcaac	taataacgct	gcttggtgct	ggctagaagc	acaagaggaa	540
gagggaagtg	gttttccagt	cagacctcag	gtacctttaa	gaccaatgac	ttacaaggga	600
gcttttagatc	ttagccactt	tttaaaagaa	aaggggggac	tggaagggtt	aatttactcc	660
ccaaaaagac	aagagatcct	tgatctgtgg	gtctaccaca	cacaaggcta	cttccctgat	720
tggcagaact	acacaccagg	gccaggggtc	agatatccac	tgacctttgg	atgggtgctc	780
aagttagtac	cagttgaacc	agatgaagaa	gagaacagca	gcctgttaca	ccctgcgagc	840
ctgcatggga	cagaggacac	ggagagagaa	gtgttaaagt	gggaagtttg	cagccatcta	900
gcatttcatc	acaaggcccg	agagctgcat	ccggagtact	acaaagactg	caagcttgag	960
ccagtagatc	ctagactaga	gccctggaag	catccaggaa	gtcagcctag	gaccccttgt	1020
accaattgct	attgtaaaaa	gtgttgctt	cattgccaag	tttgtttcac	aagaaaaggc	1080
ttaggcatct	cttatggcag	gaagaagcgg	agacagcgac	gaagagctcc	tcaagacagt	1140
cagactcatc	aagtttctct	accaaagcaa	ccctcctccc	agcaacgagg	ggacccgaca	1200
ggcccgaaga	aatcgaagaa	gaagggtggag	agagagacag	aggcagatcc	gttcgatgag	1260
gccgtgttag	acaaatggga	aaaaattcgg	ttaaggccag	ggggaaagaa	aaaatatcaa	1320
ttaaaacata	tagtatgggc	aagcaggag	ctagaacgat	tcgcagttaa	tcctggcctg	1380
ttagaacat	cagaaggctg	tagacagata	atgggacagc	tacaaccgtc	cttccagaca	1440
ggatcagaag	aacttagatc	attatataat	acagttagca	ccctctattg	tgtgcatcaa	1500
aagatagagg	taaaagacac	caaggaaagct	ttagacaagg	tagaggaaga	gcaaaacaac	1560
agtaagaaaa	aggcacagca	agaagcagct	gacgcaggaa	acagaaacca	ggtcagccaa	1620
aattacccta	tagtgcaaaa	cctacaggga	caaatggtac	atcaggccat	atcacctaga	1680
actttaaatg	catgggtaaa	agttagtgaa	gagaaggctt	tcagcccaga	agtaataccc	1740
atgttttcag	cattatcaga	aggagccacc	ccacaagatt	taaacaccat	gctaaacaca	1800
gtggggggac	atcaagcagc	catgcaaatg	ttaaaagaaa	ccatcaatga	ggaagctgca	1860
gaatgggata	gattgcaccc	agtgcattgca	gggcctattg	caccaggcca	gatgagagaa	1920
ccaaggggaa	gtgacatagc	aggaactact	agtacccttc	aggaacaaat	aggatggatg	1980
acaaataatc	cacctatccc	agtaggagaa	atatataaga	gatggataat	cctgggatta	2040
aataaaatag	taagaatgta	tagccctacc	agcattctgg	atataaaaca	aggacaaaaa	2100
gaacccttta	gagattatgt	agaccggttc	tataaaaccc	taagagccga	gcaagctaca	2160
caggaagtaa	aaaattggat	gacagaaacc	ttgttggtcc	aaaatgcgaa	tccagattgt	2220
aagactatct	taaaagcatt	aggaccagca	gctacactag	aagaaatgat	gacagcatgt	2280
cagggaagtgg	ggggaccggg	ccataaagca	agagtttttg	ctgaagcaat	gagccaagta	2340
acaggttcag	ctgccataat	gatgcagaga	ggcaatttta	ggaaccaaag	aaagactgtt	2400
aagtgtttca	attgtggcaa	agaaggccac	atagccagaa	attgcagggc	ccctaggaaa	2460
aagggtctgt	ggaaatgtgg	aaaggaagga	catcaaatga	aggattgcac	agaaagacag	2520
gctaattgcg	ccgtcatcac	cctgtggcag	cgccccctgg	tggccctgat	cgagatctgc	2580
accgagatgg	agaaggaggg	caagatcagc	aagatcgccc	ccgcccggcct	gaagaagaag	2640
aagagcgtga	ccgtgctgga	cgtggcgac	gcctacttca	gcgtgcccct	ggataaggac	2700
ttccgcaagt	acaccgcctt	caccatcccc	agcatctgga	agggcagccc	cgccatcttc	2760
cagagcagca	tgaccaagaa	gcagaacccc	gacatcgtga	tctaccagta	catggacgac	2820
ctgtacgtgc	ccatcgtgct	gcccagagaag	gacagctggc	tggtgggcaa	gctgaactgg	2880
gccagccaga	tctacgcggg	catcaaggtg	aagcagctga	tcctgaagga	gcccgtgcac	2940
ggcgtgtacg	agcccatcgt	ggcgccgag	accttctacg	tggacggcgc	cgccaaccgc	3000
gccggcaacc	tgtgggtgac	cgtgtactac	ggcgtgcccg	tgtggaagga	ggccaccacc	3060
accttggtgg	agcgctacct	gcgcgaccag	cagctgctgg	gcatctgggg	ctgcgcctgc	3120
acccctacg	acatcaacca	gatgctgcgc	ggccctggcc	gcgccttcgt	gaccatccgc	3180
cagggcagcc	tgtag					3195

<210> 21
 <211> 3020
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Hybrid protein cds comprised of Tat-Rev-Nef, truncated Gag protein and CTL (TRN-optpi7/24-CTL)

<400> 21

atggagccag	tagatcctag	actagagccc	tggaagcatc	caggaagtca	gcctaggacc	60
ccttgtacca	attgctattg	taaaaagtgt	tgccttcatt	gccaaagtgt	tttcacaaga	120
aaaggcttag	gcattctccta	tggcagggaag	aagcggagac	agcgacgaag	agctcctcaa	180
gacagtcaga	ctcatcaagt	ttctctacca	aagcaaccct	cctcccagca	acgaggggac	240
ccgacaggcc	cgaagaaatc	gaagaagaag	gtggagagag	agacagaggc	agatccgttc	300
gatactagt	caggaagaag	cgagacagc	gacgaagagc	tcctcaagac	agtcagactc	360
atcaagtttc	tctaccaaag	caaccctcct	cccagcaacg	aggggacccg	acaggcccca	420
agaaatcgaa	gaagaaggtg	gagagagaga	cagaggcaga	tccttcagat	tagtgagcgg	480
attcttagca	cttttctggg	acgacctgcg	gagcctgtgc	ctcttcagct	accgccgctt	540
gagagactta	ctcttgattg	tagcgaagat	tgtggaaact	ctgggacgca	gggggtggga	600
agtcctcaag	tattggtgga	atctcctgca	gtattggagc	caggaaactaa	agaaaagctt	660
gttggcaagt	gggtcaaaatg	tagtggatgg	cctactgtaa	gggaaagaat	gaaacaagct	720
gagcctgagc	cagcagcaga	tggggtggga	gcagcatctc	gagacctgga	aaaacatgga	780
gcaatcacia	gtagaatac	agcaactaat	aacgctgctt	gtgcctggct	agaagcacia	840
gaggaagagg	aagtgggttt	tcagtcaga	cctcaggtag	ctttaagacc	aatgacttac	900
aagggagctt	tagatcttag	ccacttttta	aaagaaaagg	ggggactgga	agggtaatt	960
tactcccaaa	aaagacaaga	gatccttgat	ctgtgggtct	accacacaca	aggctacttc	1020
cctgattggc	agaactacac	accagggcca	gggttcagat	atccactgac	ctttggatgg	1080
tgcttcaagt	tagtaccagt	tgaaccagat	gaagaagaga	acagcagcct	gttacaccct	1140
gcgagcctgc	atgggacaga	ggacacggag	agagaagtgt	taaaagtggaa	gtttgacagc	1200
catctagcat	ttcatcacia	ggcccagag	ctgcatccgg	agtactacia	agactgcgcg	1260
gccgtgggcg	caagagcctc	cgtgctgagc	ggcggagagc	tggaacaagt	ggagaagatc	1320
cgctgcgc	ccggcggaac	gaagaagtac	cagctgaagc	acatcgtgtg	ggccagccgc	1380
gagctggagc	gcttcgccgt	gaaccccggc	ctgctcgaga	ccagcgaagg	ctgccgccag	1440
atcatgggccc	agctccagcc	cagcctccag	accggcagcg	aggagctgcg	cagcctgtac	1500
aacacccgtg	ccacccgtga	ctgcgtgcac	cagaagatcg	aggtgaagga	caccaaggag	1560
gccttgga	aggtggagga	ggagcagaac	aacagcaaga	agaaggccca	gcaggaggcc	1620
gcccagcgcc	gcaaccgcaa	ccaagtacg	cagaactacc	ccatcgtgca	gaacctgcag	1680
ggccagatgg	tgacaccagg	catcagcccc	cgcacccctg	acgcctgggt	gaaggtgggt	1740
gaggagaagg	ccttcagccc	cgaggtgatc	cccatgttca	gcgccctaag	cgagggcgct	1800
accccccagg	acctgaacac	catgctgaac	accgtgggcg	gccaccaggc	cgccatgcag	1860
atgctgaagg	agaccatcaa	cgaggaggcc	gccgagtggt	accgcctgca	ccccgtgcac	1920
gccggggccca	tcgccccccg	ccagatgcgc	gagcccccg	gcagcgacat	cgccggcacc	1980
accagcacc	tcaggagca	gatcggctgg	atgaccaaca	acccccccat	ccccgtgggc	2040
gagatctaca	agcgctggat	catcctgggc	ctgaacaaga	tcgtccgcat	gtacagcccc	2100
accagcatcc	tggaacatcaa	gcaggggcccc	aaggagccct	tcgcgcgacta	cgtggaccgc	2160
ttctacaaga	ccctgcgcgc	cgagcaggcc	accaggagg	tgaagaactg	gatgaccgag	2220
accctgctgg	tgcaagaacgc	caaccccgac	tgcaagacca	tcctcaaggc	cctgggaccc	2280
gccgccaccc	tggaaggagat	gatgaccgcc	tgccaaggcg	tgggcgggccc	cgccacaaag	2340
gccgcgctgc	tgggcgccgt	catcaccctg	tggcagcgcc	ccctggtggc	cctgatcgag	2400
atctgcaccg	agatggagaa	ggagggcagg	atcagcaaga	tcggccccgc	cgccctgaag	2460
aagaagaaga	gcgtgaccgt	gctggacgtg	ggcgacgcct	acttcagcgt	gccccctggat	2520
aaggacttcc	gcaagtacac	cgccttcacc	atccccagca	tctggaagg	cagccccgc	2580
atcttccaga	gcagcatgac	caagaagcag	aacccccgaca	tcgtgatcta	ccagtacatg	2640
gacgacctgt	acgtgccccat	cgtgctgccc	gagaaggaca	gctggctgg	gggcaagctg	2700
aactggggcca	gccagatcta	cgccggcatc	aaggtgaagc	agctgatcct	gaaggagccc	2760
gtgcacggcg	tgtagcagcc	catcgtgggc	gccgagacct	tctacgtgga	cgccgcccgc	2820
aaccgcgcgc	gcaacctgtg	ggtagccgtg	tactacggcg	tgcccgtgtg	gaaggaggcc	2880
accaccaccc	tggtggagcg	ctacctgcgc	gaccagcagc	tgctgggcat	ctggggctgc	2940
gcctgcaccc	cctacgacat	caaccagatg	ctgcgcggcc	ctggccgcgc	ctcgtgacca	3000
tcgccaggg	cagcctgtag					3020

<210> 22

<211> 3021

<212> DNA

<213> Artificial Sequence

<220>

<223> Hybrid protein cdscomprised of Tat-Rev-Nef, CTL and truncated Gag protein (TRN-CTL-optp17/24)

<400> 22

atggagccag tagatcctag actagagccc tggaagcatc caggaagtca gcctaggacc 60

```

ccttgtacca attgctattg taaaaagtgt tgccttcatt gccaaagtgt tttcacaaga 120
aaaggccttag gcatctccta tggcagggaag aagcggagac agcgacgaag agctcctcaa 180
gacagtcaga ctcatcaagt ttctctacca aagcaaccct cctcccagca acgaggggac 240
ccgacaggcc cgaagaatc gaagaagaag gtggagagag agacagaggc agatccgttc 300
gatactagtg caggaagaag cggagacagc gacgaagagc tcctcaagac agtcagactc 360
atcaagtttc tctaccaaaag caaccctcct ccagcaacg agggggaccg acaggcccga 420
agaaatcgaa gaagaagggtg gagagagaga cagaggcaga tccgttcgat tagtgagcgg 480
attcttagca cttttctggg acgacctgcg gagcctgtgc ctcttcagct accgccgctt 540
gagagactta ctcttgattg tagcgaagat tgtggaaact ctgggacgca ggggggtggga 600
agtctcaag tattggtgga atctcctgca gtattggagc caggaactaa agaaaagcct 660
gtgggcaagt ggtcaaatg tagtggatgg cctactgtaa gggaaagaat gaaacaagct 720
gagcctgagc cagcagcaga tgggggtggga gcagcatctc gagacctgga aaaacatgga 780
gcaatcacaa gtacgaatac agcaactaat aacgtgctt gtgcctggct agaagcacia 840
gaggaagagg aagtgggttt tccagtcaga cctcaggtac cttaagacc aatgacttac 900
aagggagcct tagatcttag ccacttttta aaagaaaagg ggggactgga agggttaatt 960
tactcccaa aaagacaaga gatccttgat ctgtgggtct accacacaca aggctaactc 1020
cctgattggc agaactacac accaggggcca ggggtcagat atccactgac ctttgatgg 1080
tgcttcaagt tagtaccagt tgaaccagat gaagaagaga acagcagcct gttacacct 1140
gcgagcctgc atgggacaga ggacacggag agagaagtgt taaagtggaa gtttgacagc 1200
catctagcat ttcatacaaa ggcccgagag ctgcattccg agtactaaa agactgccc 1260
gccgtcatca ccctgtggca ggcggccctg gtggccctga tcgagatctg caccgagatg 1320
gagaaggagg gcaagatcag caagatcggc ccgcggcgcc tgaagaagaa gaagagcgtg 1380
accgtgctgg acgtggggca cgccacttcc agcgtgcccc tggataagga ctcccgcaag 1440
tacaccgct tcaccatccc cagcatctgg aagggcagcc ccgcatctt ccagagcagc 1500
atgaccaaga agcagaaccc cgacatcgtg atctaccagt acatggacga cctgtacgtg 1560
cccacgtgct tgcccgagaa ggacagctgg ctgggtggga agctgaactg ggcagaccag 1620
atctacgctg ccatcaaggt gaagcagctg atcctgaagg agcccggtga cggcgtgtac 1680
gagcccatcg tggcgccga gaccttctac gtggacggcg ccgccaaccg cgccggcaac 1740
ctgtgggtga ccgtgtacta cggcgtgccc gtgtgggaagg agggcaccac caccctggtg 1800
gagcgtctacc tgccgcacca gcagctgctg ggcattctgg gctgcgcctg caccctctac 1860
gacatcaacc agatgctgcg cggccctggc cgcgccttcg tgaccatccg ccagggcagc 1920
ctggcgcccg tggcgccaa agcctccgtg ctgagcggcg gagagctgga caagtgggag 1980
aagatccgcc tgcgccccgg cggcaagaag aagtaccagc tgaagcacat cgtgtggggc 2040
agccgcgagc tggagcgctt cgccgtgaac ccggcctgc tcgagaccag cgaaggctgc 2100
cgccagatca tgggcccagc ccagcccagc ctccagaccg gcagcgagga gctgcgcagc 2160
ctgtacaaca ccgtggccac cctgtactgc gtgcaccaga agatcgaggt gaaggacacc 2220
aaggaggccc tggacaaggt ggaggaggag cagaacaaca gcaagaagaa gggccagcag 2280
gaggccgccc acgcccggca ccgcaaccaa gtacagccaga actaccccat cgtgcagaac 2340
ctgcaggggc agatgggtgca ccaggccatc agcccccgca ccctgaacgc ctgggtgaag 2400
gtgggtggag agaaggcctt cagccccgag gtgatcccca tgttcagcgc cctgagcgag 2460
ggcgctacct ccaggacct gaacaccatg ctgaacaccg tggcgcgcca ccaggccgccc 2520
atgcagatgc tgaaggagac catcaacgag gaggccgccc agtgggaccg cctgcacccc 2580
gtgcacgcgc gggccatcgc ccccgccagc atgcgcgagc ccgcggcgag cgacatcgcc 2640
ggcaccacca gcaccctcca ggagcagatc ggctggatga ccaacaaccc ccccatcccc 2700
gtggcgagga tctacaagcg ctggatcatc ctgggcctga acaagatcgt ccgcatgtac 2760
agccccacca gcatcctgga catcaagcag ggccccaagg agcccttcg cgactacgtg 2820
gaccgcttct acaagacctt gcgcgcccag caggccaccc agggagtgaa gaactggatg 2880
accgagaccc tgcgtgtgca gaacgccaac ccgactgca agaccatcct caaggccctg 2940
ggaccgcgcg ccaccctgga ggagatgatg accgcctgcc aaggcgtggg cggccccggc 3000
cacaaggccc gcgtgctgtg a
3021

```

<210> 23
 <211> 3021
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Hybrid protein cds comprised of Rev-Nef-Tat, CTL and truncated Gag protein (RNT-CTL-optp17/24)

<400> 23
 atggcaggaa gaagcggaga cagcgacgaa gagctcctca agacagtcag actcatcaag 60
 tttctctacc aaagcaaccc tcctccagc aacgagggga cccgacaggc ccgaagaaat 120

```

cgaagaagaa ggtggagaga gagacagagg cagatccggt cgattagtga gcggattctt 180
agcacttttc tgggacgacc tgccggagcct gtgcctcttc agctaccgcc gcttgagaga 240
cttactcttg attgtagcga agattgtgga aactctggga cgcagggggg ggggaagtcct 300
caagtatttg tggaaatctcc tgcagttattg gagccaggaa ctaaagaaac tagtgtgggc 360
aagtggtaa aatgtagtgg atggcctact gtaagggaaa gaatgaaaca agctgagcct 420
gagccagcag cagatggggt gggagcagca tctcgagacc tggaaaaaca tggagcaatc 480
acaagtagca atacagcaac taataacgct gcttgtgcct ggctagaagc acaagaggaa 540
gaggaagtgg gttttccagt cagacctcag gtacctttaa gaccaatgac ttacaaggga 600
gcttttagatc ttagccactt ttlaaaagaa aaggggggac tgggaagggtt aatttactcc 660
ccaaaaagac aagagatcct tgatctgtgg gtctaccaca cacaaggcta cttccctgat 720
tggcagaact acacaccagg gccagggggtc agatatccac tgacctttgg atgggtgcttc 780
aagtttagtac cagttgaacc agatgaagaa gagaacagca gcctgttaca ccctgcgagc 840
ctgcatggga cagaggacac ggagagagaa gtgttaaagt ggaagtttga cagccatcta 900
gcatttcac acaaggcccg agagctgcat ccggagtact acaagactg caagcttgag 960
ccagtagatc ctgactaga gccctggaag catccaggaa gtcagcctag gaccccttgt 1020
accaattgct attgtaaaaa gtgttgccct cattgccaaag tttgtttcac aagaaaaggc 1080
ttaggcatct cctatggcag gaagaagcgg agacacggac gaagagctcc tcaagacagt 1140
cagactcatc aagtttctct accaaaagcaa ccctcctccc agcaacgagg ggacccgaca 1200
ggcccgaaga aatcgaagaa gaaggtggag agagagacag aggcagatcc gttcgatgag 1260
gccgtcatca cctgtggca gcgcccctg gtggccctga tgcagatctg caccgagatg 1320
gagaaggagg gcaagatcag caagatcggc ccgcccggcc tgaagaagaa gaagagcgtg 1380
accgtgctgg acgtggcgga cgccctacttc agcgtgcccc tggataagga cttccgcaag 1440
tacaccgcct tcaccatccc cagcatctgg aagggcagcc ccgccatctt ccagagcagc 1500
atgaccaaga agcagaaccc cgacatctgt atctaccagt acatggacga cctgtacgtg 1560
cccactgtgc tgcccagaaa ggacagctgg ctggtgggca agctgaactg ggccagccag 1620
atctacgccc gcatcaagggt gaagcagctg atcctgaagg agcccggtga cggcggttac 1680
gagcccatcg tgggcgcca gaccttctac gtggacggcg ccgccaaccg cgccggcaac 1740
ctgtgggtga ccgtgtacta cggcggtgcc gtgtggaagg aggccaccac caccctggtg 1800
gagcgctacc tgccgaccca gcagctgctg ggcactctgg gctgcgctg caccctctac 1860
gacatcaacc agatgctgag cggccctggc cgcgccctcg tgaccatccg ccagggcagc 1920
ctggcgcccg tggcgcaag agcctccgtg ctgagcggcg gagagctgga caagtgggag 1980
aagatccgcc tgcgccccgg cggcaagaag aagtaccagc tgaagcacat cgtgtgggcc 2040
agccgcgagc tggagcgctt cgccgtgaac ccgcccctgc tcgagaccag cgaaggctgc 2100
cgccagatca tgggccagct ccagcccagc ctccagaccg gcagcgagga gctgcgcagc 2160
ctgtacaaca ccgtggccac cctgtactgc gtgcaccaga agatcgaggt gaaggacacc 2220
aaggaggccc tggacaagggt ggaggaggag cagaacaaca gcaagaagaa ggcccagcag 2280
gaggccgccc acgcccggca ccgcaacca gtcagccaga actaccccat cgtgcagaac 2340
ctgcagggcc agatgggtgca ccaggccatc agcccccgca ccctgaacgc ctgggtgaag 2400
gtgggtggagg agaaggcctt cagccccgag gtgatcccc tggtcagcgc cctgagcgag 2460
atgcagatgc tgaaggagac catcaacgag gaggcgccc agtgggagcc cctgcacccc 2520
gtgcacgccc ggcccatcgc ccccgccag atgcgcgagc ccgcccggcag cgacatcgcc 2580
ggcaccacca gcacccctca ggagcagatc ggctggatga ccaacaaccc ccccatcccc 2640
gtgggcgaga tctacaagcg ctggatcatc ctgggcctga acaagatcgt ccgcatgtac 2700
agccccacca gcatcctgga catcaagcag ggcccccaagg agcccttccg cgactacgtg 2760
gaccgcttct acaagaccct gcgcgcccag caggccaccc agggagtgaa gaactggatg 2820
accagagacc tgctgggtgca gaacgccaac cccgactgca agaccatcct caaggccctg 2880
ggacccgccc ccaccttga ggagatgatg accgcctgac aaggcgtggg cggccccggc 2940
cacaaggccc gcgtgctgtg a 3000

```

<210> 24
 <211> 3021
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Hybrid protein cds comprised of Rev-Nef-Tat, truncated Gag protein and CTL (RNT-optp17/24-CTL)

```

<400> 24
atggcaggaa gaagcggaga cagcgacgaa gagctcctca agacagtcag actcatcaag 60
tttctctacc aaagcaaccc tcctcccagc aacgagggga cccgacaggc ccgaagaaat 120
cgaagaagaa ggtggagaga gagacagagg cagatccggt cgattagtga gcggattctt 180

```

```

agcacttttc tgggacgacc tgcggagcct gtgcctcttc agctaccgcc gcttgagaga 240
cttactcttg attgtagcga agatttgtga aactctggga cgcaggggggt gggagtcct 300
caagtattgg tggaaatctcc tgcagtattg gagccaggaa ctaaagaaac tagtgtgggc 360
aagtgtgcaa aatgtagtgg atggcctact gtaagggaaa gaataaaaaca agctgagcct 420
gagccagcag cagatgggggt gggagcagca tctcgagacc tggaaaaaca tggagcaatc 480
acaagtagca atacagcaac taataacgct gcttgtgcct ggctagaagc acaagaggaa 540
gaggaagtgg gttttccagt cagacctcag gtacctttaa gaccaatgac ttacaaggga 600
gcttttagatc ttagccactt tttaaaagaa aagggggggac tggaaagggtt aatttactcc 660
ccaaaaagac aagagatcct tgatctgtgg gtctaccaca cacaaggcta cttccctgat 720
tggcagaact acacaccagg gccagggggtc agatatccac tgaccttttg atggtgcttc 780
aagtttagtac cagttgaacc agatgaagaa gagaacagca gcctgttaca ccctgcgagc 840
ctgcatggga cagaggacac ggagagagaa gtgttaaagt ggaagtgtga cagccatcta 900
gcatttcac acaggcccg agagctgcat ccggagtact acaagactg caagcttgag 960
ccagtagatc ctgactaga gccctggaag catccaggaa gtcagcctag gaccocctgt 1020
accaattgct attgtaaaaa gtgttgccct cattgccaa tttgtttcac aagaaaaggc 1080
ttaggcattc cctatggcag gaagaagcgg agacagcgac gaagagctcc tcaagacagt 1140
cagactcacc aagtttctct accaaagcaa cctcctccc agcaacgagg ggaacccgaca 1200
ggcccgaaga aatcgaagaa gaaggtggag agagagacag aggcagatcc gttcgatgag 1260
gcccgtgggc caagagcctc cgtgctgagc ggcggagagc tggacaagtg ggagaagatc 1320
cgccctgcgc ccggcgccaa gaagaagtac cagctgaagc acatcgtgtg gggcagccgc 1380
gagctggagc gcttcgccgt gaaccccgcc ctgctcgaga ccagcgaagg ctgccgcccag 1440
atcatggggc agctccagcc cagcctccag accggcagcg aggagctgag cagcctgtac 1500
aacacgctgg ccaccctgta ctgcgtgcac cagaagatcg aggtgaagga caccaaggag 1560
gcccctggaca aggtggagga ggagcagaac aacagcaaga agaaggccca gcaggaggcc 1620
gccgacgccc gcaaccgcaa ccaagtcagc cagaactacc ccatcgtgca gaacctgcag 1680
ggccagatgg tgaccaggc catcagcccc cgcaccctga acgctgggt gaaggtggtg 1740
gaggagaagg ccttcagccc cgaggtgatc cccatgttca gcgccctaag cgagggcgct 1800
acccccagg acctgaacac accgtgggag gccaccaggc cgccatgcag 1860
atgctgaagg agaccatcaa cgaggaggcc gccgagtggg accgctgca ccccgctcac 1920
gccggggccc tcgccccgg ccagatgcgc gagccccgc gcagcgacat cgccggcac 1980
accagcacc tcaggagca gatcgctgg atgaccaaca accccccat ccccgctggc 2040
gagatctaca agcgttgat catcctgggc ctgaacaaga tcgtccgcat gtacagcccc 2100
accagcatcc tggacatcaa gcagggcccc aaggagccct tcgcgacta cgtggaccgc 2160
ttctacaaga ccttcgccc cgagcaggcc acccaggagg tgaagaactg gatgaccgag 2220
accctgctgg tcgagaagc caaccccgac tgcaagacca tctcaaggc cctgggaccc 2280
gccgcccccc tggaggagat gatgaccgcc tgccaaggcg tggcgggccc cggccacaag 2340
gcccgcgtgc tggcgccgt catcaccctg tggcagcgcc ccctggtggc cctgatcgag 2400
atctgcacag agatggagaa ggagggcaag atcagcaaga tcggccccgc cggcctgaag 2460
aagaagaaga gcgtgacctg gctggacgtg ggcgagccct acttcagcgt gcccctggat 2520
aaggacttcc gcaagtacac cgccttcacc atccccagca tctggaaggg cagccccgcc 2580
atcttcaga gcagcatgac caagaagcag aaccccgaca tcgtgatcta ccagtacatg 2640
gacgacctgt acgtgcccac cgtgtgccc gagaaggaca gctggctggt gggcaagctg 2700
aactgggcca gccagatcta cgccggcatc aaggtgaagc agctgatcct gaaggagccc 2760
gtgcacggcg tgtacgagcc catcgtgggc gccgagacct tctacgtgga cggcgccgcc 2820
aacccgccc gcaacctgtg ggtgaccgtg tactacggcg tgcccggtgt gaaggaggcc 2880
accaccacc tgggtggagc ctacctgcgc gaccagcagc tgctgggcat ctggggctgc 2940
gctgcaccc cctacgacat caaccagatg ctgcgcgccc ctggcgccgc cttcgtgacc 3000
atccgccagg gcagcctgta g 3021

```

<210> 25
 <211> 419
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Hybrid protein comprised of Nef-Tat-Rev (NTR)

<400> 25
 Met Val Gly Lys Trp Ser Lys Cys Ser Gly Trp Pro Thr Val Arg Glu
 1 5 10 15
 Arg Met Lys Gln Ala Glu Pro Glu Pro Ala Ala Asp Gly Val Gly Ala
 20 25 30
 Ala Ser Arg Asp Leu Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr

```

      35      40      45
Ala Thr Asn Asn Ala Ala Cys Ala Trp Leu Glu Ala Gln Glu Glu
  50      55      60
Glu Val Gly Phe Pro Val Arg Pro Gln Val Pro Leu Arg Pro Met Thr
  65      70      75      80
Tyr Lys Gly Ala Leu Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly
      85      90      95
Leu Glu Gly Leu Ile Tyr Ser Pro Lys Arg Gln Glu Ile Leu Asp Leu
      100      105      110
Trp Val Tyr His Thr Gln Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr
      115      120      125
Pro Gly Pro Gly Val Arg Tyr Pro Leu Thr Phe Gly Trp Cys Phe Lys
      130      135      140
Leu Val Pro Val Glu Pro Asp Glu Glu Glu Asn Ser Ser Leu Leu His
      145      150      155      160
Pro Ala Ser Leu His Gly Thr Glu Asp Thr Glu Arg Glu Val Leu Lys
      165      170      175
Trp Lys Phe Asp Ser His Leu Ala Phe His His Lys Ala Arg Glu Leu
      180      185      190
His Pro Glu Tyr Tyr Lys Asp Cys Thr Ser Ala Gly Arg Ser Gly Asp
      195      200      205
Ser Asp Glu Glu Leu Leu Lys Thr Val Arg Leu Ile Lys Phe Leu Tyr
      210      215      220
Gln Ser Asn Pro Pro Pro Ser Asn Glu Gly Thr Arg Gln Ala Arg Arg
      225      230      235      240
Asn Arg Arg Arg Arg Trp Arg Glu Arg Gln Arg Gln Ile Arg Ser Ile
      245      250      255
Ser Glu Arg Ile Leu Ser Thr Phe Leu Gly Arg Pro Ala Glu Pro Val
      260      265      270
Pro Leu Gln Leu Pro Pro Leu Glu Arg Leu Thr Leu Asp Cys Ser Glu
      275      280      285
Asp Cys Gly Asn Ser Gly Thr Gln Gly Val Gly Ser Pro Gln Val Leu
      290      295      300
Val Glu Ser Pro Ala Val Leu Glu Pro Gly Thr Lys Glu Lys Leu Glu
      305      310      315      320
Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser Gln Pro
      325      330      335
Arg Thr Pro Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Leu His Cys
      340      345      350
Gln Val Cys Phe Thr Arg Lys Gly Leu Gly Ile Ser Tyr Gly Arg Lys
      355      360      365
Lys Arg Arg Gln Arg Arg Arg Ala Pro Gln Asp Ser Gln Thr His Gln
      370      375      380
Val Ser Leu Pro Lys Gln Pro Ser Ser Gln Gln Arg Gly Asp Pro Thr
      385      390      395      400
Gly Pro Lys Lys Ser Lys Lys Lys Val Glu Arg Glu Thr Glu Ala Asp
      405      410      415
Pro Phe Asp

```

<210> 26

<211> 419

<212> PRT

<213> Artificial Sequence

<220>

<223> Hybrid protein comprised of Tat-Rev-Nef (TRN)

<400> 26

```

Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser
  1      5      10      15
Gln Pro Arg Thr Pro Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Leu
      20      25      30
His Cys Gln Val Cys Phe Thr Arg Lys Gly Leu Gly Ile Ser Tyr Gly

```

```

      35      40      45
Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala Pro Gln Asp Ser Gln Thr
  50      55      60
His Gln Val Ser Leu Pro Lys Gln Pro Ser Ser Gln Gln Arg Gly Asp
  65      70      75      80
Pro Thr Gly Pro Lys Lys Ser Lys Lys Val Glu Arg Glu Thr Glu
      85      90      95
Ala Asp Pro Phe Asp Thr Ser Ala Gly Arg Ser Gly Asp Ser Asp Glu
      100      105      110
Glu Leu Leu Lys Thr Val Arg Leu Ile Lys Phe Leu Tyr Gln Ser Asn
      115      120      125
Pro Pro Pro Ser Asn Glu Gly Thr Arg Gln Ala Arg Arg Asn Arg Arg
      130      135      140
Arg Arg Trp Arg Glu Arg Gln Arg Gln Ile Arg Ser Ile Ser Glu Arg
      145      150      155      160
Ile Leu Ser Thr Phe Leu Gly Arg Pro Ala Glu Pro Val Pro Leu Gln
      165      170      175
Leu Pro Pro Leu Glu Arg Leu Thr Leu Asp Cys Ser Glu Asp Cys Gly
      180      185      190
Asn Ser Gly Thr Gln Gly Val Gly Ser Pro Gln Val Leu Val Glu Ser
      195      200      205
Pro Ala Val Leu Glu Pro Gly Thr Lys Glu Lys Leu Val Gly Lys Trp
      210      215      220
Ser Lys Cys Ser Gly Trp Pro Thr Val Arg Glu Arg Met Lys Gln Ala
      225      230      235      240
Glu Pro Glu Pro Ala Ala Asp Gly Val Gly Ala Ala Ser Arg Asp Leu
      245      250      255
Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr Ala Thr Asn Asn Ala
      260      265      270
Ala Cys Ala Trp Leu Glu Ala Gln Glu Glu Glu Val Gly Phe Pro
      275      280      285
Val Arg Pro Gln Val Pro Leu Arg Pro Met Thr Tyr Lys Gly Ala Leu
      290      295      300
Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly Leu Glu Gly Leu Ile
      305      310      315      320
Tyr Ser Pro Lys Arg Gln Glu Ile Leu Asp Leu Trp Val Tyr His Thr
      325      330      335
Gln Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr Pro Gly Pro Gly Val
      340      345      350
Arg Tyr Pro Leu Thr Phe Gly Trp Cys Phe Lys Leu Val Pro Val Glu
      355      360      365
Pro Asp Glu Glu Glu Asn Ser Ser Leu Leu His Pro Ala Ser Leu His
      370      375      380
Gly Thr Glu Asp Thr Glu Arg Glu Val Leu Lys Trp Lys Phe Asp Ser
      385      390      395      400
His Leu Ala Phe His His Lys Ala Arg Glu Leu His Pro Glu Tyr Tyr
      405      410      415
Lys Asp Cys

```

<210> 27
 <211> 419
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Hybrid protein comprised of Rev-Tat-Nef (RTN)

```

<400> 27
Met Ala Gly Arg Ser Gly Asp Ser Asp Glu Glu Leu Leu Lys Thr Val
  1      5      10      15
Arg Leu Ile Lys Phe Leu Tyr Gln Ser Asn Pro Pro Pro Ser Asn Glu
      20      25      30
Gly Thr Arg Gln Ala Arg Arg Asn Arg Arg Arg Trp Arg Glu Arg

```

```

      35      40      45
Gln Arg Gln Ile Arg Ser Ile Ser Glu Arg Ile Leu Ser Thr Phe Leu
  50      55      60
Gly Arg Pro Ala Glu Pro Val Pro Leu Gln Leu Pro Pro Leu Glu Arg
  65      70      75      80
Leu Thr Leu Asp Cys Ser Glu Asp Cys Gly Asn Ser Gly Thr Gln Gly
      85      90      95
Val Gly Ser Pro Gln Val Leu Val Glu Ser Pro Ala Val Leu Glu Pro
  100      105      110
Gly Thr Lys Glu Thr Ser Glu Pro Val Asp Pro Arg Leu Glu Pro Trp
  115      120      125
Lys His Pro Gly Ser Gln Pro Arg Thr Pro Cys Thr Asn Cys Tyr Cys
  130      135      140
Lys Lys Cys Cys Leu His Cys Gln Val Cys Phe Thr Arg Lys Gly Leu
  145      150      155      160
Gly Ile Ser Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala Pro
      165      170      175
Gln Asp Ser Gln Thr His Gln Val Ser Leu Pro Lys Gln Pro Ser Ser
  180      185      190
Gln Gln Arg Gly Asp Pro Thr Gly Pro Lys Lys Ser Lys Lys Lys Val
  195      200      205
Glu Arg Glu Thr Glu Ala Asp Pro Phe Asp Lys Leu Val Gly Lys Trp
  210      215      220
Ser Lys Cys Ser Gly Trp Pro Thr Val Arg Glu Arg Met Lys Gln Ala
  225      230      235      240
Glu Pro Glu Pro Ala Ala Asp Gly Val Gly Ala Ala Ser Arg Asp Leu
      245      250      255
Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr Ala Thr Asn Asn Ala
  260      265      270
Ala Cys Ala Trp Leu Glu Ala Gln Glu Glu Glu Val Gly Phe Pro
  275      280      285
Val Arg Pro Gln Val Pro Leu Arg Pro Met Thr Tyr Lys Gly Ala Leu
  290      295      300
Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly Leu Glu Gly Leu Ile
  305      310      315      320
Tyr Ser Pro Lys Arg Gln Glu Ile Leu Asp Leu Trp Val Tyr His Thr
      325      330      335
Gln Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr Pro Gly Pro Gly Val
  340      345      350
Arg Tyr Pro Leu Thr Phe Gly Trp Cys Phe Lys Leu Val Pro Val Glu
  355      360      365
Pro Asp Glu Glu Glu Asn Ser Ser Leu Leu His Pro Ala Ser Leu His
  370      375      380
Gly Thr Glu Asp Thr Glu Arg Glu Val Leu Lys Trp Lys Phe Asp Ser
  385      390      395      400
His Leu Ala Phe His His Lys Ala Arg Glu Leu His Pro Glu Tyr Tyr
      405      410      415
Lys Asp Cys

```

<210> 28

<211> 419

<212> PRT

<213> Artificial Sequence

<220>

<223> Hybrid protein comprised of Tat-Nef-Rev (TNR)

<400> 28

```

Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser
  1      5      10      15
Gln Pro Arg Thr Pro Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Leu
      20      25      30
His Cys Gln Val Cys Phe Thr Arg Lys Gly Leu Gly Ile Ser Tyr Gly

```

```

      35      40      45
Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala Pro Gln Asp Ser Gln Thr
  50      55      60
His Gln Val Ser Leu Pro Lys Gln Pro Ser Ser Gln Gln Arg Gly Asp
  65      70      75      80
Pro Thr Gly Pro Lys Lys Ser Lys Lys Lys Val Glu Arg Glu Thr Glu
      85      90      95
Ala Asp Pro Phe Asp Thr Ser Val Gly Lys Trp Ser Lys Cys Ser Gly
      100      105      110
Trp Pro Thr Val Arg Glu Arg Met Lys Gln Ala Glu Pro Glu Pro Ala
      115      120      125
Ala Asp Gly Val Gly Ala Ala Ser Arg Asp Leu Glu Lys His Gly Ala
      130      135      140
Ile Thr Ser Ser Asn Thr Ala Thr Asn Asn Ala Ala Cys Ala Trp Leu
      145      150      155      160
Glu Ala Gln Glu Glu Glu Val Gly Phe Pro Val Arg Pro Gln Val
      165      170      175
Pro Leu Arg Pro Met Thr Tyr Lys Gly Ala Leu Asp Leu Ser His Phe
      180      185      190
Leu Lys Glu Lys Gly Gly Leu Glu Gly Leu Ile Tyr Ser Pro Lys Arg
      195      200      205
Gln Glu Ile Leu Asp Leu Trp Val Tyr His Thr Gln Gly Tyr Phe Pro
      210      215      220
Asp Trp Gln Asn Tyr Thr Pro Gly Pro Gly Val Arg Tyr Pro Leu Thr
      225      230      235      240
Phe Gly Trp Cys Phe Lys Leu Val Pro Val Glu Pro Asp Glu Glu Glu
      245      250      255
Asn Ser Ser Leu Leu His Pro Ala Ser Leu His Gly Thr Glu Asp Thr
      260      265      270
Glu Arg Glu Val Leu Lys Trp Lys Phe Asp Ser His Leu Ala Phe His
      275      280      285
His Lys Ala Arg Glu Leu His Pro Glu Tyr Tyr Lys Asp Cys Lys Leu
      290      295      300
Ala Gly Arg Ser Gly Asp Ser Asp Glu Glu Leu Leu Lys Thr Val Arg
      305      310      315      320
Leu Ile Lys Phe Leu Tyr Gln Ser Asn Pro Pro Pro Ser Asn Glu Gly
      325      330      335
Thr Arg Gln Ala Arg Arg Asn Arg Arg Arg Trp Arg Glu Arg Gln
      340      345      350
Arg Gln Ile Arg Ser Ile Ser Glu Arg Ile Leu Ser Thr Phe Leu Gly
      355      360      365
Arg Pro Ala Glu Pro Val Pro Leu Gln Leu Pro Pro Leu Glu Arg Leu
      370      375      380
Thr Leu Asp Cys Ser Glu Asp Cys Gly Asn Ser Gly Thr Gln Gly Val
      385      390      395      400
Gly Ser Pro Gln Val Leu Val Glu Ser Pro Ala Val Leu Glu Pro Gly
      405      410      415
Thr Lys Glu

```

```

<210> 29
<211> 419
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> Hybrid protein comprised of Rev-Nef-Tat (RNT)

```

```

<400> 29
Met Ala Gly Arg Ser Gly Asp Ser Asp Glu Glu Leu Leu Lys Thr Val
  1      5      10      15
Arg Leu Ile Lys Phe Leu Tyr Gln Ser Asn Pro Pro Pro Ser Asn Glu
      20      25      30
Gly Thr Arg Gln Ala Arg Arg Asn Arg Arg Arg Trp Arg Glu Arg

```

```

      35      40      45
Gln Arg Gln Ile Arg Ser Ile Ser Glu Arg Ile Leu Ser Thr Phe Leu
  50      55      60
Gly Arg Pro Ala Glu Pro Val Pro Leu Gln Leu Pro Pro Leu Glu Arg
  65      70      75      80
Leu Thr Leu Asp Cys Ser Glu Asp Cys Gly Asn Ser Gly Thr Gln Gly
      85      90      95
Val Gly Ser Pro Gln Val Leu Val Glu Ser Pro Ala Val Leu Glu Pro
      100      105      110
Gly Thr Lys Glu Thr Ser Val Gly Lys Trp Ser Lys Cys Ser Gly Trp
      115      120      125
Pro Thr Val Arg Glu Arg Met Lys Gln Ala Glu Pro Glu Pro Ala Ala
      130      135      140
Asp Gly Val Gly Ala Ala Ser Arg Asp Leu Glu Lys His Gly Ala Ile
      145      150      155      160
Thr Ser Ser Asn Thr Ala Thr Asn Asn Ala Ala Cys Ala Trp Leu Glu
      165      170      175
Ala Gln Glu Glu Glu Val Gly Phe Pro Val Arg Pro Gln Val Pro
      180      185      190
Leu Arg Pro Met Thr Tyr Lys Gly Ala Leu Asp Leu Ser His Phe Leu
      195      200      205
Lys Glu Lys Gly Gly Leu Glu Gly Leu Ile Tyr Ser Pro Lys Arg Gln
      210      215      220
Glu Ile Leu Asp Leu Trp Val Tyr His Thr Gln Gly Tyr Phe Pro Asp
      225      230      235      240
Trp Gln Asn Tyr Thr Pro Gly Pro Gly Val Arg Tyr Pro Leu Thr Phe
      245      250      255
Gly Trp Cys Phe Lys Leu Val Pro Val Glu Pro Asp Glu Glu Glu Asn
      260      265      270
Ser Ser Leu Leu His Pro Ala Ser Leu His Gly Thr Glu Asp Thr Glu
      275      280      285
Arg Glu Val Leu Lys Trp Lys Phe Asp Ser His Leu Ala Phe His His
      290      295      300
Lys Ala Arg Glu Leu His Pro Glu Tyr Tyr Lys Asp Cys Lys Leu Glu
      305      310      315      320
Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser Gln Pro
      325      330      335
Arg Thr Pro Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Leu His Cys
      340      345      350
Gln Val Cys Phe Thr Arg Lys Gly Leu Gly Ile Ser Tyr Gly Arg Lys
      355      360      365
Lys Arg Arg Gln Arg Arg Ala Pro Gln Asp Ser Gln Thr His Gln
      370      375      380
Val Ser Leu Pro Lys Gln Pro Ser Ser Gln Gln Arg Gly Asp Pro Thr
      385      390      395      400
Gly Pro Lys Lys Ser Lys Lys Lys Val Glu Arg Glu Thr Glu Ala Asp
      405      410      415
Pro Phe Asp

```

<210> 30
 <211> 387
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Protein comprised of Immunodominant parts of the Nef-Tat-Rev(NTR)

```

<400> 30
Met Gly Trp Pro Thr Val Arg Glu Arg Met Lys Gln Ala Glu Pro Glu
  1      5      10      15
Pro Ala Ala Asp Gly Val Gly Ala Ala Ser Arg Asp Leu Glu Lys His
      20      25      30
Gly Ala Ile Thr Ser Ser Asn Thr Ala Thr Asn Asn Ala Ala Cys Ala

```

```

      35      40      45
Trp Leu Glu Ala Gln Glu Glu Glu Val Gly Phe Pro Val Arg Pro
50      55      60
Gln Val Pro Leu Arg Pro Met Thr Tyr Lys Gly Ala Leu Asp Leu Ser
65      70      75      80
His Phe Leu Lys Glu Lys Gly Gly Leu Glu Gly Leu Ile Tyr Ser Pro
85      90      95
Lys Arg Gln Glu Ile Leu Asp Leu Trp Val Tyr His Thr Gln Gly Tyr
100      105      110
Phe Pro Asp Trp Gln Asn Tyr Thr Pro Gly Pro Gly Val Arg Tyr Pro
115      120      125
Leu Thr Phe Gly Trp Cys Phe Lys Leu Val Pro Val Glu Pro Asp Glu
130      135      140
Glu Glu Asn Ser Ser Leu Leu His Pro Ala Ser Leu His Gly Thr Glu
145      150      155      160
Asp Thr Glu Arg Glu Val Leu Lys Trp Lys Phe Asp Ser His Leu Ala
165      170      175
Phe His His Lys Ala Arg Glu Leu His Pro Glu Tyr Tyr Lys Asp Cys
180      185      190
Ala Leu Ala Ala Val Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys
195      200      205
His Pro Gly Ser Gln Pro Arg Thr Pro Cys Thr Asn Cys Tyr Cys Lys
210      215      220
Lys Cys Cys Leu His Cys Gln Val Cys Phe Thr Arg Lys Gly Leu Gly
225      230      235      240
Ile Ser Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Ala Pro Gln
245      250      255
Asp Ser Gln Thr His Gln Val Ser Leu Pro Lys Gln Pro Ser Ser Gln
260      265      270
Gln Arg Gly Asp Pro Thr Gly Pro Lys Lys Ser Gly Leu Ala Ile Leu
275      280      285
Leu Ser Asp Glu Glu Leu Leu Lys Thr Val Arg Leu Ile Lys Phe Leu
290      295      300
Tyr Gln Ser Asn Pro Pro Ser Asn Glu Gly Thr Arg Gln Ala Arg
305      310      315      320
Arg Asn Arg Arg Arg Trp Arg Glu Arg Gln Arg Gln Ile Arg Ser
325      330      335
Ile Ser Glu Arg Ile Leu Ser Thr Phe Leu Gly Arg Pro Ala Glu Pro
340      345      350
Val Pro Leu Gln Leu Pro Pro Leu Glu Arg Leu Thr Leu Asp Cys Ser
355      360      365
Glu Asp Cys Gly Asn Ser Gly Thr Gln Gly Val Gly Ser Pro Gln Val
370      375      380
Leu Val Glu
385

```

<210> 31
 <211> 390
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Protein comprised of Immunodominant parts of the Nef-Tat-Rev
 separated by protease sites(NTR)

```

<400> 31
Met Gly Trp Pro Thr Val Arg Glu Arg Met Lys Gln Ala Glu Pro Glu
1      5      10      15
Pro Ala Ala Asp Gly Val Gly Ala Ala Ser Arg Asp Leu Glu Lys His
20      25      30
Gly Ala Ile Thr Ser Ser Asn Thr Ala Thr Asn Asn Ala Ala Cys Ala
35      40      45
Trp Leu Glu Ala Gln Glu Glu Glu Val Gly Phe Pro Val Arg Pro

```

```

      50      55      60
Gln Val Pro Leu Arg Pro Met Thr Tyr Lys Gly Ala Leu Asp Leu Ser
65      70      75      80
His Phe Leu Lys Glu Lys Gly Gly Leu Glu Gly Leu Ile Tyr Ser Pro
      85      90      95
Lys Arg Gln Glu Ile Leu Asp Leu Trp Val Tyr His Thr Gln Gly Tyr
      100      105      110
Phe Pro Asp Trp Gln Asn Tyr Thr Pro Gly Pro Gly Val Arg Tyr Pro
      115      120      125
Leu Thr Phe Gly Trp Cys Phe Lys Leu Val Pro Val Glu Pro Asp Glu
      130      135      140
Glu Glu Asn Ser Ser Leu Leu His Pro Ala Ser Leu His Gly Thr Glu
145      150      155      160
Asp Thr Glu Arg Glu Val Leu Lys Trp Lys Phe Asp Ser His Leu Ala
      165      170      175
Phe His His Lys Ala Arg Glu Leu His Pro Glu Tyr Tyr Lys Asp Cys
      180      185      190
Ala Leu Ala Phe Lys Arg Val Glu Pro Val Asp Pro Arg Leu Glu Pro
      195      200      205
Trp Lys His Pro Gly Ser Gln Pro Arg Thr Pro Cys Thr Asn Cys Tyr
      210      215      220
Cys Lys Lys Cys Cys Leu His Cys Gln Val Cys Phe Thr Arg Lys Gly
225      230      235      240
Leu Gly Ile Ser Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala
      245      250      255
Pro Gln Asp Ser Gln Thr His Gln Val Ser Leu Pro Lys Gln Pro Ser
      260      265      270
Ser Gln Gln Arg Gly Asp Pro Thr Gly Pro Lys Lys Ser Val Arg Glu
      275      280      285
Lys Arg Leu Leu Ser Asp Glu Glu Leu Leu Lys Thr Val Arg Leu Ile
      290      295      300
Lys Phe Leu Tyr Gln Ser Asn Pro Pro Pro Ser Asn Glu Gly Thr Arg
305      310      315      320
Gln Ala Arg Arg Asn Arg Arg Arg Trp Arg Glu Arg Gln Arg Gln
      325      330      335
Ile Arg Ser Ile Ser Glu Arg Ile Leu Ser Thr Phe Leu Gly Arg Pro
      340      345      350
Ala Glu Pro Val Pro Leu Gln Leu Pro Pro Leu Glu Arg Leu Thr Leu
      355      360      365
Asp Cys Ser Glu Asp Cys Gly Asn Ser Gly Thr Gln Gly Val Gly Ser
      370      375      380
Pro Gln Val Leu Val Glu
385      390

```

<210> 32
 <211> 386
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Protein comprised of Immunodominant parts of the regulatory proteins
 Nef-Tat-Rev started from aal of Nef(N11TR)

```

<400> 32
Met Trp Pro Thr Val Arg Glu Arg Met Lys Gln Ala Glu Pro Glu Pro
1      5      10      15
Ala Ala Asp Gly Val Gly Ala Ala Ser Arg Asp Leu Glu Lys His Gly
      20      25      30
Ala Ile Thr Ser Ser Asn Thr Ala Thr Asn Asn Ala Ala Cys Ala Trp
      35      40      45
Leu Glu Ala Gln Glu Glu Glu Glu Val Gly Phe Pro Val Arg Pro Gln
      50      55      60
Val Pro Leu Arg Pro Met Thr Tyr Lys Gly Ala Leu Asp Leu Ser His

```

65 Phe Leu Lys Glu Lys 70 Gly Gly Leu Glu 75 Gly Leu Ile Tyr Ser Pro Lys 80
 85 Arg Gln Glu Ile Leu Asp Leu Trp Val Tyr His Thr Gln Gly Tyr Phe
 100 Pro Asp Trp Gln Asn Tyr Thr Pro Gly Pro Gly Val Arg Tyr Pro Leu
 115 Thr Phe Gly Trp Cys Phe Lys Leu Val Pro Val Glu Pro Asp Glu Glu
 130 Glu Asn Ser Ser Leu Leu His Pro Ala Ser Leu His Gly Thr Glu Asp
 145 Thr Glu Arg Glu Val Leu Lys Trp Lys Phe Asp Ser His Leu Ala Phe
 165 His His Lys Ala Arg Glu Leu His Pro Glu Tyr Tyr Lys Asp Cys Ala
 180 Leu Ala Ala Val Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His
 195 Pro Gly Ser Gln Pro Arg Thr Pro Cys Thr Asn Cys Tyr Cys Lys Lys
 210 Cys Cys Leu His Cys Gln Val Cys Phe Thr Arg Lys Gly Leu Gly Ile
 225 Ser Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala Pro Gln Asp
 245 Ser Gln Thr His Gln Val Ser Leu Pro Lys Gln Pro Ser Ser Gln Gln
 260 Arg Gly Asp Pro Thr Gly Pro Lys Lys Ser Gly Leu Ala Ile Leu Leu
 275 Ser Asp Glu Glu Leu Leu Lys Thr Val Arg Leu Ile Lys Phe Leu Tyr
 290 Gln Ser Asn Pro Pro Pro Ser Asn Glu Gly Thr Arg Gln Ala Arg Arg
 305 Asn Arg Arg Arg Arg Trp Arg Glu Arg Gln Arg Gln Ile Arg Ser Ile
 325 Ser Glu Arg Ile Leu Ser Thr Phe Leu Gly Arg Pro Ala Glu Pro Val
 340 Pro Leu Gln Leu Pro Pro Leu Glu Arg Leu Thr Leu Asp Cys Ser Glu
 355 Asp Cys Gly Asn Ser Gly Thr Gln Gly Val Gly Ser Pro Gln Val Leu
 370 Val Glu
 385

<210> 33
 <211> 389
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Protein comprised of Immunodominant parts of the regulatory proteins
 Nef-Tat-Rev started from aal of Nef separated by protease sites(N11TR)

<400> 33
 Met Trp Pro Thr Val Arg Glu Arg Met Lys Gln Ala Glu Pro Glu Pro
 1 5 10 15
 Ala Ala Asp Gly Val Gly Ala Ala Ser Arg Asp Leu Glu Lys His Gly
 20 25 30
 Ala Ile Thr Ser Ser Asn Thr Ala Thr Asn Asn Ala Ala Cys Ala Trp
 35 40 45
 Leu Glu Ala Gln Glu Glu Glu Val Gly Phe Pro Val Arg Pro Gln
 50 55 60
 Val Pro Leu Arg Pro Met Thr Tyr Lys Gly Ala Leu Asp Leu Ser His
 65 70 75 80
 Phe Leu Lys Glu Lys Gly Gly Leu Glu Gly Leu Ile Tyr Ser Pro Lys

```

      85      90      95
Arg Gln Glu Ile Leu Asp Leu Trp Val Tyr His Thr Gln Gly Tyr Phe
      100      105      110
Pro Asp Trp Gln Asn Tyr Thr Pro Gly Pro Gly Val Arg Tyr Pro Leu
      115      120      125
Thr Phe Gly Trp Cys Phe Lys Leu Val Pro Val Glu Pro Asp Glu Glu
      130      135      140
Glu Asn Ser Ser Leu Leu His Pro Ala Ser Leu His Gly Thr Glu Asp
      145      150      155      160
Thr Glu Arg Glu Val Leu Lys Trp Lys Phe Asp Ser His Leu Ala Phe
      165      170      175
His His Lys Ala Arg Glu Leu His Pro Glu Tyr Tyr Lys Asp Cys Ala
      180      185      190
Leu Ala Phe Lys Arg Val Glu Pro Val Asp Pro Arg Leu Glu Pro Trp
      195      200      205
Lys His Pro Gly Ser Gln Pro Arg Thr Pro Cys Thr Asn Cys Tyr Cys
      210      215      220
Lys Lys Cys Cys Leu His Cys Gln Val Cys Phe Thr Arg Lys Gly Leu
      225      230      235      240
Gly Ile Ser Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala Pro
      245      250      255
Gln Asp Ser Gln Thr His Gln Val Ser Leu Pro Lys Gln Pro Ser Ser
      260      265      270
Gln Gln Arg Gly Asp Pro Thr Gly Pro Lys Lys Ser Val Arg Glu Lys
      275      280      285
Arg Leu Leu Ser Asp Glu Glu Leu Lys Thr Val Arg Leu Ile Lys
      290      295      300
Phe Leu Tyr Gln Ser Asn Pro Pro Pro Ser Asn Glu Gly Thr Arg Gln
      305      310      315      320
Ala Arg Arg Asn Arg Arg Arg Trp Arg Glu Arg Gln Arg Gln Ile
      325      330      335
Arg Ser Ile Ser Glu Arg Ile Leu Ser Thr Phe Leu Gly Arg Pro Ala
      340      345      350
Glu Pro Val Pro Leu Gln Leu Pro Pro Leu Glu Arg Leu Thr Leu Asp
      355      360      365
Cys Ser Glu Asp Cys Gly Asn Ser Gly Thr Gln Gly Val Gly Ser Pro
      370      375      380
Gln Val Leu Val Glu
      385

```

```

<210> 34
<211> 220
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> Protein comprised of Cytotoxic T-cell epitopes of Pol and Env
genes(CTL)

```

```

<400> 34
Met Ile Thr Leu Trp Gln Arg Pro Leu Val Ala Leu Ile Glu Ile Cys
1      5      10      15
Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys Ile Gly Pro Ala Gly
20      25      30
Leu Lys Lys Lys Lys Ser Val Thr Val Leu Asp Val Gly Asp Ala Tyr
35      40      45
Phe Ser Val Pro Leu Asp Lys Asp Phe Arg Lys Tyr Thr Ala Phe Thr
50      55      60
Ile Pro Ser Ile Trp Lys Gly Ser Pro Ala Ile Phe Gln Ser Ser Met
65      70      75      80
Thr Lys Lys Gln Asn Pro Asp Ile Val Ile Tyr Gln Tyr Met Asp Asp
85      90      95
Leu Tyr Val Pro Ile Val Leu Pro Glu Lys Asp Ser Trp Leu Val Gly

```

```

      100      105      110
Lys Leu Asn Trp Ala Ser Gln Ile Tyr Ala Gly Ile Lys Val Lys Gln
      115      120      125
Leu Ile Leu Lys Glu Pro Val His Gly Val Tyr Glu Pro Ile Val Gly
      130      135      140
Ala Glu Thr Phe Tyr Val Asp Gly Ala Ala Asn Arg Ala Gly Asn Leu
145      150      155      160
Trp Val Thr Val Tyr Tyr Gly Val Pro Val Trp Lys Glu Ala Thr Thr
      165      170      175
Thr Leu Val Glu Arg Tyr Leu Arg Asp Gln Gln Leu Leu Gly Ile Trp
      180      185      190
Gly Cys Ala Cys Thr Pro Tyr Asp Ile Asn Gln Met Leu Arg Gly Pro
195      200      205
Gly Arg Ala Phe Val Thr Ile Arg Gln Gly Ser Leu
210      215      220

```

<210> 35
 <211> 421
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Truncated Gag protein sequence(dgag)

```

<400> 35
Met Leu Asp Lys Trp Glu Lys Ile Arg Leu Arg Pro Gly Gly Lys Lys
1      5      10      15
Lys Tyr Gln Leu Lys His Ile Val Trp Ala Ser Arg Glu Leu Glu Arg
      20      25      30
Phe Ala Val Asn Pro Gly Leu Leu Glu Thr Ser Glu Gly Cys Arg Gln
      35      40      45
Ile Met Gly Gln Leu Gln Pro Ser Leu Gln Thr Gly Ser Glu Glu Leu
50      55      60
Arg Ser Leu Tyr Asn Thr Val Ala Thr Leu Tyr Cys Val His Gln Lys
65      70      75      80
Ile Glu Val Lys Asp Thr Lys Glu Ala Leu Asp Lys Val Glu Glu Glu
      85      90      95
Gln Asn Asn Ser Lys Lys Lys Ala Gln Gln Glu Ala Ala Asp Ala Gly
100      105      110
Asn Arg Asn Gln Val Ser Gln Asn Tyr Pro Ile Val Gln Asn Leu Gln
115      120      125
Gly Gln Met Val His Gln Ala Ile Ser Pro Arg Thr Leu Asn Ala Trp
130      135      140
Val Lys Val Val Glu Glu Lys Ala Phe Ser Pro Glu Val Ile Pro Met
145      150      155      160
Phe Ser Ala Leu Ser Glu Gly Ala Thr Pro Gln Asp Leu Asn Thr Met
      165      170      175
Leu Asn Thr Val Gly Gly His Gln Ala Ala Met Gln Met Leu Lys Glu
180      185      190
Thr Ile Asn Glu Glu Ala Ala Glu Trp Asp Arg Leu His Pro Val His
195      200      205
Ala Gly Pro Ile Ala Pro Gly Gln Met Arg Glu Pro Arg Gly Ser Asp
210      215      220
Ile Ala Gly Thr Thr Ser Thr Leu Gln Glu Gln Ile Gly Trp Met Thr
225      230      235      240
Asn Asn Pro Pro Ile Pro Val Gly Glu Ile Tyr Lys Arg Trp Ile Ile
      245      250      255
Leu Gly Leu Asn Lys Ile Val Arg Met Tyr Ser Pro Thr Ser Ile Leu
260      265      270
Asp Ile Lys Gln Gly Pro Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg
275      280      285
Phe Tyr Lys Thr Leu Arg Ala Glu Gln Ala Thr Gln Glu Val Lys Asn
290      295      300

```

Trp Met Thr Glu Thr Leu Leu Val Gln Asn Ala Asn Pro Asp Cys Lys
 305 310 315 320
 Thr Ile Leu Lys Ala Leu Gly Pro Ala Ala Thr Leu Glu Glu Met Met
 325 330 335
 Thr Ala Cys Gln Gly Val Gly Gly Pro Gly His Lys Ala Arg Val Leu
 340 345 350
 Ala Glu Ala Met Ser Gln Val Thr Gly Ser Ala Ala Ile Met Met Gln
 355 360 365
 Arg Gly Asn Phe Arg Asn Gln Arg Lys Thr Val Lys Cys Phe Asn Cys
 370 375 380
 Gly Lys Glu Gly His Ile Ala Arg Asn Cys Arg Ala Pro Arg Lys Lys
 385 390 395 400
 Gly Cys Trp Lys Cys Gly Lys Glu Gly His Gln Met Lys Asp Cys Thr
 405 410 415
 Glu Arg Gln Ala Asn
 420

<210> 36
 <211> 363
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic p17/24 protein of Gag gene (Syn 17/24)

<400> 36
 Met Gly Ala Arg Ala Ser Val Leu Ser Gly Gly Glu Leu Asp Lys Trp
 1 5 10 15
 Glu Lys Ile Arg Leu Arg Pro Gly Gly Lys Lys Lys Tyr Gln Leu Lys
 20 25 30
 His Ile Val Trp Ala Ser Arg Glu Leu Glu Arg Phe Ala Val Asn Pro
 35 40 45
 Gly Leu Leu Glu Thr Ser Glu Gly Cys Arg Gln Ile Met Gly Gln Leu
 50 55 60
 Gln Pro Ser Leu Gln Thr Gly Ser Glu Glu Leu Arg Ser Leu Tyr Asn
 65 70 75 80
 Thr Val Ala Thr Leu Tyr Cys Val His Gln Lys Ile Glu Val Lys Asp
 85 90 95
 Thr Lys Glu Ala Leu Asp Lys Val Glu Glu Glu Gln Asn Asn Ser Lys
 100 105 110
 Lys Lys Ala Gln Gln Glu Ala Ala Asp Ala Gly Asn Arg Asn Gln Val
 115 120 125
 Ser Gln Asn Tyr Pro Ile Val Gln Asn Leu Gln Gly Gln Met Val His
 130 135 140
 Gln Ala Ile Ser Pro Arg Thr Leu Asn Ala Trp Val Lys Val Val Glu
 145 150 155 160
 Glu Lys Ala Phe Ser Pro Glu Val Ile Pro Met Phe Ser Ala Leu Ser
 165 170 175
 Glu Gly Ala Thr Pro Gln Asp Leu Asn Thr Met Leu Asn Thr Val Gly
 180 185 190
 Gly His Gln Ala Ala Met Gln Met Leu Lys Glu Thr Ile Asn Glu Glu
 195 200 205
 Ala Ala Glu Trp Asp Arg Leu His Pro Val His Ala Gly Pro Ile Ala
 210 215 220
 Pro Gly Gln Met Arg Glu Pro Arg Gly Ser Asp Ile Ala Gly Thr Thr
 225 230 235 240
 Ser Thr Leu Gln Glu Gln Ile Gly Trp Met Thr Asn Asn Pro Pro Ile
 245 250 255
 Pro Val Gly Glu Ile Tyr Lys Arg Trp Ile Ile Leu Gly Leu Asn Lys
 260 265 270
 Ile Val Arg Met Tyr Ser Pro Thr Ser Ile Leu Asp Ile Lys Gln Gly
 275 280 285
 Pro Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg Phe Tyr Lys Thr Leu

290 295 300
 Arg Ala Glu Gln Ala Thr Gln Glu Val Lys Asn Trp Met Thr Glu Thr
 305 310 315 320
 Leu Leu Val Gln Asn Ala Asn Pro Asp Cys Lys Thr Ile Leu Lys Ala
 325 330 335
 Leu Gly Pro Ala Ala Thr Leu Glu Glu Met Met Thr Ala Cys Gln Gly
 340 345 350
 Val Gly Gly Pro Gly His Lys Ala Arg Val Leu
 355 360

<210> 37
 <211> 363
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Synthetic p17/24 protein of Gag gene optimized for expression in eukaryotic cells(optp 17/24)

<400> 37
 Met Gly Ala Arg Ala Ser Val Leu Ser Gly Gly Glu Leu Asp Lys Trp
 1 5 10 15
 Glu Lys Ile Arg Leu Arg Pro Gly Gly Lys Lys Lys Tyr Gln Leu Lys
 20 25 30
 His Ile Val Trp Ala Ser Arg Glu Leu Glu Arg Phe Ala Val Asn Pro
 35 40 45
 Gly Leu Leu Glu Thr Ser Glu Gly Cys Arg Gln Ile Met Gly Gln Leu
 50 55 60
 Gln Pro Ser Leu Gln Thr Gly Ser Glu Glu Leu Arg Ser Leu Tyr Asn
 65 70 75 80
 Thr Val Ala Thr Leu Tyr Cys Val His Gln Lys Ile Glu Val Lys Asp
 85 90 95
 Thr Lys Glu Ala Leu Asp Lys Val Glu Glu Gln Asn Asn Ser Lys
 100 105 110
 Lys Lys Ala Gln Gln Glu Ala Ala Asp Ala Gly Asn Arg Asn Gln Val
 115 120 125
 Ser Gln Asn Tyr Pro Ile Val Gln Asn Leu Gln Gly Gln Met Val His
 130 135 140
 Gln Ala Ile Ser Pro Arg Thr Leu Asn Ala Trp Val Lys Val Val Glu
 145 150 155 160
 Glu Lys Ala Phe Ser Pro Glu Val Ile Pro Met Phe Ser Ala Leu Ser
 165 170 175
 Glu Gly Ala Thr Pro Gln Asp Leu Asn Thr Met Leu Asn Thr Val Gly
 180 185 190
 Gly His Gln Ala Ala Met Gln Met Leu Lys Glu Thr Ile Asn Glu Glu
 195 200 205
 Ala Ala Glu Trp Asp Arg Leu His Pro Val His Ala Gly Pro Ile Ala
 210 215 220
 Pro Gly Gln Met Arg Glu Pro Arg Gly Ser Asp Ile Ala Gly Thr Thr
 225 230 235 240
 Ser Thr Leu Gln Glu Gln Ile Gly Trp Met Thr Asn Asn Pro Pro Ile
 245 250 255
 Pro Val Gly Glu Ile Tyr Lys Arg Trp Ile Ile Leu Gly Leu Asn Lys
 260 265 270
 Ile Val Arg Met Tyr Ser Pro Thr Ser Ile Leu Asp Ile Lys Gln Gly
 275 280 285
 Pro Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg Phe Tyr Lys Thr Leu
 290 295 300
 Arg Ala Glu Gln Ala Thr Gln Glu Val Lys Asn Trp Met Thr Glu Thr
 305 310 315 320
 Leu Leu Val Gln Asn Ala Asn Pro Asp Cys Lys Thr Ile Leu Lys Ala
 325 330 335
 Leu Gly Pro Ala Ala Thr Leu Glu Glu Met Met Thr Ala Cys Gln Gly

Val Gly Gly Pro Gly His Lys Ala Arg Val Leu
 340 345 350
 355 360

<210> 38
 <211> 641
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Hybrid protein comprised of Tat-Rev-Nef and CTL(TRN-CTL)

<400> 38
 Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser
 1 5 10 15
 Gln Pro Arg Thr Pro Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Leu
 20 25 30
 His Cys Gln Val Cys Phe Thr Arg Lys Gly Leu Gly Ile Ser Tyr Gly
 35 40 45
 Arg Lys Lys Arg Arg Gln Arg Arg Ala Pro Gln Asp Ser Gln Thr
 50 55 60
 His Gln Val Ser Leu Pro Lys Gln Pro Ser Ser Gln Gln Arg Gly Asp
 65 70 75 80
 Pro Thr Gly Pro Lys Lys Ser Lys Lys Lys Val Glu Arg Glu Thr Glu
 85 90 95
 Ala Asp Pro Phe Asp Thr Ser Ala Gly Arg Ser Gly Asp Ser Asp Glu
 100 105 110
 Glu Leu Leu Lys Thr Val Arg Leu Ile Lys Phe Leu Tyr Gln Ser Asn
 115 120 125
 Pro Pro Pro Ser Asn Glu Gly Thr Arg Gln Ala Arg Arg Asn Arg Arg
 130 135 140
 Arg Arg Trp Arg Glu Arg Gln Arg Gln Ile Arg Ser Ile Ser Glu Arg
 145 150 155 160
 Ile Leu Ser Thr Phe Leu Gly Arg Pro Ala Glu Pro Val Pro Leu Gln
 165 170 175
 Leu Pro Pro Leu Glu Arg Leu Thr Leu Asp Cys Ser Glu Asp Cys Gly
 180 185 190
 Asn Ser Gly Thr Gln Gly Val Gly Ser Pro Gln Val Leu Val Glu Ser
 195 200 205
 Pro Ala Val Leu Glu Pro Gly Thr Lys Glu Lys Leu Val Gly Lys Trp
 210 215 220
 Ser Lys Cys Ser Gly Trp Pro Thr Val Arg Glu Arg Met Lys Gln Ala
 225 230 235 240
 Glu Pro Glu Pro Ala Ala Asp Gly Val Gly Ala Ala Ser Arg Asp Leu
 245 250 255
 Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr Ala Thr Asn Asn Ala
 260 265 270
 Ala Cys Ala Trp Leu Glu Ala Gln Glu Glu Glu Val Gly Phe Pro
 275 280 285
 Val Arg Pro Gln Val Pro Leu Arg Pro Met Thr Tyr Lys Gly Ala Leu
 290 295 300
 Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly Leu Glu Gly Leu Ile
 305 310 315 320
 Tyr Ser Pro Lys Arg Gln Glu Ile Leu Asp Leu Trp Val Tyr His Thr
 325 330 335
 Gln Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr Pro Gly Pro Gly Val
 340 345 350
 Arg Tyr Pro Leu Thr Phe Gly Trp Cys Phe Lys Leu Val Pro Val Glu
 355 360 365
 Pro Asp Glu Glu Glu Asn Ser Ser Leu Leu His Pro Ala Ser Leu His
 370 375 380
 Gly Thr Glu Asp Thr Glu Arg Glu Val Leu Lys Trp Lys Phe Asp Ser
 385 390 395 400

His Leu Ala Phe His His Lys Ala Arg Glu Leu His Pro Glu Tyr Tyr
 405 410 415
 Lys Asp Cys Ala Ala Val Ile Thr Leu Trp Gln Arg Pro Leu Val Ala
 420 425 430
 Leu Ile Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys
 435 440 445
 Ile Gly Pro Ala Gly Leu Lys Lys Lys Ser Val Thr Val Leu Asp
 450 455 460
 Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Lys Asp Phe Arg Lys
 465 470 475 480
 Tyr Thr Ala Phe Thr Ile Pro Ser Ile Trp Lys Gly Ser Pro Ala Ile
 485 490 495
 Phe Gln Ser Ser Met Thr Lys Lys Gln Asn Pro Asp Ile Val Ile Tyr
 500 505 510
 Gln Tyr Met Asp Asp Leu Tyr Val Pro Ile Val Leu Pro Glu Lys Asp
 515 520 525
 Ser Trp Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Ala Gly
 530 535 540
 Ile Lys Val Lys Gln Leu Ile Leu Lys Glu Pro Val His Gly Val Tyr
 545 550 555 560
 Glu Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Asp Gly Ala Ala Asn
 565 570 575
 Arg Ala Gly Asn Leu Trp Val Thr Val Tyr Tyr Gly Val Pro Val Trp
 580 585 590
 Lys Glu Ala Thr Thr Thr Leu Val Glu Arg Tyr Leu Arg Asp Gln Gln
 595 600 605
 Leu Leu Gly Ile Trp Gly Cys Ala Cys Thr Pro Tyr Asp Ile Asn Gln
 610 615 620
 Met Leu Arg Gly Pro Gly Arg Ala Phe Val Thr Ile Arg Gln Gly Ser
 625 630 635 640
 Leu

<210> 39
 <211> 641
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Hybrid protein comprised of Rev-Nef-Tat and CTL(RNT-CTL)

<400> 39
 Met Ala Gly Arg Ser Gly Asp Ser Asp Glu Leu Leu Lys Thr Val
 1 5 10 15
 Arg Leu Ile Lys Phe Leu Tyr Gln Ser Asn Pro Pro Pro Ser Asn Glu
 20 25 30
 Gly Thr Arg Gln Ala Arg Arg Asn Arg Arg Arg Trp Arg Glu Arg
 35 40 45
 Gln Arg Gln Ile Arg Ser Ile Ser Glu Arg Ile Leu Ser Thr Phe Leu
 50 55 60
 Gly Arg Pro Ala Glu Pro Val Pro Leu Gln Leu Pro Pro Leu Glu Arg
 65 70 75 80
 Leu Thr Leu Asp Cys Ser Glu Asp Cys Gly Asn Ser Gly Thr Gln Gly
 85 90 95
 Val Gly Ser Pro Gln Val Leu Val Glu Ser Pro Ala Val Leu Glu Pro
 100 105 110
 Gly Thr Lys Glu Thr Ser Val Gly Lys Trp Ser Lys Cys Ser Gly Trp
 115 120 125
 Pro Thr Val Arg Glu Arg Met Lys Gln Ala Glu Pro Glu Pro Ala Ala
 130 135 140
 Asp Gly Val Gly Ala Ala Ser Arg Asp Leu Glu Lys His Gly Ala Ile
 145 150 155 160
 Thr Ser Ser Asn Thr Ala Thr Asn Asn Ala Ala Cys Ala Trp Leu Glu

```

165      170      175
Ala Gln Glu Glu Glu Val Gly Phe Pro Val Arg Pro Gln Val Pro
180      185      190
Leu Arg Pro Met Thr Tyr Lys Gly Ala Leu Asp Leu Ser His Phe Leu
195      200      205
Lys Glu Lys Gly Gly Leu Glu Gly Leu Ile Tyr Ser Pro Lys Arg Gln
210      215      220
Glu Ile Leu Asp Leu Trp Val Tyr His Thr Gln Gly Tyr Phe Pro Asp
225      230      235
Trp Gln Asn Tyr Thr Pro Gly Pro Gly Val Arg Tyr Pro Leu Thr Phe
245      250      255
Gly Trp Cys Phe Lys Leu Val Pro Val Glu Pro Asp Glu Glu Asn
260      265      270
Ser Ser Leu Leu His Pro Ala Ser Leu His Gly Thr Glu Asp Thr Glu
275      280      285
Arg Glu Val Leu Lys Trp Lys Phe Asp Ser His Leu Ala Phe His His
290      295      300
Lys Ala Arg Glu Leu His Pro Glu Tyr Tyr Lys Asp Cys Lys Leu Glu
305      310      315
Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser Gln Pro
325      330      335
Arg Thr Pro Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Leu His Cys
340      345      350
Gln Val Cys Phe Thr Arg Lys Gly Leu Gly Ile Ser Tyr Gly Arg Lys
355      360      365
Lys Arg Arg Gln Arg Arg Ala Pro Gln Asp Ser Gln Thr His Gln
370      375      380
Val Ser Leu Pro Lys Gln Pro Ser Ser Gln Gln Arg Gly Asp Pro Thr
385      390      395
Gly Pro Lys Lys Ser Lys Lys Lys Val Glu Arg Glu Thr Glu Ala Asp
405      410      415
Pro Phe Asp Ala Ala Val Ile Thr Leu Trp Gln Arg Pro Leu Val Ala
420      425      430
Leu Ile Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys
435      440      445
Ile Gly Pro Ala Gly Leu Lys Lys Lys Ser Val Thr Val Leu Asp
450      455      460
Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Lys Asp Phe Arg Lys
465      470      475
Tyr Thr Ala Phe Thr Ile Pro Ser Ile Trp Lys Gly Ser Pro Ala Ile
485      490      495
Phe Gln Ser Ser Met Thr Lys Lys Gln Asn Pro Asp Ile Val Ile Tyr
500      505      510
Gln Tyr Met Asp Asp Leu Tyr Val Pro Ile Val Leu Pro Glu Lys Asp
515      520      525
Ser Trp Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Ala Gly
530      535      540
Ile Lys Val Lys Gln Leu Ile Leu Lys Glu Pro Val His Gly Val Tyr
545      550      555
Glu Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Asp Gly Ala Ala Asn
565      570      575
Arg Ala Gly Asn Leu Trp Val Thr Val Tyr Tyr Gly Val Pro Val Trp
580      585      590
Lys Glu Ala Thr Thr Thr Leu Val Glu Arg Tyr Leu Arg Asp Gln Gln
595      600      605
Leu Leu Gly Ile Trp Gly Cys Ala Cys Thr Pro Tyr Asp Ile Asn Gln
610      615      620
Met Leu Arg Gly Pro Gly Arg Ala Phe Val Thr Ile Arg Gln Gly Ser
625      630      635
Leu

```

<210> 40

<211> 842

<212> PRT
 <213> Artificial Sequence

<220>

<223> Hybrid protein cds comprised of Tat-Rev-Nef and truncated Gag protein(TRN-dgag)

<400> 40

```

Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser
1      5      10      15
Gln Pro Arg Thr Pro Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Leu
      20      25      30
His Cys Gln Val Cys Phe Thr Arg Lys Gly Leu Gly Ile Ser Tyr Gly
      35      40      45
Arg Lys Lys Arg Arg Gln Arg Arg Ala Pro Gln Asp Ser Gln Thr
      50      55      60
His Gln Val Ser Leu Pro Lys Gln Pro Ser Ser Gln Gln Arg Gly Asp
65      70      75      80
Pro Thr Gly Pro Lys Lys Ser Lys Lys Lys Val Glu Arg Glu Thr Glu
      85      90      95
Ala Asp Pro Phe Asp Thr Ser Ala Gly Arg Ser Gly Asp Ser Asp Glu
      100     105     110
Glu Leu Leu Lys Thr Val Arg Leu Ile Lys Phe Leu Tyr Gln Ser Asn
      115     120     125
Pro Pro Pro Ser Asn Glu Gly Thr Arg Gln Ala Arg Arg Asn Arg Arg
130     135     140
Arg Arg Trp Arg Glu Arg Gln Arg Gln Ile Arg Ser Ile Ser Glu Arg
145     150     155     160
Ile Leu Ser Thr Phe Leu Gly Arg Pro Ala Glu Pro Val Pro Leu Gln
      165     170     175
Leu Pro Pro Leu Glu Arg Leu Thr Leu Asp Cys Ser Glu Asp Cys Gly
      180     185     190
Asn Ser Gly Thr Gln Gly Val Gly Ser Pro Gln Val Leu Val Glu Ser
195     200     205
Pro Ala Val Leu Glu Pro Gly Thr Lys Glu Lys Leu Val Gly Lys Trp
210     215     220
Ser Lys Cys Ser Gly Trp Pro Thr Val Arg Glu Arg Met Lys Gln Ala
225     230     235     240
Glu Pro Glu Pro Ala Ala Asp Gly Val Gly Ala Ala Ser Arg Asp Leu
      245     250     255
Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr Ala Thr Asn Asn Ala
      260     265     270
Ala Cys Ala Trp Leu Glu Ala Gln Glu Glu Glu Val Gly Phe Pro
275     280     285
Val Arg Pro Gln Val Pro Leu Arg Pro Met Thr Tyr Lys Gly Ala Leu
290     295     300
Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly Leu Glu Gly Leu Ile
305     310     315     320
Tyr Ser Pro Lys Arg Gln Glu Ile Leu Asp Leu Trp Val Tyr His Thr
      325     330     335
Gln Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr Pro Gly Pro Gly Val
      340     345     350
Arg Tyr Pro Leu Thr Phe Gly Trp Cys Phe Lys Leu Val Pro Val Glu
355     360     365
Pro Asp Glu Glu Glu Asn Ser Ser Leu Leu His Pro Ala Ser Leu His
370     375     380
Gly Thr Glu Asp Thr Glu Arg Glu Val Leu Lys Trp Lys Phe Asp Ser
385     390     395     400
His Leu Ala Phe His His Lys Ala Arg Glu Leu His Pro Glu Tyr Tyr
      405     410     415
Lys Asp Cys Ala Val Leu Asp Lys Trp Glu Lys Ile Arg Leu Arg
420     425     430
Pro Gly Gly Lys Lys Lys Tyr Gln Leu Lys His Ile Val Trp Ala Ser

```

```

      435      440      445
Arg Glu Leu Glu Arg Phe Ala Val Asn Pro Gly Leu Leu Glu Thr Ser
      450      455      460
Glu Gly Cys Arg Gln Ile Met Gly Gln Leu Gln Pro Ser Leu Gln Thr
465      470      475      480
Gly Ser Glu Glu Leu Arg Ser Leu Tyr Asn Thr Val Ala Thr Leu Tyr
      485      490      495
Cys Val His Gln Lys Ile Glu Val Lys Asp Thr Lys Glu Ala Leu Asp
      500      505      510
Lys Val Glu Glu Glu Gln Asn Asn Ser Lys Lys Lys Ala Gln Gln Glu
      515      520      525
Ala Ala Asp Ala Gly Asn Arg Asn Gln Val Ser Gln Asn Tyr Pro Ile
      530      535      540
Val Gln Asn Leu Gln Gly Gln Met Val His Gln Ala Ile Ser Pro Arg
545      550      555      560
Thr Leu Asn Ala Trp Val Lys Val Val Glu Glu Lys Ala Phe Ser Pro
      565      570      575
Glu Val Ile Pro Met Phe Ser Ala Leu Ser Glu Gly Ala Thr Pro Gln
      580      585      590
Asp Leu Asn Thr Met Leu Asn Thr Val Gly Gly His Gln Ala Ala Met
      595      600      605
Gln Met Leu Lys Glu Thr Ile Asn Glu Glu Ala Ala Glu Trp Asp Arg
      610      615      620
Leu His Pro Val His Ala Gly Pro Ile Ala Pro Gly Gln Met Arg Glu
625      630      635      640
Pro Arg Gly Ser Asp Ile Ala Gly Thr Thr Ser Thr Leu Gln Glu Gln
      645      650      655
Ile Gly Trp Met Thr Asn Asn Pro Pro Ile Pro Val Gly Glu Ile Tyr
      660      665      670
Lys Arg Trp Ile Ile Leu Gly Leu Asn Lys Ile Val Arg Met Tyr Ser
      675      680      685
Pro Thr Ser Ile Leu Asp Ile Lys Gln Gly Pro Lys Glu Pro Phe Arg
      690      695      700
Asp Tyr Val Asp Arg Phe Tyr Lys Thr Leu Arg Ala Glu Gln Ala Thr
705      710      715      720
Gln Glu Val Lys Asn Trp Met Thr Glu Thr Leu Leu Val Gln Asn Ala
      725      730      735
Asn Pro Asp Cys Lys Thr Ile Leu Lys Ala Leu Gly Pro Ala Ala Thr
      740      745      750
Leu Glu Glu Met Met Thr Ala Cys Gln Gly Val Gly Gly Pro Gly His
      755      760      765
Lys Ala Arg Val Leu Ala Glu Ala Met Ser Gln Val Thr Gly Ser Ala
      770      775      780
Ala Ile Met Met Gln Arg Gly Asn Phe Arg Asn Gln Arg Lys Thr Val
785      790      795      800
Lys Cys Phe Asn Cys Gly Lys Glu Gly His Ile Ala Arg Asn Cys Arg
      805      810      815
Ala Pro Arg Lys Lys Gly Cys Trp Lys Cys Gly Lys Glu Gly His Gln
      820      825      830
Met Lys Asp Cys Thr Glu Arg Gln Ala Asn
      835      840

```

<210> 41
 <211> 1064
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Hybrid protein cds comprised of Tat-Rev-Nef, CTL and truncated Gag protein(TRN-TCL-dgag)

<400> 41
 Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser

```

1      5      10      15
Gln Pro Arg Thr Pro Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Leu
20      25      30
His Cys Gln Val Cys Phe Thr Arg Lys Gly Leu Gly Ile Ser Tyr Gly
35      40      45
Arg Lys Lys Arg Arg Gln Arg Arg Ala Pro Gln Asp Ser Gln Thr
50      55      60
His Gln Val Ser Leu Pro Lys Gln Pro Ser Ser Gln Gln Arg Gly Asp
65      70      75      80
Pro Thr Gly Pro Lys Lys Ser Lys Lys Lys Val Glu Arg Glu Thr Glu
85      90      95
Ala Asp Pro Phe Asp Thr Ser Ala Gly Arg Ser Gly Asp Ser Asp Glu
100     105     110
Glu Leu Leu Lys Thr Val Arg Leu Ile Lys Phe Leu Tyr Gln Ser Asn
115     120     125
Pro Pro Pro Ser Asn Glu Gly Thr Arg Gln Ala Arg Arg Asn Arg Arg
130     135     140
Arg Arg Trp Arg Glu Arg Gln Arg Gln Ile Arg Ser Ile Ser Glu Arg
145     150     155     160
Ile Leu Ser Thr Phe Leu Gly Arg Pro Ala Glu Pro Val Pro Leu Gln
165     170     175
Leu Pro Pro Leu Glu Arg Leu Thr Leu Asp Cys Ser Glu Asp Cys Gly
180     185     190
Asn Ser Gly Thr Gln Gly Val Gly Ser Pro Gln Val Leu Val Glu Ser
195     200     205
Pro Ala Val Leu Glu Pro Gly Thr Lys Glu Lys Leu Val Gly Lys Trp
210     215     220
Ser Lys Cys Ser Gly Trp Pro Thr Val Arg Glu Arg Met Lys Gln Ala
225     230     235     240
Glu Pro Glu Pro Ala Ala Asp Gly Val Gly Ala Ala Ser Arg Asp Leu
245     250     255
Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr Ala Thr Asn Asn Ala
260     265     270
Ala Cys Ala Trp Leu Glu Ala Gln Glu Glu Glu Val Gly Phe Pro
275     280     285
Val Arg Pro Gln Val Pro Leu Arg Pro Met Thr Tyr Lys Gly Ala Leu
290     295     300
Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly Leu Glu Gly Leu Ile
305     310     315     320
Tyr Ser Pro Lys Arg Gln Glu Ile Leu Asp Leu Trp Val Tyr His Thr
325     330     335
Gln Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr Pro Gly Pro Gly Val
340     345     350
Arg Tyr Pro Leu Thr Phe Gly Trp Cys Phe Lys Leu Val Pro Val Glu
355     360     365
Pro Asp Glu Glu Glu Asn Ser Ser Leu Leu His Pro Ala Ser Leu His
370     375     380
Gly Thr Glu Asp Thr Glu Arg Glu Val Leu Lys Trp Lys Phe Asp Ser
385     390     395     400
His Leu Ala Phe His His Lys Ala Arg Glu Leu His Pro Glu Tyr Tyr
405     410     415
Lys Asp Cys Ala Ala Val Ile Thr Leu Trp Gln Arg Pro Leu Val Ala
420     425     430
Leu Ile Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys
435     440     445
Ile Gly Pro Ala Gly Leu Lys Lys Lys Lys Ser Val Thr Val Leu Asp
450     455     460
Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Lys Asp Phe Arg Lys
465     470     475     480
Tyr Thr Ala Phe Thr Ile Pro Ser Ile Trp Lys Gly Ser Pro Ala Ile
485     490     495
Phe Gln Ser Ser Met Thr Lys Lys Gln Asn Pro Asp Ile Val Ile Tyr
500     505     510

```

Gln Tyr Met Asp Asp Leu Tyr Val Pro Ile Val Leu Pro Glu Lys Asp
 515 520 525
 Ser Trp Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Ala Gly
 530 535 540
 Ile Lys Val Lys Gln Leu Ile Leu Lys Glu Pro Val His Gly Val Tyr
 545 550 555 560
 Glu Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Asp Gly Ala Ala Asn
 565 570 575
 Arg Ala Gly Asn Leu Trp Val Thr Val Tyr Tyr Gly Val Pro Val Trp
 580 585 590
 Lys Glu Ala Thr Thr Thr Leu Val Glu Arg Tyr Leu Arg Asp Gln Gln
 595 600 605
 Leu Leu Gly Ile Trp Gly Cys Ala Cys Thr Pro Tyr Asp Ile Asn Gln
 610 615 620
 Met Leu Arg Gly Pro Gly Arg Ala Phe Val Thr Ile Arg Gln Gly Ser
 625 630 635 640
 Leu Ala Ala Val Leu Asp Lys Trp Glu Lys Ile Arg Leu Arg Pro Gly
 645 650 655
 Gly Lys Lys Lys Tyr Gln Leu Lys His Ile Val Trp Ala Ser Arg Glu
 660 665 670
 Leu Glu Arg Phe Ala Val Asn Pro Gly Leu Leu Glu Thr Ser Glu Gly
 675 680 685
 Cys Arg Gln Ile Met Gly Gln Leu Gln Pro Ser Leu Gln Thr Gly Ser
 690 695 700
 Glu Glu Leu Arg Ser Leu Tyr Asn Thr Val Ala Thr Leu Tyr Cys Val
 705 710 715 720
 His Gln Lys Ile Glu Val Lys Asp Thr Lys Glu Ala Leu Asp Lys Val
 725 730 735
 Glu Glu Glu Gln Asn Asn Ser Lys Lys Ala Gln Gln Glu Ala Ala
 740 745 750
 Asp Ala Gly Asn Arg Asn Gln Val Ser Gln Asn Tyr Pro Ile Val Gln
 755 760 765
 Asn Leu Gln Gly Gln Met Val His Gln Ala Ile Ser Pro Arg Thr Leu
 770 775 780
 Asn Ala Trp Val Lys Val Val Glu Glu Lys Ala Phe Ser Pro Glu Val
 785 790 795 800
 Ile Pro Met Phe Ser Ala Leu Ser Glu Gly Ala Thr Pro Gln Asp Leu
 805 810 815
 Asn Thr Met Leu Asn Thr Val Gly Gly His Gln Ala Ala Met Gln Met
 820 825 830
 Leu Lys Glu Thr Ile Asn Glu Glu Ala Ala Glu Trp Asp Arg Leu His
 835 840 845
 Pro Val His Ala Gly Pro Ile Ala Pro Gly Gln Met Arg Glu Pro Arg
 850 855 860
 Gly Ser Asp Ile Ala Gly Thr Thr Ser Thr Leu Gln Glu Gln Ile Gly
 865 870 875 880
 Trp Met Thr Asn Asn Pro Pro Ile Pro Val Gly Glu Ile Tyr Lys Arg
 885 890 895
 Trp Ile Ile Leu Gly Leu Asn Lys Ile Val Arg Met Tyr Ser Pro Thr
 900 905 910
 Ser Ile Leu Asp Ile Lys Gln Gly Pro Lys Glu Pro Phe Arg Asp Tyr
 915 920 925
 Val Asp Arg Phe Tyr Lys Thr Leu Arg Ala Glu Gln Ala Thr Gln Glu
 930 935 940
 Val Lys Asn Trp Met Thr Glu Thr Leu Leu Val Gln Asn Ala Asn Pro
 945 950 955 960
 Asp Cys Lys Thr Ile Leu Lys Ala Leu Gly Pro Ala Ala Thr Leu Glu
 965 970 975
 Glu Met Met Thr Ala Cys Gln Gly Val Gly Gly Pro Gly His Lys Ala
 980 985 990
 Arg Val Leu Ala Glu Ala Met Ser Gln Val Thr Gly Ser Ala Ala Ile
 995 1000 1005
 Met Met Gln Arg Gly Asn Phe Arg Asn Gln Arg Lys Thr Val Lys

1010 1015 1020
 Cys Phe Asn Cys Gly Lys Glu Gly His Ile Ala Arg Asn Cys Arg
 1025 1030 1035
 Ala Pro Arg Lys Lys Gly Cys Trp Lys Cys Gly Lys Glu Gly His
 1040 1045 1050
 Gln Met Lys Asp Cys Thr Glu Arg Gln Ala Asn
 1055 1060

<210> 42
 <211> 1064
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Hybrid protein comprised of Tat-Rev-Nef, CTL and truncated Gag protein(TRN-CTL-dgag)

<400> 42
 Met Ala Gly Arg Ser Gly Asp Ser Asp Glu Glu Leu Leu Lys Thr Val
 1 5 10 15
 Arg Leu Ile Lys Phe Leu Tyr Gln Ser Asn Pro Pro Pro Ser Asn Glu
 20 25 30
 Gly Thr Arg Gln Ala Arg Arg Asn Arg Arg Arg Arg Trp Arg Glu Arg
 35 40 45
 Gln Arg Gln Ile Arg Ser Ile Ser Glu Arg Ile Leu Ser Thr Phe Leu
 50 55 60
 Gly Arg Pro Ala Glu Pro Val Pro Leu Gln Leu Pro Pro Leu Glu Arg
 65 70 75 80
 Leu Thr Leu Asp Cys Ser Glu Asp Cys Gly Asn Ser Gly Thr Gln Gly
 85 90 95
 Val Gly Ser Pro Gln Val Leu Val Glu Ser Pro Ala Val Leu Glu Pro
 100 105 110
 Gly Thr Lys Glu Thr Ser Val Gly Lys Trp Ser Lys Cys Ser Gly Trp
 115 120 125
 Pro Thr Val Arg Glu Arg Met Lys Gln Ala Glu Pro Glu Pro Ala Ala
 130 135 140
 Asp Gly Val Gly Ala Ala Ser Arg Asp Leu Glu Lys His Gly Ala Ile
 145 150 155 160
 Thr Ser Ser Asn Thr Ala Thr Asn Asn Ala Ala Cys Ala Trp Leu Glu
 165 170 175
 Ala Gln Glu Glu Glu Val Gly Phe Pro Val Arg Pro Gln Val Pro
 180 185 190
 Leu Arg Pro Met Thr Tyr Lys Gly Ala Leu Asp Leu Ser His Phe Leu
 195 200 205
 Lys Glu Lys Gly Gly Leu Glu Gly Leu Ile Tyr Ser Pro Lys Arg Gln
 210 215 220
 Glu Ile Leu Asp Leu Trp Val Tyr His Thr Gln Gly Tyr Phe Pro Asp
 225 230 235 240
 Trp Gln Asn Tyr Thr Pro Gly Pro Gly Val Arg Tyr Pro Leu Thr Phe
 245 250 255
 Gly Trp Cys Phe Lys Leu Val Pro Val Glu Pro Asp Glu Glu Glu Asn
 260 265 270
 Ser Ser Leu Leu His Pro Ala Ser Leu His Gly Thr Glu Asp Thr Glu
 275 280 285
 Arg Glu Val Leu Lys Trp Lys Phe Asp Ser His Leu Ala Phe His His
 290 295 300
 Lys Ala Arg Glu Leu His Pro Glu Tyr Tyr Lys Asp Cys Lys Leu Glu
 305 310 315 320
 Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser Gln Pro
 325 330 335
 Arg Thr Pro Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Leu His Cys
 340 345 350
 Gln Val Cys Phe Thr Arg Lys Gly Leu Gly Ile Ser Tyr Gly Arg Lys

355 360 365
 Lys Arg Arg Gln Arg Arg Arg Ala Pro Gln Asp Ser Gln Thr His Gln
 370 375 380
 Val Ser Leu Pro Lys Gln Pro Ser Ser Gln Gln Arg Gly Asp Pro Thr
 385 390 395 400
 Gly Pro Lys Lys Ser Lys Lys Val Glu Arg Glu Thr Glu Ala Asp
 405 410 415
 Pro Phe Asp Ala Ala Val Ile Thr Leu Trp Gln Arg Pro Leu Val Ala
 420 425 430
 Leu Ile Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys
 435 440 445
 Ile Gly Pro Ala Gly Leu Lys Lys Lys Ser Val Thr Val Leu Asp
 450 455 460
 Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Lys Asp Phe Arg Lys
 465 470 475 480
 Tyr Thr Ala Phe Thr Ile Pro Ser Ile Trp Lys Gly Ser Pro Ala Ile
 485 490 495
 Phe Gln Ser Ser Met Thr Lys Lys Gln Asn Pro Asp Ile Val Ile Tyr
 500 505 510
 Gln Tyr Met Asp Asp Leu Tyr Val Pro Ile Val Leu Pro Glu Lys Asp
 515 520 525
 Ser Trp Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Ala Gly
 530 535 540
 Ile Lys Val Lys Gln Leu Ile Leu Lys Glu Pro Val His Gly Val Tyr
 545 550 555 560
 Glu Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Asp Gly Ala Ala Asn
 565 570 575
 Arg Ala Gly Asn Leu Trp Val Thr Val Tyr Tyr Gly Val Pro Val Trp
 580 585 590
 Lys Glu Ala Thr Thr Leu Val Glu Arg Tyr Leu Arg Asp Gln Gln
 595 600 605
 Leu Leu Gly Ile Trp Gly Cys Ala Cys Thr Pro Tyr Asp Ile Asn Gln
 610 615 620
 Met Leu Arg Gly Pro Gly Arg Ala Phe Val Thr Ile Arg Gln Gly Ser
 625 630 635 640
 Leu Ala Ala Val Leu Asp Lys Trp Glu Lys Ile Arg Leu Arg Pro Gly
 645 650 655
 Gly Lys Lys Lys Tyr Gln Leu Lys His Ile Val Trp Ala Ser Arg Glu
 660 665 670
 Leu Glu Arg Phe Ala Val Asn Pro Gly Leu Leu Glu Thr Ser Glu Gly
 675 680 685
 Cys Arg Gln Ile Met Gly Gln Leu Gln Pro Ser Leu Gln Thr Gly Ser
 690 695 700
 Glu Glu Leu Arg Ser Leu Tyr Asn Thr Val Ala Thr Leu Tyr Cys Val
 705 710 715 720
 His Gln Lys Ile Glu Val Lys Asp Thr Lys Glu Ala Leu Asp Lys Val
 725 730 735
 Glu Glu Glu Gln Asn Asn Ser Lys Lys Lys Ala Gln Gln Glu Ala Ala
 740 745 750
 Asp Ala Gly Asn Arg Asn Gln Val Ser Gln Asn Tyr Pro Ile Val Gln
 755 760 765
 Asn Leu Gln Gly Gln Met Val His Gln Ala Ile Ser Pro Arg Thr Leu
 770 775 780
 Asn Ala Trp Val Lys Val Glu Glu Lys Ala Phe Ser Pro Glu Val
 785 790 795 800
 Ile Pro Met Phe Ser Ala Leu Ser Glu Gly Ala Thr Pro Gln Asp Leu
 805 810 815
 Asn Thr Met Leu Asn Thr Val Gly Gly His Gln Ala Ala Met Gln Met
 820 825 830
 Leu Lys Glu Thr Ile Asn Glu Glu Ala Ala Glu Trp Asp Arg Leu His
 835 840 845
 Pro Val His Ala Gly Pro Ile Ala Pro Gly Gln Met Arg Glu Pro Arg
 850 855 860

Gly Ser Asp Ile Ala Gly Thr Thr Ser Thr Leu Gln Glu Gln Ile Gly
 865 870 875 880
 Trp Met Thr Asn Asn Pro Pro Ile Pro Val Gly Glu Ile Tyr Lys Arg
 885 890 895
 Trp Ile Ile Leu Gly Leu Asn Lys Ile Val Arg Met Tyr Ser Pro Thr
 900 905 910
 Ser Ile Leu Asp Ile Lys Gln Gly Pro Lys Glu Pro Phe Arg Asp Tyr
 915 920 925
 Val Asp Arg Phe Tyr Lys Thr Leu Arg Ala Glu Gln Ala Thr Gln Glu
 930 935 940
 Val Lys Asn Trp Met Thr Glu Thr Leu Leu Val Gln Asn Ala Asn Pro
 945 950 955 960
 Asp Cys Lys Thr Ile Leu Lys Ala Leu Gly Pro Ala Ala Thr Leu Glu
 965 970 975
 Glu Met Met Thr Ala Cys Gln Gly Val Gly Gly Pro Gly His Lys Ala
 980 985 990
 Arg Val Leu Ala Glu Ala Met Ser Gln Val Thr Gly Ser Ala Ala Ile
 995 1000 1005
 Met Met Gln Arg Gly Asn Phe Arg Asn Gln Arg Lys Thr Val Lys
 1010 1015 1020
 Cys Phe Asn Cys Gly Lys Glu Gly His Ile Ala Arg Asn Cys Arg
 1025 1030 1035
 Ala Pro Arg Lys Lys Gly Cys Trp Lys Cys Gly Lys Glu Gly His
 1040 1045 1050
 Gln Met Lys Asp Cys Thr Glu Arg Gln Ala Asn
 1055 1060

<210> 43
 <211> 1064
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Hybrid protein comprised of Tat-Rev-Nef, truncated Gag protein and CTL (TRN-dgag-CTL)

<400> 43
 Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser
 1 5 10 15
 Gln Pro Arg Thr Pro Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Leu
 20 25 30
 His Cys Gln Val Cys Phe Thr Arg Lys Gly Leu Gly Ile Ser Tyr Gly
 35 40 45
 Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala Pro Gln Asp Ser Gln Thr
 50 55 60
 His Gln Val Ser Leu Pro Lys Gln Pro Ser Ser Gln Gln Arg Gly Asp
 65 70 75 80
 Pro Thr Gly Pro Lys Lys Ser Lys Lys Val Glu Arg Glu Thr Glu
 85 90 95
 Ala Asp Pro Phe Asp Thr Ser Ala Gly Arg Ser Gly Asp Ser Asp Glu
 100 105 110
 Glu Leu Leu Lys Thr Val Arg Leu Ile Lys Phe Leu Tyr Gln Ser Asn
 115 120 125
 Pro Pro Pro Ser Asn Glu Gly Thr Arg Gln Ala Arg Arg Asn Arg Arg
 130 135 140
 Arg Arg Trp Arg Glu Arg Gln Arg Gln Ile Arg Ser Ile Ser Glu Arg
 145 150 155 160
 Ile Leu Ser Thr Phe Leu Gly Arg Pro Ala Glu Pro Val Pro Leu Gln
 165 170 175
 Leu Pro Pro Leu Glu Arg Leu Thr Leu Asp Cys Ser Glu Asp Cys Gly
 180 185 190
 Asn Ser Gly Thr Gln Gly Val Gly Ser Pro Gln Val Leu Val Glu Ser
 195 200 205

Pro Ala Val Leu Glu Pro Gly Thr Lys Glu Lys Leu Val Gly Lys Trp
 210 215 220
 Ser Lys Cys Ser Gly Trp Pro Thr Val Arg Glu Arg Met Lys Gln Ala
 225 230 235 240
 Glu Pro Glu Pro Ala Ala Asp Gly Val Gly Ala Ala Ser Arg Asp Leu
 245 250 255
 Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr Ala Thr Asn Asn Ala
 260 265 270
 Ala Cys Ala Trp Leu Glu Ala Gln Glu Glu Glu Val Gly Phe Pro
 275 280 285
 Val Arg Pro Gln Val Pro Leu Arg Pro Met Thr Tyr Lys Gly Ala Leu
 290 295 300
 Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly Leu Glu Gly Leu Ile
 305 310 315 320
 Tyr Ser Pro Lys Arg Gln Glu Ile Leu Asp Leu Trp Val Tyr His Thr
 325 330 335
 Gln Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr Pro Gly Pro Gly Val
 340 345 350
 Arg Tyr Pro Leu Thr Phe Gly Trp Cys Phe Lys Leu Val Pro Val Glu
 355 360 365
 Pro Asp Glu Glu Glu Asn Ser Ser Leu Leu His Pro Ala Ser Leu His
 370 375 380
 Gly Thr Glu Asp Thr Glu Arg Glu Val Leu Lys Trp Lys Phe Asp Ser
 385 390 395 400
 His Leu Ala Phe His His Lys Ala Arg Glu Leu His Pro Glu Tyr Tyr
 405 410 415
 Lys Asp Cys Ala Ala Val Leu Asp Lys Trp Glu Lys Ile Arg Leu Arg
 420 425 430
 Pro Gly Gly Lys Lys Lys Tyr Gln Leu Lys His Ile Val Trp Ala Ser
 435 440 445
 Arg Glu Leu Glu Arg Phe Ala Val Asn Pro Gly Leu Leu Glu Thr Ser
 450 455 460
 Glu Gly Cys Arg Gln Ile Met Gly Gln Leu Gln Pro Ser Leu Gln Thr
 465 470 475 480
 Gly Ser Glu Glu Leu Arg Ser Leu Tyr Asn Thr Val Ala Thr Leu Tyr
 485 490 495
 Cys Val His Gln-Lys Ile Glu Val Lys Asp Thr Lys Glu Ala Leu Asp
 500 505 510
 Lys Val Glu Glu Glu Gln Asn Asn Ser Lys Lys Lys Ala Gln Gln Glu
 515 520 525
 Ala Ala Asp Ala Gly Asn Arg Asn Gln Val Ser Gln Asn Tyr Pro Ile
 530 535 540
 Val Gln Asn Leu Gln Gly Gln Met Val His Gln Ala Ile Ser Pro Arg
 545 550 555 560
 Thr Leu Asn Ala Trp Val Lys Val Val Glu Glu Lys Ala Phe Ser Pro
 565 570 575
 Glu Val Ile Pro Met Phe Ser Ala Leu Ser Glu Gly Ala Thr Pro Gln
 580 585 590
 Asp Leu Asn Thr Met Leu Asn Thr Val Gly Gly His Gln Ala Ala Met
 595 600 605
 Gln Met Leu Lys Glu Thr Ile Asn Glu Glu Ala Ala Glu Trp Asp Arg
 610 615 620
 Leu His Pro Val His Ala Gly Pro Ile Ala Pro Gly Gln Met Arg Glu
 625 630 635 640
 Pro Arg Gly Ser Asp Ile Ala Gly Thr Thr Ser Thr Leu Gln Glu Gln
 645 650 655
 Ile Gly Trp Met Thr Asn Asn Pro Pro Ile Pro Val Gly Glu Ile Tyr
 660 665 670
 Lys Arg Trp Ile Ile Leu Gly Leu Asn Lys Ile Val Arg Met Tyr Ser
 675 680 685
 Pro Thr Ser Ile Leu Asp Ile Lys Gln Gly Pro Lys Glu Pro Phe Arg
 690 695 700
 Asp Tyr Val Asp Arg Phe Tyr Lys Thr Leu Arg Ala Glu Gln Ala Thr

```

705          710          715          720
Gln Glu Val Lys Asn Trp Met Thr Glu Thr Leu Leu Val Gln Asn Ala
      725          730          735
Asn Pro Asp Cys Lys Thr Ile Leu Lys Ala Leu Gly Pro Ala Ala Thr
      740          745          750
Leu Glu Glu Met Met Thr Ala Cys Gln Gly Val Gly Gly Pro Gly His
      755          760          765
Lys Ala Arg Val Leu Ala Glu Ala Met Ser Gln Val Thr Gly Ser Ala
      770          775          780
Ala Ile Met Met Gln Arg Gly Asn Phe Arg Asn Gln Arg Lys Thr Val
785          790          795          800
Lys Cys Phe Asn Cys Gly Lys Glu Gly His Ile Ala Arg Asn Cys Arg
      805          810          815
Ala Pro Arg Lys Lys Gly Cys Trp Lys Cys Gly Lys Glu Gly His Gln
      820          825          830
Met Lys Asp Cys Thr Glu Arg Gln Ala Asn Ala Val Ile Thr Leu
      835          840          845
Trp Gln Arg Pro Leu Val Ala Leu Ile Glu Ile Cys Thr Glu Met Glu
      850          855          860
Lys Glu Gly Lys Ile Ser Lys Ile Gly Pro Ala Gly Leu Lys Lys Lys
865          870          875          880
Lys Ser Val Thr Val Leu Asp Val Gly Asp Ala Tyr Phe Ser Val Pro
      885          890          895
Leu Asp Lys Asp Phe Arg Lys Tyr Thr Ala Phe Thr Ile Pro Ser Ile
      900          905          910
Trp Lys Gly Ser Pro Ala Ile Phe Gln Ser Ser Met Thr Lys Lys Gln
      915          920          925
Asn Pro Asp Ile Val Ile Tyr Gln Tyr Met Asp Asp Leu Tyr Val Pro
      930          935          940
Ile Val Leu Pro Glu Lys Asp Ser Trp Leu Val Gly Lys Leu Asn Trp
945          950          955          960
Ala Ser Gln Ile Tyr Ala Gly Ile Lys Val Lys Gln Leu Ile Leu Lys
      965          970          975
Glu Pro Val His Gly Val Tyr Glu Pro Ile Val Gly Ala Glu Thr Phe
      980          985          990
Tyr Val Asp Gly Ala Ala Asn Arg Ala Gly Asn Leu Trp Val Thr Val
      995          1000          1005
Tyr Tyr Gly Val Pro Val Trp Lys Glu Ala Thr Thr Thr Leu Val
      1010          1015          1020
Glu Arg Tyr Leu Arg Asp Gln Gln Leu Leu Gly Ile Trp Gly Cys
      1025          1030          1035
Ala Cys Thr Pro Tyr Asp Ile Asn Gln Met Leu Arg Gly Pro Gly
      1040          1045          1050
Arg Ala Phe Val Thr Ile Arg Gln Gly Ser Leu
      1055          1060

```

<210> 44
 <211> 1064
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Hybrid protein comprised of Rev-Nef-Tat, truncated Gag protein and CTL(RNT-dgag-CTL)

```

<400> 44
Met Ala Gly Arg Ser Gly Asp Ser Asp Glu Glu Leu Leu Lys Thr Val
1          5          10          15
Arg Leu Ile Lys Phe Leu Tyr Gln Ser Asn Pro Pro Pro Ser Asn Glu
      20          25          30
Gly Thr Arg Gln Ala Arg Arg Asn Arg Arg Arg Trp Arg Glu Arg
      35          40          45
Gln Arg Gln Ile Arg Ser Ile Ser Glu Arg Ile Leu Ser Thr Phe Leu

```

50 55 60
 Gly Arg Pro Ala Glu Pro Val Pro Leu Gln Leu Pro Pro Leu Glu Arg
 65 70 75 80
 Leu Thr Leu Asp Cys Ser Glu Asp Cys Gly Asn Ser Gly Thr Gln Gly
 85 90 95
 Val Gly Ser Pro Gln Val Leu Val Glu Ser Pro Ala Val Leu Glu Pro
 100 105 110
 Gly Thr Lys Glu Thr Ser Val Gly Lys Trp Ser Lys Cys Ser Gly Trp
 115 120 125
 Pro Thr Val Arg Glu Arg Met Lys Gln Ala Glu Pro Glu Pro Ala Ala
 130 135 140
 Asp Gly Val Gly Ala Ala Ser Arg Asp Leu Glu Lys His Gly Ala Ile
 145 150 155 160
 Thr Ser Ser Asn Thr Ala Thr Asn Asn Ala Ala Cys Ala Trp Leu Glu
 165 170 175
 Ala Gln Glu Glu Glu Val Gly Phe Pro Val Arg Pro Gln Val Pro
 180 185 190
 Leu Arg Pro Met Thr Tyr Lys Gly Ala Leu Asp Leu Ser His Phe Leu
 195 200 205
 Lys Glu Lys Gly Gly Leu Glu Gly Leu Ile Tyr Ser Pro Lys Arg Gln
 210 215 220
 Glu Ile Leu Asp Leu Trp Val Tyr His Thr Gln Gly Tyr Phe Pro Asp
 225 230 235 240
 Trp Gln Asn Tyr Thr Pro Gly Pro Gly Val Arg Tyr Pro Leu Thr Phe
 245 250 255
 Gly Trp Cys Phe Lys Leu Val Pro Val Glu Pro Asp Glu Glu Glu Asn
 260 265 270
 Ser Ser Leu Leu His Pro Ala Ser Leu His Gly Thr Glu Asp Thr Glu
 275 280 285
 Arg Glu Val Leu Lys Trp Lys Phe Asp Ser His Leu Ala Phe His His
 290 295 300
 Lys Ala Arg Glu Leu His Pro Glu Tyr Tyr Lys Asp Cys Lys Leu Glu
 305 310 315 320
 Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser Gln Pro
 325 330 335
 Arg Thr Pro Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Leu His Cys
 340 345 350
 Gln Val Cys Phe Thr Arg Lys Gly Leu Gly Ile Ser Tyr Gly Arg Lys
 355 360 365
 Lys Arg Arg Gln Arg Arg Arg Ala Pro Gln Asp Ser Gln Thr His Gln
 370 375 380
 Val Ser Leu Pro Lys Gln Pro Ser Ser Gln Gln Arg Gly Asp Pro Thr
 385 390 395 400
 Gly Pro Lys Lys Ser Lys Lys Val Glu Arg Glu Thr Glu Ala Asp
 405 410 415
 Pro Phe Asp Ala Ala Val Leu Asp Lys Trp Glu Lys Ile Arg Leu Arg
 420 425 430
 Pro Gly Gly Lys Lys Tyr Gln Leu Lys His Ile Val Trp Ala Ser
 435 440 445
 Arg Glu Leu Glu Arg Phe Ala Val Asn Pro Gly Leu Leu Glu Thr Ser
 450 455 460
 Glu Gly Cys Arg Gln Ile Met Gly Gln Leu Gln Pro Ser Leu Gln Thr
 465 470 475 480
 Gly Ser Glu Glu Leu Arg Ser Leu Tyr Asn Thr Val Ala Thr Leu Tyr
 485 490 495
 Cys Val His Gln Lys Ile Glu Val Lys Asp Thr Lys Glu Ala Leu Asp
 500 505 510
 Lys Val Glu Glu Glu Gln Asn Asn Ser Lys Lys Lys Ala Gln Gln Glu
 515 520 525
 Ala Ala Asp Ala Gly Asn Arg Asn Gln Val Ser Gln Asn Tyr Pro Ile
 530 535 540
 Val Gln Asn Leu Gln Gly Gln Met Val His Gln Ala Ile Ser Pro Arg
 545 550 555 560

Thr Leu Asn Ala Trp Val Lys Val Val Glu Glu Lys Ala Phe Ser Pro
 565 570 575
 Glu Val Ile Pro Met Phe Ser Ala Leu Ser Glu Gly Ala Thr Pro Gln
 580 585 590
 Asp Leu Asn Thr Met Leu Asn Thr Val Gly Gly His Gln Ala Ala Met
 595 600 605
 Gln Met Leu Lys Glu Thr Ile Asn Glu Glu Ala Ala Glu Trp Asp Arg
 610 615 620
 Leu His Pro Val His Ala Gly Pro Ile Ala Pro Gly Gln Met Arg Glu
 625 630 635 640
 Pro Arg Gly Ser Asp Ile Ala Gly Thr Thr Ser Thr Leu Gln Glu Gln
 645 650 655
 Ile Gly Trp Met Thr Asn Asn Pro Pro Ile Pro Val Gly Glu Ile Tyr
 660 665 670
 Lys Arg Trp Ile Ile Leu Gly Leu Asn Lys Ile Val Arg Met Tyr Ser
 675 680 685
 Pro Thr Ser Ile Leu Asp Ile Lys Gln Gly Pro Lys Glu Pro Phe Arg
 690 695 700
 Asp Tyr Val Asp Arg Phe Tyr Lys Thr Leu Arg Ala Glu Gln Ala Thr
 705 710 715 720
 Gln Glu Val Lys Asn Trp Met Thr Glu Thr Leu Leu Val Gln Asn Ala
 725 730 735
 Asn Pro Asp Cys Lys Thr Ile Leu Lys Ala Leu Gly Pro Ala Ala Thr
 740 745 750
 Leu Glu Glu Met Met Thr Ala Cys Gln Gly Val Gly Gly Pro Gly His
 755 760 765
 Lys Ala Arg Val Leu Ala Glu Ala Met Ser Gln Val Thr Gly Ser Ala
 770 775 780
 Ala Ile Met Met Gln Arg Gly Asn Phe Arg Asn Gln Arg Lys Thr Val
 785 790 795 800
 Lys Cys Phe Asn Cys Gly Lys Glu Gly His Ile Ala Arg Asn Cys Arg
 805 810 815
 Ala Pro Arg Lys Lys Gly Cys Trp Lys Cys Gly Lys Glu Gly His Gln
 820 825 830
 Met Lys Asp Cys Thr Glu Arg Gln Ala Asn Ala Ala Val Ile Thr Leu
 835 840 845
 Trp Gln Arg Pro Leu Val Ala Leu Ile Glu Ile Cys Thr Glu Met Glu
 850 855 860
 Lys Glu Gly Lys Ile Ser Lys Ile Gly Pro Ala Gly Leu Lys Lys Lys
 865 870 875 880
 Lys Ser Val Thr Val Leu Asp Val Gly Asp Ala Tyr Phe Ser Val Pro
 885 890 895
 Leu Asp Lys Asp Phe Arg Lys Tyr Thr Ala Phe Thr Ile Pro Ser Ile
 900 905 910
 Trp Lys Gly Ser Pro Ala Ile Phe Gln Ser Ser Met Thr Lys Lys Gln
 915 920 925
 Asn Pro Asp Ile Val Ile Tyr Gln Tyr Met Asp Asp Leu Tyr Val Pro
 930 935 940
 Ile Val Leu Pro Glu Lys Asp Ser Trp Leu Val Gly Lys Leu Asn Trp
 945 950 955 960
 Ala Ser Gln Ile Tyr Ala Gly Ile Lys Val Lys Gln Leu Ile Leu Lys
 965 970 975
 Glu Pro Val His Gly Val Tyr Glu Pro Ile Val Gly Ala Glu Thr Phe
 980 985 990
 Tyr Val Asp Gly Ala Ala Asn Arg Ala Gly Asn Leu Trp Val Thr Val
 995 1000 1005
 Tyr Tyr Gly Val Pro Val Trp Lys Glu Ala Thr Thr Thr Leu Val
 1010 1015 1020
 Glu Arg Tyr Leu Arg Asp Gln Gln Leu Leu Gly Ile Trp Gly Cys
 1025 1030 1035
 Ala Cys Thr Pro Tyr Asp Ile Asn Gln Met Leu Arg Gly Pro Gly
 1040 1045 1050
 Arg Ala Phe Val Thr Ile Arg Gln Gly Ser Leu

1055

1060

<210> 45
 <211> 1006
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Hybrid protein cds comprised of Tat-Rev-Nef, truncated Gag protein and CTL(TRN-optp17/24-CTL)

<400> 45

```

Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser
1      5      10      15
Gln Pro Arg Thr Pro Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Leu
      20      25      30
His Cys Gln Val Cys Phe Thr Arg Lys Gly Leu Gly Ile Ser Tyr Gly
      35      40      45
Arg Lys Lys Arg Arg Gln Arg Arg Ala Pro Gln Asp Ser Gln Thr
      50      55      60
His Gln Val Ser Leu Pro Lys Gln Pro Ser Ser Gln Gln Arg Gly Asp
65      70      75      80
Pro Thr Gly Pro Lys Lys Ser Lys Lys Lys Val Glu Arg Glu Thr Glu
      85      90      95
Ala Asp Pro Phe Asp Thr Ser Ala Gly Arg Ser Gly Asp Ser Asp Glu
      100      105      110
Glu Leu Leu Lys Thr Val Arg Leu Ile Lys Phe Leu Tyr Gln Ser Asn
      115      120      125
Pro Pro Pro Ser Asn Glu Gly Thr Arg Gln Ala Arg Arg Asn Arg Arg
      130      135      140
Arg Arg Trp Arg Glu Arg Gln Arg Gln Ile Arg Ser Ile Ser Glu Arg
145      150      155      160
Ile Leu Ser Thr Phe Leu Gly Arg Pro Ala Glu Pro Val Pro Leu Gln
      165      170      175
Leu Pro Pro Leu Glu Arg Leu Thr Leu Asp Cys Ser Glu Asp Cys Gly
      180      185      190
Asn Ser Gly Thr Gln Gly Val Gly Ser Pro Gln Val Leu Val Glu Ser
      195      200      205
Pro Ala Val Leu Glu Pro Gly Thr Lys Glu Lys Leu Val Gly Lys Trp
      210      215      220
Ser Lys Cys Ser Gly Trp Pro Thr Val Arg Glu Arg Met Lys Gln Ala
225      230      235      240
Glu Pro Glu Pro Ala Ala Asp Gly Val Gly Ala Ala Ser Arg Asp Leu
      245      250      255
Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr Ala Thr Asn Asn Ala
      260      265      270
Ala Cys Ala Trp Leu Glu Ala Gln Glu Glu Glu Val Gly Phe Pro
      275      280      285
Val Arg Pro Gln Val Pro Leu Arg Pro Met Thr Tyr Lys Gly Ala Leu
      290      295      300
Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly Leu Glu Gly Leu Ile
305      310      315      320
Tyr Ser Pro Lys Arg Gln Glu Ile Leu Asp Leu Trp Val Tyr His Thr
      325      330      335
Gln Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr Pro Gly Pro Gly Val
      340      345      350
Arg Tyr Pro Leu Thr Phe Gly Trp Cys Phe Lys Leu Val Pro Val Glu
      355      360      365
Pro Asp Glu Glu Glu Asn Ser Ser Leu Leu His Pro Ala Ser Leu His
      370      375      380
Gly Thr Glu Asp Thr Glu Arg Glu Val Leu Lys Trp Lys Phe Asp Ser
385      390      395      400
His Leu Ala Phe His His Lys Ala Arg Glu Leu His Pro Glu Tyr Tyr

```

405 410 415
 Lys Asp Cys Ala Ala Val Gly Ala Arg Ala Ser Val Leu Ser Gly Gly
 420 425 430
 Glu Leu Asp Lys Trp Glu Lys Ile Arg Leu Arg Pro Gly Gly Lys Lys
 435 440 445
 Lys Tyr Gln Leu Lys His Ile Val Trp Ala Ser Arg Glu Leu Glu Arg
 450 455 460
 Phe Ala Val Asn Pro Gly Leu Leu Glu Thr Ser Glu Gly Cys Arg Gln
 465 470 475 480
 Ile Met Gly Gln Leu Gln Pro Ser Leu Gln Thr Gly Ser Glu Glu Leu
 485 490 495
 Arg Ser Leu Tyr Asn Thr Val Ala Thr Leu Tyr Cys Val His Gln Lys
 500 505 510
 Ile Glu Val Lys Asp Thr Lys Glu Ala Leu Asp Lys Val Glu Glu Glu
 515 520 525
 Gln Asn Asn Ser Lys Lys Lys Ala Gln Gln Glu Ala Ala Asp Ala Gly
 530 535 540
 Asn Arg Asn Gln Val Ser Gln Asn Tyr Pro Ile Val Gln Asn Leu Gln
 545 550 555 560
 Gly Gln Met Val His Gln Ala Ile Ser Pro Arg Thr Leu Asn Ala Trp
 565 570 575
 Val Lys Val Val Glu Glu Lys Ala Phe Ser Pro Glu Val Ile Pro Met
 580 585 590
 Phe Ser Ala Leu Ser Glu Gly Ala Thr Pro Gln Asp Leu Asn Thr Met
 595 600 605
 Leu Asn Thr Val Gly Gly His Gln Ala Ala Met Gln Met Leu Lys Glu
 610 615 620
 Thr Ile Asn Glu Glu Ala Ala Glu Trp Asp Arg Leu His Pro Val His
 625 630 635 640
 Ala Gly Pro Ile Ala Pro Gly Gln Met Arg Glu Pro Arg Gly Ser Asp
 645 650 655
 Ile Ala Gly Thr Thr Ser Thr Leu Gln Glu Gln Ile Gly Trp Met Thr
 660 665 670
 Asn Asn Pro Pro Ile Pro Val Gly Glu Ile Tyr Lys Arg Trp Ile Ile
 675 680 685
 Leu Gly Leu Asn Lys Ile Val Arg Met Tyr Ser Pro Thr Ser Ile Leu
 690 695 700
 Asp Ile Lys Gln Gly Pro Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg
 705 710 715 720
 Phe Tyr Lys Thr Leu Arg Ala Glu Gln Ala Thr Gln Glu Val Lys Asn
 725 730 735
 Trp Met Thr Glu Thr Leu Leu Val Gln Asn Ala Asn Pro Asp Cys Lys
 740 745 750
 Thr Ile Leu Lys Ala Leu Gly Pro Ala Ala Thr Leu Glu Glu Met Met
 755 760 765
 Thr Ala Cys Gln Gly Val Gly Gly Pro Gly His Lys Ala Arg Val Leu
 770 775 780
 Ala Ala Val Ile Thr Leu Trp Gln Arg Pro Leu Val Ala Leu Ile Glu
 785 790 795 800
 Ile Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys Ile Gly Pro
 805 810 815
 Ala Gly Leu Lys Lys Lys Lys Ser Val Thr Val Leu Asp Val Gly Asp
 820 825 830
 Ala Tyr Phe Ser Val Pro Leu Asp Lys Asp Phe Arg Lys Tyr Thr Ala
 835 840 845
 Phe Thr Ile Pro Ser Ile Trp Lys Gly Ser Pro Ala Ile Phe Gln Ser
 850 855 860
 Ser Met Thr Lys Lys Gln Asn Pro Asp Ile Val Ile Tyr Gln Tyr Met
 865 870 875 880
 Asp Asp Leu Tyr Val Pro Ile Val Leu Pro Glu Lys Asp Ser Trp Leu
 885 890 895
 Val Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Ala Gly Ile Lys Val
 900 905 910

```

Lys Gln Leu Ile Leu Lys Glu Pro Val His Gly Val Tyr Glu Pro Ile
    915          920          925
Val Gly Ala Glu Thr Phe Tyr Val Asp Gly Ala Ala Asn Arg Ala Gly
    930          935          940
Asn Leu Trp Val Thr Val Tyr Tyr Gly Val Pro Val Trp Lys Glu Ala
    945          950          955          960
Thr Thr Thr Leu Val Glu Arg Tyr Leu Arg Asp Gln Gln Leu Leu Gly
    965          970          975
Ile Trp Gly Cys Ala Cys Thr Pro Tyr Asp Ile Asn Gln Met Leu Arg
    980          985          990
Gly Pro Gly Arg Ala Phe Val Thr Ile Arg Gln Gly Ser Leu
    995          1000          1005

```

<210> 46
 <211> 1006
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Hybrid protein cdscomprised of Tat-Rev-Nef, CTL and truncated Gag
 protein (TRN-CTL-optp17/24)

```

<400> 46
Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser
1          5          10          15
Gln Pro Arg Thr Pro Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Leu
    20          25          30
His Cys Gln Val Cys Phe Thr Arg Lys Gly Leu Gly Ile Ser Tyr Gly
    35          40          45
Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala Pro Gln Asp Ser Gln Thr
    50          55          60
His Gln Val Ser Leu Pro Lys Gln Pro Ser Ser Gln Gln Arg Gly Asp
    65          70          75          80
Pro Thr Gly Pro Lys Lys Ser Lys Lys Val Glu Arg Glu Thr Glu
    85          90          95
Ala Asp Pro Phe Asp Thr Ser Ala Gly Arg Ser Gly Asp Ser Asp Glu
    100          105          110
Glu Leu Leu Lys Thr Val Arg Leu Ile Lys Phe Leu Tyr Gln Ser Asn
    115          120          125
Pro Pro Pro Ser Asn Glu Gly Thr Arg Gln Ala Arg Arg Asn Arg Arg
    130          135          140
Arg Arg Trp Arg Glu Arg Gln Arg Gln Ile Arg Ser Ile Ser Glu Arg
    145          150          155          160
Ile Leu Ser Thr Phe Leu Gly Arg Pro Ala Glu Pro Val Pro Leu Gln
    165          170          175
Leu Pro Pro Leu Glu Arg Leu Thr Leu Asp Cys Ser Glu Asp Cys Gly
    180          185          190
Asn Ser Gly Thr Gln Gly Val Gly Ser Pro Gln Val Leu Val Glu Ser
    195          200          205
Pro Ala Val Leu Glu Pro Gly Thr Lys Glu Lys Leu Val Gly Lys Trp
    210          215          220
Ser Lys Cys Ser Gly Trp Pro Thr Val Arg Glu Arg Met Lys Gln Ala
    225          230          235          240
Glu Pro Glu Pro Ala Ala Asp Gly Val Gly Ala Ala Ser Arg Asp Leu
    245          250          255
Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr Ala Thr Asn Asn Ala
    260          265          270
Ala Cys Ala Trp Leu Glu Ala Gln Glu Glu Glu Val Gly Phe Pro
    275          280          285
Val Arg Pro Gln Val Pro Leu Arg Pro Met Thr Tyr Lys Gly Ala Leu
    290          295          300
Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly Leu Glu Gly Leu Ile
    305          310          315          320

```

Tyr Ser Pro Lys Arg Gln Glu Ile Leu Asp Leu Trp Val Tyr His Thr
 325 330 335
 Gln Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr Pro Gly Pro Gly Val
 340 345 350
 Arg Tyr Pro Leu Thr Phe Gly Trp Cys Phe Lys Leu Val Pro Val Glu
 355 360 365
 Pro Asp Glu Glu Glu Asn Ser Ser Leu Leu His Pro Ala Ser Leu His
 370 375 380
 Gly Thr Glu Asp Thr Glu Arg Glu Val Leu Lys Trp Lys Phe Asp Ser
 385 390 395 400
 His Leu Ala Phe His His Lys Ala Arg Glu Leu His Pro Glu Tyr Tyr
 405 410 415
 Lys Asp Cys Ala Ala Val Ile Thr Leu Trp Gln Arg Pro Leu Val Ala
 420 425 430
 Leu Ile Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys
 435 440 445
 Ile Gly Pro Ala Gly Leu Lys Lys Lys Ser Val Thr Val Leu Asp
 450 455 460
 Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Lys Asp Phe Arg Lys
 465 470 475 480
 Tyr Thr Ala Phe Thr Ile Pro Ser Ile Trp Lys Gly Ser Pro Ala Ile
 485 490 495
 Phe Gln Ser Ser Met Thr Lys Lys Gln Asn Pro Asp Ile Val Ile Tyr
 500 505 510
 Gln Tyr Met Asp Asp Leu Tyr Val Pro Ile Val Leu Pro Glu Lys Asp
 515 520 525
 Ser Trp Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Ala Gly
 530 535 540
 Ile Lys Val Lys Gln Leu Ile Leu Lys Glu Pro Val His Gly Val Tyr
 545 550 555 560
 Glu Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Asp Gly Ala Ala Asn
 565 570 575
 Arg Ala Gly Asn Leu Trp Val Thr Val Tyr Tyr Gly Val Pro Val Trp
 580 585 590
 Lys Glu Ala Thr Thr Thr Leu Val Glu Arg Tyr Leu Arg Asp Gln Gln
 595 600 605
 Leu Leu Gly Ile Trp Gly Cys Ala Cys Thr Pro Tyr Asp Ile Asn Gln
 610 615 620
 Met Leu Arg Gly Pro Gly Arg Ala Phe Val Thr Ile Arg Gln Gly Ser
 625 630 635 640
 Leu Ala Ala Val Gly Ala Arg Ala Ser Val Leu Ser Gly Gly Glu Leu
 645 650 655
 Asp Lys Trp Glu Lys Ile Arg Leu Arg Pro Gly Gly Lys Lys Tyr
 660 665 670
 Gln Leu Lys His Ile Val Trp Ala Ser Arg Glu Leu Glu Arg Phe Ala
 675 680 685
 Val Asn Pro Gly Leu Leu Glu Thr Ser Glu Gly Cys Arg Gln Ile Met
 690 695 700
 Gly Gln Leu Gln Pro Ser Leu Gln Thr Gly Ser Glu Glu Leu Arg Ser
 705 710 715 720
 Leu Tyr Asn Thr Val Ala Thr Leu Tyr Cys Val His Gln Lys Ile Glu
 725 730 735
 Val Lys Asp Thr Lys Glu Ala Leu Asp Lys Val Glu Glu Glu Gln Asn
 740 745 750
 Asn Ser Lys Lys Lys Ala Gln Gln Glu Ala Ala Asp Ala Gly Asn Arg
 755 760 765
 Asn Gln Val Ser Gln Asn Tyr Pro Ile Val Gln Asn Leu Gln Gly Gln
 770 775 780
 Met Val His Gln Ala Ile Ser Pro Arg Thr Leu Asn Ala Trp Val Lys
 785 790 795 800
 Val Val Glu Glu Lys Ala Phe Ser Pro Glu Val Ile Pro Met Phe Ser
 805 810 815
 Ala Leu Ser Glu Gly Ala Thr Pro Gln Asp Leu Asn Thr Met Leu Asn

```

      820      825      830
Thr Val Gly Gly His Gln Ala Ala Met Gln Met Leu Lys Glu Thr Ile
      835      840      845
Asn Glu Glu Ala Ala Glu Trp Asp Arg Leu His Pro Val His Ala Gly
      850      855      860
Pro Ile Ala Pro Gly Gln Met Arg Glu Pro Arg Gly Ser Asp Ile Ala
865      870      875      880
Gly Thr Thr Ser Thr Leu Gln Glu Gln Ile Gly Trp Met Thr Asn Asn
      885      890      895
Pro Pro Ile Pro Val Gly Glu Ile Tyr Lys Arg Trp Ile Ile Leu Gly
      900      905      910
Leu Asn Lys Ile Val Arg Met Tyr Ser Pro Thr Ser Ile Leu Asp Ile
      915      920      925
Lys Gln Gly Pro Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg Phe Tyr
      930      935      940
Lys Thr Leu Arg Ala Glu Gln Ala Thr Gln Glu Val Lys Asn Trp Met
945      950      955      960
Thr Glu Thr Leu Leu Val Gln Asn Ala Asn Pro Asp Cys Lys Thr Ile
      965      970      975
Leu Lys Ala Leu Gly Pro Ala Ala Thr Leu Glu Glu Met Met Thr Ala
      980      985      990
Cys Gln Gly Val Gly Gly Pro Gly His Lys Ala Arg Val Leu
      995      1000      1005

```

<210> 47
 <211> 1006
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Hybrid protein comprised of Rev-Nef-Tat, CTL and truncated Gag protein (RNT-CTL-optp17/24)

```

<400> 47
Met Ala Gly Arg Ser Gly Asp Ser Asp Glu Glu Leu Leu Lys Thr Val
1      5      10      15
Arg Leu Ile Lys Phe Leu Tyr Gln Ser Asn Pro Pro Pro Ser Asn Glu
      20      25      30
Gly Thr Arg Gln Ala Arg Arg Asn Arg Arg Arg Trp Arg Glu Arg
      35      40      45
Gln Arg Gln Ile Arg Ser Ile Ser Glu Arg Ile Leu Ser Thr Phe Leu
      50      55      60
Gly Arg Pro Ala Glu Pro Val Pro Leu Gln Leu Pro Pro Leu Glu Arg
65      70      75      80
Leu Thr Leu Asp Cys Ser Glu Asp Cys Gly Asn Ser Gly Thr Gln Gly
      85      90      95
Val Gly Ser Pro Gln Val Leu Val Glu Ser Pro Ala Val Leu Glu Pro
      100      105      110
Gly Thr Lys Glu Thr Ser Val Gly Lys Trp Ser Lys Cys Ser Gly Trp
      115      120      125
Pro Thr Val Arg Glu Arg Met Lys Gln Ala Glu Pro Glu Pro Ala Ala
      130      135      140
Asp Gly Val Gly Ala Ala Ser Arg Asp Leu Glu Lys His Gly Ala Ile
145      150      155      160
Thr Ser Ser Asn Thr Ala Thr Asn Asn Ala Ala Cys Ala Trp Leu Glu
      165      170      175
Ala Gln Glu Glu Glu Val Gly Phe Pro Val Arg Pro Gln Val Pro
      180      185      190
Leu Arg Pro Met Thr Tyr Lys Gly Ala Leu Asp Leu Ser His Phe Leu
      195      200      205
Lys Glu Lys Gly Gly Leu Glu Gly Leu Ile Tyr Ser Pro Lys Arg Gln
      210      215      220
Glu Ile Leu Asp Leu Trp Val Tyr His Thr Gln Gly Tyr Phe Pro Asp

```

225 230 235 240
 Trp Gln Asn Tyr Thr Pro Gly Pro Gly Val Arg Tyr Pro Leu Thr Phe
 245 250 255
 Gly Trp Cys Phe Lys Leu Val Pro Val Glu Pro Asp Glu Glu Glu Asn
 260 265 270
 Ser Ser Leu Leu His Pro Ala Ser Leu His Gly Thr Glu Asp Thr Glu
 275 280 285
 Arg Glu Val Leu Lys Trp Lys Phe Asp Ser His Leu Ala Phe His His
 290 295 300
 Lys Ala Arg Glu Leu His Pro Glu Tyr Tyr Lys Asp Cys Lys Leu Glu
 305 310 315 320
 Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser Gln Pro
 325 330 335
 Arg Thr Pro Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Leu His Cys
 340 345 350
 Gln Val Cys Phe Thr Arg Lys Gly Leu Gly Ile Ser Tyr Gly Arg Lys
 355 360 365
 Lys Arg Arg Gln Arg Arg Arg Ala Pro Gln Asp Ser Gln Thr His Gln
 370 375 380
 Val Ser Leu Pro Lys Gln Pro Ser Ser Gln Gln Arg Gly Asp Pro Thr
 385 390 395 400
 Gly Pro Lys Lys Ser Lys Lys Lys Val Glu Arg Glu Thr Glu Ala Asp
 405 410 415
 Pro Phe Asp Ala Ala Val Ile Thr Leu Trp Gln Arg Pro Leu Val Ala
 420 425 430
 Leu Ile Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys
 435 440 445
 Ile Gly Pro Ala Gly Leu Lys Lys Lys Ser Val Thr Val Leu Asp
 450 455 460
 Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Lys Asp Phe Arg Lys
 465 470 475 480
 Tyr Thr Ala Phe Thr Ile Pro Ser Ile Trp Lys Gly Ser Pro Ala Ile
 485 490 495
 Phe Gln Ser Ser Met Thr Lys Lys Gln Asn Pro Asp Ile Val Ile Tyr
 500 505 510
 Gln Tyr Met Asp Asp Leu Tyr Val Pro Ile Val Leu Pro Glu Lys Asp
 515 520 525
 Ser Trp Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Ala Gly
 530 535 540
 Ile Lys Val Lys Gln Leu Ile Leu Lys Glu Pro Val His Gly Val Tyr
 545 550 555 560
 Glu Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Asp Gly Ala Ala Asn
 565 570 575
 Arg Ala Gly Asn Leu Trp Val Thr Val Tyr Tyr Gly Val Pro Val Trp
 580 585 590
 Lys Glu Ala Thr Thr Thr Leu Val Glu Arg Tyr Leu Arg Asp Gln Gln
 595 600 605
 Leu Leu Gly Ile Trp Gly Cys Ala Cys Thr Pro Tyr Asp Ile Asn Gln
 610 615 620
 Met Leu Arg Gly Pro Gly Arg Ala Phe Val Thr Ile Arg Gln Gly Ser
 625 630 635 640
 Leu Ala Ala Val Gly Ala Arg Ala Ser Val Leu Ser Gly Gly Glu Leu
 645 650 655
 Asp Lys Trp Glu Lys Ile Arg Leu Arg Pro Gly Gly Lys Lys Tyr
 660 665 670
 Gln Leu Lys His Ile Val Trp Ala Ser Arg Glu Leu Glu Arg Phe Ala
 675 680 685
 Val Asn Pro Gly Leu Leu Glu Thr Ser Glu Gly Cys Arg Gln Ile Met
 690 695 700
 Gly Gln Leu Gln Pro Ser Leu Gln Thr Gly Ser Glu Glu Leu Arg Ser
 705 710 715 720
 Leu Tyr Asn Thr Val Ala Thr Leu Tyr Cys Val His Gln Lys Ile Glu
 725 730 735

Val Lys Asp Thr Lys Glu Ala Leu Asp Lys Val Glu Glu Glu Gln Asn
 740 745 750
 Asn Ser Lys Lys Lys Ala Gln Gln Glu Ala Ala Asp Ala Gly Asn Arg
 755 760 765
 Asn Gln Val Ser Gln Asn Tyr Pro Ile Val Gln Asn Leu Gln Gly Gln
 770 775 780
 Met Val His Gln Ala Ile Ser Pro Arg Thr Leu Asn Ala Trp Val Lys
 785 790 795 800
 Val Val Glu Glu Lys Ala Phe Ser Pro Glu Val Ile Pro Met Phe Ser
 805 810 815
 Ala Leu Ser Glu Gly Ala Thr Pro Gln Asp Leu Asn Thr Met Leu Asn
 820 825 830
 Thr Val Gly Gly His Gln Ala Ala Met Gln Met Leu Lys Glu Thr Ile
 835 840 845
 Asn Glu Glu Ala Ala Glu Trp Asp Arg Leu His Pro Val His Ala Gly
 850 855 860
 Pro Ile Ala Pro Gly Gln Met Arg Glu Pro Arg Gly Ser Asp Ile Ala
 865 870 875 880
 Gly Thr Thr Ser Thr Leu Gln Glu Gln Ile Gly Trp Met Thr Asn Asn
 885 890 895
 Pro Pro Ile Pro Val Gly Glu Ile Tyr Lys Arg Trp Ile Ile Leu Gly
 900 905 910
 Leu Asn Lys Ile Val Arg Met Tyr Ser Pro Thr Ser Ile Leu Asp Ile
 915 920 925
 Lys Gln Gly Pro Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg Phe Tyr
 930 935 940
 Lys Thr Leu Arg Ala Glu Gln Ala Thr Gln Glu Val Lys Asn Trp Met
 945 950 955 960
 Thr Glu Thr Leu Leu Val Gln Asn Ala Asn Pro Asp Cys Lys Thr Ile
 965 970 975
 Leu Lys Ala Leu Gly Pro Ala Ala Thr Leu Glu Glu Met Met Thr Ala
 980 985 990
 Cys Gln Gly Val Gly Gly Pro Gly His Lys Ala Arg Val Leu
 995 1000 1005

<210> 48
 <211> 1006
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Hybrid protein comprised of Rev-Nef-Tat, truncated Gag protein and CTL (RNT-optp17/24-CTL)

<400> 48
 Met Ala Gly Arg Ser Gly Asp Ser Asp Glu Glu Leu Leu Lys Thr Val
 1 5 10 15
 Arg Leu Ile Lys Phe Leu Tyr Gln Ser Asn Pro Pro Pro Ser Asn Glu
 20 25 30
 Gly Thr Arg Gln Ala Arg Arg Arg Arg Arg Trp Arg Glu Arg
 35 40 45
 Gln Arg Gln Ile Arg Ser Ile Ser Glu Arg Ile Leu Ser Thr Phe Leu
 50 55 60
 Gly Arg Pro Ala Glu Pro Val Pro Leu Gln Leu Pro Pro Leu Glu Arg
 65 70 75 80
 Leu Thr Leu Asp Cys Ser Glu Asp Cys Gly Asn Ser Gly Thr Gln Gly
 85 90 95
 Val Gly Ser Pro Gln Val Leu Val Glu Ser Pro Ala Val Leu Glu Pro
 100 105 110
 Gly Thr Lys Glu Thr Ser Val Gly Lys Trp Ser Lys Cys Ser Gly Trp
 115 120 125
 Pro Thr Val Arg Glu Arg Met Lys Gln Ala Glu Pro Glu Pro Ala Ala
 130 135 140

Asp Gly Val Gly Ala Ala Ser Arg Asp Leu Glu Lys His Gly Ala Ile
 145 150 155 160
 Thr Ser Ser Asn Thr Ala Thr Asn Asn Ala Ala Cys Ala Trp Leu Glu
 165 170 175
 Ala Gln Glu Glu Glu Val Gly Phe Pro Val Arg Pro Gln Val Pro
 180 185 190
 Leu Arg Pro Met Thr Tyr Lys Gly Ala Leu Asp Leu Ser His Phe Leu
 195 200 205
 Lys Glu Lys Gly Gly Leu Glu Gly Leu Ile Tyr Ser Pro Lys Arg Gln
 210 215 220
 Glu Ile Leu Asp Leu Trp Val Tyr His Thr Gln Gly Tyr Phe Pro Asp
 225 230 235 240
 Trp Gln Asn Tyr Thr Pro Gly Pro Gly Val Arg Tyr Pro Leu Thr Phe
 245 250 255
 Gly Trp Cys Phe Lys Leu Val Pro Val Glu Pro Asp Glu Glu Glu Asn
 260 265 270
 Ser Ser Leu Leu His Pro Ala Ser Leu His Gly Thr Glu Asp Thr Glu
 275 280 285
 Arg Glu Val Leu Lys Trp Lys Phe Asp Ser His Leu Ala Phe His His
 290 295 300
 Lys Ala Arg Glu Leu His Pro Glu Tyr Tyr Lys Asp Cys Lys Leu Glu
 305 310 315 320
 Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser Gln Pro
 325 330 335
 Arg Thr Pro Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Leu His Cys
 340 345 350
 Gln Val Cys Phe Thr Arg Lys Gly Leu Gly Ile Ser Tyr Gly Arg Lys
 355 360 365
 Lys Arg Arg Gln Arg Arg Arg Ala Pro Gln Asp Ser Gln Thr His Gln
 370 375 380
 Val Ser Leu Pro Lys Gln Pro Ser Ser Gln Gln Arg Gly Asp Pro Thr
 385 390 395 400
 Gly Pro Lys Lys Ser Lys Lys Lys Val Glu Arg Glu Thr Glu Ala Asp
 405 410 415
 Pro Phe Asp Ala Ala Val Gly Ala Arg Ala Ser Val Leu Ser Gly Gly
 420 425 430
 Glu Leu Asp Lys Trp Glu Lys Ile Arg Leu Arg Pro Gly Gly Lys Lys
 435 440 445
 Lys Tyr Gln Leu Lys His Ile Val Trp Ala Ser Arg Glu Leu Glu Arg
 450 455 460
 Phe Ala Val Asn Pro Gly Leu Leu Glu Thr Ser Glu Gly Cys Arg Gln
 465 470 475 480
 Ile Met Gly Gln Leu Gln Pro Ser Leu Gln Thr Gly Ser Glu Glu Leu
 485 490 495
 Arg Ser Leu Tyr Asn Thr Val Ala Thr Leu Tyr Cys Val His Gln Lys
 500 505 510
 Ile Glu Val Lys Asp Thr Lys Glu Ala Leu Asp Lys Val Glu Glu Glu
 515 520 525
 Gln Asn Asn Ser Lys Lys Lys Ala Gln Gln Glu Ala Ala Asp Ala Gly
 530 535 540
 Asn Arg Asn Gln Val Ser Gln Asn Tyr Pro Ile Val Gln Asn Leu Gln
 545 550 555 560
 Gly Gln Met Val His Gln Ala Ile Ser Pro Arg Thr Leu Asn Ala Trp
 565 570 575
 Val Lys Val Val Glu Glu Lys Ala Phe Ser Pro Glu Val Ile Pro Met
 580 585 590
 Phe Ser Ala Leu Ser Glu Gly Ala Thr Pro Gln Asp Leu Asn Thr Met
 595 600 605
 Leu Asn Thr Val Gly Gly His Gln Ala Ala Met Gln Met Leu Lys Glu
 610 615 620
 Thr Ile Asn Glu Glu Ala Ala Glu Trp Asp Arg Leu His Pro Val His
 625 630 635 640
 Ala Gly Pro Ile Ala Pro Gly Gln Met Arg Glu Pro Arg Gly Ser Asp

```

        645                650                655
Ile Ala Gly Thr Thr Ser Thr Leu Gln Glu Ile Gly Trp Met Thr
        660                665                670
Asn Asn Pro Pro Ile Pro Val Gly Glu Ile Tyr Lys Arg Trp Ile Ile
        675                680                685
Leu Gly Leu Asn Lys Ile Val Arg Met Tyr Ser Pro Thr Ser Ile Leu
        690                695                700
Asp Ile Lys Gln Gly Pro Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg
        705                710                715                720
Phe Tyr Lys Thr Leu Arg Ala Glu Gln Ala Thr Gln Glu Val Lys Asn
        725                730                735
Trp Met Thr Glu Thr Leu Leu Val Gln Asn Ala Asn Pro Asp Cys Lys
        740                745                750
Thr Ile Leu Lys Ala Leu Gly Pro Ala Ala Thr Leu Glu Glu Met Met
        755                760                765
Thr Ala Cys Gln Gly Val Gly Gly Pro Gly His Lys Ala Arg Val Leu
        770                775                780
Ala Ala Val Ile Thr Leu Trp Gln Arg Pro Leu Val Ala Leu Ile Glu
        785                790                795                800
Ile Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys Ile Gly Pro
        805                810                815
Ala Gly Leu Lys Lys Lys Lys Ser Val Thr Val Leu Asp Val Gly Asp
        820                825                830
Ala Tyr Phe Ser Val Pro Leu Asp Lys Asp Phe Arg Lys Tyr Thr Ala
        835                840                845
Phe Thr Ile Pro Ser Ile Trp Lys Gly Ser Pro Ala Ile Phe Gln Ser
        850                855                860
Ser Met Thr Lys Lys Gln Asn Pro Asp Ile Val Ile Tyr Gln Tyr Met
        865                870                875                880
Asp Asp Leu Tyr Val Pro Ile Val Leu Pro Glu Lys Asp Ser Trp Leu
        885                890                895
Val Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Ala Gly Ile Lys Val
        900                905                910
Lys Gln Leu Ile Leu Lys Glu Pro Val His Gly Val Tyr Glu Pro Ile
        915                920                925
Val Gly Ala Glu Thr Phe Tyr Val Asp Gly Ala Ala Asn Arg Ala Gly
        930                935                940
Asn Leu Trp Val Thr Val Tyr Tyr Gly Val Pro Val Trp Lys Glu Ala
        945                950                955                960
Thr Thr Thr Leu Val Glu Arg Tyr Leu Arg Asp Gln Gln Leu Leu Gly
        965                970                975
Ile Trp Gly Cys Ala Cys Thr Pro Tyr Asp Ile Asn Gln Met Leu Arg
        980                985                990
Gly Pro Gly Arg Ala Phe Val Thr Ile Arg Gln Gly Ser Leu
        995                1000                1005

```

<210> 49
 <211> 7945
 <212> DNA
 <213> Bovine papillomavirus

<220>
 <221> misc_feature
 <222> 1205
 <223> n = A,T,C or G

<400> 49
 gttaacaata atcacaccat caccgttttt tcaagcggga aaaaatagcc agctaactat 60
 aaaaagctgc tgacagaccc cggttttcac atggacctga aaccttttgc aagaaccaat 120
 ccattctcag ggttgattg tctgtggtgc agagagcctc ttacagaagt tgatgctttt 180
 aggtgcatgg tcaaaagactt tcatgttgta attcgggaag gctgtagata tggatgcatgt 240
 accatttgtc ttgaaaactg tttagctact gaaagaagac tttggcaagg tgttcagta 300
 acaggtgagg aagctgaatt attgcatggc aaaacacttg ataggctttg cataagatgc 360

```

tgctactgtg ggggcaaaact aacaaaaaat gaaaaacatc ggcatgtgct ttttaatgag 420
cctttctgca aaaccagagc taacataatt agaggacgct gctacgactg ctgcagacat 480
gggtcaaggt ccaaatatccc atagaaaactt ggatgattca cctgcaggac cggtgctgat 540
tttaagtcca tgtgcaggca caccctaccag gtctcctgca gcacctgatg caccctgattt 600
cagacttccg tgccatttctg gccgtccctac taggaagcga ggtccacta cccctccgct 660
ttcctctccc ggaaaaactgt gtgcaacagg gccacgtcga gtgtattctg tgactgtctg 720
ctgtggaac tgccgaaaaag agctgacttt tgctgtgaag accagctcga cgtccctgct 780
tggtttgaa caccttttaa actcagattt agacctcttg tgtccacgtt gtgaatctcg 840
cgagcgtcat ggcaaacgat aaaggtagca attgggattc gggcttggga tgctcatatc 900
tgctgactga ggcagaatgt gaaagtgaac aagagaatga ggaacccggg gcaggtgtag 960
aactgtctgt ggaatctgat cggtagata gccaggatga ggattttgtt gacaatgcat 1020
cagtccttca gggaaatcac ctggaggctt tccaggcatt agagaaaaag gcgggtgagg 1080
agcagatttt aaatttgaaa agaaaagtat tggggagttc gcaaaacagc agcgggtccg 1140
aagcatctga aactccagtt aaaagacgga aatcaggagc aaagcgaaga ttatttgctg 1200
aaaangaagc taaccgtgtt cttacgcccc tccaggtaga gggggagggg gaggggaggc 1260
aagaacttaa tgaggagcag gcaattagtc atctacatct gcagcttggt aaatctaaaa 1320
atgctacagt ttttaagctg gggctcttta aatctttgtt cctttgtagc ttccatgata 1380
ttacagggtt gtttaagaat gataagacca ctaatcagca atgggtgctg gctgtgtttg 1440
gccttcgaga ggtgtttttt gaggcgagtt tccgaactcct aaagaagcag tgtagttttc 1500
tgcagatgca aaaaagatct catgaaggag gaacttgtgc agtttactta atctgcttta 1560
acacagctaa aagcagagaa acagtcgga atctgatggc aaacacgcta aatgtaagag 1620
aagagtgttt gatgctgcag ccagctaaaa ttcgaggact cagcgcagct ctattctggt 1680
tbaaaagtag tttgtcaccg gctacactta aacatggtgc tttacctgag tggatacggg 1740
cgcaaacctac tctgaacgag agcttcgaga ccgagaaatt cgacttcgga actatggtgc 1800
aatgggccta tgatcacaaa tatgctgagg agtctaaaat agcctatgaa tatgctttgg 1860
ctgcaggatc tgatagcaat gcacgggctt ttttagcaac taacagccaa gctaagcatg 1920
tgaaggactg tgcaactatg gtaagacact atctaagagc tgaaacacaa gcattaagca 1980
tgcttcgata tattaagct aggtgcaagc tggcaactgg ggaaggaagc tggaaagtcta 2040
tcctaacttt ttttaactat cagaatattg aattaattac ctttattaat gctttaaagc 2100
tctggctaaa aggaattcca aaaaaaaact gttagcattt tattggccct ccaaacacag 2160
gcaagctcat gctctgcaac tcattaattc attttttggg tggtagtgtt ttactttttg 2220
ccaaccataa aagtcacttt tggcttgctt ccctagcaga tactagagct gcttttagtag 2280
atgatgctac tcatgcttgc tggaggtact ttgacacata cctcagaaat gcattggatg 2340
gctaccctgt cagtatgtat agaaaacaca aagcagcggg tcaaatataa gctccacccc 2400
tcctggtaac cagtaaatatt gatgtgcagg cagaggacag atatttgtac ttgcatagtc 2460
gggtgcaaac ctttcgcttt gaggcagcat gcacagatga atcgggtgag caacctttta 2520
atattactga tgcagattgg aaatcttttt ttgtaaggtt atgggggctg ttagacctga 2580
ttgacaggga ggaggatagt gaagaggatg gagacagcat gcgaacgttt acatgtagcg 2640
caagaaacac aaatgcagtt gattgagaaa agtagtgata agttgcaaga tcatatactg 2700
tactggactg ctgttagaac tgagaacaca ctgctttatg ctgcaaggaa aaaaggggtg 2760
actgtcctag gacactgcag agtaccacac tctgtagttt gtcaagagag agccaagcag 2820
gccattgaaa tgcagttgtc tttgcaggag ttaagcaaaa ctgagtttgg ggatgaacca 2880
tggtctttgc ttgacacaag ctgggaccga tatatgtcag aaactaaacg gtgctttaag 2940
aaagcgcca ggttggtaga gatggaaatg caagcaatac aaactggtac 3000
actgtctaca gcaatttgta catgcgcaca gaggacggct ggcagcttgc gaaggctggg 3060
gctgacggaa ctgggctcta ctactgcacc atggcgggtg ctggacgcat ttactattct 3120
cgctttgggt acgaggcagc cagatttagt acaacagggc attactctgt aagagatcag 3180
gacagagtgat atgtggtgt ctcactccac tcttctgatt ttagagatcg ccagacgga 3240
gtctgggtcg catccgaagg acctgaagga gacctgcag gaaaagaagc cgagccagcc 3300
cagcctgtct cttctttgct cggctccccc gcctgcggtc ccatcagagc aggcctcggt 3360
tgggtacggg acggtcctcg ctgcacccc tacaattttc ctgcaggctc ggggggctct 3420
attctccgct ctctctccac cccgtgcagg gcacggtagc ggtggacttg gcatcaaggc 3480
aggaagaaga ggagcagtcg cccgactcca cagaggaaga accagtgact ctcccaaggc 3540
gcaccaccaa tgatggatc caccgtttaa aggcaggagg gtcatgcttt gctctaattt 3600
caggaactgc taaccaggtc aagtgtatc gctttcggtt gaaaaagaac catagacatc 3660
gctacgagaa ctgcaccacc acctggttca cagttgtcga caacggtgct gaaagacaag 3720
gacaagcaca aatactgatc acctttggat cgccaagtca aaggcaagac tttctgaaac 3780
atgtaccact acctcctgga atgaacattt ccgcttttac agccagcttg gacttctgat 3840
cactgccatt gccttttctt catctgactg gtgtactatg ccaaactctat ggtttctatt 3900
gttcttggga ctagtgtctg caatgcaact gctgctatta ctgttcttac tcttgttttt 3960
tcttgatac tgggatcatt ttgagtgtc ctgtacaggt ctgccctttt aatgccttta 4020
catcactggc tattggctgt gttttttact ttgtgtggat ttgatttgtt ttatatactg 4080
tatgaagttt ttcatttgt gcttgtattg ctgtttgtaa gttttttact agagtttgta 4140

```

```

ttccccctgc tcagatttta tatggtttaa gctgcagcaa taaaaatgag tgcacgaaaa 4200
agagtaaaac gtgccagtgc ctatgacctg tacaggacat gcaagcaagc gggcacatgt 4260
ccaccagatg tgataccaaa ggtagaagga gatactatag cagataaaat tttgaaattt 4320
gggggtcttg caatctactt aggaggggcta ggaataggaa catgggtctac tgggaagggtt 4380
gctgcagggtg gatcaccaag gtacacacca ctccgaacag cagggtccac atcatcgctt 4440
gcatcaatag gatccagagc tgaacacagca gggacccgcc ccagtatagg tgcgggcatt 4500
ccttttagaca ccttgaaac tcttggggcc ttgcgtccag ggggtgatga ggacactgtg 4560
ctaccagagg cccctgcaat agtcactcct gatgctgttc ctgcagattc agggcttgat 4620
gccctgtcca taggtacaga ctgcgtccacg gagacctca ttactctgct agagcctgag 4680
gggtcccgagg acatagcggg tcttgagctg caaccctgg accgtccaac ttggcaagta 4740
agcaatgctg ttcatcagtc ctctgcatac caccgccctc tgcagctgca atcgctcatt 4800
gcagaaacat ctggtttaga aaatatTTTT gtaggaggct cgggtttagg ggatacagga 4860
ggagaaaaaca ttgaactgac atacttcggg tccccacgaa caagcacgcc ccgcagtatt 4920
gcctctaact cacgtggcat tttaaactgg ttcagtaaac ggtactacac acagggtgcc 4980
acggaagatc ctgaagtgtt ttcatcccaa acatttgcaa acccactgta tgaagcagaa 5040
ccagctgtgc ttaagggacc tagtgagcgt gttggactca gtcagggtta taaacctgat 5100
acacttacaa cacgtagcgg gacagagggt ggaccacagc tacatgtcag gtactcattg 5160
agtactatac atgaagatgt agaagcaatc ccctacacag ttgatgaaaa tacacaggga 5220
cttgcatctg tacccttgca tgaagagcaa gcaggttttg aggagataga attagatgat 5280
tttagtgaga cacatagact gctacctcag aacacctctt ctacacctgt tggtagtggt 5340
gtacgaagaa gccctattcc aactcaggaa tttagtcaa caccggcctac aggtgttgta 5400
acctatggct cactgcacac ttactctgct agcccagtta ctgacctga ttctacctct 5460
cctagtctag ttatcgatga cactactact acaccaatca ttataattga tgggcacaca 5520
gttgatttgt acagcagtaa ctacaccttg catccctcct tgttgaggaa acgaaaaaaa 5580
cggaaacatg cctaattttt ttgacagatg gcgttgtggc aacaaggcca gaagctgtat 5640
ctccctccaa cccctgtaag caaggtgctt tgcagtgaac cctatgtgca aagaaaaagc 5700
atTTTTtatt atgcagaaac ggagcgcctg ctaactatag gacatccata ttaccctagt 5760
tctatcgggg ccaaaactgt tcctaaggtc tctgcaaatc agtatagggt attttaaata 5820
caactacctg atcccaatca atttgactca cctgacagga ctgttcacaa cccaagtaaa 5880
gagcggcttg tgtgggcagt cataggtgtg caggtgtcca gagggcagcc tcttgagggt 5940
actgtaactg ggcaccccac ttttaagtct ttgcttgatg cagaaaaatg gaatagaaaa 6000
gtcaccaccc aaacaacaga tgacaggaaa caaacaggcc tagatgctaa gcaacaacag 6060
attctgttgc taggctgtac cctgctgaa ggggaatatt ggacaacagc ccgtccatgt 6120
gttactgatc gtctagaaaa tggcgcctgc cctcctcttg aattaaaaaa caagcacata 6180
gaagatgggg atatgatgga aattgggttt ggtgcagcca acttcaaaga aattaatgca 6240
agtaaatcag atctacctct tgacattcaa aatgagatct gctgtacccc agactacctc 6300
aaaatggctg aggacgctgc tggtaatagc atgttctttt ttgcaaggaa agaacagggtg 6360
tatgttagac acatctggac cagagggggc tcggagaaag aagcccctac cacagatttt 6420
tatttaaaga ataataaagg ggatgccacc cttaaaatac ccagtgtgca ttttggtagt 6480
cccagtggct cactagtctc aactgataat caaattttta atcggcccta ctggctattc 6540
cgtgccaggg gcatgaacaa tgggaattgca tgggaataatt tattgttttt aacagtgggg 6600
gacaatacac gtgtgtactaa tcttaccata agtgtagcct cagatggaac cccactaaca 6660
gagtatgata gctcaaaatt caatgtatac catagacata tggagaataa taagctagcc 6720
tttatattag agctatgctc tgtggaaatc acagctcaaa ctgtgtcaca tctgcaagga 6780
cttatgccct ctgtgcttga aaattgggaa ataggtgtgc agcctcctac ctcatcgata 6840
ttagaggaca cctatcgcta tatagagtct cctgcaacta aatgtgcaag caatgtaatt 6900
cctgcaaaag aagaccctta tgcagggttt aagttttgga acatagatct taaagaaaag 6960
ctttcttttg acttagatca atttcccttg ggaagaagat ttttagcaca gcaaggggca 7020
ggatgttcaa ctgtgagaaa acgaagaatt agccaaaaaa cttccagtaa gcctgcaaaa 7080
aaaaaaaaaa aataaaagct aagtttctat aaatgttctg taaatgtaaa acagaaggta 7140
agtcaactgc acctaataaaa aatcacttaa tagcaatgtg ctgtgtcagt tgtttatttg 7200
aaccacaccg ggtacacatc ctgtccagca tttgcagtgc gtgcattgaa ttattgtgct 7260
ggctagactt catggcgctt ggcaccgaat cctgccttct cagcgaataa gaataattgc 7320
tttgttgcca agaaactaag catcaatggg acgcgtgcaa agcacggcg gcggtagatg 7380
cggggttaagt actgaatttt aattcgacct atcccggtaa agcgaaagcg acacgctttt 7440
ttttcacaca tagcgggacc gaacacgtta taagtatcga ttaggctcat ttttgcctct 7500
ctgtcggaac cagaactggg aaaaagtttcc attgcgtctg ggctgtgcta tcattgctgc 7560
tctatggttt ttggaggatt agacggggcc accagtaatg gtgcatagcg gatgtctgta 7620
ccgccatcgt tgcaccgata taggttttgg gctcccgaag ggactgctgg gatgacagct 7680
tcatattata ttgaatgggc gcataatcag ctttaattggg gaggacaagc tacaagtgtg 7740
aacctgatct ccacaaagta cgttgccggg cggggtcaaa ccgtcttcgg tgcctgaaac 7800
cgcttaaac tacagacagg tcccagccaa gtaggcggat caaaacctca aaaaggcg 7860
agccaatcaa aatgcagcat tataatttaa gctcaccgaa accggttaag aaagactatg 7920

```

tattttttcc cagtgaataa ttggt

7945

<210> 50

<211> 306

<212> PRT

<213> bovine papillomavirus type 1

<400> 50

Met Glu Thr Ala Cys Glu Arg Leu His Val Ala Gln Glu Thr Gln Met
 1 5 10 15
 Gln Leu Ile Glu Lys Ser Ser Asp Lys Leu Gln Asp His Ile Leu Tyr
 20 25 30
 Trp Thr Ala Val Arg Thr Glu Asn Thr Leu Leu Tyr Ala Ala Arg Lys
 35 40 45
 Lys Gly Val Thr Val Leu Gly His Cys Arg Val Pro His Ser Val Val
 50 55 60
 Cys Gln Glu Arg Ala Lys Gln Ala Ile Glu Met Gln Leu Ser Leu Gln
 65 70 75 80
 Glu Leu Ser Lys Thr Glu Phe Gly Asp Glu Pro Trp Ser Leu Leu Asp
 85 90 95
 Thr Ser Trp Asp Arg Tyr Met Ser Glu Pro Lys Arg Cys Phe Lys Lys
 100 105 110
 Gly Ala Arg Val Val Glu Val Glu Phe Asp Gly Asn Ala Ser Asn Thr
 115 120 125
 Asn Trp Tyr Thr Val Tyr Ser Asn Leu Tyr Met Arg Thr Glu Asp Gly
 130 135 140
 Trp Gln Leu Ala Lys Ala Gly Ala Asp Gly Thr Gly Leu Tyr Tyr Cys
 145 150 155 160
 Thr Met Ala Gly Ala Gly Arg Ile Tyr Tyr Ser Arg Phe Gly Asp Glu
 165 170 175
 Ala Ala Arg Phe Ser Thr Thr Gly His Tyr Ser Val Arg Asp Gln Asp
 180 185 190
 Arg Val Tyr Ala Gly Val Ser Ser Thr Ser Ser Asp Phe Arg Asp Arg
 195 200 205
 Pro Asp Gly Val Trp Val Ala Ser Glu Gly Pro Glu Gly Asp Pro Ala
 210 215 220
 Gly Lys Glu Ala Glu Pro Ala Gln Pro Val Ser Ser Leu Leu Gly Ser
 225 230 235 240
 Pro Ala Cys Gly Pro Ile Arg Ala Gly Leu Gly Trp Val Arg Asp Gly
 245 250 255
 Pro Arg Ser His Pro Tyr Asn Phe Pro Ala Gly Ser Gly Gly Ser Ile
 260 265 270
 Leu Arg Ser Ser Ser Thr Pro Cys Arg Ala Arg Tyr Arg Trp Thr Trp
 275 280 285
 His Gln Gly Arg Lys Lys Arg Ser Ser Arg Pro Thr Pro Gln Arg Lys
 290 295 300
 Asn Gln
 305

<210> 51

<211> 622

<212> DNA

<213> Human herpesvirus 4

<400> 51

gggtatcata tgctgactgt atatgcatga ggatagcata tgctaccagg atacagatta 60
 ggatagcata tactaccag atatagatta ggatagcata tgctaccag atatagatta 120
 ggatagccta tgctaccag atataaatta ggatagcata tactaccag atatagatta 180
 ggatagcata tgctaccag atatagatta ggatagccta tgctaccag atatagatta 240
 ggatagcata tgctaccag atatagatta ggatagcata tgctatccag atatttgggt 300
 agtatatgct acccagatat aaattaggat agcatatact accctaact ctattaggat 360
 agcatatgct acccgatata agattaggat agcatatact acccagatat agattaggat 420
 agcatatgct acccagatat agattaggat agcctatgct acccagatat aaattaggat 480

agcatatact acccagatat agattaggat agcatatgct acccagatat agattaggat 540
 agcctatgct acccagatat agattaggat agcatatgct atccagatat ttgggtagta 600
 tatgctaccc atggcaacat ta 622

<210> 52

<211> 641

<212> PRT

<213> Human herpesvirus 4

<400> 52

Met Ser Asp Glu Gly Pro Gly Thr Gly Pro Gly Asn Gly Leu Gly Glu
 1 5 10 15
 Lys Gly Asp Thr Ser Gly Pro Glu Gly Ser Gly Gly Ser Gly Pro Gln
 20 25 30
 Arg Arg Gly Gly Asp Asn His Gly Arg Gly Arg Gly Arg Gly
 35 40 45
 Arg Gly Gly Gly Arg Pro Gly Ala Pro Gly Gly Ser Gly Ser Gly Pro
 50 55 60
 Arg His Arg Asp Gly Val Arg Arg Pro Gln Lys Arg Pro Ser Cys Ile
 65 70 75 80
 Gly Cys Lys Gly Thr His Gly Gly Thr Gly Ala Gly Ala Gly Ala Gly
 85 90 95
 Gly Ala Gly Ala Gly Gly Ala Gly Ala Gly Gly Gly Ala Gly Ala Gly
 100 105 110
 Gly Gly Ala Gly Gly Ala Gly Gly Ala Gly Gly Ala Gly Ala Gly Gly
 115 120 125
 Gly Ala Gly Ala Gly Gly Gly Ala Gly Gly Ala Gly Ala Gly Ala
 130 135 140
 Gly Gly Gly Ala Gly Ala Gly Gly Gly Ala Gly Gly Ala Gly Ala Gly
 145 150 155 160
 Gly Gly Ala Gly Gly Ala Gly Gly Ala Gly Ala Gly Gly Gly Ala Gly
 165 170 175
 Ala Gly Gly Gly Ala Gly Gly Ala Gly Ala Gly Gly Gly Ala Gly Gly
 180 185 190
 Ala Gly Gly Ala Gly Ala Gly Gly Gly Ala Gly Ala Gly Gly Ala Gly
 195 200 205
 Gly Ala Gly Gly Ala Gly Ala Gly Gly Ala Gly Ala Gly Gly Gly Ala
 210 215 220
 Gly Gly Ala Gly Gly Ala Gly Ala Gly Gly Ala Gly Ala Gly Gly Ala
 225 230 235 240
 Gly Ala Gly Gly Ala Gly Ala Gly Gly Ala Gly Gly Ala Gly Ala Gly
 245 250 255
 Gly Ala Gly Gly Ala Gly Ala Gly Gly Ala Gly Gly Ala Gly Ala Gly
 260 265 270
 Gly Gly Ala Gly Gly Ala Gly Ala Gly Gly Gly Ala Gly Gly Ala Gly
 275 280 285
 Ala Gly Gly Ala Gly Gly Ala Gly Ala Gly Gly Ala Gly Gly Ala Gly
 290 295 300
 Ala Gly Gly Ala Gly Gly Ala Gly Ala Gly Gly Ala Gly Ala Gly
 305 310 315 320
 Gly Ala Gly Ala Gly Gly Gly Gly Arg Gly Arg Gly Gly Ser Gly Gly
 325 330 335
 Arg Gly Arg Gly Gly Ser Gly Gly Arg Gly Arg Gly Gly Ser Gly Gly
 340 345 350
 Arg Arg Gly Arg Gly Arg Glu Arg Ala Arg Gly Gly Ser Arg Glu Arg
 355 360 365
 Ala Arg Gly Arg Gly Arg Gly Arg Gly Glu Lys Arg Pro Arg Ser Pro
 370 375 380
 Ser Ser Gln Ser Ser Ser Ser Gly Ser Pro Pro Arg Arg Pro Pro Pro
 385 390 395 400
 Gly Arg Arg Pro Phe Phe His Pro Val Gly Glu Ala Asp Tyr Phe Glu
 405 410 415
 Tyr His Gln Glu Gly Gly Pro Asp Gly Glu Pro Asp Val Pro Pro Gly

Ala	Ile	Glu	Gln	Gly	Pro	Ala	Asp	Asp	Pro	Gly	Glu	Gly	Pro	Ser	Thr
		420						425					430		
Gly	Pro	Arg	Gly	Gln	Gly	Asp	Gly	Gly	Arg	Arg	Lys	Lys	Gly	Gly	Trp
	435						440					445			
Phe	Gly	Lys	His	Arg	Gly	Gln	Gly	Gly	Ser	Asn	Pro	Lys	Phe	Glu	Asn
	450					455					460				
Ile	Ala	Glu	Gly	Leu	Arg	Ala	Leu	Leu	Ala	Arg	Ser	His	Val	Glu	Arg
	465				470					475				480	
Thr	Thr	Asp	Glu	Gly	Thr	Trp	Val	Ala	Gly	Val	Phe	Val	Tyr	Gly	Gly
		500						505					510		
Ser	Lys	Thr	Ser	Leu	Tyr	Asn	Leu	Arg	Arg	Gly	Thr	Ala	Leu	Ala	Ile
	515						520					525			
Pro	Gln	Cys	Arg	Leu	Thr	Pro	Leu	Ser	Arg	Leu	Pro	Phe	Gly	Met	Ala
	530					535					540				
Pro	Gly	Pro	Gly	Pro	Gln	Pro	Gly	Pro	Leu	Arg	Glu	Ser	Ile	Val	Cys
	545				550					555				560	
Tyr	Phe	Met	Val	Phe	Leu	Gln	Thr	His	Ile	Phe	Ala	Glu	Val	Leu	Lys
			565					570						575	
Asp	Ala	Ile	Lys	Asp	Leu	Val	Met	Thr	Lys	Pro	Ala	Pro	Thr	Cys	Asn
		580						585					590		
Ile	Arg	Val	Thr	Val	Cys	Ser	Phe	Asp	Asp	Gly	Val	Asp	Leu	Pro	Pro
	595						600					605			
Trp	Phe	Pro	Pro	Met	Val	Glu	Gly	Ala	Ala	Ala	Glu	Gly	Asp	Asp	Gly
	610					615					620				
Asp	Asp	Gly	Asp	Glu	Gly	Gly	Asp	Gly	Asp	Glu	Gly	Glu	Glu	Gly	Gln
	625				630					635					640
Glu															

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 02/00379

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C12N 15/86, C12N 15/63, C12N 15/85, A61K 48/00, A61P 31/00
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, PAJ, WPI-DATA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Journal of Virology, Volume 73, No. 5, 1999, Ivar Ilves et al: "Long-Term Episomal Maintenance of Bovine Papillomavirus Type 1 Plasmids Is Determined by Attachment to Host Chromosomes, Which Is Mediated by the Viral E2 Protein and Its Binding Sites", pages 4404-4412, page 4404 right column lines 12-35, page 4405 left column first paragraph, page 4409 left column third paragraph and page 4411 left column second paragraph lines 17-25 --	1-80
X	Eur. J. Biochem, Volume 267, 2000, Kathleen Van Craenenbroeck et al: "Episomal vectors for gene expression in mammalian cells", pages 5665-5678, page 5669, left column last paragraph - page 5672 right column second paragraph --	1-80

☒ Further documents are listed in the continuation of Box C.
 ☒ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

Date of mailing of the international search report

3 Sept 2002

04-09-2002

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

SARA NILSSON/BS
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 02/00379

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Vaccine, Volume 18, 2000, Auni Collings et al: "Humoral and cellular immune responses to HIV-1 Nef in mice DNA-immunised with non-replication of self-replicating expression vectors", pages 460-467, page 461 right column third paragraph and page 466 left column last paragraph --	1-80
X	Gene Therapy, Volume 4, 1997, S. Mücke et al: "Suitability of Epstein - Barr virus-based episomal vectors for expression of cytokine genes in human lymphoma cells", pages 82-92, page 85, figure 1(b) --	1-80
A	PNAS, Volume 13, Siu Chun Hung et al: "Maintenance of Epstein-Barr virus (EBV) oriP-based episomes requires EBV-encoded nuclear antigen-1 chromosome-binding domains, which can be replaced by high-mobility group-1 or histone H1, pages 1865-1870, page 1865, left column last paragraph, page 1869 right column paragraph 4 --	1-80
A	Virology, Volume 270, 2000, Nathalie Bastien et al: "Interaction of the Papillomavirus E2 with Mitotic Chromosomes", pages 124-134 --	1-80
A	WO 9807876 A2 (MEDICAL RESEARCH COUNCIL), 26 February 1998 (26.02.98) -- -----	1-80

INTERNATIONAL SEARCH REPORT

International application No.
PCT/FI02/00379

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 53-58
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet*
2. ☒ Claims Nos.: 1-80 partially
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
see next sheet**
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/FI02/00379

*

Claims 53-58 relate to methods of treatment of the human or animal body by surgery or by therapy (Rule. 39.1.(iv)). Nevertheless, a search has been executed for these claims. The search has been based on the vector used and on the alleged effects of the vector.

**

Due to the wording "an expression vector **comprising...**", present claim 1 relate to an extremely large number of possible expression vectors. Support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the vectors claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts related to the vectors prepared in the examples. In these expression vectors, the nuclear-anchoring protein is the E2 protein of Bovine papilloma virus type 1 or Epstein-Barr virus nuclear antigen 1.

INTERNATIONAL SEARCH REPORT
Information on patent family members

06/07/02

International application No.
PCT/FI 02/00379

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9807876 A2	26/02/98	AT 199570 T	15/03/01
		AU 725474 B	12/10/00
		AU 4020997 A	06/03/98
		DE 69704206 D,T	30/08/01
		DK 918874 T	14/05/01
		EP 0918874 A,B	02/06/99
		SE 0918874 T3	
		ES 2157084 T	01/08/01
		GB 9617214 D	00/00/00
		JP 2000516472 T	12/12/00
		PT 918874 T	30/08/01

